

Welcome to STN International! Enter x:x

LOGINID:sssptaul25rxt

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the
present
NEWS 4 Jul 15 Data from 1960-1976 added to RDISCLOSURE
NEWS 5 Jul 21 Identification of STN records implemented
NEWS 6 Jul 21 Polymer class term count added to REGISTRY
NEWS 7 Jul 22 INPADOC: Basic index (/BI) enhanced; Simultaneous Left and
Right Truncation available
NEWS 8 AUG 05 New pricing for EUROPATFULL and PCTFULL effective
August 1, 2003
NEWS 9 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 10 AUG 15 PATDPAFULL: one FREE connect hour, per account, in
September 2003
NEWS 11 AUG 15 PCTGEN: one FREE connect hour, per account, in
September 2003
NEWS 12 AUG 15 RDISCLOSURE: one FREE connect hour, per account, in
September 2003
NEWS 13 AUG 15 TEMA: one FREE connect hour, per account, in
September 2003
NEWS 14 AUG 18 Data available for download as a PDF in RDISCLOSURE
NEWS 15 AUG 18 Simultaneous left and right truncation added to PASCAL
NEWS 16 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right
Truncation
NEWS 17 AUG 18 Simultaneous left and right truncation added to ANABSTR
NEWS 18 SEP 22 DIPPR file reloaded
NEWS 19 SEP 25 INPADOC: Legal Status data to be reloaded

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:17:21 ON 29 SEP 2003

AN 1994:261080 CAPLUS
 DN 120:261080
 TI **Intrathecal** injection of lysine acetylsalicylic acid in the rat:
 a neurotoxicological study
 AU Svensson, B. A.; Karlsten, R.; Kristensen, J. D.; Sottile, A.; Bennett,
 A.; Gordh, T. Jr.
 CS Dep. Anat., Uppsala Univ., Uppsala, Swed.
 SO Acta Anaesthesiologica Scandinavica (1993), 37(8), 799-805
 CODEN: AANEAB; ISSN: 0001-5172
 DT Journal
 LA English
 CC 1-11 (Pharmacology)
 AB Lysine acetylsalicylic acid has been reported to induce analgesic effects
 in humans after **intrathecal** (i.t.) injection. Before conducting
 further studies in humans with this drug, it is important to evaluate
 potential toxicol. effects on the spinal cord in animals. In the present
 study the effects of chronic **intrathecal** administration of
 provocative doses of lysine acetylsalicylic acid (L-ASA) on the rat spinal
 cord were evaluated using light and electron microscopy and a quant.
 morphometric method. The authors also investigated the effects of single
 doses of the drug on the spinal cord blood flow (SCBF) using the
 laser-Doppler flowmetry technique. No histopathol. changes or differences
 in no. or d. of neuronal cells could be seen after chronic administration
 of L-ASA as compared to controls. The SCBF decreased immediately after
 i.t. injection of a large dose (4 mg) of L-ASA and returned to predrug
 levels within 10 min. At the end of the expt. metabolic acidosis was
 detected, indicating a systemic effect of acetylsalicylic acid. It is
 concluded that no neurotoxic effects on the spinal cord were seen after
 chronic i.t. injection of L-ASA. From a neurotoxicol. point of view, the
 authors' findings do not contraindicate the spinal use of L-ASA in humans.
 ST lysine acetylsalicylic acid toxicity spinal cord; analgesic lysine
 acetylsalicylic acid toxicity
 IT Analgesics
 (lysine acetylsalicylic acid as, neurotoxicity of, to spinal cord,
 after **intrathecal** injection)
 IT Spinal cord
 (lysine acetylsalicylic acid neurotoxicity to, after
intrathecal injection)
 IT Nerve, toxic chemical and physical damage
 (lysine acetylsalicylic acid toxicity to, in spinal cord, after
intrathecal injection)
 IT Acidosis
 (neurotoxic effect of lysine acetylsalicylic acid in relation to, in
 spinal cord, after **intrathecal** injection)
 IT Circulation
 (of spinal cord, lysine acetylsalicylic acid effect on, neurotoxicity
 after **intrathecal** injection in relation to)
 IT **62952-06-1**
 RL: PRP (Properties)
 (neurotoxicity of, to spinal cord, after **intrathecal**
 injection)

=>

AN 1994:261080 CAPLUS
 DN 120:261080
 TI **Intrathecal** injection of lysine acetylsalicylic acid in the rat:
 a neurotoxicological study
 AU Svensson, B. A.; Karlsten, R.; Kristensen, J. D.; Sottile, A.; Bennett,
 A.; Gordh, T. Jr.
 CS Dep. Anat., Uppsala Univ., Uppsala, Swed.
 SO Acta Anaesthesiologica Scandinavica (1993), 37(8), 799-805
 CODEN: AANEAB; ISSN: 0001-5172
 DT Journal
 LA English
 CC 1-11 (Pharmacology)
 AB Lysine acetylsalicylic acid has been reported to induce analgesic effects
 in humans after **intrathecal** (i.t.) injection. Before conducting
 further studies in humans with this drug, it is important to evaluate
 potential toxicol. effects on the spinal cord in animals. In the present
 study the effects of chronic **intrathecal** administration of
 provocative doses of lysine acetylsalicylic acid (L-ASA) on the rat spinal
 cord were evaluated using light and electron microscopy and a quant.
 morphometric method. The authors also investigated the effects of single
 doses of the drug on the spinal cord blood flow (SCBF) using the
 laser-Doppler flowmetry technique. No histopathol. changes or differences
 in no. or d. of neuronal cells could be seen after chronic administration
 of L-ASA as compared to controls. The SCBF decreased immediately after
 i.t. injection of a large dose (4 mg) of L-ASA and returned to predrug
 levels within 10 min. At the end of the expt. metabolic acidosis was
 detected, indicating a systemic effect of acetylsalicylic acid. It is
 concluded that no neurotoxic effects on the spinal cord were seen after
 chronic i.t. injection of L-ASA. From a neurotoxicol. point of view, the
 authors' findings do not contraindicate the spinal use of L-ASA in humans.
 ST lysine acetylsalicylic acid toxicity spinal cord; analgesic lysine
 acetylsalicylic acid toxicity
 IT Analgesics
 (lysine acetylsalicylic acid as, neurotoxicity of, to spinal cord,
 after **intrathecal** injection)
 IT Spinal cord
 (lysine acetylsalicylic acid neurotoxicity to, after
intrathecal injection)
 IT Nerve, toxic chemical and physical damage
 (lysine acetylsalicylic acid toxicity to, in spinal cord, after
intrathecal injection)
 IT Acidosis
 (neurotoxic effect of lysine acetylsalicylic acid in relation to, in
 spinal cord, after **intrathecal** injection)
 IT Circulation
 (of spinal cord, lysine acetylsalicylic acid effect on, neurotoxicity
 after **intrathecal** injection in relation to)
 IT **62952-06-1**
 RL: PRP (Properties)
 (neurotoxicity of, to spinal cord, after **intrathecal**
 injection)

=>

AN 1994:261080 CAPLUS
 DN 120:261080
 TI **Intrathecal** injection of lysine acetylsalicylic acid in the rat:
 a neurotoxicological study
 AU Svensson, B. A.; Karlsten, R.; Kristensen, J. D.; Sottile, A.; Bennett,
 A.; Gordh, T. Jr.
 CS Dep. Anat., Uppsala Univ., Uppsala, Swed.
 SO Acta Anaesthesiologica Scandinavica (1993), 37(8), 799-805
 CODEN: AANEAB; ISSN: 0001-5172
 DT Journal
 LA English
 CC 1-11 (Pharmacology)
 AB Lysine acetylsalicylic acid has been reported to induce analgesic effects
 in humans after **intrathecal** (i.t.) injection. Before conducting
 further studies in humans with this drug, it is important to evaluate
 potential toxicol. effects on the spinal cord in animals. In the present
 study the effects of chronic **intrathecal** administration of
 provocative doses of lysine acetylsalicylic acid (L-ASA) on the rat spinal
 cord were evaluated using light and electron microscopy and a quant.
 morphometric method. The authors also investigated the effects of single
 doses of the drug on the spinal cord blood flow (SCBF) using the
 laser-Doppler flowmetry technique. No histopathol. changes or differences
 in no. or d. of neuronal cells could be seen after chronic administration
 of L-ASA as compared to controls. The SCBF decreased immediately after
 i.t. injection of a large dose (4 mg) of L-ASA and returned to predrug
 levels within 10 min. At the end of the expt. metabolic acidosis was
 detected, indicating a systemic effect of acetylsalicylic acid. It is
 concluded that no neurotoxic effects on the spinal cord were seen after
 chronic i.t. injection of L-ASA. From a neurotoxicol. point of view, the
 authors' findings do not contraindicate the spinal use of L-ASA in humans.
 ST lysine acetylsalicylic acid toxicity spinal cord; analgesic lysine
 acetylsalicylic acid toxicity
 IT Analgesics
 (lysine acetylsalicylic acid as, neurotoxicity of, to spinal cord,
 after **intrathecal** injection)
 IT Spinal cord
 (lysine acetylsalicylic acid neurotoxicity to, after
intrathecal injection)
 IT Nerve, toxic chemical and physical damage
 (lysine acetylsalicylic acid toxicity to, in spinal cord, after
intrathecal injection)
 IT Acidosis
 (neurotoxic effect of lysine acetylsalicylic acid in relation to, in
 spinal cord, after **intrathecal** injection)
 IT Circulation
 (of spinal cord, lysine acetylsalicylic acid effect on, neurotoxicity
 after **intrathecal** injection in relation to)
 IT **62952-06-1**
 RL: PRP (Properties)
 (neurotoxicity of, to spinal cord, after **intrathecal**
 injection)

=>

AN 1997:454047 CAPLUS
 DN 127:60626
 TI Method of delaying onset of **Alzheimer's** disease symptoms with a
 non-steroidal anti-inflammatory agent and/or a histamine H2
 receptor-blocking agent
 IN Breitner, John C. S.; Welsh, Kathleen A.
 PA Duke University, USA
 SO U.S., 10 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 IC ICM A61K031-60
 ICS A61K031-615; A61K031-54; A61K031-44; A61K031-425; A61K031-42;
 A61K031-415; A61K031-40; A61K031-38; A61K031-34; A61K031-195;
 A61K031-19
 NCL 514570000
 CC 1-11 (Pharmacology)
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5643960	A	19970701	US 1994-228019	19940415
	US 6025395	A	20000215	US 1997-843217	19970414
PRAI	US 1994-228019		19940415		
AB	A method is disclosed for preventing or delaying the onset of Alzheimer's disease and related neurodegenerative disorders. The method involves the administration to individuals at risk of developing the disease (or disorder) a non-steroidal anti-inflammatory agent and/or a histamine H2 receptor-blocking agent. The invention also relates to a method of treating Alzheimer's disease and related neurodegenerative disorders that involves the use of such agents.				
ST	Alzheimer disease NSAID H2 antihistaminic; neurodegenerative disease NSAID H2 antihistaminic				
IT	Apolipoproteins RL: BSU (Biological study, unclassified); BIOL (Biological study) (E, .epsilon.4 or .epsilon.2 allele at locus for; non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating Alzheimer's disease and related neurodegenerative disorders)				
IT	Antihistamines (H2; non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating Alzheimer's disease and related neurodegenerative disorders)				
IT	Nervous system (degeneration; non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating Alzheimer's disease and related neurodegenerative disorders)				
IT	Alzheimer's disease Narcotics Susceptibility (genetic) (non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating Alzheimer's disease and related neurodegenerative disorders)				
IT	Glucocorticoids RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) (non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating Alzheimer's disease and related neurodegenerative disorders)				
IT	Anti-inflammatory agents (nonsteroidal; non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating Alzheimer's disease and related neurodegenerative disorders)				

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.epsilon.4 or .epsilon.2 allele, for apolipoprotein E; non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer's** disease and related neurodegenerative disorders)

IT **50-78-2**, Aspirin 103-90-2, Acetaminophen 22204-53-1, Naproxen
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer's** disease and related neurodegenerative disorders)

=>

AN 1999:103337 CAPLUS
 DN 130:280248
 TI Increased expression of cyclooxygenases and peroxisome
 proliferator-activated receptor-.gamma. in **Alzheimer's** disease
 brains
 AU Kitamura, Yoshihisa; Shimohama, Shun; Koike, Hideyasu; Kakimura, Jun-Ichi;
 Matsuoka, Yasuji; Nomura, Yasuyuki; Gebicke-Haerter, Peter J.; Taniguchi,
 Takashi
 CS Department of Neurobiology, Kyoto Pharmaceutical University, Kyoto,
 607-8412, Japan
 SO Biochemical and Biophysical Research Communications (1999), 254(3),
 582-586
 CODEN: BBRCA9; ISSN: 0006-291X
 PB Academic Press
 DT Journal
 LA English
 CC 14-10 (Mammalian Pathological Biochemistry)
 Section cross-reference(s): 1
 AB Recent studies suggest that inflammatory events are assocd. with plaque
 formation in the brains of patients with **Alzheimer's** disease
 (AD). Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) of
 these patients appears to slow the progression of disease. The authors
 assessed the occurrence of cyclooxygenases (COX-1 and -2) and peroxisome
 proliferator-activated receptor-.gamma. (PPAR.gamma.) in temporal cortex
 from normal and AD brains using specific antibodies. In AD brains,
 protein levels of COX-1 were increased in both cytosolic and particulate
 fractions, and COX-2 protein was also increased in the particulate
 fraction. PPAR.gamma. level was increased in the cytosolic fraction but
 not in the particulate fraction. Thus, expression levels of COX-1, COX-2,
 and PPAR.gamma. may change in AD brains. In addn., several NSAIDs which
 are also PPAR.gamma. activators, such as indomethacin, inhibited COX-2
 expression in glial cells. These results suggest that PPAR.gamma.
 activators have inhibitory effects on inflammatory events in AD brains.
 (c) 1999 Academic Press.
 ST brain cyclooxygenase peroxisome proliferator activated receptor gamma
Alzheimer disease
 IT Cytoplasm
 (cytosol; increased expression of cyclooxygenases and peroxisome
 proliferator-activated receptor-.gamma. in brains from humans with
Alzheimer's disease)
 IT Gene
 (expression; increased expression of cyclooxygenases and peroxisome
 proliferator-activated receptor-.gamma. in brains from humans with
Alzheimer's disease)
 IT **Alzheimer's** disease
 Encephalitis
 Neuroglia
 (increased expression of cyclooxygenases and peroxisome
 proliferator-activated receptor-.gamma. in brains from humans with
Alzheimer's disease)
 IT Anti-inflammatory agents
 (nonsteroidal; increased expression of cyclooxygenases and peroxisome
 proliferator-activated receptor-.gamma. in brains from humans with
Alzheimer's disease)
 IT Brain
 (temporal cortex; increased expression of cyclooxygenases and
 peroxisome proliferator-activated receptor-.gamma. in brains from
 humans with **Alzheimer's** disease)
 IT Peroxisome proliferator-activated receptors
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified);
 BIOL (Biological study); OCCU (Occurrence)
 (.gamma.; increased expression of cyclooxygenases and peroxisome

proliferator-activated receptor-.gamma. in brains from humans with
Alzheimer's disease)

IT 39391-18-9

RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)

(1 and 2; increased expression of cyclooxygenases and peroxisome
proliferator-activated receptor-.gamma. in brains from humans with
Alzheimer's disease)

IT 50-78-2, Aspirin 53-86-1, Indomethacin 41598-07-6, PGD2
87893-55-8 123653-11-2, NS398

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(increased expression of cyclooxygenases and peroxisome
proliferator-activated receptor-.gamma. in brains from humans with
Alzheimer's disease)

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Bauer, M; Eur J Biochem 1997, V243, P726 CAPLUS
- (2) Bonventre, J; Nature 1997, V390, P622 CAPLUS
- (3) Chang, J; Neurobiol Aging 1996, V17, P801 CAPLUS
- (4) Clemens, J; Stroke 1996, V27, P527 CAPLUS
- (5) Farooqui, A; Neurochem Int 1997, V30, P517 CAPLUS
- (6) Forman, B; Cell 1995, V83, P803 CAPLUS
- (7) Gattaz, W; Biol Psychiatry 1995, V37, P13 MEDLINE
- (8) Guastadisegni, C; FEBS Lett 1997, V413, P314 CAPLUS
- (9) Jiang, C; Nature 1998, V391, P82 CAPLUS
- (10) Kitamura, Y; Neurosci Lett 1997, V237, P17 CAPLUS
- (11) Lehmann, J; J Biol Chem 1997, V272, P3406 CAPLUS
- (12) Lehtonen, J; Biochemistry 1996, V35, P9407 CAPLUS
- (13) Lukiw, W; J Neurosci Res 1997, V50, P937 CAPLUS
- (14) Mangelsdorf, D; Cell 1995, V83, P835 CAPLUS
- (15) Mirra, S; Neurology 1991, V41, P479 MEDLINE
- (16) Morita, I; J Biol Chem 1995, V270, P10902 CAPLUS
- (17) Nogawa, S; J Neurosci 1997, V17, P2746 CAPLUS
- (18) Oka, A; NeuroReport 1997, V8, P1161 CAPLUS
- (19) Pasinetti, G; Neuroscience 1998, V87, P319 CAPLUS
- (20) Ricote, M; Nature 1998, V391, P79 CAPLUS
- (21) Rogers, J; Neurology 1993, V43, P1609 MEDLINE
- (22) Sanz, O; Neuroscience 1997, V80, P221 CAPLUS
- (23) Shimohama, S; J Neural Transm 1990, V30(Suppl), P69
- (24) Shimohama, S; J Neurochem 1995, V64, P2629 CAPLUS
- (25) Shimohama, S; Neurology 1993, V43, P1407 MEDLINE
- (26) Spencer, A; J Biol Chem 1998, V273, P9886 CAPLUS
- (27) Stephenson, D; Neurobiol Dis 1996, V3, P51 CAPLUS
- (28) Tocco, G; Exp Neurol 1997, V144, P339 CAPLUS
- (29) Vane, J; Ann Rev Pharmacol Toxicol 1998, V38, P97 CAPLUS

=>

AN 1998:780621 CAPLUS
 DN 130:232124
 TI Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS [central nervous system]
 AU Hauss-Wegrzyniak, Beatrice; Willard, Lauren B.; Del Soldato, Piero; Pepeu, Giancarlo; Wenk, Gary L.
 CS Memory and Aging, Division of Neural Systems, Arizona Research Laboratories, University of Arizona, Tucson, AZ, 85724, USA
 SO Brain Research (1999), 815(1), 36-43
 CODEN: BRREAP; ISSN: 0006-8993
 PB Elsevier Science B.V.
 DT Journal
 LA English
 CC 1-7 (Pharmacology)
 AB This study investigated whether nitroflurbiprofen (NFP) or nitro-aspirin can reduce the inflammatory response induced by continuous infusion of lipopolysaccharide (LPS) into the 4th ventricular space of the rat brain for 30 days. The chronic LPS infusion produced an extensive inflammation that was particularly evident in the hippocampus, subiculum and entorhinal and piriform cortices. Daily peripheral administration of NFP dose-dependently attenuated the brain inflammation, as indicated by the decreased d. and reactive state of microglial cells. Daily peripheral administration of nitro-aspirin also attenuated the brain inflammation, but to a much lesser degree than NFP. The results demonstrated that nonsteroidal anti-inflammatory drugs can reduce brain inflammation and that NFP is an effective anti-inflammatory agent.
 ST brain inflammation inhibition nitroflurbiprofen nitroaspirin; nonsteroidal antiinflammatory drug brain inflammation
 IT Encephalitis
 (nitroflurbiprofen and nitroaspirin inhibition of)
 IT **Alzheimer's** disease
 (nitroflurbiprofen and nitroaspirin inhibition of brain inflammation in relation to)
 IT Anti-inflammatory agents
 (nonsteroidal; brain inflammation inhibition by nitroflurbiprofen and nitroaspirin as)
 IT **17336-14-0** 158836-71-6, Nitroflurbiprofen
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (brain inflammation inhibition by)
 RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE
 (1) Aisen, P; Am J Psychiatr 1994, V151, P1105 MEDLINE
 (2) Allison, M; N Engl J Med 1992, V327, P749 MEDLINE
 (3) Altstiel, L; Prog Neuropsychopharmacol Biol Psychiatr 1991, V15, P481 CAPLUS
 (4) Banati, R; Glia 1993, V7, P111 MEDLINE
 (5) Bannwarth, B; Therapie 1986, V41, P409 CAPLUS
 (6) Breder, C; Brain Res 1996, V713, P64 CAPLUS
 (7) Breitner, J; Neurobiol Aging 1996, V17, P789 MEDLINE
 (8) Burrell, R; Crit Rev Microbiol 1990, V17, P188
 (9) Cacabelos, R; Meth Find Exp Clin Pharmacol 1994, V16, P141 MEDLINE
 (10) Chiang, C; Dev Neurosci 1994, V16, P212 CAPLUS
 (11) Das, S; Neuron 1995, V14, P447 CAPLUS
 (12) Eikelenboom, P; Virchows Arch B Cell Pathol 1989, V56, P259 MEDLINE
 (13) Elmquist, J; J Comp Neurol 1997, V381, P119 CAPLUS
 (14) Greenblatt, D; Arzneimittelforschung 1983, V33, P1671 CAPLUS
 (15) Griffin, W; Proc Natl Acad Sci USA 1989, V86, P7611 MEDLINE
 (16) Hauss-Wegrzyniak, B; Brain Res 1998, V794, P211 CAPLUS
 (17) Hauss-Wegrzyniak, B; Brain Res 1998, V780, P294 CAPLUS
 (18) Jenkinson, M; Br J Rheumatol 1989, V28, P86 MEDLINE

- (19) Kitagawa, H; J Pharmacol Exp Therap 1990, V253, P1133 CAPLUS
- (20) Macnaughton, W; Life Sci 1989, V45, P1869 CAPLUS
- (21) McGeer, P; Brain Res Rev 1995, V21, P195 MEDLINE
- (22) McGeer, P; Lancet 1990, V335, P1037 MEDLINE
- (23) McGeer, P; Neurosci Lett 1988, V79, P195
- (24) McGeer, P; Neurosci Lett 1989, V107, P341 MEDLINE
- (25) Mrak, R; Human Pathol 1995, V26, P816 MEDLINE
- (26) Myllykangas-Luosujarvi, R; Br J Rheumatol 1994, V33, P501 MEDLINE
- (27) Rogers, J; Drug Res 1995, V45, P439 CAPLUS
- (28) Rogers, J; Neurobiol Aging 1996, V17, P681 MEDLINE
- (29) Rogers, J; Neurology 1993, V43, P1609 MEDLINE
- (30) Roth, S; Ann Intern Med 1988, V109, P353 MEDLINE
- (31) Santini, G; Eur J Pharmacol 1996, V316, P65 CAPLUS
- (32) Sheng, J; Neurobiol Aging 1996, V17, P761 CAPLUS
- (33) Strauss, S; Lab Invest 1992, V66, P223 MEDLINE
- (34) Vandenabeele, P; Immunol Today 1991, V12, P217 CAPLUS
- (35) Wallace, J; Gastroenterology 1994, V107, P173 CAPLUS
- (36) Wallace, J; Trends Pharmacol Sci 1992, V13, P129 MEDLINE
- (37) Watson; Paxinos 1986

=>

DN 130:105154
 TI Molecular characterization of the neuroprotective activity of salicylates
 AU Grilli, M.; Pizzi, M.; Goffi, F.; Benarese, M.; Gerardi, G. M.; Memo, M.; Spano, P. F.
 CS Division of Pharmacology Department of Biomedical Sciences and Biotechnologies School of Medicine, University of Brescia, Brescia, Italy
 SO Advances in Behavioral Biology (1998), 49(Progress in Alzheimer's and Parkinson's Diseases), 99-103
 CODEN: ADBBBW; ISSN: 0099-6246
 PB Plenum Publishing Corp.
 DT Journal
 LA English
 CC 1-11 (Pharmacology)
 AB Aspirin and its metabolite sodium salicylate prevent glutamate-induced neurotoxicity in rats. The neuroprotective effect of aspirin does not appear to correlate with the anti-inflammatory properties of this compd.
 ST neuroprotectant salicylate antiinflammatory neurodegenerative disorder **Alzheimer**
 IT Transcription factors
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (NF-.kappa.B (nuclear factor .kappa.B); mol. characterization of the neuroprotective activity of salicylates)
 IT Nervous system
 (degeneration; mol. characterization of the neuroprotective activity of salicylates)
 IT Anti-**Alzheimer**'s agents
 (mol. characterization of the neuroprotective activity of salicylates)
 IT Cytoprotective agents
 (neuroprotectants; mol. characterization of the neuroprotective activity of salicylates)
 IT Anti-inflammatory agents
 (nonsteroidal; mol. characterization of the neuroprotective activity of salicylates)
 IT 54-21-7, Sodium salicylate
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
 (mol. characterization of the neuroprotective activity of salicylates)
 IT 50-78-2, Aspirin 69-72-7D, analogs
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (mol. characterization of the neuroprotective activity of salicylates)
 RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Amin, A; Proc Natl Acad Sci USA 1995, V92, P7926 CAPLUS
- (2) Curran, T; Cell 1988, V55, P395 CAPLUS
- (3) Gallo, V; Proc Natl Acad Sci USA 1982, V79, P7919 CAPLUS
- (4) Garthwaite, G; Neurosci Lett 1989, V97, P316 CAPLUS
- (5) Grilli, M; Int Rev Cytol 1993, V143, P1 CAPLUS
- (6) Grilli, M; J Biol Chem 1995, V270, P26774 CAPLUS
- (7) Grilli, M; J Biol Chem 1996, V271, P15002 CAPLUS
- (8) Grilli, M; Science 1996, V274, P1383 CAPLUS
- (9) Guerrini, L; Proc Natl Acad Sci USA 1995, V92, P9077 CAPLUS
- (10) Insel, P; Goodman and Gilman's The Pharmacological Basis of Therapeutics 1996, P617
- (11) Kaltschmidt, C; Mol Cell Biol 1994, V14, P3981 CAPLUS
- (12) Kaltschmidt, C; Proc Natl Acad Sci USA 1995, V92, P9618 CAPLUS
- (13) Kopp, E; Science 1994, V265, P956 MEDLINE
- (14) Lipton, S; New Engl J Med 1995, V330, P613
- (15) McGeer, P; Brain Res Rev 1995, V21, P195 MEDLINE

- (16) Pizzi, M; Eur J Neurosci 1996, V8, P1516 MEDLINE
- (17) Pizzi, M; Mol Pharmacol 1996, V49, P586 CAPLUS
- (18) Rogers, J; Neurology 1993, V43, P1609 MEDLINE
- (19) Yan, S; Nature Med 1995, V1, P693 CAPLUS

=>

AN 1998:338114 CAPLUS
 DN 129:12755
 TI Use of selected nonsteroidal antiinflammatory compounds for the prevention
 and the treatment of neurodegenerative diseases
 IN Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco
 PA Universita' Degli Studi di Brescia - Dipartimento di Scienze Biomediche,
 Italy; Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano,
 Pierfranco
 SO PCT Int. Appl., 24 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-00
 ICS A61K031-60
 CC 1-11 (Pharmacology)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9820864	A2	19980522	WO 1997-EP6323	19971113
	WO 9820864	A3	19981015		
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	IT 1996-MI2356		19961113		
OS	MARPAT 129:12755				
AB	Nonsteroidal antiinflammatory compds. are used for the prevention and the treatment of neurodegenerative diseases, e.g. Alzheimer's disease and Parkinson's disease.				
ST	neurodegenerative disease nonsteroidal antiinflammatory drug; Parkinson disease nonsteroidal antiinflammatory drug; Alzheimer disease nonsteroidal antiinflammatory drug; NSAID neurodegenerative disease				
IT	Transcription factors RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (AP-1 (activator protein 1); nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	Nervous system (Huntington's chorea; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	Transcription factors RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (NF-.kappa.B (nuclear factor .kappa.B); nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	Glutamate receptors RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (NMDA-binding; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	Nervous system (amyotrophic lateral sclerosis; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	Nervous system (ataxia telangiectasia; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	Nervous system (degeneration; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	AIDS (disease) (dementia assocd. with; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	Mental disorder				

(dementia, multi-infarct; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Brain
(dentate gyrus; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Mental disorder
(diffuse Lewy body disease; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Brain
(hippocampus, sector CA1; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Brain
(hippocampus, sector CA3; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Infection
(infective neurodegenerative disease; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Nerve, disease
(injury; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Metabolism
(metabolic neuropathies; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Epilepsy
(neurodegenerative processes related to; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Prion diseases
(neurodegenerative syndromes in; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Hypoxia, animal
(neuropathy from; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Brain, disease
(neuropathy, ischemic; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Nerve, disease
(neuropathy; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Cytoprotective agents
(neuroprotectants; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Anti-Alzheimer's agents
Anti-ischemic agents
Antiparkinsonian agents
Multiple sclerosis
(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Glutamate receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Anti-inflammatory agents
(nonsteroidal; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Nerve, disease
(peripheral neuropathy, ischemic; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Brain, disease
Spinal cord
Spinal cord
(trauma; nonsteroidal antiinflammatory compds. for prevention and

treatment of neurodegenerative diseases)

IT 50-99-7, D-Glucose, biological studies
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified);
 BIOL (Biological study); OCCU (Occurrence)
 (blood; glycemic damage-assocd. neuropathy; nonsteroidal
 antiinflammatory compds. for prevention and treatment of
 neurodegenerative diseases)

IT 53-86-1, Indomethacin 56-86-0, L-Glutamic acid, biological studies
 6384-92-5, NMDA
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); BIOL (Biological study)
 (nonsteroidal antiinflammatory compds. for prevention and treatment of
 neurodegenerative diseases)

IT 50-33-9, Phenylbutazone, biological studies 50-33-9D, Phenylbutazone,
 metabolites **50-78-2**, Acetylsalicylic acid **50-78-2D**,
 Acetylsalicylic acid, derivs. 54-21-7, Sodium salicylate 58-15-1,
 Aminopyrine 58-15-1D, Aminopyrine, metabolites 60-80-0, Antipyrine
 60-80-0D, Antipyrine, metabolites 65-45-2, Salicylamide 65-85-0,
 Benzoic acid, biological studies 65-85-0D, Benzoic acid, metabolites,
 biological studies **69-46-5**, Calcium acetylsalicylate 87-28-5,
 Glycol salicylate 89-57-6, Mesalamine 118-57-0, Acetaminosalol
 119-36-8, Methyl salicylate 129-20-4, Oxyphenbutazone 129-20-4D,
 Oxyphenbutazone, metabolites **134-55-4**, Phenyl acetylsalicylate
 147-90-0, Morpholine salicylate 303-38-8, 2,3-Dihydroxybenzoic acid
 303-38-8D, 2,3-Dihydroxybenzoic acid, metabolites 487-48-9, Salacetamide
 490-79-9, Gentisic acid 550-97-0, 1-Naphthyl salicylate 552-94-3,
 Salsalate **580-02-9**, Methyl acetylsalicylate 599-79-1,
 Sulfasalazine **5003-48-5**, Benorylate 5104-49-4, Flurbiprofen
 5104-49-4D, Flurbiprofen, metabolites 5663-71-8 6385-02-0, Sodium
 meclofenamate 6385-02-0D, Sodium meclofenamate, metabolites
 13539-59-8, Apazone 13539-59-8D, Apazone, metabolites 13586-98-6
 15307-86-5, Diclofenac 15307-86-5D, Diclofenac, metabolites 15687-27-1
 15687-27-1D, metabolites 15722-48-2, Olsalazine 21256-18-8, Oxaprozin
 21256-18-8D, Oxaprozin, metabolites 22071-15-4, Ketoprofen
 22071-15-4D, Ketoprofen, metabolites 22204-53-1, Naproxen 22204-53-1D,
 Naproxen, metabolites 22494-27-5, Flufenisal 22494-42-4 26171-23-3,
 Tolmetin 26171-23-3D, Tolmetin, metabolites 29679-58-1, Fenoprofen
 29679-58-1D, Fenoprofen, metabolites 30653-83-9, Parsalmide
 36322-90-4, Piroxicam 36322-90-4D, Piroxicam, metabolites 36364-49-5,
 Imidazole salicylate 37933-78-1, Lysine acetylsalicylate 38194-50-2,
 Sulindac 38194-50-2D, Sulindac, metabolites 41340-25-4, Etodolac
 41340-25-4D, Etodolac, metabolites 42924-53-8, Nabumetone 42924-53-8D,
 Nabumetone, metabolites 51803-78-2, Nimesulide 51803-78-2D,
 Nimesulide, metabolites 53597-27-6, Fendosal 59804-37-4, Tenoxicam
 59804-37-4D, Tenoxicam, metabolites 62992-61-4, Etersalate 71125-38-7,
 Meloxicam 71125-38-7D, Meloxicam, metabolites 74103-06-3, Ketorolac
 74103-06-3D, Ketorolac, metabolites 111406-87-2, Zileuton
 111406-87-2D, Zileuton, metabolites
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (nonsteroidal antiinflammatory compds. for prevention and treatment of
 neurodegenerative diseases)

IT 7440-70-2, Calcium, biological studies 39391-18-9, Cyclooxygenase
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
 (Biological study); PROC (Process)
 (nonsteroidal antiinflammatory compds. for prevention and treatment of
 neurodegenerative diseases)

=>

AN 1993:175822 CAPLUS
 DN 118:175822
 TI Cure for diabetes, bronchitis, arthritis, and arteriosclerosis
 IN Carantinos, Spyros
 PA Australia
 SO Pat. Specif. (Aust.), 11 pp.
 CODEN: ALXXAP
 DT Patent
 LA English
 IC ICM A61K031-19
 ICS A61K033-30; A61K031-215
 CC 63-6 (Pharmaceuticals)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	AU 629520	B2	19921008	AU 1988-26677	19881208
	AU 8826677	A1	19890608		
PRAI	AU 1987-5803		19871208		
AB	A pharmaceutical contg. ferric ammonium citrate in admixt. with ZnO and optionally including aspirin, NaHCO ₃ , and citric acid is effective in treating arthritis, bronchitis, diabetes, arteriosclerosis, broken bones, Parkinson's disease, high blood cholesterol, liver cirrhosis, and enlargement of the prostate gland.				
ST	ferric ammonium citrate zinc oxide pharmaceutical				
IT	Antiartherosclerotics				
	Anticholesteremics and Hypolipemics				
	Antidiabetics and Hypoglycemics				
	(ferric ammonium citrate and zinc oxide as)				
IT	Cirrhosis				
	Parkinsonism				
	(treatment of, ferric ammonium citrate and zinc oxide for)				
IT	Inflammation inhibitors				
	(antiarthritics, ferric ammonium citrate and zinc oxide as)				
IT	Prostate gland				
	(disease, hyperplasia, treatment of, ferric ammonium citrate and zinc oxide for)				
IT	Bronchi				
	(diseases, bronchitis, treatment of, ferric ammonium citrate and zinc oxide for)				
IT	Bone, disease				
	(fracture, treatment of, ferric ammonium citrate and zinc oxide for)				
IT	50-78-2, Aspirin 59-43-8, Vitamin B1, biological studies				
	77-92-9, Citric acid, biological studies 94-20-2, Chlorpropamide				
	144-55-8, Sodium bicarbonate, biological studies				
	RL: BIOL (Biological study)				
	(pharmaceuticals contg. ferric ammonium citrate and zinc oxide and, for treatment of infections and immune diseases)				
IT	1314-13-2, Zinc oxide, biological studies				
	RL: BIOL (Biological study)				
	(pharmaceuticals contg. ferric ammonium citrate and, for treatment of infections and immune diseases)				
IT	1185-57-5, Ferric ammonium citrate				
	RL: BIOL (Biological study)				
	(pharmaceuticals contg. zinc oxide and, for treatment of infections and immune diseases)				

=>

AN 1998:700744 CAPLUS
 DN 130:60774
 TI Nonsteroidal anti-inflammatory drugs increase tumor necrosis factor
 production in the periphery but not in the central nervous system in mice
 and rats
 AU Sacco, Silvano; Agnello, Davide; Sottocorno, Marcello; Lozza, Gianluca;
 Monopoli, Angela; Villa, Pia; Ghezzi, Pietro
 CS Laboratory of Neuroimmunology, "Mario Negri" Institute for Pharmacological
 Research, Milan, 20157, Italy
 SO Journal of Neurochemistry (1998), 71(5), 2063-2070
 CODEN: JONRA9; ISSN: 0022-3042
 PB Lippincott-Raven Publishers
 DT Journal
 LA English
 CC 1-7 (Pharmacology)
 AB Nonsteroidal anti-inflammatory drugs (**NSAIDs**), which inhibit
 prostaglandin (PG) synthesis, augment prodn. of tumor necrosis factor
 (TNF) in most exptl. models. We investigated the effect of two
NSAIDs, indomethacin and ibuprofen, on the prodn. of TNF in the
 CNS induced by intracerebroventricular injection of lipopolysaccharide
 (LPS). Indomethacin and ibuprofen, administered i.p., augmented (three-
 to ninefold) the levels of TNF in serum and peripheral organs of mice
 injected i.p. with LPS and in rats with adjuvant arthritis (up to a
 sevenfold increase). However, **NSAIDs** (i.p. or
 intracerebroventricularly) did not increase brain TNF prodn. induced by
 i.v. LPS. In fact, indomethacin decreased (1.4-1.8-fold) TNF levels in
 the spinal cord of rats with exptl. autoimmune encephalomyelitis and in
 the cortex of rats with focal cerebral **ischemia**. Systemic
 administration of iloprost inhibited serum TNF levels after i.p. LPS,
 whereas intracerebroventricular injection of iloprost or PGE2 did not
 inhibit brain TNF induced by intracerebroventricular LPS. Both peripheral
 and central TNF productions were inhibited by cAMP level-elevating agents
 or dexamethasone. Thus, a PG-driven neg. feedback controls TNF prodn. in
 the periphery but not in the CNS.
 ST antiinflammatory **NSAIDs** TNF peripheral central nervous system
 IT Anti-inflammatory agents
 Brain
 (**NSAIDs** increase TNF prodn. in peripheral but not central
 nervous system in mice and rats)
 IT Tumor necrosis factors
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
 (Biological study); PROC (Process)
 (**NSAIDs** increase TNF prodn. in peripheral but not central
 nervous system in mice and rats)
 IT Encephalomyelitis
 (autoimmune; **NSAIDs** increase TNF prodn. in peripheral but not
 central nervous system in mice and rats)
 IT Nervous system
 (central; **NSAIDs** increase TNF prodn. in peripheral but not
 central nervous system in mice and rats)
 IT Brain, disease
 (**ischemia**; **NSAIDs** increase TNF prodn. in peripheral
 but not central nervous system in mice and rats)
 IT Anti-inflammatory agents
 (nonsteroidal; **NSAIDs** increase TNF prodn. in peripheral but
 not central nervous system in mice and rats)
 IT Nervous system
 (peripheral; **NSAIDs** increase TNF prodn. in peripheral but not
 central nervous system in mice and rats)
 IT 53-86-1, Indomethacin 15687-27-1, Ibuprofen
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)

(**NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT 60-92-4, CAMP

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(**NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Aggarwal, B; J Biol Chem 1985, V260, P2345 CAPLUS
- (2) Asanuma, M; Neurosci Lett 1997, V225, P109 CAPLUS
- (3) Bagby, G; J Appl Physiol 1994, V77, P1542 CAPLUS
- (4) Benigni, F; Mol Med 1995, V1, P568 CAPLUS
- (5) Breder, C; J Comp Neurol 1993, V337, P543 CAPLUS
- (6) Breitner, J; Annu Rev Med 1996, V47, P401 CAPLUS
- (7) Brosnan, C; Neurology 1995, V45(Suppl 6), PS16
- (8) Bruce, A; Nature Med 1996, V2, P788 CAPLUS
- (9) Di Santo, E; Cytokine 1997, V9, P300 CAPLUS
- (10) Di Santo, E; Eur J Pharmacol 1997, V336, P197 CAPLUS
- (11) Di Santo, E; Neuroimmunomodulation 1995, V2, P149 CAPLUS
- (12) Dickson, D; Glia 1993, V7, P75 MEDLINE
- (13) Dinarello, C; Am J Med 1982, V72, P799 CAPLUS
- (14) Dinarello, C; Rev Infect Dis 1988, V10, P168 CAPLUS
- (15) Faggioni, R; Infect Immun 1995, V63, P1473 CAPLUS
- (16) Fattori, E; J Exp Med 1994, V180, P1243 CAPLUS
- (17) Gahring, L; Neuroimmunomodulation 1996, V3, P289 CAPLUS
- (18) Grundmann, H; J Infect Dis 1992, V165, P501 CAPLUS
- (19) Haley, T; Br J Pharmacol 1957, V12, P12 CAPLUS
- (20) Honda, A; J Biol Chem 1993, V268, P7759 CAPLUS
- (21) Irani, D; J Immunol 1997, V158, P2318 CAPLUS
- (22) Knudsen, P; J Immunol 1986, V137, P3189 CAPLUS
- (23) Lipton, J; Peptides 1991, V12, P795 CAPLUS
- (24) Liu, T; Stroke 1994, V25, P1481 CAPLUS
- (25) Martich, G; J Exp Med 1991, V173, P1021 CAPLUS
- (26) Meistrell, M; Shock 1997, V8, P341
- (27) Mengozzi, M; Immunology 1994, V82, P207 CAPLUS
- (28) Mustafa, M; Am J Dis Child 1990, V144, P883 MEDLINE
- (29) Mustafa, M; J Clin Invest 1989, V84, P1253 CAPLUS
- (30) Nataf, S; Acta Neurol Scand 1993, V88, P97 CAPLUS
- (31) Noel, P; Life Sci 1990, V47, P1023 CAPLUS
- (32) Olsson, T; Neurology 1995, V45(Suppl 6), PS11
- (33) Reder, A; J Neuroimmunol 1994, V54, P117 CAPLUS
- (34) Renz, H; J Immunol 1988, V141, P2388 CAPLUS
- (35) Ruddle, N; J Exp Med 1990, V172, P1193 CAPLUS
- (36) Saez-Llorens, X; Antimicrob Agents Chemother 1990, V34, P837 CAPLUS
- (37) Saukkonen, K; J Exp Med 1990, V171, P439 CAPLUS
- (38) Schooltink, H; FEBS Lett 1992, V314, P280 CAPLUS
- (39) Selmaj, K; Neurology 1995, V45(Suppl 6), PS44
- (40) Shigeno, T; Surg Neurol 1985, V24, P47 MEDLINE
- (41) Sironi, M; Int J Immunopharmacol 1992, V14, P1045 CAPLUS
- (42) Sommer, N; Nature Med 1995, V1, P244 CAPLUS
- (43) Spengler, R; Infect Immun 1989, V57, P2837 CAPLUS
- (44) Stewart, W; Neurology 1997, V48, P626 MEDLINE
- (45) Sugimoto, Y; J Biol Chem 1992, V267, P6463 CAPLUS
- (46) Sugimoto, Y; Neuroscience 1994, V62, P919 CAPLUS
- (47) van der Poll, T; J Immunol 1995, V155, P5397 CAPLUS
- (48) Watabe, A; J Biol Chem 1993, V268, P20175 CAPLUS
- (49) Zuckerman, S; Eur J Immunol 1989, V19, P301 CAPLUS

=>

AN 1998:605885 CAPLUS
 DN 129:339797
 TI Influence of aspirin on nerve injury of experimental **cerebral ischemia** in rabbits
 AU Liu, Shi-Xiang; Hou, Jing-Bian; Yang, Qing-Zhou; Zhang, Jia-Lin; Huang, Li-Chun; Liang, Yan
 CS Dep. Neurol., Kunming Gen. Hosp., Kunming, 650032, Peop. Rep. China
 SO Zhongguo Bingli Shengli Zazhi (1997), 13(2), 162-164
 CODEN: ZBSZEB; ISSN: 1000-4718
 PB Jinan Daxue
 DT Journal
 LA Chinese
 CC 1-11 (Pharmacology)
 AB Platelet play an important role in **cerebral** ischemial nerve injury. Aspirin (ASA) had been used to treat and prevent stroke in clinic. 30 Rabbits were randomly divided into A, B and C groups. In group A ASA was given orally at a daily dosage of 15 mg/kg per rabbit for 5 days before **cerebral ischemia**; group B **cerebral ischemia** without giving ASA, and group C was normal rabbits as controls. The **cerebral** ischemial model was produced by occluding bilateral carotid arteries and bleeding from femoral artery. The results indicated that there was an obvious decrease of platelet aggregation and TXA2 and had no significance changes in free radicals increasing and Ca2+ rising from **cerebral** tissue in group A. The **cerebral** edema of group A was less severe than group B. It seemed that ASA had a protective effect on the nerve injury of **cerebral ischemia**. The derangement of ASA, platelet, free radicals and calcium ions interrelation and their significance on the nerve injury should be further studied.
 ST aspirin nerve injury brain **ischemia** TXA2
 IT Brain, disease
 (cerebral cortex, **ischemia**; influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)
 IT Platelet aggregation inhibitors
 (influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)
 IT Nerve, disease
 (injury; influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)
 IT Cytoprotective agents
 (neuroprotectants; influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)
 IT 50-78-2, Aspirin
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)
 IT 57576-52-0, Thromboxane A2
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)

=>

DN 126:14735
 TI Diaspirin cross-linked hemoglobin resuscitation improves cerebral
 perfusion after **head** injury and shock
 AU Chappell, James E.; McBride, Whitney J.; Shackford, Steven R.
 CS Department Surgery, University Vermont, Burlington, VT, 05401, USA
 SO Journal of Trauma: Injury, Infection, and Critical Care (1996), 41(5),
 781-788
 CODEN: JOTRFA; ISSN: 1079-6061
 PB Williams & Wilkins
 DT Journal
 LA English
 CC 1-12 (Pharmacology)
 AB Shock assocd. with traumatic brain injury (TBI) doubles the mortality of
 TBI alone by inducing a secondary ischemic injury. Rapid correction of
 cerebral perfusion pressure (CPP) is thought to be essential to improving
 outcome. Diaspirin cross-linked Hb (DCLHb) has been shown to improve
 cerebral blood flow, increase mean arterial pressure (MAP), and reduce
 lesion size in models of occlusive cerebral ischemia but has not been
 evaluated in a model of TBI combined with hemorrhagic shock. The authors
 studied the effects of DCLHb resuscitation in a porcine model of cryogenic
 TBI and hemorrhagic shock (MAP = 50 mmHg). After combined insults,
 animals were randomized to receive a bolus of 4 mL/kg of either lactated
 Ringer's soln. or DCLHb. Lactated Ringer's soln. was then infused in both
 groups to maintain MAP at baseline. Shed blood was returned 1 h after the
 initiation of resuscitation (R1). Animals were studied for 24 h. DCLHb
 infusion resulted in a significantly greater MAP at R1 and R24 (95 vs. 82
 and 99 vs. 85 mm Hg, resp.) and a significantly greater CPP at R1 and R24
 (83 vs. 68 and 89 vs. 71 mm Hg, resp.). Intracranial pressure was lower
 in the DCLHb group, but this difference was not significant. There was no
 significant difference between the groups in cerebral oxygen delivery.
 DCLHb animals required less fluid to maintain MAP (12,094 vs. 15,542 mL).
 These data suggest that DCLHb is beneficial in the early resuscitation of
head injury and shock and that further investigation is warranted.
 ST diaspirin crosslinked Hb brain **trauma** shock; resuscitation
 hemorrhagic shock diaspirin crosslinked Hb
 IT Hemoglobins
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (crosslinked, with diaspirin; diaspirin cross-linked Hb resuscitation
 improves cerebral perfusion after **head** injury and shock)
 IT Shock (circulatory collapse)
 (hemorrhagic; diaspirin cross-linked Hb resuscitation improves cerebral
 perfusion after **head** injury and shock)
 IT Respiration, animal
 Respiration, animal
 Therapy
 Therapy
 (resuscitation; diaspirin cross-linked Hb resuscitation improves
 cerebral perfusion after **head** injury and shock)
 IT Brain, disease
 (**trauma**; diaspirin cross-linked Hb resuscitation improves
 cerebral perfusion after **head** injury and shock)
 IT **578-19-8D**, Diaspirin, Hb cross-linked derivs.
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (diaspirin cross-linked Hb resuscitation improves cerebral perfusion
 after **head** injury and shock)

=>

NEWS 38 AUG 18 Simultaneous left and right truncation added to ANABSTR

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:07:02 ON 15 SEP 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:07:15 ON 15 SEP 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 SEP 2003 HIGHEST RN 585509-69-9

DICTIONARY FILE UPDATES: 14 SEP 2003 HIGHEST RN 585509-69-9

TSKA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> e acetaminophen

E1	1	ACETOMIDO/BI
E2	1	ACETOMIDOPHENYL/BI
E3	0 -->	ACETAMINOPHEN/BI
E4	2	ACETOMONO/BI
E5	1	ACETOMONOLAU/BI
E6	1	ACETOMONOLAU/BI
E7	1	ACETOMORPHIN/BI
E8	1	ACETOMORPHINE/BI
E9	7	ACETOMORPHOL/BI

E10	1	ACETOMORPHOLI/BI
E11	6	ACETOMORPHOLIDE/BI
E12	1	ACETOMORPHOLIDI/BI

=> e acetaminophen

E1	1	ACETOMIDO/BI
E2	1	ACETOMIDOPHENYL/BI
E3	0 -->	ACETAMINOPHEN/BI
E4	2	ACETOMONO/BI
E5	1	ACETOMONOLAU/BI
E6	1	ACETOMONOLAU/BI
E7	1	ACETOMORPHIN/BI
E8	1	ACETOMORPHINE/BI
E9	7	ACETOMORPHOL/BI
E10	1	ACETOMORPHOLI/BI
E11	6	ACETOMORPHOLIDE/BI
E12	1	ACETOMORPHOLIDI/BI

=> acetaminophen

ACETAMINOPHEN IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> e acetaminophen

E1	1	ACETOMIDO/BI
E2	1	ACETOMIDOPHENYL/BI
E3	0 -->	ACETAMINOPHEN/BI
E4	2	ACETOMONO/BI
E5	1	ACETOMONOLAU/BI
E6	1	ACETOMONOLAU/BI
E7	1	ACETOMORPHIN/BI
E8	1	ACETOMORPHINE/BI
E9	7	ACETOMORPHOL/BI
E10	1	ACETOMORPHOLI/BI
E11	6	ACETOMORPHOLIDE/BI
E12	1	ACETOMORPHOLIDI/BI

=> e nsaid

E1	2	NSAF/BI
E2	4	NSAH9/BI
E3	9 -->	NSAID/BI
E4	1	NSAN/BI
E5	1	NSANI/BI
E6	1	NSANIDI/BI
E7	1	NSANIDINE/BI
E8	2	NSANT1/BI
E9	6	NSAP1/BI
E10	16	NSB/BI
E11	2	NSB1/BI
E12	1	NSB105/BI

=> s e3

L1 9 NSAID/BI

=> d 11 9

L1 ANSWER 9 OF 9 REGISTRY COPYRIGHT 2003 ACS on STN

RN 204298-06-6 REGISTRY

CN **DNA (rat liver NSAID-regulated gene protein-specifying cDNA
594-nucleic acid) (9CI) (CA INDEX NAME)**

OTHER NAMES:

CN 8: PN: WO0138579 PAGE: 13 claimed DNA
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

=> d 11 1

L1 ANSWER 1 OF 9 REGISTRY COPYRIGHT 2003 ACS on STN
RN 534782-70-2 REGISTRY
CN DNA (human clone D104 gene KIAA0101 protein cDNA plus flanks) (9CI) (CA
INDEX NAME)

OTHER NAMES:

CN 2: PN: US20030100540 SEQID: 2 claimed DNA
CN **DNA (human clone D104 gene NRG-1 (NSAID regulated gene 1) protein
cDNA plus flanks)**
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

=> e aspirin

E1	1	ASPIRALIS/BI
E2	1	ASPIRDROPS/BI
E3	52 -->	ASPIRIN/BI
E4	2	ASPIRINA/BI
E5	1	ASPIRINATE/BI
E6	1	ASPIRISINE/BI
E7	11	ASPIRO/BI
E8	1	ASPIROCH/BI
E9	2	ASPIROCHLORINE/BI
E10	1	ASPIROCHOLINE/BI
E11	1	ASPIROCHYL/BI
E12	4	ASPIRYL/BI

=> s e3

L2 52 ASPIRIN/BI

=> e indomethacin

E1	1	INDOMETACINE/BI
E2	1	INDOMETHA/BI
E3	52 -->	INDOMETHACIN/BI
E4	1	INDOMETHACINATE/BI
E5	1	INDOMETHACINE/BI

E6	1	INDOMETHACINOYL/BI
E7	1	INDOMETHAPHEN/BI
E8	1	INDOMETHIN/BI
E9	1	INDOMETHINE/BI
E10	2	INDOMIDE/BI
E11	1	INDOMOD/BI
E12	1	INDOMOLYBDO/BI

=> s e3

L3	52	INDOMETHACIN/BI
----	----	-----------------

=> e ketoprofin

E1	1	KETOPROFENATO/BI
E2	1	KETOPROFENE/BI
E3	0 -->	KETOPROFIN/BI
E4	7	KETOPROGESTER/BI
E5	7	KETOPROGESTERONE/BI
E6	1	KETOPRON/BI
E7	1	KETOPROP/BI
E8	1	KETOPROPAMIDE/BI
E9	1	KETOPROPAN/BI
E10	1	KETOPROPANE/BI
E11	1	KETOPROPANOIC/BI
E12	2	KETOPROPHEN/BI

=> e ketoprofen

E1	2	KETOPRO/BI
E2	1	KETOPROF/BI
E3	50 -->	KETOPROFEN/BI
E4	1	KETOPROFENATO/BI
E5	1	KETOPROFENE/BI
E6	7	KETOPROGESTER/BI
E7	7	KETOPROGESTERONE/BI
E8	1	KETOPRON/BI
E9	1	KETOPROP/BI
E10	1	KETOPROPAMIDE/BI
E11	1	KETOPROPAN/BI
E12	1	KETOPROPANE/BI

=> s e3

L4	50	KETOPROFEN/BI
----	----	---------------

=> e trilisatr

E1	4	TRILISA/BI
E2	1	TRILISATE/BI
E3	0 -->	TRILISATR/BI
E4	12	TRILITH/BI
E5	12	TRILITHATE/BI
E6	1	TRILITHE/BI
E7	26	TRILITHIO/BI
E8	1	TRILITHIOAL/BI
E9	1	TRILITHIOALLEN/BI
E10	1	TRILITHIOALLENYL/BI
E11	2	TRILITHIOANILINE/BI
E12	2	TRILITHIOBENZENE/BI

=> e trilisate

E1	1	TRILIS/BI
E2	4	TRILISA/BI
E3	1 -->	TRILISATE/BI
E4	12	TRILITH/BI
E5	12	TRILITHATE/BI

```

E6          1      TRILITHE/BI
E7          26     TRILITHIO/BI
E8          1      TRILITHIOAL/BI
E9          1      TRILITHIOALLEN/BI
E10         1      TRILITHIOALLENYL/BI
E11         2      TRILITHIOANILINE/BI
E12         2      TRILITHIOBENZENE/BI

```

=> s e3

```

L5          1      TRILISATE/BI

```

=> s salicylamide

```

L6          1158   SALICYLAMIDE

```

=> s sodium salicylate

```

          274664   SODIUM
          2322    SALICYLATE
L7          30    SODIUM SALICYLATE
          (SODIUM(W) SALICYLATE)

```

=> s salicylic acid

```

          6741    SALICYLIC
          6074610 ACID
L8          6694   SALICYLIC ACID
          (SALICYLIC(W) ACID)

```

=> dhis

DHIS IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> his

HIS IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d his

(FILE 'HOME' ENTERED AT 15:07:02 ON 15 SEP 2003)

FILE 'REGISTRY' ENTERED AT 15:07:15 ON 15 SEP 2003

```

          E ACETOMINOPHEN
          E ACETOMINOPHEN
          E ACETOMINOPHEN
          E NSAID
L1          9 S E3
          E ASPIRIN
L2          52 S E3
          E INDOMETHACIN
L3          52 S E3
          E KETOPROFIN
          E KETOPROFEN
L4          50 S E3
          E TRILISATR
          E TRILISATE
L5          1 S E3
L6          1158 S SALICYLAMIDE
L7          30 S SODIUM SALICYLATE
L8          6694 S SALICYLIC ACID

```

=> e acetaminophen

E1	1	ACETOMIDO/BI
E2	1	ACETOMIDOPHENYL/BI
E3	0 -->	ACETAMINOPHEN/BI
E4	2	ACETOMONO/BI
E5	1	ACETOMONOLAU/BI
E6	1	ACETOMONOLAU/BI
E7	1	ACETOMORPHIN/BI
E8	1	ACETOMORPHINE/BI
E9	7	ACETOMORPHOL/BI
E10	1	ACETOMORPHOLI/BI
E11	6	ACETOMORPHOLIDE/BI
E12	1	ACETOMORPHOLIDI/BI

=> e acetaminophen

E1	1	ACETAMINOMETHYLBENZENESULFON/BI
E2	1	ACETAMINOMETHYLBENZENESULFONYL/BI
E3	130 -->	ACETAMINOPHEN/BI
E4	1	ACETAMINOPHENACYL/BI
E5	1	ACETAMINOPHENACYLMETHYL/BI
E6	16	ACETAMINOPHENOL/BI
E7	1	ACETAMINOPHENOXAZIN/BI
E8	16	ACETAMINOPHENOXOXY/BI
E9	1	ACETAMINOPHENOXOXYACET/BI
E10	1	ACETAMINOPHENOXOXYACETAMIDE/BI
E11	1	ACETAMINOPHENOXOXYETHYL/BI
E12	3	ACETAMINOPHENOXOXYMETHYL/BI

=> s e3

L9 130 ACETAMINOPHEN/BI

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	58.18	58.39

FILE 'CAPLUS' ENTERED AT 15:20:03 ON 15 SEP 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Sep 2003 VOL 139 ISS 12

FILE LAST UPDATED: 14 Sep 2003 (20030914/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 15:07:02 ON 15 SEP 2003)

FILE 'REGISTRY' ENTERED AT 15:07:15 ON 15 SEP 2003

E ACETOMINOPHEN
E ACETOMINOPHEN
E ACETOMINOPHEN
E NSAID
L1 9 S E3
E ASPIRIN
L2 52 S E3
E INDOMETHACIN
L3 52 S E3
E KETOPROFIN
E KETOPROFEN
L4 50 S E3
E TRILISATR
E TRILISATE
L5 1 S E3
L6 1158 S SALICYLAMIDE
L7 30 S SODIUM SALICYLATE
L8 6694 S SALICYLIC ACID
E ACETOMINOPHEN
E ACETAMINOPHEN
L9 130 S E3

FILE 'CAPLUS' ENTERED AT 15:20:03 ON 15 SEP 2003

=> s 12

L10 17725 L2

=> s cns

L11 28561 CNS

=> d l10 and l11

L11 IS NOT VALID HERE

For an explanation, enter "HELP DISPLAY".

=> s l10 and l11

L12 28 L10 AND L11

=> d l12 10-28

L12 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:780621 CAPLUS

DN 130:232124

TI Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the **CNS** [central nervous system]

AU Hauss-Wegrzyniak, Beatrice; Willard, Lauren B.; Del Soldato, Piero; Pepeu, Giancarlo; Wenk, Gary L.

CS Memory and Aging, Division of Neural Systems, Arizona Research Laboratories, University of Arizona, Tucson, AZ, 85724, USA

SO Brain Research (1999), 815(1), 36-43

CODEN: BRREAP; ISSN: 0006-8993

PB Elsevier Science B.V.

DT Journal

LA English

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:43243 CAPLUS

DN 128:149902

TI Modulation of Brewer's yeast-induced peripheral inflammation and
nociception in rats by centrally administered prostaglandins and their
inhibitors
AU Hore, S. K.; Dumka, V. K.; Tandan, S. K.; Tripathi, H. C.; Kumar, Dinesh
CS Division of Pharmacology and Toxicology, Indian Veterinary Research
Institute, Izatnagar, 243 122, India
SO Indian Journal of Pharmacology (1997), 29(6), 416-419
CODEN: INJPD2; ISSN: 0253-7613
PB Indian Pharmacological Society
DT Journal
LA English
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:646511 CAPLUS
DN 125:276575
TI Preparation of arginine analogs having nitric oxide synthase inhibitor
activity
IN Broquet, Colette; Chabrier, De Lassauniere, Pierre-Etienne
PA Societe De Conseils De Recherches Et D'application, Fr.
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9627593	A1	19960912	WO 1996-FR337	19960304
	W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN			
	CA 2215476	AA	19960912	CA 1996-2215476	19960304
	AU 9649479	A1	19960923	AU 1996-49479	19960304
	AU 700871	B2	19990114		
	EP 813529	A1	19971229	EP 1996-905907	19960304
	EP 813529	B1	20020911		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, IE, SI, LT, LV, FI			
	CN 1179774	A	19980422	CN 1996-192885	19960304
	CN 1071328	B	20010919		
	JP 11501043	T2	19990126	JP 1996-526657	19960304
	RU 2168493	C2	20010610	RU 1997-116496	19960304
	AT 223907	E	20020915	AT 1996-905907	19960304
	CZ 290747	B6	20021016	CZ 1997-2687	19960304
	SK 282664	B6	20021106	SK 1997-1121	19960304
	ES 2182964	T3	20030316	ES 1996-905907	19960304
	US 5972940	A	19991026	US 1997-913455	19970910
	HK 1013777	A1	20020705	HK 1998-110921	19980924
PRAI	GB 1995-4350	A	19950304		
	WO 1996-FR337	W	19960304		
OS	MARPAT 125:276575				

L12 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:245721 CAPLUS
DN 125:48415
TI Effect of NM441 and its active form on GABA receptor binding
AU Hori, Seiji; Shimada, Jingoro
CS Div. Clin. Pharmacol. Inst. Med. Sci., St. Marianna Univ. Sch. Med.,
Kawasaki, 216, Japan

SO Nippon Kagaku Ryoho Gakkai Zasshi (1996), 44(Suppl. 1), 97-101
 CODEN: NKRZE5; ISSN: 1340-7007
 DT Journal
 LA Japanese

L12 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1995:365390 CAPLUS
 DN 122:204992
 TI Neuronal expression of FOS protein in the nucleus tractus solitarii and the dorsal motor nucleus of the vagus nerve after i.p. injection of ulcerogenic aspirin
 AU Takahashi, Akio; Miura, Mitsuhiro
 CS Department of Physiology 1st Division, Gunma University School of Medicine, 3-39-22 Showa-machi, Maebashi-shi, 371, Japan
 SO Neuroscience Letters (1995), 185(3), 214-16
 CODEN: NELED5; ISSN: 0304-3940
 PB Elsevier
 DT Journal
 LA English

L12 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1994:499126 CAPLUS
 DN 121:99126
 TI Mechanism of quinolone-induced convulsion and anticonvulsant effect of barbiturate for this seizure
 AU Kanemitsu, Keiji
 CS Dep. Intern. Med. and Lab. Med., St. Marianna Univ. Sch. Med., Kawasaki, 216, Japan
 SO Sei Marianna Ika Daigaku Zasshi (1993), 21(6), 1177-85
 CODEN: SMIZDS; ISSN: 0387-2289
 DT Journal
 LA Japanese

L12 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1993:573380 CAPLUS
 DN 119:173380
 TI Acetylsalicylic acid and related compounds depress nociceptive activity in the thalamus by a central action: indications for the involvement of prostaglandins
 AU Jurna, I.
 CS Inst. Pharmakol. Toxikol., Univ. Saarlandes, Homburg/Saar, D-6650, Germany
 SO Progress in Pharmacology and Clinical Pharmacology (1993), 10(1), 51-68
 CODEN: PPCPEP; ISSN: 0934-9545
 DT Journal; General Review
 LA English

L12 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1992:676 CAPLUS
 DN 116:676
 TI Central analgesic effects of acetylsalicylic acid in healthy men
 AU Bromm, B.; Rundshagen, I.; Scharein, E.
 CS Inst. Physiol., Univ. Hosp. Eppendorf, Hamburg, W-2000/20, Germany
 SO Arzneimittel-Forschung (1991), 41(11), 1123-9
 CODEN: ARZNAD; ISSN: 0004-4172
 DT Journal
 LA English

L12 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1990:91116 CAPLUS
 DN 112:91116
 TI Effects of pentazocine and acetylsalicylic acid on pain-rating, pain-related evoked potentials and vigilance in relationship to

pharmacokinetic parameters

AU Kobal, G.; Hummel, C.; Nuernberg, B.; Brune, K.
CS Inst. Pharmakol. Toxikol., Univ. Erlangen-Nuernberg, Erlangen, D-8520,
Germany
SO Agents and Actions (1990), 29(3-4), 342-59
CODEN: AGACBH; ISSN: 0065-4299
DT Journal
LA English

L12 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1987:60703 CAPLUS

DN 106:60703

TI In vitro metabolism of teratogens by differentiating rat embryo cells

AU Brown, L. P.; Flint, O. P.; Orton, T. C.; Gibson, G. G.

CS Biochem. Dep., Univ. Surrey, Guildford/Surrey, GU2 5XH, UK

SO Food and Chemical Toxicology (1986), 24(6-7), 737-42

CODEN: FCTOD7; ISSN: 0278-6915

DT Journal

LA English

L12 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1985:73624 CAPLUS

DN 102:73624

TI An in vitro assay for teratogens with cultures of rat embryo midbrain and
limb bud cells

AU Flint, O. P.; Orton, T. C.

CS Saf. Med. Dep., Imp. Chem. Ind. PLC, Macclesfield/Cheshire, SK10 4TG, UK

SO Toxicology and Applied Pharmacology (1984), 76(2), 383-95

CODEN: TXAPA9; ISSN: 0041-008X

DT Journal

LA English

L12 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1981:114385 CAPLUS

DN 94:114385

TI The antipyretic effects of aminopyrine and sodium acetylsalicylate on
endotoxin-induced fever in rabbits

AU Nishio, Akira; Kanoh, Seizaburo

CS Fac. Agric., Kagoshima Univ., Kagoshima, 890, Japan

SO Nippon Yakurigaku Zasshi (1981), 77(1), 9-13

CODEN: NYKZAU; ISSN: 0015-5691

DT Journal

LA Japanese

L12 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1979:535333 CAPLUS

DN 91:135333

TI Prostaglandin synthetase inhibitors antagonize the depressant effects of
ethanol

AU George, Frank R.; Collins, Allan C.

CS Inst. Behav. Genet., Univ. Colorado, Boulder, CO, 80309, USA

SO Pharmacology, Biochemistry and Behavior (1979), 10(6), 865-9

CODEN: PBBHAU; ISSN: 0091-3057

DT Journal

LA English

L12 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1978:499779 CAPLUS

DN 89:99779

TI Pharmacological characterization of benzodiazepine receptors in the brain

AU Braestrup, Claus; Squires, Richard F.

CS Res. Lab., A/S Ferrosan, Soeborg, Den.

SO European Journal of Pharmacology (1978), 48(3), 263-70
 CODEN: EJPHAZ; ISSN: 0014-2999
 DT Journal
 LA English

L12 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1975:601968 CAPLUS
 DN 83:201968
 TI Mechanism of the synaptic effects of morphine, indomethacin, and
 prostaglandins
 AU Ehrenpreis, Seymour; Greenberg, Joel
 CS New York State Res. Inst. Neurochem. Drug Addict., New York, NY, USA
 SO Clin. Pharmacol. Psychoact. Drugs, [Proc. Int. Symp. Alcohol Drug Res.]
 (1975), Meeting Date 1973, 171-82. Editor(s): Sellers, E. M. Publisher:
 Alcohol. Drug Addit. Res. Found., Toronto, Can.
 CODEN: 31QKAO
 DT Conference
 LA English

L12 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1972:107738 CAPLUS
 DN 76:107738
 TI Drug interactions. **CNS** [central nervous system] drugs
 analgesics and antipyretics
 AU Hartshorn, Edward A.
 CS Pharm. Serv., Evanston Hosp., Evanston, IL, USA
 SO Drug Intelligence (1971), 5(11), 356-60
 CODEN: DRUIA6; ISSN: 0012-6578
 DT Journal; General Review
 LA English

L12 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1969:113689 CAPLUS
 DN 70:113689
 TI N-Aralkylanthranilic acid derivatives as **CNS** [central nervous
 system] depressants
 AU Sisodia, P.; Rao, G. S. Rama; Sidhu, Gurbachan S.; Sattur, Prolhad B.;
 Hashim, Riaz
 CS Gandhi Med. Coll., Hyderabad, India
 SO CNS (Cent. Nerv. Syst.) Drugs, Symp. (1966), 238-48 Publisher: Counc. Sci.
 and Ind. Res., New Delhi, India.
 CODEN: 20REAT
 DT Conference
 LA English

L12 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1968:113200 CAPLUS
 DN 68:113200
 TI Drug effects on electrically induced extensor seizures and clinical
 implications
 AU Chen, Graham; Ensor, Charles R.; Bohner, Barbara
 CS Parke, Davis and Co., Ann Arbor, MI, USA
 SO Archives Internationales de Pharmacodynamie et de Therapie (1968), 172(1),
 183-218
 CODEN: AIPTAK; ISSN: 0003-9780
 DT Journal
 LA English

L12 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1962:15164 CAPLUS
 DN 56:15164
 OREF 56:2857g-i,2858a

TI Classification of **CNS** drugs by a mouse screening battery
AU Bastian, J. W.
CS Armour Pharmaceutical Co., Kankakee, IL
SO Archives Internationales de Pharmacodynamie et de Therapie (1961), 133,
347-64
CODEN: AIPTAK; ISSN: 0003-9780
DT Journal
LA Unavailable

=> e trauma

E1	1	TRAULVETTERI/BI
E2	2	TRAUM/BI
E3	11866 -->	TRAUMA/BI
E4	6	TRAUMACEL/BI
E5	1	TRAUMAFID/BI
E6	1	TRAUMAFUSIN/BI
E7	1	TRAUMAHEMORRHAGE/BI
E8	1	TRAUMAINDUCED/BI
E9	1	TRAUMAN/BI
E10	1	TRAUMANET/BI
E11	13	TRAUMANN/BI
E12	1	TRAUMAPLAST/BI

=> s e3

L13 11866 TRAUMA/BI

=> s l13 and l10

L14 68 L13 AND L10

=> e head

E1	2	HEACY/BI
E2	1	HEACYCLEN/BI
E3	94345 -->	HEAD/BI
E4	1	HEAD00/BI
E5	3	HEAD1/BI
E6	1	HEAD103A/BI
E7	1	HEAD107/BI
E8	1	HEAD12/BI
E9	1	HEAD12HAVING/BI
E10	1	HEAD12OF/BI
E11	1	HEAD13/BI
E12	1	HEAD1ALONG/BI

=> s e3

L15 94345 HEAD/BI

=> s l14 and l15

L16 12 L14 AND L15

=> d l16 1-12

L16 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:883043 CAPLUS

DN 137:345844

TI Intracranial complications of preinjury anticoagulation in **trauma**
patients with **head** injury

AU Mina, Alfred A.; Knipfer, John F.; Park, David Y.; Bair, Holly A.;
Howells, Greg A.; Bendick, Phillip J.

CS Division of Trauma Surgery and the Department of Surgery, William Beaumont
Hospital, Royal Oak, MI, 48073, USA

SO Journal of Trauma: Injury, Infection, and Critical Care (2002), 53(4),

668-672

CODEN: JOTRFA; ISSN: 1079-6061

PB Lippincott Williams & Wilkins

DT Journal

LA English

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:588980 CAPLUS

DN 137:135080

TI Modification of NSAIDs by sulfur-containing functional groups

IN Lai, Ching-San; Wang, Tingmin

PA Medinox, Inc., USA

SO U.S., 27 pp., Cont.-in-part of U.S. Ser. No. 602,688.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6429223	B1	20020806	US 2000-715767	20001117
	US 6355666	B1	20020312	US 2000-602688	20000623
	WO 2002000167	A2	20020103	WO 2001-US19750	20010619
	WO 2002000167	A3	20020404		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,				
	RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,				
	UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001070010	A5	20020108	AU 2001-70010	20010619
	EP 1296929	A2	20030402	EP 2001-948537	20010619
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003088111	A1	20030508	US 2002-97197	20020312
PRAI	US 2000-602688	A2	20000623		
	US 2000-715767	A1	20001117		
	WO 2001-US19750	W	20010619		

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:488246 CAPLUS

DN 137:57576

TI Methods and compositions using ion-dependent cotransporter modulators for
treating conditions of the central and peripheral nervous systems using
non-synaptic mechanisms

IN Hochman, Daryl W.

PA Cytoscan Sciences L.L.C., USA

SO U.S. Pat. Appl. Publ., 29 pp., Cont.-in-part of U.S. Ser. No. 470,637.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002082252	A1	20020627	US 2002-56528	20020123
	US 6495601	B1	20021217	US 1999-470637	19991222

PRAI US 1998-113620P P 19981223
US 1999-470637 A2 19991222
US 2001-263830P P 20010123

L16 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:438743 CAPLUS
DN 137:41504
TI Antiplatelet therapy: an alternative to heparin for blunt carotid injury
AU Wahl, Wendy L.; Brandt, Mary-Margaret; Thompson, B. Gregory; Taheri, Paul
A.; Greenfield, Lazar J.
CS Division of Trauma Burn and Emergency Surgery, University of Michigan
Health System, Ann Arbor, MI, 48109-0033, USA
SO Journal of Trauma: Injury, Infection, and Critical Care (2002), 52(5),
896-901
CODEN: JOTRFA; ISSN: 1079-6061
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:772458 CAPLUS
DN 133:317566
TI A composition and method for treatment of cerebral ischemia using caffeine
and alcohol
IN Grotta, James C.; Strong, Roger A.; Aronowski, Jaroslaw Adam
PA Board of Regents, the University of Texas System, USA
SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000064448	A1	20001102	WO 2000-US10692	20000420
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI US 1999-131166P P 19990427
RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:556279 CAPLUS
DN 132:48501
TI Brain TXA2 and PGI2 levels related to diffuse brain injury with secondary
insults
AU Zhou, Fei; Xiang, Zhang; Yu, Yi Sheng; Jun, Song Shao; Piper, I. R.;
Thomson, D.; Miller, J. D.
CS Department of Neurosurgery, Xijing Hospital, Xian, 710032, Peop. Rep.
China
SO Journal of Clinical Neuroscience (1999), 6(4), 306-308
CODEN: JCNUE6; ISSN: 0967-5868
PB Churchill Livingstone
DT Journal

LA English

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:705957 CAPLUS

DN 129:298400

TI Method using citicoline for protecting brain tissue from cerebral
infarction subsequent to ischemia

IN Sandage, Bobby W., Jr.; Fisher, Marc; Locke, Kenneth W.

PA Interneuron Pharmaceuticals, Inc., USA

SO U.S., 12 pp., Cont.-in-part of U.S. Ser. No. 603,102.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5827832	A	19981027	US 1996-609448	19960301
	US 5872108	A	19990216	US 1996-603102	19960220
	CA 2213000	AA	19960912	CA 1996-2213000	19960306
	WO 9627380	A1	19960912	WO 1996-US3159	19960306
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
	AU 9653047	A1	19960923	AU 1996-53047	19960306
	BR 9607206	A	19971111	BR 1996-7206	19960306
	EP 813416	A1	19971229	EP 1996-909616	19960306
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1181015	A	19980506	CN 1996-193176	19960306
	JP 11511732	T2	19991012	JP 1996-527057	19960306
	NZ 337305	A	20010427	NZ 1996-337305	19960306
	PL 185124	B1	20030228	PL 1996-322061	19960306
	NO 9704076	A	19971028	NO 1997-4076	19970904
PRAI	US 1995-399262	B2	19950306		
	US 1996-603102	A2	19960220		
	US 1996-609448	A	19960301		
	NZ 1996-305114	A1	19960306		
	WO 1996-US3159	W	19960306		

RE.CNT 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:527193 CAPLUS

DN 129:166193

TI Therapeutic treatment and prevention of infections with a bioactive
material encapsulated within a biodegradable-biocompatible polymeric
matrix

IN Setterstrom, Jean A.; Van Hamont, John E.; Reid, Robert H.; Jacob, Elliot;
Jeyanthi, Ramasubbu; Boedeker, Edgar C.; McQueen, Charles E.; Tice, Thomas
R.; Roberts, F. Donald; Friden, Phil

PA United States Dept. of the Army, USA; Van Hamont, John E.; et al.

SO PCT Int. Appl., 363 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 15

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	WO 9832427	A1	19980730	WO 1998-US1556	19980127
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	US 6309669	B1	20011030	US 1997-789734	19970127
	AU 9863175	A1	19980818	AU 1998-63175	19980127
PRAI	US 1997-789734	A	19970127		
	US 1984-590308	B1	19840316		
	US 1992-867301	A2	19920410		
	US 1995-446148	A2	19950522		
	US 1995-446149	B2	19950522		
	US 1996-590973	B2	19960124		
	WO 1998-US1556	W	19980127		

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:47183 CAPLUS
DN 126:99089
TI Effect of hemodilution with diaspirin cross-linked hemoglobin on intracranial pressure, cerebral perfusion pressure, and fluid requirements after **head** injury and shock
AU Chappell, James E.; Shackford, Steven R.; McBride, Whitney J.
CS College Medicine, University Vermont, Burlington, VT, USA
SO Journal of Neurosurgery (1997), 86(1), 131-138
CODEN: JONSAC; ISSN: 0022-3085
PB American Association of Neurological Surgeons
DT Journal
LA English

L16 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:735900 CAPLUS
DN 126:14735
TI Diaspirin cross-linked hemoglobin resuscitation improves cerebral perfusion after **head** injury and shock
AU Chappell, James E.; McBride, Whitney J.; Shackford, Steven R.
CS Department Surgery, University Vermont, Burlington, VT, 05401, USA
SO Journal of Trauma: Injury, Infection, and Critical Care (1996), 41(5), 781-788
CODEN: JOTRFA; ISSN: 1079-6061
PB Williams & Wilkins
DT Journal
LA English

L16 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:660964 CAPLUS
DN 125:293028
TI Reduction of infarct volume using citicoline
IN Sandage, Bobby Winston; Fisher, Marc; Locke, Kenneth W.
PA Interneuron Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	WO 9627380	A1	19960912	WO 1996-US3159	19960306
	W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI			
	RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML			
	US 5872108	A	19990216	US 1996-603102	19960220
	US 5827832	A	19981027	US 1996-609448	19960301
	AU 9653047	A1	19960923	AU 1996-53047	19960306
	BR 9607206	A	19971111	BR 1996-7206	19960306
	EP 813416	A1	19971229	EP 1996-909616	19960306
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	JP 11511732	T2	19991012	JP 1996-527057	19960306
	PL 185124	B1	20030228	PL 1996-322061	19960306
	NO 9704076	A	19971028	NO 1997-4076	19970904
PRAI	US 1995-399262	A	19950306		
	US 1996-603102	A	19960220		
	US 1996-609448	A	19960301		
	WO 1996-US3159	W	19960306		

L16 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1974:514759 CAPLUS
DN 81:114759
TI Effect of aspirin on bleeding time and survival of rats after **head trauma**
AU Davis, James W.; Phillips, Phyllis E.; Ellison, June M.; Lucas, Shannon R.
CS Hematol. Res. Lab., VA Hosp., Kansas City, MO, USA
SO Journal of Medicine (Westbury, NY, United States) (1974), 5(5), 229-33
CODEN: JNMDBO; ISSN: 0025-7850
DT Journal
LA English

=> d 116 10 all

L16 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:735900 CAPLUS
DN 126:14735
TI Diaspirin cross-linked hemoglobin resuscitation improves cerebral perfusion after **head** injury and shock
AU Chappell, James E.; McBride, Whitney J.; Shackford, Steven R.
CS Department Surgery, University Vermont, Burlington, VT, 05401, USA
SO Journal of Trauma: Injury, Infection, and Critical Care (1996), 41(5), 781-788
CODEN: JOTRFA; ISSN: 1079-6061
PB Williams & Wilkins
DT Journal
LA English
CC 1-12 (Pharmacology)
AB Shock assocd. with traumatic brain injury (TBI) doubles the mortality of TBI alone by inducing a secondary ischemic injury. Rapid correction of cerebral perfusion pressure (CPP) is thought to be essential to improving outcome. Diaspirin cross-linked Hb (DCLHb) has been shown to improve cerebral blood flow, increase mean arterial pressure (MAP), and reduce lesion size in models of occlusive cerebral ischemia but has not been evaluated in a model of TBI combined with hemorrhagic shock. The authors studied the effects of DCLHb resuscitation in a porcine model of cryogenic TBI and hemorrhagic shock (MAP = 50 mmHg). After combined insults, animals were randomized to receive a bolus of 4 mL/kg of either lactated

Ringer's soln. or DCLHb. Lactated Ringer's soln. was then infused in both groups to maintain MAP at baseline. Shed blood was returned 1 h after the initiation of resuscitation (R1). Animals were studied for 24 h. DCLHb infusion resulted in a significantly greater MAP at R1 and R24 (95 vs. 82 and 99 vs. 85 mm Hg, resp.) and a significantly greater CPP at R1 and R24 (83 vs. 68 and 89 vs. 71 mm Hg, resp.). Intracranial pressure was lower in the DCLHb group, but this difference was not significant. There was no significant difference between the groups in cerebral oxygen delivery. DCLHb animals required less fluid to maintain MAP (12,094 vs. 15,542 mL). These data suggest that DCLHb is beneficial in the early resuscitation of **head** injury and shock and that further investigation is warranted.

- ST diaspirin crosslinked Hb brain **trauma** shock; resuscitation
- hemorrhagic shock diaspirin crosslinked Hb
- IT Hemoglobins
- RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
- (crosslinked, with diaspirin; diaspirin cross-linked Hb resuscitation improves cerebral perfusion after **head** injury and shock)
- IT Shock (circulatory collapse)
- (hemorrhagic; diaspirin cross-linked Hb resuscitation improves cerebral perfusion after **head** injury and shock)
- IT Respiration, animal
- Respiration, animal
- Therapy
- Therapy
- (resuscitation; diaspirin cross-linked Hb resuscitation improves cerebral perfusion after **head** injury and shock)
- IT Brain, disease
- (**trauma**; diaspirin cross-linked Hb resuscitation improves cerebral perfusion after **head** injury and shock)
- IT **578-19-8D**, Diaspirin, Hb cross-linked derivs.
- RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
- (diaspirin cross-linked Hb resuscitation improves cerebral perfusion after **head** injury and shock)

=> d 116 9 all

- L16 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN
- AN 1997:47183 CAPLUS
- DN 126:99089
- TI Effect of hemodilution with diaspirin cross-linked hemoglobin on intracranial pressure, cerebral perfusion pressure, and fluid requirements after **head** injury and shock
- AU Chappell, James E.; Shackford, Steven R.; McBride, Whitney J.
- CS College Medicine, University Vermont, Burlington, VT, USA
- SO Journal of Neurosurgery (1997), 86(1), 131-138
- CODEN: JONSAC; ISSN: 0022-3085
- PB American Association of Neurological Surgeons
- DT Journal
- LA English
- CC 1-8 (Pharmacology)
- AB Hemodilution has been shown to increase cerebral blood flow (CBF) and reduce lesion vol. in models of occlusive cerebral ischemia, but it has not been evaluated in the setting of **head trauma** and shock in which ischemia is thought to play a role in the evolution of secondary injury. In a porcine model of brain injury and shock the authors compared hemodilution with diaspirin cross-linked Hb (DCLHb) to a std. resuscitation regimen using Ringer's lactate soln. and shed blood.

After creation of a cryogenic brain injury followed by hemorrhage, the animals received a bolus of either 4 mL/kg of Ringer's lactate soln. (Group 1, six animals) or DCLHb (Group 2, six animals), followed by infusion of Ringer's lactate soln. to restore mean arterial pressure (MAP) to baseline. Group 1 received shed blood 1 h after hemorrhage (R1) in the form of packed red blood cells. Group 2 received shed blood only for an Hb count of less than 5 g/dL. The animals were monitored for 24 h. At R1, Group 2 had a significantly greater cerebral perfusion pressure ([CPP] 88 \pm 5.7 vs. 68 \pm 2.4 mm Hg, $p < 0.05$). By 3 h after hemorrhage (R3) Group 2 had a significantly lower Hb concn. (8.5 \pm 0.4 vs. 12.1 \pm 0.3 g/dL, $p < 0.05$) and a significantly lower intracranial pressure ([ICP] 9 \pm 0.8 vs. 14 \pm 0.6 mm Hg, $p < 0.05$). The total 24-h fluid requirement was significantly less in Group 2 (10,654 \pm 505 mL vs. 15,542 \pm 1094 mL, $p < 0.05$). There was no difference between the groups regarding levels of regional CBF in the injured hemisphere. Cerebral O₂ delivery was not significantly different between groups at any time. Lesion vol. as detd. at postmortem examn. was not significantly different between the groups. The increased MAP and CPP and lower ICP obsd. in the Group 2 animals indicate that hemodilution with DCLHb may be beneficial in the treatment of **head** injury and shock.

- ST hemodilution diaspirin crosslinked Hb cerebral circulation; **head**
injury shock hemodilution diaspirin Hb; cerebral ischemia shock
hemodilution diaspirin Hb
- IT Circulation
(cerebral; hemodilution with diaspirin cross-linked Hb effect on
intracranial pressure, cerebral perfusion pressure, and fluid
requirements after **head** injury and shock)
- IT Hemoglobins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(diaspirin cross-linked; hemodilution with diaspirin cross-linked Hb
effect on intracranial pressure, cerebral perfusion pressure, and fluid
requirements after **head** injury and shock)
- IT Blood
(diln.; hemodilution with diaspirin cross-linked Hb effect on
intracranial pressure, cerebral perfusion pressure, and fluid
requirements after **head** injury and shock)
- IT Shock (circulatory collapse)
(hemodilution with diaspirin cross-linked Hb effect on intracranial
pressure, cerebral perfusion pressure, and fluid requirements after
head injury and shock)
- IT **Head**
(injury; hemodilution with diaspirin cross-linked Hb effect on
intracranial pressure, cerebral perfusion pressure, and fluid
requirements after **head** injury and shock)
- IT Brain, disease
(ischemia; hemodilution with diaspirin cross-linked Hb effect on
intracranial pressure, cerebral perfusion pressure, and fluid
requirements after **head** injury and shock)
- IT **578-19-8, Diaspirin**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(cross-linked Hb; hemodilution with diaspirin cross-linked Hb effect on
intracranial pressure, cerebral perfusion pressure, and fluid
requirements after **head** injury and shock)

=> d 116 7 all

AN 1998:705957 CAPLUS
 DN 129:298400
 TI Method using citicoline for protecting brain tissue from cerebral
 infarction subsequent to ischemia
 IN Sandage, Bobby W., Jr.; Fisher, Marc; Locke, Kenneth W.
 PA Interneuron Pharmaceuticals, Inc., USA
 SO U.S., 12 pp., Cont.-in-part of U.S. Ser. No. 603,102.
 CODEN: USXXAM
 DT Patent
 LA English
 IC ICM A61K031-70
 NCL 514049000
 CC 1-11 (Pharmacology)
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5827832	A	19981027	US 1996-609448	19960301
	US 5872108	A	19990216	US 1996-603102	19960220
	CA 2213000	AA	19960912	CA 1996-2213000	19960306
	WO 9627380	A1	19960912	WO 1996-US3159	19960306
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
	AU 9653047	A1	19960923	AU 1996-53047	19960306
	BR 9607206	A	19971111	BR 1996-7206	19960306
	EP 813416	A1	19971229	EP 1996-909616	19960306
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1181015	A	19980506	CN 1996-193176	19960306
	JP 11511732	T2	19991012	JP 1996-527057	19960306
	NZ 337305	A	20010427	NZ 1996-337305	19960306
	PL 185124	B1	20030228	PL 1996-322061	19960306
	NO 9704076	A	19971028	NO 1997-4076	19970904
PRAI	US 1995-399262	B2	19950306		
	US 1996-603102	A2	19960220		
	US 1996-609448	A	19960301		
	NZ 1996-305114	A1	19960306		
	WO 1996-US3159	W	19960306		

AB The invention is directed to a method of reducing the extent of infarction, particularly cerebral infarction subsequent to cerebral ischemia, by the administration of citicoline shortly after an ischemic episode and continuing daily treatment for up to about 30 days, preferably for at least about 6 wk. The method is useful in the treatment of stroke and severe **head trauma** patients and maximizes the chances for a full or substantially full recovery of the patient. Combination treatment regimens are also disclosed along with compns. for use therewith.

ST postischemic cerebral infarction citicoline

IT Anti-ischemic agents

Ischemia

(citicoline for protecting brain tissue from cerebral infarction subsequent to ischemia)

IT Brain, disease

(infarction; citicoline for protecting brain tissue from cerebral infarction subsequent to ischemia)

IT Brain, disease

(ischemia; citicoline for protecting brain tissue from cerebral infarction subsequent to ischemia)

IT Brain, disease

(stroke; citicoline for protecting brain tissue from cerebral infarction subsequent to ischemia)

IT Head

(trauma; citicoline for protecting brain tissue from cerebral infarction subsequent to ischemia)

IT 50-78-2, Aspirin 58-32-2, Dipyridamole 9002-01-1, Streptokinase 9039-53-6, Urokinase 139639-23-9, Tissue plasminogen activator

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(citicoline and second agent for protecting brain tissue from cerebral infarction subsequent to ischemia)

IT 987-78-0, Citicoline

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(citicoline for protecting brain tissue from cerebral infarction subsequent to ischemia)

RE.CNT 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Aguilar; Arzneimittel Forschung-Drug Research 1983, V33(II), P1051
- (2) Agut; Arzneimittel Forschung-Drug Research 1983, V33(II), P1016
- (3) Agut; Arzneimittel Forschung-Drug Research 1983, V33(II), P1029
- (4) Agut; Arzneimittel Forschung-Drug Research 1983, V33(II), P1045
- (5) Agut; Arzneimittel Forschung-Drug Research 1983, V33(II), P1048
- (6) Algate; Arzneimittel Forschung-Drug Research 1983, V33(II), P1013
- (7) Altman, R; British Medical Journal 1994, V308, P81
- (8) Arrannz; Arzneimittel Forschung-Drug Research 1983, V33(II), P1071
- (9) Barinaga; Science 1996, V272, P664 CAPLUS
- (10) Bell, R; Stroke 1991, V22, P80 MEDLINE
- (11) Braso; Arzneimittel Forschung-Drug Research 1983, V33(II), P1043
- (12) Budavari; The Merck Index (11th Ed) 1989, P361
- (13) Buyukuysal, R; Journal of Neurochemistry 1990, V54(4), P1302 CAPLUS
- (14) de Medio, G; Journal of Neuroscience Research 1984, V11, P49 CAPLUS
- (15) Del Zoppo, G; Seminars in Neurology 1991, V11(4), P368 MEDLINE
- (16) Demeurisse, G; Stroke 1983, V14(1), P77 MEDLINE
- (17) Diener, H; Stroke 1995, V26, P30
- (18) Dinsdale; Arzneimittel Forschung-Drug Research 1983, V33(II), P1061
- (19) Dinsdale; Arzneimittel Forschung-Drug Research 1983, V33(II), P1066
- (20) D'Orlando, K; Neurological Research 1995, V17, P281 CAPLUS
- (21) Fernandez; Arzneimittel Forschung-Drug Research 1983, V33(II), P1073
- (22) Fukunaga; Anesthesia and Analgesia 1982, V61(3), P273 CAPLUS
- (23) Gannaro; Remington's Pharmaceutical Sciences, 18th ed 1990, P867
- (24) Grau; Arzneimittel Forschung-Drug Research 1983, V33(II), P1025
- (25) Grau; Arzneimittel Forschung-Drug Research 1983, V33(II), P1033
- (26) Grosset, D; Journal of Cardiovascular Pharmacology 1995, V25(5), P705 CAPLUS
- (27) Grotta, J; Stroke 1987, V18(1), P264 MEDLINE
- (28) Hacke, W; Stroke 1995, V26, P167
- (29) Horrocks; US 4386078 1983 CAPLUS
- (30) Johannes, W; European Stroke Conference 1995
- (31) Kakihana; CAPLUS 1988:143195 1988
- (32) Kaste, M; Stroke 1994, V25, P1348 MEDLINE
- (33) Kinouchi, H; Proc Natl Acad Sci USA 1991, V88, P11158 CAPLUS
- (34) Kogure, K; Annals of Neurology 1980, V8(3), P278 CAPLUS
- (35) Kottler, P; Physiology and Behavior 1992, V8, P291
- (36) Lo, E; Neuroscience Letters 1991, V131, P17 CAPLUS
- (37) Longa, Z; Stroke 1989, V20, P84
- (38) Makishima; Arzneimittel Forsch Dtsh 1971, V21(9), P1343 MEDLINE
- (39) McCulloch, J; Acta Neurochir 1993, V57(Suppl), P73
- (40) Minematsu, K; Cerebrovasc Dis 1993, V3, P99

- (41) Nilsson; Clin Pharmacol Drug Epidemiol 1979, V2, P273 CAPLUS
- (42) Ochiai, C; Stroke 1982, V13(6), P788 CAPLUS
- (43) Olney, J; Science 1991, V254, P1515 CAPLUS
- (44) Ortiz, J; Arzneimittel Forschung-Drug Research 1983, V33(II), P1009
- (45) Petkov, V; Effects of Cytidine Diphosphate Choline on Rats with Memory Deficits
- (46) Phuong; Bull Soc Chim Fr Pt II 1979, 9-10, P518
- (47) Romero; Arzneimittel Forschung-Drug Research 1983, V33(II), P1035
- (48) Romero; Arzneimittel Forschung-Drug Research 1983, V33(II), P1038
- (49) Romero; Arzneimittel Forschung-Drug Research 1983, V33(II), P1054
- (50) Romero; Arzneimittel Forschung-Drug Research 1983, V33(II), P1056
- (51) Romero; Arzneimittel Forschung-Drug Research 1983, V33(II), P1058
- (52) Rossi, M; No publication given 1993
- (53) Sanchez; Arzneimittel Forschung-Drug Research 1983, V33(II), P1011
- (54) Savci, V; Journal of Neurochemistry 1995, V64(1), P378 CAPLUS
- (55) Schabitz, W; Journal of the Neurological Sciences 1996, V138, P21 CAPLUS
- (56) The Ancrod Stroke Study Investigators; Stroke 1994, V25, P1755
- (57) The Ancrod Study Investigators; Stroke 1994, V25, P1755
- (58) The Canadian Cooperative Study Group; New England Journal of Medicine 1978, V299, P53
- (59) The Esps Group; Stroke 1990, V21, P1122
- (60) Tornos; Arzneimittel Forschung-Drug Research 1983, V33(II), P1018
- (61) Tornos; Arzneimittel Forschung-Drug Research 1983, V33(II), P1022
- (62) Tornos; Arzneimittel Forschung-Drug Research 1983, V33(II), P1026
- (63) Trovarelli, G; Neurochemical Research 1982, V7(10), P1199 CAPLUS
- (64) Trovarelli, G; Neurochemical Research 1984, V9(1), P73 CAPLUS
- (65) Trovarelli, G; Neurochemical Research 1987, V12(3), P227 CAPLUS
- (66) Tuor, U; Stroke 1993, V24(3), P452 CAPLUS
- (67) Ulus, I; Brain Research 1989, V484, P217 CAPLUS
- (68) Windholtz; The Merck Index, 19th Ed 1983, P329
- (69) Wurtman, R; The 'Autocannibalism' of Choline-Containing Membrane Phospholipids in the Pathogenesis of Alzheimer's Disease

=> e ischemia

E1	6	ISCHELIUM/BI
E2	142	ISCHEM/BI
E3	9 -->	ISCHEMA/BI
E4	1	ISCHEMAI/BI
E5	1	ISCHEMATIC/BI
E6	1	ISCHEME/BI
E7	2	ISCHEMI/BI
E8	53068	ISCHEMIA/BI
E9	2	ISCHEMIAC/BI
E10	1	ISCHEMIAIN/BI
E11	1	ISCHEMIAINDUCED/BI
E12	3	ISCHEMIAL/BI

=> s e5-e8

	1	ISCHEMATIC/BI
	1	ISCHEME/BI
	2	ISCHEMI/BI
	53068	ISCHEMIA/BI
L17	53069	(ISCHEMATIC/BI OR ISCHEME/BI OR ISCHEMI/BI OR ISCHEMIA/BI)

=> s l17 and l10

L18 356 L17 AND L10

=> sd his

SD IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> d his

(FILE 'HOME' ENTERED AT 15:07:02 ON 15 SEP 2003)

FILE 'REGISTRY' ENTERED AT 15:07:15 ON 15 SEP 2003

```

      E ACETOMINOPHEN
      E ACETOMINOPHEN
      E ACETOMINOPHEN
      E NSAID
L1      9 S E3
      E ASPIRIN
L2      52 S E3
      E INDOMETHACIN
L3      52 S E3
      E KETOPROFIN
      E KETOPROFEN
L4      50 S E3
      E TRILISATR
      E TRILISATE
L5      1 S E3
L6      1158 S SALICYLAMIDE
L7      30 S SODIUM SALICYLATE
L8      6694 S SALICYLIC ACID
      E ACETOMINOPHEN
      E ACETAMINOPHEN
L9      130 S E3
```

FILE 'CAPLUS' ENTERED AT 15:20:03 ON 15 SEP 2003

```

L10     17725 S L2
L11     28561 S CNS
L12     28 S L10 AND L11
      E TRAUMA
L13     11866 S E3
L14     68 S L13 AND L10
      E HEAD
L15     94345 S E3
L16     12 S L14 AND L15
      E ISCHEMA
L17     53069 S E5-E8
L18     356 S L17 AND L10
```

=> e cerebral

```

E1      1      CEREBRACIDE/BI
E2      1      CEREBRAE/BI
E3      78138 --> CEREBRAL/BI
E4      1      CEREBRALCRAST/BI
E5      1      CEREBRALCYST/BI
E6      5      CEREBRALE/BI
E7      4      CEREBRALECTOMIZED/BI
E8      2      CEREBRALEN/BI
E9      3      CEREBRALES/BI
E10     1      CEREBRALHEMISPHERES/BI
E11     29     CEREBRALIS/BI
E12     2      CEREBRALIZATION/BI
```

=> s e3

L19 78138 CEREBRAL/BI

=> s 118 and 19

407853 19

L20 14 L18 AND 19

=> s 118 and 119

L21 66 L18 AND L19

=> d 121 40-66

L21 ANSWER 40 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:705957 CAPLUS

DN 129:298400

TI Method using citicoline for protecting brain tissue from **cerebral**
infarction subsequent to **ischemia**

IN Sandage, Bobby W., Jr.; Fisher, Marc; Locke, Kenneth W.

PA Interneuron Pharmaceuticals, Inc., USA

SO U.S., 12 pp., Cont.-in-part of U.S. Ser. No. 603,102.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5827832	A	19981027	US 1996-609448	19960301
	US 5872108	A	19990216	US 1996-603102	19960220
	CA 2213000	AA	19960912	CA 1996-2213000	19960306
	WO 9627380	A1	19960912	WO 1996-US3159	19960306
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
	AU 9653047	A1	19960923	AU 1996-53047	19960306
	BR 9607206	A	19971111	BR 1996-7206	19960306
	EP 813416	A1	19971229	EP 1996-909616	19960306
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1181015	A	19980506	CN 1996-193176	19960306
	JP 11511732	T2	19991012	JP 1996-527057	19960306
	NZ 337305	A	20010427	NZ 1996-337305	19960306
	PL 185124	B1	20030228	PL 1996-322061	19960306
	NO 9704076	A	19971028	NO 1997-4076	19970904
PRAI	US 1995-399262	B2	19950306		
	US 1996-603102	A2	19960220		
	US 1996-609448	A	19960301		
	NZ 1996-305114	A1	19960306		
	WO 1996-US3159	W	19960306		

RE.CNT 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 41 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:605885 CAPLUS

DN 129:339797

TI Influence of aspirin on nerve injury of experimental **cerebral**
ischemia in rabbits

AU Liu, Shi-Xiang; Hou, Jing-Bian; Yang, Qing-Zhou; Zhang, Jia-Lin; Huang, Li-Chun; Liang, Yan

CS Dep. Neurol., Kunming Gen. Hosp., Kuming, 650032, Peop. Rep. China

SO Zhongguo Bingli Shengli Zazhi (1997), 13(2), 162-164

CODEN: ZBSZEB; ISSN: 1000-4718

PB Jinan Daxue

DT Journal

LA Chinese

L21 ANSWER 42 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:605876 CAPLUS
 DN 129:339796
 TI Effects of acetylsalicylic acid on **cerebral** and cardiac function during thrombotic **cerebral ischemia**
 AU Li, Shu Qing; Zou, Lian-Fang
 CS Dep. Pathophysiology, Kunming Med. Coll., Kunming, 650031, Peop. Rep. China
 SO Zhongguo Bingli Shengli Zazhi (1997), 13(2), 158-161
 CODEN: ZBSZEB; ISSN: 1000-4718
 PB Jinan Daxue
 DT Journal
 LA Chinese

L21 ANSWER 43 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:523321 CAPLUS
 DN 129:239678
 TI Potential application of copper aspirinate in preventing and treating thromboembolic diseases
 AU Liu, Weiping; Xiong, Huizhou; Yang, Yikun; Li, Ling; Shen, Zhiqiang; Chen, Zhihe
 CS Institute of Precious Metals, Kunming, 650221, Peop. Rep. China
 SO Metal-Based Drugs (1998), 5(3), 123-126
 CODEN: MBADEI; ISSN: 0793-0291
 PB Freund Publishing House Ltd.
 DT Journal
 LA English

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 44 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:137657 CAPLUS
 DN 128:278783
 TI Risk factors and antiplatelet therapy in TIA and stroke patients
 AU Puranen, Juha; Laakso, Markku; Riekkinen, Paaavo; Sivenius, Juhani
 CS Department of Neurology, Kuopio University, Kuopio, Finland
 SO Journal of the Neurological Sciences (1998), 154(2), 200-204
 CODEN: JNSCAG; ISSN: 0022-510X
 PB Elsevier Science B.V.
 DT Journal
 LA English

RE.CNT 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 45 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:97670 CAPLUS
 DN 128:212696
 TI Intravenously administered acetylsalicylic acid in combination with low-dose heparin in acute ischemic stroke: a safety analysis
 AU Buttner, Th.; Hellwig, K.; Muller, Th.; Kuhn, W.
 CS Department of Neurology, St. Josef-Hospital Bochum, Ruhr-University, Bochum, D-44791, Germany
 SO Clinical Neuropharmacology (1998), 21(1), 48-51
 CODEN: CLNEDB; ISSN: 0362-5664
 PB Lippincott-Raven Publishers
 DT Journal
 LA English

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 46 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:14862 CAPLUS
DN 128:136304
TI A randomized trial of anticoagulants versus aspirin after **cerebral ischemia** of presumed arterial origin
CS Stroke Prevention in Reversible Ischemia trial (SPIRIT) Study Group, Neth.
SO Annals of Neurology (1997), 42(6), 857-865
CODEN: ANNED3; ISSN: 0364-5134
PB Lippincott-Raven Publishers
DT Journal
LA English
RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 47 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:7118 CAPLUS
DN 128:110606
TI Experimental subarachnoid hemorrhage in rats: effect of intravenous .alpha.-.alpha. diaspirin crosslinked hemoglobin on hypoperfusion and neuronal death
AU Cole, Daniel J.; Nary, Jeffrey C.; Reynolds, Lowell W.; Patel, Piyush M.; Drummond, John C.
CS Departments of Anesthesiology, Loma Linda University, Loma Linda, CA, USA
SO Anesthesiology (1997), 87(6), 1486-1493
CODEN: ANESAV; ISSN: 0003-3022
PB Lippincott-Raven Publishers
DT Journal
LA English
RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 48 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:413643 CAPLUS
DN 127:144994
TI Prevention of thromboembolic events in atrial fibrillation
AU Gade Koefoed, Birgitte; Lemche Gullov, Annette; Petersen, Palle
CS AFASAK 2 Study Center, Copenhagen, DK-1112, Den.
SO Thrombosis and Haemostasis (1997), 78(1), 377-381
CODEN: THHADQ; ISSN: 0340-6245
PB Schattauer
DT Journal
LA English

L21 ANSWER 49 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:266014 CAPLUS
DN 126:301593
TI .alpha.-.alpha. Diaspirin crosslinked hemoglobin, nitric oxide, and **cerebral** ischemic injury in rats
AU Cole, D. J.; Nary, J. C.; Drummond, J. C.; Patel, P. M.; Jacobsen, W. K.
CS Sch. Med., Loma Linda Univ., Loma Linda, CA, 92354, USA
SO Artificial Cells, Blood Substitutes, and Immobilization Biotechnology (1997), 25(1 & 2), 141-152
CODEN: ABSBE4; ISSN: 1073-1199
PB Dekker
DT Journal
LA English

L21 ANSWER 50 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:47183 CAPLUS
DN 126:99089
TI Effect of hemodilution with diaspirin cross-linked hemoglobin on intracranial pressure, **cerebral** perfusion pressure, and fluid requirements after head injury and shock

AU Chappell, James E.; Shackford, Steven R.; McBride, Whitney J.
 CS College Medicine, University Vermont, Burlington, VT, USA
 SO Journal of Neurosurgery (1997), 86(1), 131-138
 CODEN: JONSAC; ISSN: 0022-3085
 PB American Association of Neurological Surgeons
 DT Journal
 LA English

L21 ANSWER 51 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1996:735900 CAPLUS
 DN 126:14735
 TI Diaspirin cross-linked hemoglobin resuscitation improves **cerebral**
 perfusion after head injury and shock
 AU Chappell, James E.; McBride, Whitney J.; Shackford, Steven R.
 CS Department Surgery, University Vermont, Burlington, VT, 05401, USA
 SO Journal of Trauma: Injury, Infection, and Critical Care (1996), 41(5),
 781-788
 CODEN: JOTRFA; ISSN: 1079-6061
 PB Williams & Wilkins
 DT Journal
 LA English

L21 ANSWER 52 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1996:660964 CAPLUS
 DN 125:293028
 TI Reduction of infarct volume using citicoline
 IN Sandage, Bobby Winston; Fisher, Marc; Locke, Kenneth W.
 PA Interneuron Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9627380	A1	19960912	WO 1996-US3159	19960306
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML				
	US 5872108	A	19990216	US 1996-603102	19960220
	US 5827832	A	19981027	US 1996-609448	19960301
	AU 9653047	A1	19960923	AU 1996-53047	19960306
	BR 9607206	A	19971111	BR 1996-7206	19960306
	EP 813416	A1	19971229	EP 1996-909616	19960306
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 11511732	T2	19991012	JP 1996-527057	19960306
	PL 185124	B1	20030228	PL 1996-322061	19960306
	NO 9704076	A	19971028	NO 1997-4076	19970904
PRAI	US 1995-399262	A	19950306		
	US 1996-603102	A	19960220		
	US 1996-609448	A	19960301		
	WO 1996-US3159	W	19960306		

L21 ANSWER 53 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1996:520215 CAPLUS
 DN 125:212206
 TI Effect of oncotic pressure of diaspirin cross-linked hemoglobin (DCLHb) on
 brain injury after temporary focal **cerebral ischemia**

in rats

AU Cole, Daniel J.; Drummond, John C.; Patel, Piyush M.; Nary, Jeffrey C.;
Applegate, Richard L. II

CS Departments Anesthesiology, Loma Linda University, Loma Linda, CA, 92354,
USA

SO Anesthesia & Analgesia (Baltimore) (1996), 83(2), 342-347
CODEN: AACRAT; ISSN: 0003-2999

PB Williams & Wilkins

DT Journal

LA English

L21 ANSWER 54 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1996:72079 CAPLUS

DN 124:164820

TI A rat middle **cerebral** artery thrombosis model for evaluation of
thrombolytic and antithrombotic agents

AU Liu, X. G.; Xu, L. N.

CS Inst. Materia Medica, Chin. Acad. Med. Sci., Beijing, 100050, Peop. Rep.
China

SO Yaoxue Xuebao (1995), 30(9), 662-7
CODEN: YHHPAL; ISSN: 0513-4870

PB Chinese Academy of Medical Sciences, Institute of Materia Media

DT Journal

LA Chinese

L21 ANSWER 55 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1995:867995 CAPLUS

DN 123:274896

TI The efficacy of aspirin administration on ischemic cerebrovascular disease

AU Hamano, Hitoshi; Shinohara, Yukito

CS Sch. Med., Tokai Univ., Isehara, 259-11, Japan

SO Sogo Rinsho (1995), 44(10), 2397-401
CODEN: SORIAX; ISSN: 0371-1900

DT Journal; General Review

LA Japanese

L21 ANSWER 56 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1994:645651 CAPLUS

DN 121:245651

TI Diaspirin crosslinked hemoglobin (DCLHb): effect of hemodilution during
focal **cerebral ischemia** in rats

AU Cole, D.J.; Schell, R.M.; Drummond, J.C.

CS Department of Anesthesiology, Loma Linda University, Loma Linda, CA,
92354, USA

SO Artificial Cells, Blood Substitutes, and Immobilization Biotechnology
(1994), 22(3), 813-18
CODEN: ABSBE4; ISSN: 1073-1199

DT Journal

LA English

L21 ANSWER 57 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1993:662355 CAPLUS

DN 119:262355

TI Effect of policosanol on **cerebral ischemia** in
Mongolian gerbils: role of prostacyclin and thromboxane A2

AU Arruzazabala, M. L.; Molina, V.; Carbajal, D.; Valdes, S.; Mas, R.

CS Cent. Nat. Prod., CNIC, Havana, Cuba

SO Prostaglandins, Leukotrienes and Essential Fatty Acids (1993), 49(2),
695-7
CODEN: PLEAEU; ISSN: 0952-3278

DT Journal

LA English

L21 ANSWER 58 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1993:139579 CAPLUS
 DN 118:139579
 TI Focal **cerebral ischemia** in rats: effect of
 hypovolemic hemodilution with diaspirin cross-linked hemoglobin versus
 albumin on brain injury and edema
 AU Cole, Daniel J.; Schell, Randall M.; Drummond, John C.; Reynolds, Lowell
 CS Dep. Anesthesiol., Loma Linda Univ., Loma Linda, CA, USA
 SO Anesthesiology (1993), 78(2), 335-42
 CODEN: ANESAV; ISSN: 0003-3022
 DT Journal
 LA English

L21 ANSWER 59 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1992:584681 CAPLUS
 DN 117:184681
 TI EEG and higher nervous activity alterations in rats during anti-ischemic
 brain protection with atselizin
 AU Tel'pukhov, V. I.; Bilenko, M. V.; Khokhlov, A. V.; Komarov, P. G.
 CS All-Union Sci. Surg. Cent., Russia
 SO Byulleten Eksperimental'noi Biologii i Meditsiny (1992), 113(3), 245-7
 CODEN: BEBMAE; ISSN: 0365-9615
 DT Journal
 LA Russian

L21 ANSWER 60 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1991:505705 CAPLUS
 DN 115:105705
 TI Effects of triflusal and acetylsalicylic acid on microthrombi formation
 in experimental brain **ischemia**
 AU Heye, N.; Campos, A.; Kannuki, S.; Cervos-Navarro, J.
 CS Inst. Neuropathol., Free Univ., Berlin, W-1000/45, Germany
 SO Experimental Pathology (1991), 41(1), 31-6
 CODEN: EXPADD; ISSN: 0232-1513
 DT Journal
 LA English

L21 ANSWER 61 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1986:491040 CAPLUS
 DN 105:91040
 TI Effect of cilostazol on experimental **cerebral** infarction in
 rabbits
 AU Watanabe, K.; Nakase, H.; Kimura, Y.
 CS Tokushima Res. Inst., Otsuka Pharm. Co., Ltd., Tokushima, Japan
 SO Arzneimittel-Forschung (1986), 36(7), 1022-4
 CODEN: ARZNAD; ISSN: 0004-4172
 DT Journal
 LA English

L21 ANSWER 62 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1985:55873 CAPLUS
 DN 102:55873
 TI Central and peripheral hemodynamic effects of non-steroidal
 anti-inflammatory drugs in man
 AU Wennmalm, A.; Carlsson, I.; Edlund, A.; Eriksson, S.; Kaijser, L.; Nowak,
 J.
 CS Dep. Clin. Physiol., Karolinska Inst., Stockholm, 104 01, Swed.
 SO Archives of Toxicology, Supplement (1984), 7(Dis. Metab. Reprod. Toxic
 Response Drugs Other Chem.), 350-9
 CODEN: ATSUDG; ISSN: 0171-9750
 DT Journal

LA English

L21 ANSWER 63 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1983:173886 CAPLUS
DN 98:173886
TI Measurement of plasma thromboxane B2 in ischemic cerebrovascular diseases
AU Shimada, Yukihiro; Sakurai, Heiichiro
CS Med. Sch., Tokyo Univ., Tokyo, Japan
SO Rinsho Kagaku Shinpojumu (1981), 21, 63-7
CODEN: RKASDA; ISSN: 0386-3417
DT Journal
LA Japanese

L21 ANSWER 64 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1979:413741 CAPLUS
DN 91:13741
TI Platelet emboli and **ischemia** in rabbit's brain caused by ADP or arachidonic acid and the protective effect of ASA and dipyridamole
AU Fieschi, C.; Volante, F.
CS Clin. Malattie Nerv. Ment., Univ. Siena, Siena, Italy
SO Biochemistry and Experimental Biology (1977), 13(3), 315-19
CODEN: BEXBBO; ISSN: 0366-0060
DT Journal
LA English

L21 ANSWER 65 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1979:115447 CAPLUS
DN 90:115447
TI Acetylsalicylic Acid in **Cerebral Ischemia** and Coronary Heart Disease. [Proceedings of the 5th Colfarit Symposium, Berlin, 1977]
AU Breddin, Klaus; Dorndorf, W.; Loew, D.; Marx, R.; Editors
CS Fed. Rep. Ger.
SO (1978) Publisher: (F. K. Schattauer Verlag, Stuttgart, Ger.), 176 pp.
DT Book
LA English

L21 ANSWER 66 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1978:44925 CAPLUS
DN 88:44925
TI Experimental observations on platelet emboli in focal brain **ischemia**
AU Fieschi, C.; Volante, F.; Battistini, N.; Zanette, E.
CS Dep. Neurol. Psychiatry, Univ. Siena, Siena, Italy
SO Platelet Aggregation Pathog. Cerebrovasc. Disord., Proc. Round Table Conf. (1977), Meeting Date 1974, 87-92. Editor(s): Agnoli, Alessandro; Fazio, Cornelio. Publisher: Springer, Berlin, Ger.
CODEN: 36WKAL
DT Conference
LA English

=>

=> d 121 30-39

L21 ANSWER 30 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:306966 CAPLUS
DN 132:317825
TI Low molecular-weight heparin versus aspirin in patients with acute ischemic stroke and atrial fibrillation: a double-blind randomized study
AU Berge, E.; Abdelnoor, M.; Nakstad, P. H.; Sandset, P. M.; Abdelnoor, M.; Abildgaard, U.; Indredavik, B.; Nakstad, P. H.; Russell, D.; Smith, G.; Pedersen, T. R.; Arnesen, H.; Dahl, T.; Nordal, H.; Nakstad, P. H.;

Johnsen, U.; Smith, G.; Gjestvang, F. T.; Bjornstad, K.; Holo, L.; Solhoff, R.; Jorgensen, E. B.; Lofsnæs, I. L.; Svendsen, T. J.; Naess, H.; Ofstad, R.; Kvambe, V.; Urnes, S.; Heggdal, H.; Hareide, S.; Dahl-Eriksen, O.; Saggurthi, D.; Bergo, F.; Moen, F.; Eriksen, L.; Kildahl-Andersen, O.; Thomassen, L.; Graesdal, A.; Ellekjaer, E.; Vejle, A.; Berget, K.; Asak, T.; Brandt, E.; Omland, T.; Holm, B.; Olavsen, J.; Rian, U.; Rana; Nesje, P.; Johnsen, S. H.; Indredavik, B.; Pettersen, A. A.; Thoresen, L.; Krogseth, S. B.; Karlsson, A. G.; Skogen, O. R.; Bondevik, A.; Bergqvist, F.; Larssen-Aas, F.; Spønning, A. B.; Ronning, Y.; Andersen, A.; Berge, E.; Rygh, J.; Sjobrend, K.; Friis, P.; Skogen, P.

CS Department of Haematology, Haematological Research Laboratory, Ulleval University Hospital, Oslo, N-0407, Norway

SO Lancet (2000), 355(9211), 1205-1210

CODEN: LANCAO; ISSN: 0140-6736

PB Lancet Ltd.

DT Journal

LA English

RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 31 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:165906 CAPLUS

DN 132:202882

TI Randomized pilot trial of postoperative aspirin in subarachnoid hemorrhage

AU Hop, J. W.; Rinkel, G. J. E.; Algra, A.; Van Der Sprenkel, J. W. Berkelbach; Van Gijn, J.

CS University Department of Neurology, Utrecht, 3508 GA, Neth.

SO Neurology (2000), 54(4), 872-878

CODEN: NEURAI; ISSN: 0028-3878

PB Lippincott Williams & Wilkins

DT Journal

LA English

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 32 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2000:144772 CAPLUS

DN 132:189689

TI Bioconjugative conjugates for drug targeting

IN Adams, Ged; Blake, David; Naughton, Declan; Stratford, Ian

PA Theramark Limited, UK; Adams, Margaret

SO PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000010610	A2	20000302	WO 1999-GB2606	19990819
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9954296	A1	20000314	AU 1999-54296	19990819
PRAI	GB 1998-18027	A	19980819		
	GB 1998-18156	A	19980820		
	WO 1999-GB2606	W	19990819		

OS MARPAT 132:189689

L21 ANSWER 33 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:790325 CAPLUS
DN 132:303188
TI Protective effect of aspirin against local **cerebral ischemia** in rats and its mechanism of action
AU Lin, Chun; Zheng, Shuqiu; Chen, Chonghong; Yan, Guangmei
CS Dept of Pharmacology, Sun Yat-sen University of Medical Sciences, Canton, 510080, Peop. Rep. China
SO Zhongguo Yaolixue Tongbao (1999), 15(5), 418-421
CODEN: ZYTOE8; ISSN: 1001-1978
PB Anhui Yike Daxue Linchuan Yaoli Yanjiuso
DT Journal
LA Chinese

L21 ANSWER 34 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:685959 CAPLUS
DN 132:18712
TI Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus
AU Baik, E. J.; Kim, E. J.; Lee, S. H.; Moon, C.-H.
CS School of Medicine, Department of Physiology, Ajou University, Suwon, S. Korea
SO Brain Research (1999), 843(1-2), 118-129
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier Science B.V.
DT Journal
LA English

RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 35 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:501659 CAPLUS
DN 131:138720
TI Aspirin and heparin in acute ischemic stroke in older patients
AU Gubitz, Gordon J.; Sandercock, Peter A. G.
CS Neurosciences Trials Unit, Department of Clinical Neurosciences, The University of Edinburgh, Edinburgh, UK
SO Drugs & Aging (1999), 15(1), 29-36
CODEN: DRAGE6; ISSN: 1170-229X
PB Adis International Ltd.
DT Journal; General Review
LA English

RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 36 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:406725 CAPLUS
DN 131:194178
TI Primary hypoxic tolerance and chemical preconditioning during estrus cycle in mice
AU Kasischke, Karl; Huber, Roman; Li, Hongge; Timmler, Melanie; Riepe, Matthias W.
CS Department of Neurology, University of Ulm, Ulm, Germany
SO Stroke (1999), 30(6), 1256-1262
CODEN: SJCCA7; ISSN: 0039-2499
PB Lippincott Williams & Wilkins
DT Journal
LA English

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 37 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:373742 CAPLUS
 DN 131:208862
 TI Neuroprotective effects of acetylsalicylic acid in an animal model of focal brain **ischemia**
 AU Khayyam, Naiyar; Thavendiranathan, Paaladinesh; Carmichael, F. J.; Kus, Bart; Jay, Venita; Burnham, W. McIntyre
 CS Department of Pharmacology and Bloorview Epilepsy Program, University of Toronto, Toronto, ON, M5S 1A8, Can.
 SO NeuroReport (1999), 10(2), 371-374
 CODEN: NERPEZ; ISSN: 0959-4965
 PB Lippincott Williams & Wilkins
 DT Journal
 LA English

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 38 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:247624 CAPLUS
 DN 130:305927
 TI Antiplatelet therapy in acute **cerebral ischemia**
 AU Bednar, Martin M.; Gross, Cordell E.
 CS Divisions of Neurosurgery and Surgical Research and the Department of, University of Vermont, Burlington, VT, 05405, USA
 SO Stroke (1999), 30(4), 887-893
 CODEN: SJCCA7; ISSN: 0039-2499
 PB Lippincott Williams & Wilkins
 DT Journal; General Review
 LA English

RE.CNT 99 THERE ARE 99 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L21 ANSWER 39 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:88971 CAPLUS
 DN 131:521
 TI Effects of butylphthalide on extracellular 6-keto-PGF1.alpha., TXB2 and 6-keto-PGF1.alpha./TXB2 ratio in cultured rat cortical neurons
 AU Yan, Chaohua; Feng, Yipu
 CS Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, Peop. Rep. China
 SO Yaoxue Xuebao (1998), 33(12), 881-885
 CODEN: YHHPAL; ISSN: 0513-4870
 PB Chinese Academy of Medical Sciences, Institute of Materia Media
 DT Journal
 LA Chinese

=> d 121 60 all

L21 ANSWER 60 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1991:505705 CAPLUS
 DN 115:105705
 TI Effects of triflusal and acetylsalicylic acid on microthrombi formation in experimental brain **ischemia**
 AU Heye, N.; Campos, A.; Kannuki, S.; Cervos-Navarro, J.
 CS Inst. Neuropathol., Free Univ., Berlin, W-1000/45, Germany
 SO Experimental Pathology (1981) (1991), 41(1), 31-6
 CODEN: EXPADD; ISSN: 0232-1513
 DT Journal
 LA English
 CC 1-8 (Pharmacology)

AB Ischemic **cerebral** infarcts induce hypercoagulation and microthrombosis, thus leading to vessel occlusion and redn. of local **cerebral** blood flow. Antiaggregant therapy can reduce the formation of microthrombi. The authors tested the effect of acetylsalicylic acid (ASA) and triflusal (2-acetoxy-4-trifluoromethylbenzoic acid) on the formation of microthrombi after middle **cerebral** artery (MCA) occlusion. Six groups of rats, each consisting of six animals received either ASA or triflusal at dosages of 12.5, 25, or 50 mg/L 1000 g b.wt./day. One control group was sham-operated, in another control group MCA occlusion was performed; both groups received no therapy. The no. of microthrombi was counted 7 days after MCA occlusion on paraffin sections. The highest no. of microthrombi was found in the group with MCAO and without therapy (mean 28 microthrombi/animal). In treated groups a redn. of the no. of microthrombi could be stated. The strongest redn. was achieved in the group treated with 12.5 mg triflusal (mean 5.2). No difference in the no. of microthrombi was found between the groups treated with 12.5 mg triflusal and 50 mg ASA (mean 8.7) compared to sham-operated control animals (mean 4.3). Treatment with 12.5 mg triflusal was superior to 50 mg ASA in preventing microthrombi formation. These results indicate, that in exptl. brain **ischemia** the no. of microthrombi can be effectively reduced by application of antiaggregatory drugs.

ST triflusal acetylsalicyllate brain **ischemia** microthrombus

IT Brain, disease or disorder
(**ischemia**, brain microthrombi formation induced by, treatment of, with acetylsalicyllate or triflusal)

IT Thrombus and Blood clot
(micro-, treatment of brain **ischemia**-induced, with acetylsalicylic or triflusal)

IT 50-78-2, Acetylsalicylic acid 322-79-2, Triflusal

RL: BIOL (Biological study)
(brain **ischemia**-induced brain microthrombus treatment with)

=> d 121 51 all

L21 ANSWER 51 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1996:735900 CAPLUS

DN 126:14735

TI Diaspirin cross-linked hemoglobin resuscitation improves **cerebral** perfusion after head injury and shock

AU Chappell, James E.; McBride, Whitney J.; Shackford, Steven R.

CS Department Surgery, University Vermont, Burlington, VT, 05401, USA

SO Journal of Trauma: Injury, Infection, and Critical Care (1996), 41(5), 781-788

CODEN: JOTRFA; ISSN: 1079-6061

PB Williams & Wilkins

DT Journal

LA English

CC 1-12 (Pharmacology)

AB Shock assocd. with traumatic brain injury (TBI) doubles the mortality of TBI alone by inducing a secondary ischemic injury. Rapid correction of **cerebral** perfusion pressure (CPP) is thought to be essential to improving outcome. Diaspirin cross-linked Hb (DCLHb) has been shown to improve **cerebral** blood flow, increase mean arterial pressure (MAP), and reduce lesion size in models of occlusive **cerebral ischemia** but has not been evaluated in a model of TBI combined with hemorrhagic shock. The authors studied the effects of DCLHb resuscitation in a porcine model of cryogenic TBI and hemorrhagic shock (MAP = 50 mmHg). After combined insults, animals were randomized to receive a bolus of 4 mL/kg of either lactated Ringer's soln. or DCLHb. Lactated Ringer's soln. was then infused in both groups to maintain MAP at

baseline. Shed blood was returned 1 h after the initiation of resuscitation (R1). Animals were studied for 24 h. DCLHb infusion resulted in a significantly greater MAP at R1 and R24 (95 vs. 82 and 99 vs. 85 mm Hg, resp.) and a significantly greater CPP at R1 and R24 (83 vs. 68 and 89 vs. 71 mm Hg, resp.). Intracranial pressure was lower in the DCLHb group, but this difference was not significant. There was no significant difference between the groups in **cerebral** oxygen delivery. DCLHb animals required less fluid to maintain MAP (12,094 vs. 15,542 mL). These data suggest that DCLHb is beneficial in the early resuscitation of head injury and shock and that further investigation is warranted.

- ST diaspirin crosslinked Hb brain trauma shock; resuscitation hemorrhagic shock diaspirin crosslinked Hb
- IT Hemoglobins
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (crosslinked, with diaspirin; diaspirin cross-linked Hb resuscitation improves **cerebral** perfusion after head injury and shock)
- IT Shock (circulatory collapse)
 (hemorrhagic; diaspirin cross-linked Hb resuscitation improves **cerebral** perfusion after head injury and shock)
- IT Respiration, animal
 Respiration, animal
 Therapy
 Therapy
 (resuscitation; diaspirin cross-linked Hb resuscitation improves **cerebral** perfusion after head injury and shock)
- IT Brain, disease
 (trauma; diaspirin cross-linked Hb resuscitation improves **cerebral** perfusion after head injury and shock)
- IT 578-19-8D, Diaspirin, Hb cross-linked derivs.
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (diaspirin cross-linked Hb resuscitation improves **cerebral** perfusion after head injury and shock)

=> d 121 41 all

- L21 ANSWER 41 OF 66 CAPLUS COPYRIGHT 2003 ACS on STN
- AN 1998:605885 CAPLUS
- DN 129:339797
- TI Influence of aspirin on nerve injury of experimental **cerebral ischemia** in rabbits
- AU Liu, Shi-Xiang; Hou, Jing-Bian; Yang, Qing-Zhou; Zhang, Jia-Lin; Huang, Li-Chun; Liang, Yan
- CS Dep. Neurol., Kunming Gen. Hosp., Kunming, 650032, Peop. Rep. China
- SO Zhongguo Bingli Shengli Zazhi (1997), 13(2), 162-164
 CODEN: ZBSZEB; ISSN: 1000-4718
- PB Jinan Daxue
- DT Journal
- LA Chinese
- CC 1-11 (Pharmacology)
- AB Platelet play an important role in **cerebral** ischemial nerve injury. Aspirin (ASA) had been used to treat and prevent stroke in clinic. 30 Rabbits were randomly divided into A, B and C groups. In group A ASA was given orally at a daily dosage of 15 mg/kg per rabbit for 5 days before **cerebral ischemia**; group B **cerebral ischemia** without giving ASA, and group C was normal rabbits as controls. The **cerebral** ischemial model was

produced by occluding bilateral carotid arteries and bleeding from femoral artery. The results indicated that there was an obvious decrease of platelet aggregation and TXA2 and had no significance changes in free radicals increasing and Ca2+ rising from **cerebral** tissue in group A. The **cerebral** edema of group A was less severe than group B. It seemed that ASA had a protective effect on the nerve injury of **cerebral ischemia**. The derangement of ASA, platelet, free radicals and calcium ions interrelation and their significance on the nerve injury should be further studied.

ST aspirin nerve injury brain **ischemia** TXA2
 IT Brain, disease
 (**cerebral** cortex, **ischemia**; influence of aspirin on
 nerve injury of exptl. **cerebral ischemia** in
 rabbits)
 IT Platelet aggregation inhibitors
 (influence of aspirin on nerve injury of exptl. **cerebral**
 ischemia in rabbits)
 IT Nerve, disease
 (injury; influence of aspirin on nerve injury of exptl.
 cerebral ischemia in rabbits)
 IT Cytoprotective agents
 (neuroprotectants; influence of aspirin on nerve injury of exptl.
 cerebral ischemia in rabbits)
 IT 50-78-2, Aspirin
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (influence of aspirin on nerve injury of exptl. **cerebral**
 ischemia in rabbits)
 IT 57576-52-0, Thromboxane A2
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
 (Biological study); PROC (Process)
 (influence of aspirin on nerve injury of exptl. **cerebral**
 ischemia in rabbits)

=> d his

(FILE 'HOME' ENTERED AT 15:07:02 ON 15 SEP 2003)

FILE 'REGISTRY' ENTERED AT 15:07:15 ON 15 SEP 2003

	E ACETAMINOPHEN
	E ACETAMINOPHEN
	E ACETAMINOPHEN
	E NSAID
L1	9 S E3
	E ASPIRIN
L2	52 S E3
	E INDOMETHACIN
L3	52 S E3
	E KETOPROFIN
	E KETOPROFEN
L4	50 S E3
	E TRILISATR
	E TRILISATE
L5	1 S E3
L6	1158 S SALICYLAMIDE
L7	30 S SODIUM SALICYLATE
L8	6694 S SALICYLIC ACID
	E ACETAMINOPHEN
	E ACETAMINOPHEN
L9	130 S E3

FILE 'CAPLUS' ENTERED AT 15:20:03 ON 15 SEP 2003

L10 17725 S L2
L11 28561 S CNS
L12 28 S L10 AND L11
E TRAUMA
L13 11866 S E3
L14 68 S L13 AND L10
E HEAD
L15 94345 S E3
L16 12 S L14 AND L15
E ISCHEMIA
L17 53069 S E5-E8
L18 356 S L17 AND L10
E CEREBRAL
L19 78138 S E3
L20 14 S L18 AND 19
L21 66 S L18 AND L19

=> s l19 and l12
L22 2 L19 AND L12

=> s l10 and l19
L23 211 L10 AND L19

=> s l23 and l17
L24 66 L23 AND L17

=> s l24 not l21
L25 0 L24 NOT L21

=> s l12 and l17
L26 2 L12 AND L17

=> d l26 1-2

L26 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:657907 CAPLUS
DN 137:195592
TI Chimeric compounds co-inducing cholinergic up-regulation and inflammation
down-regulation, and use for treatment and/or prevention of central
nervous system diseases
IN Amitai, Gabriel; Adani, Rachel; Rabinovitz, Ishai; Sod-Moriah, Gali;
Meshulam, Haim
PA Israel Institute for Biological Research, Israel
SO PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----		-----	-----	-----
PI	WO 2002065977	A2	20020829	WO 2002-IL122	20020217
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,				

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002160988 A1 20021031 US 2001-906952 20010716

PRAI US 2001-269343P P 20010220

US 2001-906952 A 20010716

OS MARPAT 137:195592

L26 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:488246 CAPLUS

DN 137:57576

TI Methods and compositions using ion-dependent cotransporter modulators for treating conditions of the central and peripheral nervous systems using non-synaptic mechanisms

IN Hochman, Daryl W.

PA Cytoscan Sciences L.L.C., USA

SO U.S. Pat. Appl. Publ., 29 pp., Cont.-in-part of U.S. Ser. No. 470,637.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002082252	A1	20020627	US 2002-56528	20020123
	US 6495601	B1	20021217	US 1999-470637	19991222
PRAI	US 1998-113620P	P	19981223		
	US 1999-470637	A2	19991222		
	US 2001-263830P	P	20010123		

=> d 19

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:n

=> s 19

L27 10826 L9

=> s 15

L28 46 L5

=> d 128 20-46

L28 ANSWER 20 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1996:367739 CAPLUS

DN 125:19043

TI Bioadhesive-wound healing composition

IN Leung, Sau-Hung S.; Martin, Alain

PA Warner-Lambert Company, USA

SO PCT Int. Appl., 159 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 28

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9606640	A1	19960307	WO 1995-US8568	19950707
	W: AU, CA, JP, MX, NZ, SG				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5658956	A	19970819	US 1995-445824	19950522
	AU 9530045	A1	19960322	AU 1995-30045	19950707
	AU 707353	B2	19990708		
	EP 779820	A1	19970625	EP 1995-926209	19950707
	R: BE, CH, DE, DK, ES, FR, GB, GR, IT, LI				
	JP 10505057	T2	19980519	JP 1996-508729	19950707

	ZA 9507245	A	19970630	ZA 1995-7245	19950829
PRAI	US 1994-298521	A	19940830		
	US 1995-445824	A	19950522		
	US 1991-663500	B1	19910301		
	US 1993-53922	B2	19930426		
	WO 1995-US8568	W	19950707		

L28 ANSWER 21 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:318495 CAPLUS
DN 124:352761
TI Antifungal-wound healing compositions containing pyruvates and
antioxidants and fatty acids
IN Martin, Alain
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 28

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9603149	A1	19960208	WO 1995-US8551	19950707
	W: AU, CA, JP, MX, NZ, SG				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5663208	A	19970902	US 1995-445831	19950522
	AU 9530042	A1	19960222	AU 1995-30042	19950707
	AU 701179	B2	19990121		
	EP 773795	A1	19970521	EP 1995-926203	19950707
	R: BE, CH, DE, DK, ES, FR, GB, GR, IT, LI				
	JP 10503200	T2	19980324	JP 1995-505755	19950707
	ZA 9506117	A	19970421	ZA 1995-6117	19950721
PRAI	US 1994-279462	A	19940722		
	US 1995-445831	A	19950522		
	US 1991-663500	B1	19910301		
	US 1993-53922	B2	19930426		
	WO 1995-US8551	W	19950707		

L28 ANSWER 22 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:171907 CAPLUS
DN 124:212140
TI Anti-inflammatory wound healing compositions containing pyruvates and
antioxidants and fatty acids
IN Martin, Alain
PA Warner-Lambert Co., USA
SO PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 28

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9600584	A1	19960111	WO 1995-US7942	19950622
	W: AU, CA, JP, MX, NZ, SG				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5648380	A	19970715	US 1995-445845	19950522
	AU 9529080	A1	19960125	AU 1995-29080	19950622
	AU 701454	B2	19990128		
	EP 759783	A1	19970305	EP 1995-924660	19950622
	R: BE, CH, DE, DK, ES, FR, GB, GR, IT, LI				
	JP 10502345	T2	19980303	JP 1995-503323	19950622
	NZ 289287	A	20010223	NZ 1995-289287	19950622
	ZA 9505408	A	19970401	ZA 1995-5408	19950629

PRAI US 1994-268429 A 19940630
 US 1995-445845 A 19950522
 US 1991-663500 B1 19910301
 US 1993-53922 B2 19930426
 WO 1995-US7942 W 19950622

L28 ANSWER 23 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1995:604005 CAPLUS
 DN 123:970
 TI Compositions and methods for inhibiting uterine contractility
 IN Bockow, Barry I.; Erlitz, Marc D.
 PA USA
 SO U.S., 5 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5409955	A	19950425	US 1993-62459	19930513
PRAI	US 1993-62459		19930513		
OS	MARPAT 123:970				

L28 ANSWER 24 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1994:38058 CAPLUS
 DN 120:38058
 TI choline magnesium trisalicylate tablets
 AU Zhou, Jianping; Zhang, Junshou; Chen, Jidong
 CS Div. Pharm., China Pharm. Univ., Nanjing, Peop. Rep. China
 SO Zhongguo Yaoke Daxue Xuebao (1993), 24(5), 287-9
 CODEN: ZHYXE9; ISSN: 1000-5048
 DT Journal
 LA Chinese

L28 ANSWER 25 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1993:524839 CAPLUS
 DN 119:124839
 TI Compositions for regulating skin wrinkles and/or skin atrophy
 IN Blank, Roy Lonnie; Doughty, Darell Gene; Linares, Carlos Gabriel
 PA Richardson-Vicks, Inc., USA
 SO PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9310755	A1	19930610	WO 1992-US9737	19921109
	W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
AU	9230736	A1	19930628	AU 1992-30736	19921109
EP	614353	A1	19940914	EP 1992-924418	19921109
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE				
CA	2122923	C	19990119	CA 1992-2122923	19921109
CN	1073859	A	19930707	CN 1992-111816	19921125
CN	1063627	B	20010328		
US	5605894	A	19970225	US 1994-342673	19941121
US	5776917	A	19980707	US 1996-768095	19961216
US	5776918	A	19980707	US 1996-771332	19961216
US	5811413	A	19980922	US 1996-768053	19961216

	US 5837697	A	19981117	US 1996-767551	19961216
	US 5780459	A	19980714	US 1997-921424	19970829
	US 5786345	A	19980728	US 1997-921422	19970829
	US 5789396	A	19980804	US 1997-921018	19970829
	US 5804572	A	19980908	US 1997-920641	19970829
	US 5869470	A	19990209	US 1997-920642	19970829
	US 5883085	A	19990316	US 1998-63480	19980420
PRAI	US 1991-796749	A	19911125		
	WO 1992-US9737	A	19921109		
	US 1993-47602	B1	19930414		
	US 1994-342673	A1	19941121		
	US 1996-767050	B1	19961216		
	US 1996-767533	B1	19961216		
	US 1996-767549	B1	19961216		
	US 1996-767552	B1	19961216		
	US 1996-768086	B1	19961216		
	US 1996-768095	A1	19961216		

L28 ANSWER 26 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1993:247651 CAPLUS
 DN 118:247651
 TI Nonsteroidal anti-rheumatoid arthritic drugs in the treatment of dementia
 IN McGeer, Patrick L.; Rogers, Joseph; Sibley, John; McGeer, Edith
 PA Can.
 SO U.S., 6 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	----	-----	-----
PI	US 5192753	A	19930309	US 1991-689499	19910423
	WO 9324115	A1	19931209	WO 1992-CA229	19920529
	W: JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	EP 642336	A1	19950315	EP 1992-910600	19920529
	EP 642336	B1	19980114		
	R: DE, FR, GB, IT				
	JP 07506559	T2	19950720	JP 1992-509619	19920529
PRAI	US 1991-689499		19910423		
	WO 1992-CA229		19920529		

L28 ANSWER 27 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1993:131920 CAPLUS
 DN 118:131920
 TI Bioequivalence evaluation of commercially available choline magnesium trisalicylate tablets in healthy volunteers
 AU Park, Kyoung Ho; Shin, Hyun Taek; Lee, Min Hwa; Goh, Young Yul
 CS Dep. Pharm., Seoul Natl. Univ. Hosp., Seoul, S. Korea
 SO Yakche Hakhoechi (1992), 22(3), 229-36
 CODEN: YAHAEX; ISSN: 0259-2347
 DT Journal
 LA English

L28 ANSWER 28 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1993:66852 CAPLUS
 DN 118:66852
 TI Sucralfate-cyclodextrin complexes as gastroprotective agents
 IN Koslo, Randy J.; Farina, Vincent J.
 PA Bristol-Myers Co., USA
 SO U.S., 4 pp.
 CODEN: USXXAM

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 5164379	A	19921117	US 1991-734370	19910715
PRAI	US 1991-734370		19910715		

L28 ANSWER 29 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:45816 CAPLUS
DN 118:45816
TI Stabilized solid dosage forms of choline salicylate
IN Oshlack, Benjamin; Pedi, Frank C., Jr.; Zirllis, Joseph
PA Euro-Celtique S.A., Luxembourg
SO Eur. Pat. Appl., 15 pp.
CODEN: EPXXDW

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 519371	A1	19921223	EP 1992-110049	19920615
	EP 519371	B1	19960828		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
	US 5217965	A	19930608	US 1991-716547	19910617
	IN 173260	A	19940319	IN 1992-CA351	19920525
	AU 9217309	A1	19921224	AU 1992-17309	19920529
	AU 645205	B2	19940106		
	ZA 9204002	A	19930224	ZA 1992-4002	19920602
	CA 2071262	AA	19921218	CA 1992-2071262	19920615
	CA 2071262	C	19980203		
	AT 141795	E	19960915	AT 1992-110049	19920615
	ES 2093740	T3	19970101	ES 1992-110049	19920615
PRAI	US 1991-716547		19910617		

L28 ANSWER 30 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1991:74872 CAPLUS
DN 114:74872
TI The effect of antirheumatic drugs on interleukin 1 (IL-1) activity and IL-1 and IL-1 inhibitor production by human monocytes
AU Chang, Deh Ming; Baptiste, Paul; Schur, Peter H.
CS Dep. Rheumatol./Immunol., Brigham and Women's Hosp., Boston, MA, 02115, USA
SO Journal of Rheumatology (1990), 17(9), 1148-57
CODEN: JRHUA9; ISSN: 0315-162X

DT Journal
LA English

L28 ANSWER 31 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1989:13568 CAPLUS
DN 110:13568
TI Gastric-resistant liposomes containing nonsteroidal antiinflammatory agents and glycolipids
IN Weiner, Alan L.; Cullis, Pieter R.
PA Liposome Co., Inc., USA
SO Eur. Pat. Appl., 21 pp.
CODEN: EPXXDW

DT Patent
LA English

FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----

PI	EP 249561	A2	19871216	EP 1987-401327	19870612
	EP 249561	A3	19881026		
	EP 249561	B1	19920513		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 09040550	A2	19970210	JP 1996-191707	19850411
	WO 8707506	A1	19871217	WO 1987-US1402	19870612
	W: AU, DK, FI, HU, JP, KR, NO				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	AU 8775438	A1	19880111	AU 1987-75438	19870612
	JP 01501622	T2	19890608	JP 1987-503771	19870612
	AT 75937	E	19920515	AT 1987-401327	19870612
	IL 82863	A1	19930221	IL 1987-82863	19870612
	IL 96284	A1	19930221	IL 1987-96284	19870612
	ES 2036593	T3	19930601	ES 1987-401327	19870612
	CA 1320130	A1	19930713	CA 1987-539517	19870612
	JP 07100367	A2	19950418	JP 1993-268664	19931027
	JP 2568034	B2	19961225		
PRAI	US 1986-873584	A	19860612		
	US 1986-934151	A	19861124		
	US 1987-61186	A	19870611		
	JP 1985-502090		19850411		
	JP 1993-268664	A3	19850411		
	EP 1987-401327	A	19870612		
	WO 1987-US1402	A	19870612		

L28 ANSWER 32 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1987:432999 CAPLUS
DN 107:32999
TI Replacing the acetyl linkage in aspirin with choline and magnesium
moieties reduces the occurrence of gastric mucosal injury
AU Danesh, B. J. Z.; Nelson, L. M.; Russell, R I.; Docherty, C.
CS Gastroenterol. Unit, R. Infirm., Glasgow, G31 2ER, UK
SO Alimentary Pharmacology and Therapeutics (1987), 1(1), 51-6
CODEN: APTHEN; ISSN: 0269-2813
DT Journal
LA English

L28 ANSWER 33 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1985:220523 CAPLUS
DN 102:220523
TI Synthesis of choline magnesium trisalicylate
AU Li, Jie
CS Jilin Pharm. Co., Jilin, Peop. Rep. China
SO Yiyao Gongye (1985), 16(2), 79-80
CODEN: YIGODN; ISSN: 0255-7223
DT Journal
LA Chinese

L28 ANSWER 34 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1984:465538 CAPLUS
DN 101:65538
TI Choline magnesium trisalicylate: comparative pharmacokinetic study of
once-daily and twice-daily dosages
AU Levitt, Monte J.; Kann, Jules
CS Biodecision Lab., Inc., Pittsburgh, PA, 15213, USA
SO Journal of Pharmaceutical Sciences (1984), 73(7), 977-9
CODEN: JPMSAE; ISSN: 0022-3549
DT Journal
LA English

L28 ANSWER 35 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1984:96605 CAPLUS

DN 100:96605
 TI The effect of the non-steroidal anti-inflammatory drug choline magnesium trisalicylate on gastric mucosal cell exfoliation
 AU Mitchell, K. G.; Hearn, J.; Crean, G. P.
 CS Dep. Surg., Gartnavel Gen. Hosp., Glasgow, UK
 SO British Journal of Clinical Pharmacology (1984), 17(1), 27-30
 CODEN: BCPHBM; ISSN: 0306-5251
 DT Journal
 LA English

L28 ANSWER 36 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1983:172771 CAPLUS
 DN 98:172771
 TI Effect of choline magnesium trisalicylate on prostacyclin production by isolated vascular tissue of the rat
 AU Levy, Joseph V.
 CS Pharmacol. Lab., Kuzell Inst. Arthritis Res., San Francisco, CA, 94115, USA
 SO Thrombosis Research (1983), 29(2), 149-54
 CODEN: THBRAA; ISSN: 0049-3848
 DT Journal
 LA English

L28 ANSWER 37 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1983:132330 CAPLUS
 DN 98:132330
 TI Antiinflammatory compositions exhibiting minimized gastric damage
 IN Paulson, Joy Lee; Feller, Martha Rosand
 PA Procter and Gamble Co., USA
 SO Eur. Pat. Appl., 28 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 66918	A1	19821215	EP 1982-200618	19820519
	R: BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	AU 8283791	A1	19821209	AU 1982-83791	19820518
	ES 512808	A1	19830801	ES 1982-512808	19820603
	JP 58041821	A2	19830311	JP 1982-96094	19820604
PRAI	US 1981-270283		19810604		

L28 ANSWER 38 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1982:634 CAPLUS
 DN 96:634
 TI Salicylate prevents gallbladder stasis and cholesterol gallstones in the prairie dog
 AU Kuckenbecker, Stephen L.; Doty, Jeffrey E.; Pitt, Henry A.; DenBesten, Lawrence
 CS Surg. Res. Serv., VA Med. Cent., Sepulveda, CA, USA
 SO Surgical Forum (1981), 32, 154-5
 CODEN: SUFOAX; ISSN: 0071-8041
 DT Journal
 LA English

L28 ANSWER 39 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1981:52798 CAPLUS
 DN 94:52798
 TI Comparative plasma salicylate and urine salicylurate levels following administration of aspirin, magnesium salicylate, and choline magnesium trisalicylate

AU Mason, William D.
CS Sch. Pharm., Univ. Missouri, Kansas City, MO, 64108, USA
SO Journal of Pharmaceutical Sciences (1980), 69(11), 1355-6
CODEN: JPMSAE; ISSN: 0022-3549
DT Journal
LA English

L28 ANSWER 40 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1980:453898 CAPLUS
DN 93:53898
TI A comparison of two oral dosage forms of choline magnesium trisalicylate:
a bioavailability/bioequivalence study
AU Cohen, Albert
CS Peninsular Testing Corp., Miami, FL, USA
SO Current Therapeutic Research (1980), 27(5), 692-8
CODEN: CTCEA9; ISSN: 0011-393X
DT Journal
LA English

L28 ANSWER 41 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1979:468417 CAPLUS
DN 91:68417
TI Comparison of the effects of diflunisal and other salicylates on the
intra gastric electropotential
AU Torchiana, Mary Lou; Wiese, Sylvia R.; Westrick, Barbara L.
CS Merck Inst. Ther. Res., West Point, PA, USA
SO Journal of Pharmacy and Pharmacology (1979), 31(2), 112-13
CODEN: JPPMAB; ISSN: 0022-3573
DT Journal
LA English

L28 ANSWER 42 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1979:432619 CAPLUS
DN 91:32619
TI Steady-state serum salicylate levels in hospitalized patients with
rheumatoid arthritis. Comparison of two dosage schedules of choline
magnesium trisalicylate
AU Cassell, Sidney; Furst, Daniel; Dromgoole, Sydney; Paulus, Harold
CS Sch. Med., Univ. California, Los Angeles, CA, USA
SO Arthritis & Rheumatism (1979), 22(4), 384-8
CODEN: ARHEAW; ISSN: 0004-3591
DT Journal
LA English

L28 ANSWER 43 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1978:590696 CAPLUS
DN 89:190696
TI Serum concentration, safety and tolerance of oral doses of choline
magnesium trisalicylate
AU Cohen, Albert; Thomas, G. B.; Cohen, E. B.
CS Peninsular Test. Corp., Miami, FL, USA
SO Current Therapeutic Research (1978), 23(3, Sect. 1), 358-64
CODEN: CTCEA9; ISSN: 0011-393X
DT Journal
LA English

L28 ANSWER 44 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1978:573531 CAPLUS
DN 89:173531
TI Differential influences of salicylate compounds on platelet aggregation
and serotonin release
AU Zucker, Marjorie B.; Rothwell, Kenneth G.

CS Dep. Pathol., New York Univ. Med. Cent., New York, NY, USA
SO Current Therapeutic Research (1978), 23(2, Sect. 1), 194-9
CODEN: CTCEA9; ISSN: 0011-393X
DT Journal
LA English

L28 ANSWER 45 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1978:552647 CAPLUS
DN 89:152647
TI A comparative blood salicylate study of two salicylate tablet formulations
utilizing normal volunteers
AU Cohen, Albert
CS Peninsular Test. Corp., Miami, FL, USA
SO Current Therapeutic Research (1978), 23(6), 772-8
CODEN: CTCEA9; ISSN: 0011-393X
DT Journal
LA English

L28 ANSWER 46 OF 46 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1978:183166 CAPLUS
DN 88:183166
TI Comparison of choline magnesium trisalicylate and acetylsalicylic acid in
relation to fecal blood loss
AU Cohen, Albert; Garber, Harold E.
CS Peninsular Test. Corp., Miami, FL, USA
SO Current Therapeutic Research (1978), 23(2, Sect. 1), 187-93
CODEN: CTCEA9; ISSN: 0011-393X
DT Journal
LA English

=> s l12 and l10
L29 28 L12 AND L10

=> d l29 1-28

L29 ANSWER 1 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:280985 CAPLUS
DN 139:143565
TI Paracetamol effectively reduces prostaglandin E2 synthesis in brain
macrophages by inhibiting enzymatic activity of cyclooxygenase but not
phospholipase and prostaglandin E synthase
AU Greco, Anita; Ajmone-Cat, Maria Antonietta; Nicolini, Alessia; Sciulli,
Maria Gina; Minghetti, Luisa
CS Laboratory of Pathophysiology, Istituto Superiore di Sanita, Rome,
299-00161, Italy
SO Journal of Neuroscience Research (2003), 71(6), 844-852
CODEN: JNREDK; ISSN: 0360-4012
PB Wiley-Liss, Inc.
DT Journal
LA English

RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:242167 CAPLUS
DN 138:248536
TI Methods using cholinesterase inhibitors for treating and preventing
migraine
IN Pratt, Raymond
PA Eisai Co., Ltd., Japan
SO PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003024456	A1	20030327	WO 2002-US29734	20020920
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2001-323310P P 20010920

US 2002-349244P P 20020118

OS MARPAT 138:248536

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:657907 CAPLUS

DN 137:195592

TI Chimeric compounds co-inducing cholinergic up-regulation and inflammation down-regulation, and use for treatment and/or prevention of central nervous system diseases

IN Amitai, Gabriel; Adani, Rachel; Rabinovitz, Ishai; Sod-Moriah, Gali; Meshulam, Haim

PA Israel Institute for Biological Research, Israel

SO PCT Int. Appl., 139 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002065977	A2	20020829	WO 2002-IL122	20020217
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2002160988 A1 20021031

US 2001-906952 20010716

PRAI US 2001-269343P P 20010220

US 2001-906952 A 20010716

OS MARPAT 137:195592

L29 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:488246 CAPLUS

DN 137:57576

TI Methods and compositions using ion-dependent cotransporter modulators for treating conditions of the central and peripheral nervous systems using non-synaptic mechanisms

IN Hochman, Daryl W.
PA Cytoscan Sciences L.L.C., USA
SO U.S. Pat. Appl. Publ., 29 pp., Cont.-in-part of U.S. Ser. No. 470,637.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 2002082252	A1	20020627	US 2002-56528	20020123
	US 6495601	B1	20021217	US 1999-470637	19991222
PRAI	US 1998-113620P	P	19981223		
	US 1999-470637	A2	19991222		
	US 2001-263830P	P	20010123		

L29 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:856855 CAPLUS
DN 136:194095
TI Antinociceptive profiles of aspirin and acetaminophen in formalin, substance P and glutamate pain models
AU Choi, Seong-Soo; Lee, Jin-Koo; Suh, Hong-Won
CS Department of Pharmacology, Hallym University, College of Medicine, and Institute of Natural Medicine, Kangwon-Do, Chunchon, 200-702, S. Korea
SO Brain Research (2001), 921(1,2), 233-239
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:797561 CAPLUS
DN 137:103455
TI Paradoxical effect of aspirin on the growth of C6 rat glioma and on time of development of ENU-induced tumors of the nervous system
AU Arrieta, Oscar; Guevara, Patricia; Reyes, Sandra; Palencia, Guadalupe; Rivera, Erika; Sotelo, Julio
CS Neuroimmunology Unit, Instituto Nacional de Neurologia y Neurocirugia and Instituto de Investigaciones Biomedicas, Mexico City, 14269, Mex.
SO Journal of Cancer Research and Clinical Oncology (2001), 127(11), 681-686
CODEN: JCROD7; ISSN: 0171-5216
PB Springer-Verlag
DT Journal
LA English
RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:704905 CAPLUS
DN 134:51168
TI NSAID Treatment Suppresses VSV Propagation in Mouse **CNS**
AU Chen, Nannan; Warner, Jennifer L.; Reiss, Carol Shoshkes
CS Department of Biology, New York University, New York, NY, 10003, USA
SO Virology (2000), 276(1), 44-51
CODEN: VIRLAX; ISSN: 0042-6822
PB Academic Press
DT Journal
LA English
RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:598508 CAPLUS
 DN 134:114081
 TI Incidence, clinical features and outcome of essential thrombocythemia in a well defined geographical area
 AU Jensen, Morten Krogh; De Nully Brown, Peter; Nielsen, Ove Juul; Hasselbalch, Hans Carl
 CS Department of Haematology, Herlev Hospital, University Hospital of Copenhagen, Copenhagen, Den.
 SO European Journal of Haematology (2000), 65(2), 132-139
 CODEN: EJHAEC; ISSN: 0902-4441
 PB Munksgaard International Publishers Ltd.
 DT Journal
 LA English
 RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:576796 CAPLUS
 DN 131:204626
 TI Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID
 IN Artman, Linda D.; Balandrin, Manuel F.
 PA NPS Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 38 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9944623	A1	19990910	WO 1999-US4786	19990304
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2321737	AA	19990910	CA 1999-2321737	19990304
	AU 9928945	A1	19990920	AU 1999-28945	19990304
	EP 1059930	A1	20001220	EP 1999-909827	19990304
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002505296	T2	20020219	JP 2000-534224	19990304
	US 6383527	B1	20020507	US 2001-623384	20010222
PRAI	US 1998-76737P	A2	19980304		
	WO 1999-US4786	W	19990304		

OS MARPAT 131:204626
 RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:780621 CAPLUS
 DN 130:232124
 TI Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS [central nervous system]
 AU Hauss-Wegrzyniak, Beatrice; Willard, Lauren B.; Del Soldato, Piero; Pepeu, Giancarlo; Wenk, Gary L.

CS Memory and Aging, Division of Neural Systems, Arizona Research
Laboratories, University of Arizona, Tucson, AZ, 85724, USA
SO Brain Research (1999), 815(1), 36-43
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:43243 CAPLUS
DN 128:149902
TI Modulation of Brewer's yeast-induced peripheral inflammation and
nociception in rats by centrally administered prostaglandins and their
inhibitors
AU Hore, S. K.; Dumka, V. K.; Tandan, S. K.; Tripathi, H. C.; Kumar, Dinesh
CS Division of Pharmacology and Toxicology, Indian Veterinary Research
Institute, Izatnagar, 243 122, India
SO Indian Journal of Pharmacology (1997), 29(6), 416-419
CODEN: INJPD2; ISSN: 0253-7613
PB Indian Pharmacological Society
DT Journal
LA English
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:646511 CAPLUS
DN 125:276575
TI Preparation of arginine analogs having nitric oxide synthase inhibitor
activity
IN Broquet, Colette; Chabrier, De Lassauniere, Pierre-Etienne
PA Societe De Conseils De Recherches Et D'application, Fr.
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9627593	A1	19960912	WO 1996-FR337	19960304
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
CA 2215476	AA	19960912	CA 1996-2215476	19960304
AU 9649479	A1	19960923	AU 1996-49479	19960304
AU 700871	B2	19990114		
EP 813529	A1	19971229	EP 1996-905907	19960304
EP 813529	B1	20020911		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, IE, SI, LT, LV, FI				
CN 1179774	A	19980422	CN 1996-192885	19960304
CN 1071328	B	20010919		
JP 11501043	T2	19990126	JP 1996-526657	19960304
RU 2168493	C2	20010610	RU 1997-116496	19960304
AT 223907	E	20020915	AT 1996-905907	19960304
CZ 290747	B6	20021016	CZ 1997-2687	19960304
SK 282664	B6	20021106	SK 1997-1121	19960304
ES 2182964	T3	20030316	ES 1996-905907	19960304

	US 5972940	A	19991026	US 1997-913455	19970910
	HK 1013777	A1	20020705	HK 1998-110921	19980924
PRAI	GB 1995-4350	A	19950304		
	WO 1996-FR337	W	19960304		
OS	MARPAT 125:276575				

L29 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1996:245721 CAPLUS
 DN 125:48415
 TI Effect of NM441 and its active form on GABA receptor binding
 AU Hori, Seiji; Shimada, Jingoro
 CS Div. Clin. Pharmacol. Inst. Med. Sci., St. Marianna Univ. Sch. Med.,
 Kawasaki, 216, Japan
 SO Nippon Kagaku Ryoho Gakkai Zasshi (1996), 44(Suppl. 1), 97-101
 CODEN: NKRZE5; ISSN: 1340-7007
 DT Journal
 LA Japanese

L29 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1995:365390 CAPLUS
 DN 122:204992
 TI Neuronal expression of FOS protein in the nucleus tractus solitarii and
 the dorsal motor nucleus of the vagus nerve after i.p. injection of
 ulcerogenic aspirin
 AU Takahashi, Akio; Miura, Mitsuhiko
 CS Department of Physiology 1st Division, Gunma University School of
 Medicine, 3-39-22 Showa-machi, Maebashi-shi, 371, Japan
 SO Neuroscience Letters (1995), 185(3), 214-16
 CODEN: NELED5; ISSN: 0304-3940
 PB Elsevier
 DT Journal
 LA English

L29 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1994:499126 CAPLUS
 DN 121:99126
 TI Mechanism of quinolone-induced convulsion and anticonvulsant effect of
 barbiturate for this seizure
 AU Kanemitsu, Keiji
 CS Dep. Intern. Med. and Lab. Med., St. Marianna Univ. Sch. Med., Kawasaki,
 216, Japan
 SO Sei Marianna Ika Daigaku Zasshi (1993), 21(6), 1177-85
 CODEN: SMIZDS; ISSN: 0387-2289
 DT Journal
 LA Japanese

L29 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1993:573380 CAPLUS
 DN 119:173380
 TI Acetylsalicylic acid and related compounds depress nociceptive activity in
 the thalamus by a central action: indications for the involvement of
 prostaglandins
 AU Jurna, I.
 CS Inst. Pharmacol. Toxikol., Univ. Saarlandes, Homburg/Saar, D-6650, Germany
 SO Progress in Pharmacology and Clinical Pharmacology (1993), 10(1), 51-68
 CODEN: PPCPEP; ISSN: 0934-9545
 DT Journal; General Review
 LA English

L29 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1992:676 CAPLUS
 DN 116:676

TI Central analgesic effects of acetylsalicylic acid in healthy men
AU Bromm, B.; Rundshagen, I.; Scharein, E.
CS Inst. Physiol., Univ. Hosp. Eppendorf, Hamburg, W-2000/20, Germany
SO Arzneimittelforschung (1991), 41(11), 1123-9
CODEN: ARZNAD; ISSN: 0004-4172
DT Journal
LA English

L29 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1990:91116 CAPLUS
DN 112:91116
TI Effects of pentazocine and acetylsalicylic acid on pain-rating,
pain-related evoked potentials and vigilance in relationship to
pharmacokinetic parameters
AU Kobal, G.; Hummel, C.; Nuernberg, B.; Brune, K.
CS Inst. Pharmakol. Toxikol., Univ. Erlangen-Nuernberg, Erlangen, D-8520,
Germany
SO Agents and Actions (1990), 29(3-4), 342-59
CODEN: AGACBH; ISSN: 0065-4299
DT Journal
LA English

L29 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1987:60703 CAPLUS
DN 106:60703
TI In vitro metabolism of teratogens by differentiating rat embryo cells
AU Brown, L. P.; Flint, O. P.; Orton, T. C.; Gibson, G. G.
CS Biochem. Dep., Univ. Surrey, Guildford/Surrey, GU2 5XH, UK
SO Food and Chemical Toxicology (1986), 24(6-7), 737-42
CODEN: FCTOD7; ISSN: 0278-6915
DT Journal
LA English

L29 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1985:73624 CAPLUS
DN 102:73624
TI An in vitro assay for teratogens with cultures of rat embryo midbrain and
limb bud cells
AU Flint, O. P.; Orton, T. C.
CS Saf. Med. Dep., Imp. Chem. Ind. PLC, Macclesfield/Cheshire, SK10 4TG, UK
SO Toxicology and Applied Pharmacology (1984), 76(2), 383-95
CODEN: TXAPA9; ISSN: 0041-008X
DT Journal
LA English

L29 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1981:114385 CAPLUS
DN 94:114385
TI The antipyretic effects of aminopyrine and sodium acetylsalicylate on
endotoxin-induced fever in rabbits
AU Nishio, Akira; Kanoh, Seizaburo
CS Fac. Agric., Kagoshima Univ., Kagoshima, 890, Japan
SO Nippon Yakurigaku Zasshi (1981), 77(1), 9-13
CODEN: NYKZAU; ISSN: 0015-5691
DT Journal
LA Japanese

L29 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1979:535333 CAPLUS
DN 91:135333
TI Prostaglandin synthetase inhibitors antagonize the depressant effects of
ethanol

AU George, Frank R.; Collins, Allan C.
CS Inst. Behav. Genet., Univ. Colorado, Boulder, CO, 80309, USA
SO Pharmacology, Biochemistry and Behavior (1979), 10(6), 865-9
CODEN: PBBHAU; ISSN: 0091-3057
DT Journal
LA English

L29 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1978:499779 CAPLUS
DN 89:99779
TI Pharmacological characterization of benzodiazepine receptors in the brain
AU Braestrup, Claus; Squires, Richard F.
CS Res. Lab., A/S Ferrosan, Soeborg, Den.
SO European Journal of Pharmacology (1978), 48(3), 263-70
CODEN: EJPHAZ; ISSN: 0014-2999
DT Journal
LA English

L29 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1975:601968 CAPLUS
DN 83:201968
TI Mechanism of the synaptic effects of morphine, indomethacin, and
prostaglandins
AU Ehrenpreis, Seymour; Greenberg, Joel
CS New York State Res. Inst. Neurochem. Drug Addict., New York, NY, USA
SO Clin. Pharmacol. Psychoact. Drugs, [Proc. Int. Symp. Alcohol Drug Res.]
(1975), Meeting Date 1973, 171-82. Editor(s): Sellers, E. M. Publisher:
Alcohol. Drug Addit. Res. Found., Toronto, Can.
CODEN: 31QKAO
DT Conference
LA English

L29 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1972:107738 CAPLUS
DN 76:107738
TI Drug interactions. **CNS** [central nervous system] drugs
analgesics and antipyretics
AU Hartshorn, Edward A.
CS Pharm. Serv., Evanston Hosp., Evanston, IL, USA
SO Drug Intelligence (1971), 5(11), 356-60
CODEN: DRUIA6; ISSN: 0012-6578
DT Journal; General Review
LA English

L29 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1969:113689 CAPLUS
DN 70:113689
TI N-Aralkylanthranilic acid derivatives as **CNS** [central nervous
system] depressants
AU Sisodia, P.; Rao, G. S. Rama; Sidhu, Gurbachan S.; Sattur, Prolhad B.;
Hashim, Riaz
CS Gandhi Med. Coll., Hyderabad, India
SO CNS (Cent. Nerv. Syst.) Drugs, Symp. (1966), 238-48 Publisher: Counc. Sci.
and Ind. Res., New Delhi, India.
CODEN: 20REAT
DT Conference
LA English

L29 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1968:113200 CAPLUS
DN 68:113200
TI Drug effects on electrically induced extensor seizures and clinical

implications

AU Chen, Graham; Ensor, Charles R.; Bohner, Barbara
CS Parke, Davis and Co., Ann Arbor, MI, USA
SO Archives Internationales de Pharmacodynamie et de Therapie (1968), 172(1),
183-218
CODEN: AIPTAK; ISSN: 0003-9780
DT Journal
LA English

L29 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1962:15164 CAPLUS

DN 56:15164

OREF 56:2857g-i,2858a

TI Classification of **CNS** drugs by a mouse screening battery

AU Bastian, J. W.

CS Armour Pharmaceutical Co., Kankakee, IL

SO Archives Internationales de Pharmacodynamie et de Therapie (1961), 133,
347-64

CODEN: AIPTAK; ISSN: 0003-9780

DT Journal

LA Unavailable

=> d 129 27 all

L29 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1968:113200 CAPLUS

DN 68:113200

TI Drug effects on electrically induced extensor seizures and clinical
implications

AU Chen, Graham; Ensor, Charles R.; Bohner, Barbara

CS Parke, Davis and Co., Ann Arbor, MI, USA

SO Archives Internationales de Pharmacodynamie et de Therapie (1968), 172(1),
183-218

CODEN: AIPTAK; ISSN: 0003-9780

DT Journal

LA English

CC 15 (Pharmacodynamics)

AB The central nervous system depressants (**CNS** depressants) produce an elevation of the extensor-seizure threshold (ExST) in mice to electroshock. The ExST raising action at non-neurotoxic doses is an essential property of drugs for grand mal epilepsy. The different types of **CNS** depressants caused a maximal increase in ExST of mice at doses that produced different degrees of central depression. The relation between ExST and the degree of depression may be taken for the characterization of the various types of **CNS** depressants. The excitants and those drugs having both a central stimulating and depressant action also produced an increase of ExST. On the other hand, the convulsants which do not possess a depressant component lowered the ExST at subconvulsive doses. A lowering of ExST was obtained with some other **CNS** depressants. Reserpine and tetrabenazine were the most active; their effect was dose dependent. Chlorpromazine, haloperidol, and a no. of other major tranquilizers produced a slight lowering of the ExST at low doses but an elevation of ExST at higher doses. The ExST lowering effect of the major tranquilizers may be related to the extrapyramidal syndrome seen in subjects under therapy with these drugs. The effect on ExST of reserpine or tetrabenazine was a useful indicator for testing the activity of monoamine oxidase inhibitors and for investigating the pharmacology of the biogenic amines in the central nervous system. A dichotomy was observed between the sympathetic drugs and the parasympathetic drugs in their effects on elec. induced extensor seizure (ExS) in mice: the sympathomimetics and the anticholinergics caused an

increase in ExST while the parasympathetics and the adrenergic blockers lowered it. Different mechanisms were involved in the elevation of ExST by the various drugs. In reserpinized mice, diphenylhydantoin, amphetamine, hyoscine, and some other drugs were still effective in producing an increase in ExST, while acetazolamide, methazolamide, and oxotremorine were ineffective. Quant. studies of the combined effects of DPHD (diphenylhydantoin) and of amphetamine or hyoscine on extensor seizure showed that these drugs affect the ExST by diverse actions. 45 references.

ST ANTIEPILEPTIC DRUGS; ANTICONVULSANT DRUGS; DIPHENYLHYDANTOIN SEIZURES;
DRUGS ANTIEPILEPTIC; RESERPINE SEIZURES; NERVES DEPRESSANTS

IT Convulsions

(psychotropic agents effect on)

IT 50-13-5 50-35-1 50-48-6 50-49-7 50-53-3, biological studies
50-55-5, biological studies 50-67-9, biological studies **50-78-2**
, biological studies 51-34-3 52-86-8 54-92-2 54-95-5 57-30-7
57-33-0 57-53-4 58-08-2, biological studies 58-25-3 58-39-9
58-40-2 58-46-8 60-45-7 63-84-3 64-31-3 66-05-7 66-32-0
77-10-1 77-65-6 77-67-8 113-45-1 117-89-5 127-48-0 144-02-5
146-54-3 300-62-9, biological studies 302-17-0, biological studies
305-96-4 439-14-5 467-60-7 555-30-6 555-57-7 630-93-3 658-48-0
1421-14-3 1867-66-9 3721-28-6 7632-10-2

RL: BIOL (Biological study)

(convulsion threshold response to)

=> d 129 28 all

L29 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1962:15164 CAPLUS

DN 56:15164

OREF 56:2857g-i,2858a

TI Classification of **CNS** drugs by a mouse screening battery

AU Bastian, J. W.

CS Armour Pharmaceutical Co., Kankakee, IL

SO Archives Internationales de Pharmacodynamie et de Therapie (1961), 133,
347-64

CODEN: AIPTAK; ISSN: 0003-9780

DT Journal

LA Unavailable

CC 73 (Pharmacodynamics)

AB Forty-two central nervous system (**CNS**) drugs and 16 non**CNS** drugs were studied on a battery of mouse screening tests. The following end-points were measured in each animal: motor activity; ataxia; body temp.; metrazole threshold as described by Bastian, et al. (CA 54, 671h); block of Metrazole-induced extensor tonus; and time to Metrazole death. Twenty-four of the **CNS** drugs were found to raise Metrazole threshold. This group, made up of **CNS** depressants, included mainly hypnotics, antiepileptic drugs, and antineurotic tranquilizers. The remaining group of **CNS** drugs, which included depressants as well as stimulants, failed to cause an appreciable elevation of Metrazole threshold. Some of the stimulants lowered the threshold. None of the 16 non-**CNS** drugs had any marked effect on this endpoint. Most drugs which elevated Metrazole threshold also caused increased motor activity. Most **CNS** depressants which did not elevate Metrazole threshold were found to lower body temp. Normal or elevated levels of motor activity were assocd. with body temps. of 99.degree.F. or higher, whereas low body temps. were always assocd. with low motor activities. This was true for drugs with a variety of types of pharmacol. effects.

IT Polyoxymethylenes

(nervous system response to)

IT Pharmacology

(of central nervous system drugs)

IT Nervous system
 (pharmaceuticals affecting central, classification of)

IT 5H-Tetrazoloazepine, 6,7,8,9-tetrahydro-
 Ammonium, hexamethylenebis[trimethyl-, chloride
 Benzoxazole, 2-acetamido-5-chloro-
 Benzyl alcohol, .alpha.-[(2-pyridylamino)methyl]-, (-)-
 Carbamic acid (aminoformic acid), 1-ethynylcyclohexyl ester
 Carbamic acid (aminoformic acid), 2-hydroxy-3-(o-methoxyphenoxy)propyl
 ester
 Carbamic acid (aminoformic acid), 2-methyl-2-propyltrimethylene ester
 meprobamate
 Carbamic acid (aminoformic acid), .alpha.,.beta.-diethyl-.beta.-
 hydroxyphenethyl ester
 Carbamic acid (aminoformic acid), .beta.-ethyl-.beta.-hydroxyphenethyl
 ester
 Carbamic acid (aminoformic acid), .beta.-hydroxyphenethyl ester
 Lysergamide, N,N-diethyl-
 (nervous system response to)

IT 50-33-9, 3,5-Pyrazolidinedione, 4-butyl-1,2-diphenyl- 50-49-7,
 5H-Dibenz[b,f]azepine, 5-[3-(dimethylamino)propyl]-10,11-dihydro-
 50-53-3, Phenothiazine, 2-chloro-10-[3-(dimethylamino)propyl]- 50-55-5,
 Reserpine 50-67-9, Indol-5-ol, 3-(2-aminoethyl) **50-78-2**,
 Acetylsalicylic acid 51-45-6, Histamine 51-55-8, Atropine 51-79-6,
 Ethyl carbamate 54-11-5, Nicotine 57-24-9, Strychnine 57-41-0,
 Hydantoin, 5,5-diphenyl- 57-44-3, Barbituric acid, 5,5-diethyl-
 57-47-6, Physostigmine 58-08-2, Caffeine 58-25-3, 3H-1,4-
 Benzodiazepine, 7-chloro-2-(methylamino)-5-phenyl-, 4-oxide 58-73-1,
 Ethylamine, 2-(diphenylmethoxy)-N,N-dimethyl- 59-47-2, 1,2-Propanediol,
 3-(o-tolyloxy)- 59-67-6, Nicotinic acid 60-40-2, 2-Norbornanamine,
 N,2,3,3-tetramethyl- 62-44-2, p-Acetophenetidide 64-17-5, Ethyl
 alcohol 64-95-9, Acetic acid, diphenyl-, 2-(diethylamino)ethyl ester)
 66-40-0, Ammonium, tetraethyl 75-87-6, Chloral 76-74-4, Barbituric
 acid, 5-ethyl-5-(1-methylbutyl)- 77-38-3, Ethylamine,
 2-[(p-chloro-.alpha.-methyl-.alpha.-phenylbenzyl)oxy]-N,N-dimethyl-
 80-77-3, 4H-1,3-Thiazin-4-one, 2-(p-chlorophenyl)tetrahydro-3-methyl-,
 1,1-dioxide 83-98-7, Ethylamine, N,N-dimethyl-2-[(o-methyl-.alpha.-
 phenylbenzyl)oxy]- 90-49-3, Urea, (2-phenylbutyryl)- 92-12-6,
 Ethylamine, N,N-dimethyl-2-[(.alpha.-phenyl-o-tolyl)oxy] 95-25-0,
 2-Benzoxazolinone, 5-chloro- 113-18-8, 1-Penten-4-yn-3-ol,
 1-chloro-3-ethyl- 113-45-1, 2-Piperidineacetic acid, .alpha.-phenyl-,
 methyl ester 115-76-4, 1,3-Propanediol, 2,2-diethyl- 125-64-4,
 2,4-Piperidinedione, 3,3-diethyl-5-methyl- 127-48-0,
 2,4-Oxazolidinedione, 3,5,5-trimethyl- 300-62-9, Phenethylamine,
 .alpha.-methyl- 631-07-2, Hydantoin, 5-ethyl-5-phenyl- 7647-15-6,
 Sodium bromide 13454-23-4, Carbamic acid, dimethyl-,
 2-hydroxy-2,2-diphenylethyl ester 90871-96-8, Urea, [(2-
 phenylacetamido)methyl]-
 (nervous system response to)

IT 77-41-8, Succinimide, N,2-dimethyl-2-phenyl- 5586-60-7, 3,4-Hexanediol,
 3-phenyl-, 4-carbamate
 (nervous-system response to)

=> d 129 17 all

L29 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1992:676 CAPLUS

DN 116:676

TI Central analgesic effects of acetylsalicylic acid in healthy men

AU Bromm, B.; Rundshagen, I.; Scharein, E.

CS Inst. Physiol., Univ. Hosp. Eppendorf, Hamburg, W-2000/20, Germany

SO Arzneimittel-Forschung (1991), 41(11), 1123-9
 CODEN: ARZNAD; ISSN: 0004-4172

DT Journal
 LA English
 CC 1-11 (Pharmacology)

AB Acetylsalicylic acid (1000 mg orally) was investigated in a non-inflammatory exptl. pain model in healthy men. Phasic pain was induced by intracutaneously applied elec. pulses of const. current. The nociceptive responses measured were pain ratings, cerebral potentials, and EEG delta powers in response to stimuli. Spontaneous EEG, auditory evoked potentials, and reaction times were evaluated to det. effects on the vigilance system. Acetylsalicylic acid produced clear analgesic effects in all pain relevant target variables. The effects increased with postmediation time, becoming different from placebo 90 min after medication. At this time the pain ratings were reduced by 4%, the pain related cerebral potentials by 15%, and the stimulus-induced delta power of EEG by 20%. The findings suggest a central action of acetylsalicylic acid by attenuation of exptl. induced nociceptive activity. No influences could be obsd. on auditory evoked potentials, spontaneous EEG, and reaction times. Acetylsalicylic acid did not change vigilance by unspecific alterations of the CNS. The plasma concn. of acetylsalicylic acid reached mean values of 2.5 .mu.g/mL within 25 min after medication and remained const. during the entire post-medication period of 105 min. The concn. of the metabolite salicylic acid increased steadily, reaching mean values of 32.0 .mu.g/mL at the end of the investigated period. Although both the analgesic efficacy and the concn. of salicylate increased with post-medication time, no correlations were found between individual plasma level and effects.

ST aspirin analgesia central vigilance pharmacokinetics

IT Analgesia
 (central, from aspirin, vigilance and pharmacokinetics in, in humans)

IT Mental activity
 (vigilance, aspirin-induced central analgesia effects on, in humans)

IT 50-78-2, Aspirin
 RL: BIOL (Biological study)
 (central analgesia from, vigilance and pharmacokinetics in, in humans)

IT 69-72-7, Salicylic acid, biological studies
 RL: BIOL (Biological study)
 (of blood plasma, as aspirin metabolite, central analgesia in relation to, in human)

=> d 129 10 all

L29 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:780621 CAPLUS

DN 130:232124

TI Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS [central nervous system]

AU Hauss-Wegrzyniak, Beatrice; Willard, Lauren B.; Del Soldato, Piero; Pepeu, Giancarlo; Wenk, Gary L.

CS Memory and Aging, Division of Neural Systems, Arizona Research Laboratories, University of Arizona, Tucson, AZ, 85724, USA

SO Brain Research (1999), 815(1), 36-43
 CODEN: BRREAP; ISSN: 0006-8993

PB Elsevier Science B.V.

DT Journal

LA English

CC 1-7 (Pharmacology)

AB This study investigated whether nitroflurbiprofen (NFP) or nitro-aspirin can reduce the inflammatory response induced by continuous infusion of

lipopolysaccharide (LPS) into the 4th ventricular space of the rat brain for 30 days. The chronic LPS infusion produced an extensive inflammation that was particularly evident in the hippocampus, subiculum and entorhinal and piriform cortices. Daily peripheral administration of NFP dose-dependently attenuated the brain inflammation, as indicated by the decreased d. and reactive state of microglial cells. Daily peripheral administration of nitro-aspirin also attenuated the brain inflammation, but to a much lesser degree than NFP. The results demonstrated that nonsteroidal anti-inflammatory drugs can reduce brain inflammation and that NFP is an effective anti-inflammatory agent.

ST brain inflammation inhibition nitroflurbiprofen nitroaspirin; nonsteroidal antiinflammatory drug brain inflammation

IT Encephalitis

(nitroflurbiprofen and nitroaspirin inhibition of)

IT Alzheimer's disease

(nitroflurbiprofen and nitroaspirin inhibition of brain inflammation in relation to)

IT Anti-inflammatory agents

(nonsteroidal; brain inflammation inhibition by nitroflurbiprofen and nitroaspirin as)

IT **17336-14-0** 158836-71-6, Nitroflurbiprofen

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(brain inflammation inhibition by)

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Aisen, P; Am J Psychiatr 1994, V151, P1105 MEDLINE

(2) Allison, M; N Engl J Med 1992, V327, P749 MEDLINE

(3) Altstiel, L; Prog Neuropsychopharmacol Biol Psychiatr 1991, V15, P481 CAPLUS

(4) Banati, R; Glia 1993, V7, P111 MEDLINE

(5) Bannwarth, B; Therapie 1986, V41, P409 CAPLUS

(6) Breder, C; Brain Res 1996, V713, P64 CAPLUS

(7) Breitner, J; Neurobiol Aging 1996, V17, P789 MEDLINE

(8) Burrell, R; Crit Rev Microbiol 1990, V17, P188

(9) Cacabelos, R; Meth Find Exp Clin Pharmacol 1994, V16, P141 MEDLINE

(10) Chiang, C; Dev Neurosci 1994, V16, P212 CAPLUS

(11) Das, S; Neuron 1995, V14, P447 CAPLUS

(12) Eikelenboom, P; Virchows Arch B Cell Pathol 1989, V56, P259 MEDLINE

(13) Elmquist, J; J Comp Neurol 1997, V381, P119 CAPLUS

(14) Greenblatt, D; Arzneimittelforschung 1983, V33, P1671 CAPLUS

(15) Griffin, W; Proc Natl Acad Sci USA 1989, V86, P7611 MEDLINE

(16) Hauss-Wegrzyniak, B; Brain Res 1998, V794, P211 CAPLUS

(17) Hauss-Wegrzyniak, B; Brain Res 1998, V780, P294 CAPLUS

(18) Jenkinson, M; Br J Rheumatol 1989, V28, P86 MEDLINE

(19) Kitagawa, H; J Pharmacol Exp Therap 1990, V253, P1133 CAPLUS

(20) Macnaughton, W; Life Sci 1989, V45, P1869 CAPLUS

(21) McGeer, P; Brain Res Rev 1995, V21, P195 MEDLINE

(22) McGeer, P; Lancet 1990, V335, P1037 MEDLINE

(23) McGeer, P; Neurosci Lett 1988, V79, P195

(24) McGeer, P; Neurosci Lett 1989, V107, P341 MEDLINE

(25) Mrak, R; Human Pathol 1995, V26, P816 MEDLINE

(26) Myllykangas-Luosujarvi, R; Br J Rheumatol 1994, V33, P501 MEDLINE

(27) Rogers, J; Drug Res 1995, V45, P439 CAPLUS

(28) Rogers, J; Neurobiol Aging 1996, V17, P681 MEDLINE

(29) Rogers, J; Neurology 1993, V43, P1609 MEDLINE

(30) Roth, S; Ann Intern Med 1988, V109, P353 MEDLINE

(31) Santini, G; Eur J Pharmacol 1996, V316, P65 CAPLUS

(32) Sheng, J; Neurobiol Aging 1996, V17, P761 CAPLUS

(33) Strauss, S; Lab Invest 1992, V66, P223 MEDLINE

(34) Vandenabeele, P; Immunol Today 1991, V12, P217 CAPLUS

(35) Wallace, J; Gastroenterology 1994, V107, P173 CAPLUS
 (36) Wallace, J; Trends Pharmacol Sci 1992, V13, P129 MEDLINE
 (37) Watson; Paxinos 1986

=> e lupus

E1 1 LUPUR/BI
 E2 1 LUPURENE/BI
 E3 11819 --> LUPUS/BI
 E4 13 LUPUSLIKE/BI
 E5 1 LUPUSS/BI
 E6 2 LUPUTRIONE/BI
 E7 2 LUPUTRIONES/BI
 E8 15 LUQ/BI
 E9 1 LUQ1/BI
 E10 1 LUQ3/BI
 E11 4 LUQAS/BI
 E12 1 LUQB/BI

=> s e3

L30 11819 LUPUS/BI

=> s l30 and l10

L31 53 L30 AND L10

=> d l31 30-53

L31 ANSWER 30 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1999:282073 CAPLUS

DN 130:320863

TI Use of inhaled nitric oxide for lessening or preventing non-pulmonary
 ischemia-reperfusion injury or inflammation

IN Zapol, Warren M.; Bloch, Kenneth D.; Rosenzweig, Anthony

PA The General Hospital Corporation, USA

SO PCT Int. Appl., 19 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9920251	A1	19990429	WO 1998-US22044	19981019
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2309038	AA	19990429	CA 1998-2309038	19981019
	AU 9911012	A1	19990510	AU 1999-11012	19981019
	AU 751853	B2	20020829		
	EP 1073416	A1	20010207	EP 1998-953702	19981019
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	ZA 9809550	A	19990721	ZA 1998-9550	19981020
PRAI	US 1997-62926P	P	19971021		
	US 1997-971003	A	19971114		
	WO 1998-US22044	W	19981019		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 31 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:806633 CAPLUS
 DN 130:57211
 TI Preparation of conjugates of dithiocarbamates with drugs
 IN Lai, Ching-san
 PA Medinox, Inc., USA
 SO PCT Int. Appl., 66 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9855453	A1	19981210	WO 1998-US10295	19980519
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5916910	A	19990629	US 1997-869158	19970604
	AU 9875828	A1	19981221	AU 1998-75828	19980519
	AU 743205	B2	20020124		
	EP 1001932	A1	20000524	EP 1998-923563	19980519
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002511858	T2	20020416	JP 1999-502493	19980519
	US 6407135	B1	20020618	US 1999-453608	19991203
	US 2003087840	A1	20030508	US 2002-176396	20020618
PRAI	US 1997-869158	A1	19970604		
	WO 1998-US10295	W	19980519		
	US 1999-453608	A3	19991203		

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 32 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:766188 CAPLUS
 DN 130:166818
 TI Anti-phospholipid syndrome: from patient's bedside to experimental animal models and back to the patient's bedside
 AU Ziporen, L.; Shoenfeld, Y.
 CS Research Unit. of Autoimmune Diseases, Department of Medicine B, Sheba Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Israel
 SO Hematology and Cell Therapy (1998), 40(5), 175-182
 CODEN: HCTHFA; ISSN: 1430-2772
 PB Springer-Verlag France
 DT Journal; General Review
 LA English

RE.CNT 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 33 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:708808 CAPLUS
 DN 129:310911
 TI TGF-.beta.-elevating compounds and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods
 IN Grainger, David J.; Metcalfe, James C.; Kasina, Sudhakar
 PA Neorx Corp., USA
 SO PCT Int. Appl., 153 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9846588	A2	19981022	WO 1998-US7063	19980409
	WO 9846588	A3	19990107		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9869598	A1	19981111	AU 1998-69598	19980409
	US 6117911	A	20000912	US 1998-57323	19980409
	US 6410587	B1	20020625	US 2000-567558	20000505
	US 2003064970	A1	20030403	US 2002-170971	20020613
PRAI	US 1997-43852P	P	19970411		
	US 1998-57323	A1	19980409		
	WO 1998-US7063	W	19980409		
	US 2000-567558	A3	20000505		
OS	MARPAT 129:310911				

L31 ANSWER 34 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:584280 CAPLUS
DN 129:342593
TI Recurrent abortion and moderate or strong antiphospholipid antibody production
AU Ogasawara, M.; Sasa, H.; Katano, K.; Aoyama, T.; Aoki, K.; Suzumori, K.
CS Department of Obstetrics and Gynecology, Nagoya City University Medical School, Nagoya, Japan
SO International Journal of Gynecology & Obstetrics (1998), 62(2), 183-188
CODEN: IJGOAL; ISSN: 0020-7292
PB Elsevier Science Ireland Ltd.
DT Journal
LA English
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 35 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:341491 CAPLUS
DN 129:12742
TI Methods and compositions using thalidomide or other angiogenesis-inhibitory compound and anti-inflammatory agent for inhibition of angiogenesis
IN D'Amato, Robert J.
PA Children's Medical Center, USA
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9819649	A2	19980514	WO 1997-US20116	19971104
	WO 9819649	A3	19980625		
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT,				

RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN,
YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
GN, ML, MR, NE, SN, TD, TG

AU 9851973 A1 19980529 AU 1998-51973 19971104
AU 746713 B2 20020502
EP 963200 A2 19991215 EP 1997-946884 19971104

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI

NZ 336035 A 20020328 NZ 1997-336035 19971104
JP 2002513391 T2 20020508 JP 1998-521728 19971104

PRAI US 1996-28708P P 19961105
US 1997-963058 A 19971103
WO 1997-US20116 W 19971104

OS MARPAT 129:12742

L31 ANSWER 36 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:167985 CAPLUS

DN 128:293600

TI The effect of sera from women with systemic **lupus** erythematosus
and/or antiphospholipid syndrome on rat embryos in culture

AU Ornoy, A.; Yacobi, S.; Avraham, S.; Blumenfeld, Z.

CS Laboratory of Teratology, Department of Anatomy & Cell Biology, Hebrew
University Hadassah Medical School, Jerusalem, 91120, Israel

SO Reproductive Toxicology (1998), 12(2), 185-191

CODEN: REPTED; ISSN: 0890-6238

PB Elsevier Science Inc.

DT Journal

LA English

RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 37 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1997:804013 CAPLUS

DN 128:60525

TI Coagulation and fibrinolysis in pregnant women with antiphospholipid
antibodies

AU Amemiya, Teruko; Nakabayashi, Masao; Adachi, Tomoko; Takeda, Yoshihiko

CS Dep. Obstet. Gynecol., Tokyo Women's Med. Coll., Tokyo, 162, Japan

SO Tokyo Joshi Ika Daigaku Zasshi (1997), 67(11), 892-901

CODEN: TJIZAF; ISSN: 0040-9022

PB Tokyo Joshi Ika Daigaku Gakkai

DT Journal

LA Japanese

L31 ANSWER 38 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1997:746178 CAPLUS

DN 128:21484

TI Classification of asthma patients using polymorphisms in the
5-lipoxygenase gene

IN Drazen, Jeffrey M.; In, Kwang-Ho; Asano, Koichiro; Beier, David; Grobholz,
James

PA Brigham and Women's Hospital, USA

SO PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9742347	A2	19971113	WO 1997-US7137	19970429

WO 9742347 A3 19980108
W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NZ
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
US 6090547 A 20000718 US 1997-846020 19970425
AU 9729277 A1 19971126 AU 1997-29277 19970429
EP 896633 A2 19990217 EP 1997-923486 19970429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI
ZA 9703849 A 19980204 ZA 1997-3849 19970505
US 6355434 B1 20020312 US 2000-617871 20000717
PRAI US 1996-16890P P 19960506
US 1997-846020 A 19970425
WO 1997-US7137 W 19970429

L31 ANSWER 39 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:520584 CAPLUS
DN 127:171563
TI Prednisone and aspirin in women with autoantibodies and unexplained
recurrent fetal loss
AU Laskin, Carl A.; Bombardier, Claire; Hannah, Mary E.; Mandel, Fred P.;
Ritchie, J.W. Knox; Farewell, Vern; Farine, Dan; Spitzer, Karen; Fielding,
Lynda; Soloninka, Christine A.; Yeung, Maria
CS Department of Medicine, Division of Rheumatology, University of Toronto,
Toronto, Can.
SO New England Journal of Medicine (1997), 337(3), 148-153
CODEN: NEJMAG; ISSN: 0028-4793
PB Massachusetts Medical Society
DT Journal
LA English

L31 ANSWER 40 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:498354 CAPLUS
DN 127:160341
TI Effect of antiphospholipid antibodies in women undergoing in-vitro
fertilization: role of heparin and aspirin
AU Kutteh, William H.; Yetman, Deborah L.; Chantilis, Samuel J.; Crain, Jack
CS Memphis Health Science Center, The University of Tennessee, Memphis, TN,
USA
SO Human Reproduction (1997), 12(6), 1171-1175
CODEN: HUREEE; ISSN: 0268-1161
PB Oxford University Press
DT Journal
LA English

L31 ANSWER 41 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:343267 CAPLUS
DN 127:13431
TI Antiphospholipid antibodies in pregnant patients
AU Caruso, A.; De Carolis, S.; Ferrazzani, S.; De Santis, L.; Carducci, B.;
Trivellinil, C.; Mancuso, S.
CS Department Obstetrics Gynecology, Catholic University Rome, Rome, 00168,
Italy
SO International Journal of Immunopathology and Pharmacology (1997), 10(2,
Suppl.), 137-138
CODEN: IJIPE4; ISSN: 0394-6320
PB Biomedical Research Press
DT Journal
LA English

L31 ANSWER 42 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:68836 CAPLUS
DN 124:193785

TI The effect of aspirin and indomethacin on prostacyclin and thromboxane production by placental tissue incubated with immunoglobulin G fractions from patients with **lupus** anticoagulant
 AU Peaceman, Alan M.; Rehnberg, Karen A.
 CS Medical School, Northwestern University, Chicago, IL, 60611, USA
 SO American Journal of Obstetrics and Gynecology (1995), 173(5), 1391-6
 CODEN: AJOGAH; ISSN: 0002-9378
 PB Mosby-Year Book
 DT Journal
 LA English

L31 ANSWER 43 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1993:400486 CAPLUS
 DN 119:486
 TI Production of prostacyclin and thromboxane in **lupus** pregnancies: effect of small dose of aspirin
 AU Kaaja, Risto; Julkunen, Heikki; Viinikka, Lasse; Ylikorkala, Olavi
 CS Dep. I II Obstetr. Gynceol., Univ. Cent. Hosp. Helsinki, Helsinki, Finland
 SO Obstetrics & Gynecology (New York, NY, United States) (1993), 81(3), 327-31
 CODEN: OBGNAS; ISSN: 0029-7844
 DT Journal
 LA English

L31 ANSWER 44 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1991:400390 CAPLUS
 DN 115:390
 TI Selective inhibition of platelet-derived thromboxane A2 in patients with **lupus** anticoagulant using low doses aspirin as assessed by enzyme immunoassay
 AU Lellouche, Franck; Falcon, , Cristina; Carreras, Luis; Maclof, Jacques
 CS Hop. Lariboisiere, Paris, 75475, Fr.
 SO Advances in Prostaglandin, Thromboxane, and Leukotriene Research (1990), 21B(Prostaglandins Relat. Compd.), 611-14
 CODEN: ATLRD6; ISSN: 0732-8141
 DT Journal
 LA English

L31 ANSWER 45 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1991:22375 CAPLUS
 DN 114:22375
 TI Interleukin-4 (IL-4) in method and compositions for degradation and prevention of fibrin deposits associated with pathological conditions
 IN Hamilton, John Allan; Hart, Prudence Hamilton
 PA University of Melbourne, Australia
 SO PCT Int. Appl., 23 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	----	-----	-----
PI	WO 9007932	A1	19900726	WO 1990-AU13	19900119
	W: AU, CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
	CA 2045574	AA	19900721	CA 1990-2045574	19900119
	AU 9049645	A1	19900813	AU 1990-49645	19900119
	AU 639903	B2	19930812		
	EP 454736	A1	19911106	EP 1990-902120	19900119
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	JP 04503062	T2	19920604	JP 1990-502488	19900119
	JP 06011706	B4	19940216		

	US 5236705	A	19930817	US 1991-720868	19910918
PRAI	AU 1989-2356		19890120		
	WO 1990-AU13		19900119		

- L31 ANSWER 46 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1991:564 CAPLUS
 DN 114:564
 TI Scavengers of free radical oxygen affect the generation of low molecular weight DNA in stimulated lymphocytes from patients with systemic **lupus** erythematosus
 AU Benke, Paul J.; Levcovitz, Henrique; Paupe, Jean; Tozman, Elaine
 CS Sch. Med., Univ. Miami, Miami, FL, USA
 SO Metabolism, Clinical and Experimental (1990), 39(12), 1278-84
 CODEN: METAAJ; ISSN: 0026-0495
 DT Journal
 LA English
- L31 ANSWER 47 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1987:188817 CAPLUS
 DN 106:188817
 TI Assessment of kininases in rheumatic diseases and the effect of therapeutic agents
 AU Sheikh, Iftikhar A.; Kaplan, Allen P.
 CS Dep. Med., SUNY, Stony Brook, NY, USA
 SO Arthritis & Rheumatism (1987), 30(2), 138-45
 CODEN: ARHEAW; ISSN: 0004-3591
 DT Journal
 LA English
- L31 ANSWER 48 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1984:504080 CAPLUS
 DN 101:104080
 TI Effects of oral aspirin and oxaprozin on the development of **lupus** -like disease in MRL/l mice
 AU Carlson, Richard P.; Gilman, Steven C.; Hodge, Thomas G.; O'Neill-Davis, Lynn; Blazek, Eileen M.; Lewis, Alan J.
 CS Dep. Exp. Ther., Wyeth Lab., Inc., Philadelphia, PA, 19101, USA
 SO Journal of Immunopharmacology (1984), 6(1-2), 69-78
 CODEN: JOIMD6; ISSN: 0163-0571
 DT Journal
 LA English
- L31 ANSWER 49 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1979:197800 CAPLUS
 DN 90:197800
 TI Salicylate hepatotoxicity in systemic **lupus** erythematosus: a common occurrence?
 AU Travers, R. L.; Hughes, G. R. V.
 CS R. Postgrad. Med. Sch., Hammersmith Hosp., London, UK
 SO British Medical Journal (1978), 2(6151), 1532-3
 CODEN: BMJOAE; ISSN: 0007-1447
 DT Journal
 LA English
- L31 ANSWER 50 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1978:609248 CAPLUS
 DN 89:209248
 TI Elevated urinary prostaglandins and the effects of aspirin on renal function in **lupus** erythematosus
 AU Kimberly, Robert P.; Gill, John R., Jr.; Bowden, Robert E.; Keiser, Harry R.; Plotz, Paul H.
 CS Natl. Inst. Arthritis, Metab. Dig. Dis., NIH, Bethesda, MD, USA

SO Annals of Internal Medicine (1978), 89(3), 336-41
CODEN: AIMEAS; ISSN: 0003-4819
DT Journal
LA English

L31 ANSWER 51 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1978:45148 CAPLUS
DN 88:45148
TI Aspirin and renal function
AU Spooner, J. B.; Cleaver, G. J.
CS Winthrop Lab., Surbiton-upon-Thames/Surrey, UK
SO Lancet (1977), 8028, 88
CODEN: LANCAO; ISSN: 0140-6736
DT Journal
LA English

L31 ANSWER 52 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1973:37784 CAPLUS
DN 78:37784
TI Spectrum of drug-induced pulmonary disease
AU Rosenow, E. C. III
CS Mayo Clin. and Mayo Found., Rochester, MN, USA
SO Annals of Internal Medicine (1972), 77(6), 977-91
CODEN: AIMEAS; ISSN: 0003-4819
DT Journal; General Review
LA English

L31 ANSWER 53 OF 53 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1963:484674 CAPLUS
DN 59:84674
OREF 59:15746a-b
TI Impairments of aromatic amino acid metabolism in collagenoses; their contribution to the conception of systemic **lupus**
AU Grupper, Ch.; Legrand, J. C.; Gonnard, P.
CS Hop. St. Louis, Paris
SO Semaine des Hopitaux (1962), 38, 70-6
CODEN: SHPAAI; ISSN: 0037-1777
DT Journal
LA Unavailable

=> e alzheimers

E1	1	ALZHEIMERISTS/BI
E2	1	ALZHEIMERLIKE/BI
E3	1977 -->	ALZHEIMERS/BI
E4	2	ALZHEIMERSDISEASE/BI
E5	1	ALZHEIMR/BI
E6	1	ALZHEINER/BI
E7	1	ALZHEINIER/BI
E8	1	ALZHEMER/BI
E9	3	ALZHEMIER/BI
E10	1	ALZHEMIERS/BI
E11	1	ALZHEMIMER/BI
E12	1	ALZHIEMER/BI

=> s e3

L32 1977 ALZHEIMERS/BI

=> s l10 and l32

L33 8 L10 AND L32

=> d l33 1-8

L33 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2003:633484 CAPLUS
 DN 139:173796
 TI Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
 IN Haas, Werner; Romao, Carlos; Royo, Beatriz; Fernandes, Ana Cristina; Goncalves, Isabel
 PA Port.
 SO PCT Int. Appl., 76 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003066067	A2	20030814	WO 2003-IB932	20030203
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2002-353233P	P	20020204		

L33 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:262912 CAPLUS
 DN 136:363747
 TI An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting
 AU Bilikiewicz, Adam; Opala, Grzegorz; Podemski, Ryszard; Puzynski, Stanislaw; Lapin, Joanna; Soltys, Krzysztof; Ochudlo, Stanislaw; Barcikowska, Maria; Pfeffer, Anna; Bilinska, Malgorzata; Paradowski, Boguslaw; Parnowski, Tadeusz; Gabryelewicz, Tomasz
 CS 2nd Clinic of Mental Diseases, Medical University of Gdansk, Gdansk, 80-282, Pol.
 SO Medical Science Monitor (2002), 8(2), PI9-PI15
 CODEN: MSMOFR; ISSN: 1234-1010
 PB Medical Science International Publishing Co., Ltd.
 DT Journal
 LA English
 RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:597824 CAPLUS
 DN 135:175406
 TI Methods and compositions for treatment of Alzheimer's disease by enhancing plasmin or plasmin-like activity
 IN Dotti, Carlos G.; Ledesma, Maria D.
 PA The European Molecular Biology Laboratory, Germany
 SO PCT Int. Appl., 59 pp.
 CODEN: PIXXD2
 DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001058476	A2	20010816	WO 2001-EP1517	20010212
	WO 2001058476	A3	20020328		
	W: AU, CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,				
	PT, SE, TR				
PRAI	US 2000-502448	A	20000211		
	US 2000-714928	A	20001117		

L33 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:83218 CAPLUS
DN 135:102424
TI Regulation of APP synthesis and secretion by neuroimmunophilin ligands and cyclooxygenase inhibitors
AU Lee, Robert K. K.; Wurtman, Richard J.
CS Division of Health Sciences and Technology, Harvard University-Massachusetts Institute of Technology, Cambridge, MA, 02139, USA
SO Annals of the New York Academy of Sciences (2000), 920(Molecular Basis of Dementia), 261-268
CODEN: ANYAA9; ISSN: 0077-8923
PB New York Academy of Sciences
DT Journal
LA English
RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:445101 CAPLUS
DN 133:68575
TI Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County Study
AU Anthony, J. C.; Breitner, J. C. S.; Zandi, P. P.; Meyer, M. R.; Jurasova, I.; Norton, M. C.; Stone, S. V.; Burke, James; Calvert, Tony; Gau, Barbara; Helms, Michael; Khachaturian, Ara; Leslie, Carole; Newman, Tiffany; Plassman, Brenda; Steffens, David C.; Steinberg, Martin; Tschanz, JoAnn T.; Welsh-Bohmer, Kathleen A.; West, Nancy; Wyse, Bonita
CS Cache County Memory Study Group, Department of Mental Hygiene, School of Hygiene and Public Health, Johns Hopkins University, Baltimore, MD, USA
SO Neurology (2000), 54(11), 2066-2071
CODEN: NEURAI; ISSN: 0028-3878
PB Lippincott Williams & Wilkins
DT Journal
LA English
RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:438032 CAPLUS
DN 131:193920
TI Toxicity of human THP-1 monocytic cells towards neuron-like cells is reduced by non-steroidal anti-inflammatory drugs (NSAIDs)
AU Klegeris, A.; Walker, D. G.; McGeer, P. L.
CS Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, BC, V6T 1Z3, Can.
SO Neuropharmacology (1999), 38(7), 1017-1025
CODEN: NEPHBW; ISSN: 0028-3908
PB Elsevier Science Ltd.
DT Journal
LA English
RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L33 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1996:97266 CAPLUS
 DN 124:135727
 TI Method and use of agents to inhibit protein polymerization, methods of identifying these agents, and use of the agents as antithrombotics and for the treatment of Alzheimer's disease
 IN Bjornsson, Thorir D.
 PA Thomas Jefferson University, USA
 SO PCT Int. Appl., 18 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9531192	A1	19951123	WO 1995-US6383	19950515
	W: CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	US 1994-243114		19940516		
OS	MARPAT 124:135727				

L33 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1989:206625 CAPLUS
 DN 110:206625
 TI Hormone treatment for central nervous system diseases such as **Alzheimers** disease and Parkinsons disease
 IN Aroonsakul, Chaovanee
 PA USA
 SO U.S., 4 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4791099	A	19881213	US 1984-666254	19841029
	EP 324037	A1	19890719	EP 1988-100233	19880111
	EP 324037	B1	19970903		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 157546	E	19970915	AT 1988-100233	19880111
	ES 2109914	T3	19980201	ES 1988-100233	19880111
	US 4898856	A	19900206	US 1988-156242	19880216
	JP 01216940	A2	19890830	JP 1988-39323	19880222
	JP 09216837	A2	19970819	JP 1997-38275	19880222
	US 4897389	A	19900130	US 1989-293134	19890103
	US 4902680	A	19900220	US 1989-293017	19890103
	US 4898857	A	19900206	US 1989-293132	19890203
PRAI	US 1984-666254		19841029		
	US 1986-852645		19860416		
	EP 1988-100233		19880111		
	US 1988-156242		19880216		
	JP 1988-39323		19880222		

=> e nsaid5

E1	1	NSAID5/BI
E2	1	NSAIDH/BI
E3	3367 -->	NSAIDS/BI
E4	3	NSAIDSS/BI
E5	1	NSAIFA/BI

E6 1 NSAIFD/BI
 E7 2 NSAIIDS/BI
 E8 1 NSAIO/BI
 E9 6 NSAIS/BI
 E10 1 NSAISS/BI
 E11 2 NSAIW/BI
 E12 1 NSAJDS/BI

=> s e3

L34 3367 NSAIDS/BI

=> s 134 and 117

L35 36 L34 AND L17

=> d 135 20-36

L35 ANSWER 20 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:368364 CAPLUS
 DN 133:12744
 TI Phospholipid derivatives of nonsteroidal antiinflammatory drugs
 IN Kozak, Alexander; Shapiro, Israel
 PA D-Pharm Ltd., Israel
 SO PCT Int. Appl., 76 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000031083	A1	20000602	WO 1999-IL623	19991118
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2346869	AA	20000602	CA 1999-2346869	19991118
	EP 1131326	A1	20010912	EP 1999-956297	19991118
	EP 1131326	B1	20030507		
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002530410	T2	20020917	JP 2000-583911	19991118
	NZ 510938	A	20021126	NZ 1999-510938	19991118
	AT 239739	E	20030515	AT 1999-956297	19991118
PRAI	IL 1998-127143	A	19981119		
	WO 1999-IL623	W	19991118		

OS MARPAT 133:12744

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 21 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2000:176859 CAPLUS
 DN 132:303172
 TI Glutamate and kynurenate in the rat central nervous system following treatments with tail **ischemia** or diclofenac
 AU Edwards, Stephen R.; Mather, Laurence E.; Lin, Yiguang; Power, Ian; Cousins, Michael J.
 CS Department of Anaesthesia and Pain Management, University of Sydney at Royal North Shore Hospital, St Leonards, 2065, Australia

SO Journal of Pharmacy and Pharmacology (2000), 52(1), 59-66
CODEN: JPPMAB; ISSN: 0022-3573
PB Royal Pharmaceutical Society of Great Britain
DT Journal
LA English
RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 22 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:399998 CAPLUS
DN 131:164908
TI Antirheumatic agents and leukocyte recruitment: new light on the mechanism
of action of oxaceprol
AU Parnham, Michael J.
CS Pharmacological Institute for the Life Sciences, J. W. Goethe University,
Frankfurt am Main, D-60439, Germany
SO Biochemical Pharmacology (1999), 58(2), 209-215
CODEN: BCPA6; ISSN: 0006-2952
PB Elsevier Science Inc.
DT Journal; General Review
LA English
RE.CNT 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 23 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:396786 CAPLUS
DN 131:208462
TI Renal side effects of **NSAIDs**: role of COX-1 and COX-2
AU Frolich, J. C.; Stichtenoth, D. O.
CS Institute of Clinical Pharmacology, Hannover Medical School, Hannover,
30623, Germany
SO Selective COX-2 Inhibitors: Pharmacology, Clinical Effects and Therapeutic
Potential, Proceedings of a Conference, Cannes, Fr., Mar. 20-21, 1997
(1998), Meeting Date 1997, 87-98. Editor(s): Vane, John R.; Botting, Jack
H. Publisher: Kluwer, Dordrecht, Neth.
CODEN: 67UBAO
DT Conference; General Review
LA English
RE.CNT 79 THERE ARE 79 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 24 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:316752 CAPLUS
DN 131:129302
TI Short-term vitamin E supplementation before marathon running: a
placebo-controlled trial
AU Buchman, Alan L.; Killip, Donna; Ou, Ching-Nan; Rognerud, Cheryl L.;
Pownall, Henry; Dennis, Kenneth; Dunn, J. Kay
CS Division of Gastroenterology, University of Texas Houston Health Science
Center, Houston, TX, 77030, USA
SO Nutrition (New York) (1999), 15(4), 278-283
CODEN: NUTRER; ISSN: 0899-9007
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 25 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:744944 CAPLUS
DN 130:10625
TI COX-2-selective carprofen and related compounds for treating pain and

inflammation in dogs
IN Lundy, Kristin Marie; Ricketts, Anthony Paul
PA Pfizer Inc., USA
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9850033	A1	19981112	WO 1998-IB662	19980501
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9869321	A1	19981127	AU 1998-69321	19980501
	EP 988034	A1	20000329	EP 1998-915041	19980501
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO			
	BR 9808720	A	20000711	BR 1998-8720	19980501
	JP 2000513020	T2	20001003	JP 1998-547869	19980501
	NZ 500183	A	20020426	NZ 1998-500183	19980501
	ZA 9803722	A	19991104	ZA 1998-3722	19980504
	MX 9910148	A	20000228	MX 1999-10148	19991104
PRAI	US 1997-45635P	P	19970505		
	WO 1998-IB662	W	19980501		

OS MARPAT 130:10625

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 26 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:700744 CAPLUS
DN 130:60774
TI Nonsteroidal anti-inflammatory drugs increase tumor necrosis factor production in the periphery but not in the central nervous system in mice and rats
AU Sacco, Silvano; Agnello, Davide; Sottocorno, Marcello; Lozza, Gianluca; Monopoli, Angela; Villa, Pia; Ghezzi, Pietro
CS Laboratory of Neuroimmunology, "Mario Negri" Institute for Pharmacological Research, Milan, 20157, Italy
SO Journal of Neurochemistry (1998), 71(5), 2063-2070
CODEN: JONRA9; ISSN: 0022-3042
PB Lippincott-Raven Publishers
DT Journal
LA English

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 27 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:92958 CAPLUS
DN 128:212888
TI The effect of prednisolone and non-steroidal anti-inflammatory agents on the normal and noise-damaged guinea pig inner ear
AU Lamm, Kerstin; Arnold, Wolfgang
CS Department of Otolaryngology, Head and Neck Surgery, Klinikum rechts der Isar, Technical University of Munich, Munich, D-81675, Germany
SO Hearing Research (1998), 115(1-2), 149-161
CODEN: HERED3; ISSN: 0378-5955

PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

- L35 ANSWER 28 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:255183 CAPLUS
DN 126:288084
TI Protective effect of taurine on indomethacin-induced gastric mucosal injury
AU Son, Miwon; Kim, Hee Kee; Kim, Won Bae; Yang, Junnick; Kim, Byong Kak
CS Research Laboratories of Dong-A Pharmaceutical Co., Ltd., Kyungki, 449-900, S. Korea
SO Advances in Experimental Medicine and Biology (1996), 403(Taurine 2), 147-155
CODEN: AEMBAP; ISSN: 0065-2598
PB Plenum
DT Journal
LA English
- L35 ANSWER 29 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:659613 CAPLUS
DN 125:292562
TI Superior mesenteric artery blood flow and indomethacin-induced intestinal injury and inflammation
AU Battarbee, Harold D.; Grisham, Matthew B.; Johnson, Glenda G.; Zavecz, James H.
CS Dep. Physiology Pharmacology, Louisiana State Univ. Med. Center, Shreveport, LA, 71130-3932, USA
SO American Journal of Physiology (1996), 271(4, Pt. 1), G605-G612
CODEN: AJPHAP; ISSN: 0002-9513
PB American Physiological Society
DT Journal
LA English
- L35 ANSWER 30 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:629649 CAPLUS
DN 125:265970
TI Omeprazole attenuates oxygen-derived free radical production from human neutrophils
AU Suzuki, Masayuki; Mori, Miki; Miura, Soichiro; Suematsu, Makoto; Fukumura, Dai; Kimura, Hiroyuki; Ishii, Hiromasa
CS School of Medicine, Keio Univ., Tokyo, Japan
SO Free Radical Biology & Medicine (1996), 21(5), 727-731
CODEN: FRBMEH; ISSN: 0891-5849
PB Elsevier
DT Journal
LA English
- L35 ANSWER 31 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:302882 CAPLUS
DN 125:794
TI Protective effect of taurine on indomethacin-induced gastric mucosal injury
AU Son, Miwon; Kim, Hee Kee; Kim, Won Bae; Yang, Junnick; Kim, Byong Kak
CS Res. Lab. Dong-A Pharm. Co. Ltd., Kyungki-DO, 449-900, S. Korea
SO Archives of Pharmacal Research (1996), 19(2), 85-90
CODEN: APHRDQ; ISSN: 0253-6269
PB Pharmaceutical Society of Korea
DT Journal
LA English

L35 ANSWER 32 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1995:480859 CAPLUS
 DN 122:262793
 TI Prostanoid synthesis in the spinal cord enhances excitability of dorsal
 horn convergent neurons during reperfusion of ischemic receptive fields on
 the rat's tail
 AU Gelgor, L.; Mitchell, D.
 CS Department Physiology, University the Witwatersrand Medical School,
 Johannesburg, 2193, S. Afr.
 SO Pain (1995), 60(2), 181-7
 CODEN: PAINDB; ISSN: 0304-3959
 DT Journal
 LA English

L35 ANSWER 33 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1994:508239 CAPLUS
 DN 121:108239
 TI Nitric ester derivatives of nonsteroidal antiinflammatories and process
 for their preparation
 IN Arena, Barbara
 PA HCT-Health Care Trading Ltd., Ire.
 SO PCT Int. Appl., 38 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9412463	A1	19940609	WO 1993-EP3193	19931115
	W: AU, BR, CA, CZ, FI, HU, JP, KP, KR, NO, NZ, PL, RO, RU, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2150229	AA	19940609	CA 1993-2150229	19931115
	AU 9456241	A1	19940622	AU 1994-56241	19931115
	AU 676527	B2	19970313		
	EP 670825	A1	19950913	EP 1994-901797	19931115
	EP 670825	B1	19970423		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
	JP 08504191	T2	19960507	JP 1993-512701	19931115
	HU 73773	A2	19960930	HU 1995-1531	19931115
	HU 215437	B	20001228		
	AT 152092	E	19970515	AT 1994-901797	19931115
	ES 2103563	T3	19970916	ES 1994-901797	19931115
	RU 2127723	C1	19990320	RU 1995-114376	19931115
	BR 9307530	A	19990525	BR 1993-7530	19931115
	JP 3231043	B2	20011119	JP 1994-512701	19931115
	US 5621000	A	19970415	US 1995-446624	19950526
PRAI	IT 1992-MI2699	A	19921126		
	WO 1993-EP3193	W	19931115		
OS	MARPAT 121:108239				

L35 ANSWER 34 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1992:165941 CAPLUS
 DN 116:165941
 TI Effects of systemic nonsteroidal antiinflammatory drugs on nociception
 during tail **ischemia** and on reperfusion hyperalgesia in rats
 AU Gelgor, Linda; Butkow, Neil; Mitchell, Duncan
 CS Med. Sch., Univ. Witwatersrand, Johannesburg, 2193, S. Afr.
 SO British Journal of Pharmacology (1992), 105(2), 412-16
 CODEN: BJPCBM; ISSN: 0007-1188
 DT Journal
 LA English

L35 ANSWER 35 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:165595 CAPLUS
DN 116:165595
TI Progress of active oxygen research in inflammation
AU Oyanagui, Yoshihiko
CS Prod. Dev. Res. Lab., Fujisawa Pharm. Co., Japan
SO Ensho (1992), 12(1), 9-18
CODEN: ENSHEE; ISSN: 0389-4290
DT Journal; General Review
LA Japanese

L35 ANSWER 36 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1987:114179 CAPLUS
DN 106:114179
TI Inhibition of prostaglandin synthesis in rat kidney perfused with and without erythrocytes: implication for analgesic nephropathy
AU Brezis, Mayer; Rosen, Seymour; Stoff, Jeffrey S.; Spokes, Katherine; Silva, Patricio; Epstein, Franklin H.
CS Dep. Med., Hadassah Univ. Hosp., Jerusalem, Israel
SO Mineral and Electrolyte Metabolism (1987), Volume Date 1986, 12(5-6), 326-32
CODEN: MELMDI; ISSN: 0378-0392
DT Journal
LA English

=> d 135 34 all

L35 ANSWER 34 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:165941 CAPLUS
DN 116:165941
TI Effects of systemic nonsteroidal antiinflammatory drugs on nociception during tail **ischemia** and on reperfusion hyperalgesia in rats
AU Gelgor, Linda; Butkow, Neil; Mitchell, Duncan
CS Med. Sch., Univ. Witwatersrand, Johannesburg, 2193, S. Afr.
SO British Journal of Pharmacology (1992), 105(2), 412-16
CODEN: BJPCBM; ISSN: 0007-1188
DT Journal
LA English
CC 1-7 (Pharmacology)
AB The authors have investigated the effects of five non-steroidal antiinflammatory drugs (**NSAIDs**) on nociception during **ischemia** and on reperfusion hyperalgesia in rats. Tail **ischemia** was induced in conscious rats by applying a tourniquet at the base of the tail until the rats exhibited co-ordinated escape behavior when the tourniquet was released. Hyperalgesia was assessed by measuring the tail flick latency following tail immersion in water at 49.degree., before applying and immediately after releasing the tourniquet, and then at 30 min intervals for 2 h. I.p. injection of **NSAIDs** prior to applying the tourniquet had no effect on the coordinated escape behavior during **ischemia**, nor on tail flick latency in the absence of prior **ischemia**. However all the drugs attenuated reperfusion hyperalgesia in a log dose-dependent manner. Doses required to abolish hyperalgesia, were indomethacin 5 mg/kg, diclofenac sodium 42 mg/kg, ibuprofen 54 mg/kg, dipyron 168 mg/kg and paracetamol 170 mg/kg. The authors conclude that the mechanisms underlying nociception during **ischemia** are not the same as those underlying reperfusion hyperalgesia. Moreover this procedure provides a rapid and more humane method for measuring the antinociceptive potency of **NSAIDs**.
ST **ischemia** reperfusion hyperalgesia nonsteroidal antiinflammatory analgesia

IT **Ischemia**
 (nociception during, nonsteroidal antiinflammatory drugs effect on)

IT Analgesics
 (nonsteroidal antiinflammatory drugs, effects on nociception during **ischemia** and reperfusion hyperalgesia)

IT Inflammation inhibitors
 (nonsteroidal, nociception during **ischemia** and reperfusion hyperalgesia inhibition by)

IT Pain
 (hyperalgesia, from reperfusion after **ischemia**, nonsteroidal antiinflammatory drugs effect on)

IT 53-86-1, Indomethacin 68-89-3, Dipyrone 103-90-2, Paracetamol 15307-86-5, Diclofenac 15687-27-1, Ibuprofen
 RL: BIOL (Biological study)
 (nociception during **ischemia** and reperfusion hyperalgesia inhibition by)

=> d 135 35 all

L35 ANSWER 35 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1992:165595 CAPLUS
 DN 116:165595
 TI Progress of active oxygen research in inflammation
 AU Oyanagui, Yoshihiko
 CS Prod. Dev. Res. Lab., Fujisawa Pharm. Co., Japan
 SO Ensho (1992), 12(1), 9-18
 CODEN: ENSHEE; ISSN: 0389-4290
 DT Journal; General Review
 LA Japanese
 CC 1-0 (Pharmacology)
 Section cross-reference(s): 14

AB A review with 27 refs. Active oxygens (O2-, H2O2, .cntdot.OH, OCl-, 1O2, 1OO.cntdot., LO.cntdot.) are involved in various inflammatory processes. Leukocytes generate O2- and H2O2 to attack the invaded bacteria and xenobiotics, but excess prodn. results in inflammation. Antigen-antibody complex, cytokines etc. also generate active oxygens. Clin. using non-steroidal antiinflammatory drugs (**NSAIDs**, diclofenac sodium, indomethacin etc.) inhibit leukocyte O2- prodn. Immune diseases, **ischemia** and atherosclerosis develop organ inflammation via formation of active oxygens. Vascular tone-regulating EDRF (NO.cntdot.) is decompd. by O2- and proteinases may react to the proteins which were degenerated by active oxygens. Free and modified SODs are under animal and clin. trails as well as antioxidant derivs.

ST review active oxygen inflammation antiinflammatory drug; antioxidant drug inflammation review

IT Inflammation
 (active oxygens in pathophysiol. of)

IT Inflammation inhibitors
 (as antioxidants)

IT Reactive oxygen species
 RL: BIOL (Biological study)
 (in inflammation)

IT Antioxidants
 (inflammation inhibitors as)

=> d 135 27 all

L35 ANSWER 27 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:92958 CAPLUS
 DN 128:212888

TI The effect of prednisolone and non-steroidal anti-inflammatory agents on
 the normal and noise-damaged guinea pig inner ear
 AU Lamm, Kerstin; Arnold, Wolfgang
 CS Department of Otolaryngology, Head and Neck Surgery, Klinikum rechts der
 Isar, Technical University of Munich, Munich, D-81675, Germany
 SO Hearing Research (1998), 115(1-2), 149-161
 CODEN: HERED3; ISSN: 0378-5955
 PB Elsevier Science B.V.
 DT Journal
 LA English
 CC 1-7 (Pharmacology)
 Section cross-reference(s): 2
 AB The effect of anti-inflammatory agents, such as the synthetic
 glucocorticoid prednisolone, diclofenac sodium, and histamine H1-receptor
 antagonist, was studied in unexposed and noise-exposed (broad-band noise,
 bandwidth 1-12 kHz, 106 dB SPL, 30 min) guinea pigs. The results were
 compared with the results obtained from no treatment and with isotonic
 saline (placebo) therapy. The cochlear blood flow (CoBF) and the partial
 oxygen pressure in the perilymph (PL-pO2) were continuously and
 simultaneously recorded over a period of 210 min. In addn., cochlear
 microphonics (CMs), compd. action potentials of the auditory nerve (CAPs),
 and auditory brain stem responses (ABRs) were registered. Noise-induced
 hearing loss paralleled a decrease of PL-pO2. Both were found to occur
 before evidence of reduced CoBF. PL-pO2 and CoBF progressively declined
 post-exposure, while CMs, CAPs, and ABRs did not further deteriorate nor
 showed signs of recovery up to 180 min after cessation of noise.
 Treatment started 60 min post-exposure, or after 90 min without
 manipulation and was then further studied for 120 min. In the unexposed
 animals, diclofenac sodium and prednisolone induced a significant decline
 of PL-pO2, while CoBF, CMs, CAPs, and ABRs revealed no change. Isotonic
 saline did not influence the measured parameters. After infusion of the
 histamine H1-receptor antagonist, a significant decrease of CoBF together
 with blood pressure and CMs was obsd., while PL-pO2, CAPs, and ABRs showed
 no change. In the noise-exposed animals, diclofenac sodium induced
 partial restoration of CM and CAP amplitudes and full restoration of ABRs.
 Following a high dose of prednisolone (25 mg), partial restoration of CMs
 and full restoration of CAPs and ABRs were registered. This effect was
 significantly less pronounced following a low dose of prednisolone (2.5
 mg). Restoration of CMs, CAPs, and ABRs was immediate (i.e. 50 min after
 infusion) and remained stable for another 60 min until the end of the
 recording period. The histamine H1-receptor antagonist and isotonic
 saline did not influence CMs, CAPs, and ABRs. None of the applied drugs
 resulted in relief of progressive noise-induced cochlear hypoxia and
 post-traumatic **ischemia**. These findings indicate direct
 cellular effects of prednisolone and diclofenac sodium in the cochlea
 taking into account no blood flow and oxygenation. The possible
 mechanisms involved are discussed.
 ST glucocorticoid NSAID hearing loss noise
 IT Antihistamines
 (H1; effect of glucocorticoid and **NSAIDs** on normal and
 noise-damaged guinea pig inner ear)
 IT Nerve
 (auditory; effect of glucocorticoid and **NSAIDs** on normal and
 noise-damaged guinea pig inner ear)
 IT Ear
 (cochlea, hypoxia and **ischemia**; effect of glucocorticoid and
NSAIDs on normal and noise-damaged guinea pig inner ear)
 IT Hypoxia, animal
Ischemia
 (cochlear; effect of glucocorticoid and **NSAIDs** on normal and
 noise-damaged guinea pig inner ear)
 IT Ear

(disease, noise-induced; effect of glucocorticoid and **NSAIDs** on normal and noise-damaged guinea pig inner ear)

IT Acoustic noise
(effect of glucocorticoid and **NSAIDs** on normal and noise-damaged guinea pig inner ear)

IT Glucocorticoids
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of glucocorticoid and **NSAIDs** on normal and noise-damaged guinea pig inner ear)

IT Anti-inflammatory agents
(nonsteroidal; effect of glucocorticoid and **NSAIDs** on normal and noise-damaged guinea pig inner ear)

IT Brain
(stem, auditory system; effect of glucocorticoid and **NSAIDs** on normal and noise-damaged guinea pig inner ear)

IT 3614-69-5, Fenistil
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(effect of glucocorticoid and **NSAIDs** on normal and noise-damaged guinea pig inner ear)

IT 50-24-8, Prednisolone 15307-86-5, Diclofenac
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of glucocorticoid and **NSAIDs** on normal and noise-damaged guinea pig inner ear)

RE.CNT 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Axelsson, A; Hear Res 1987, V31, P183 MEDLINE
- (2) Axelsson, A; New Perspectives on Noise-induced Hearing Loss 1982, P49
- (3) Barnes, P; Trends Pharmacol Ssci 1993, V14, P436 CAPLUS
- (4) Baulieu, E; Endocrinology 1989, P16
- (5) Borg, E; Scand Audiol Suppl 1995, V40, P1 MEDLINE
- (6) Brooks, P; New Engl J Med 1991, V324, P1716 MEDLINE
- (7) Brown, J; Am J Physiol 1994, V266, PH458 MEDLINE
- (8) Campbell, W; Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edn 1990, P600
- (9) Dengerink, H; Acta Otolaryngol (Stockh) 1985, V100, P19 MEDLINE
- (10) Erichsen, S; Acta Otolaryngol (Stockh) 1996, V116, P721 MEDLINE
- (11) Erichsen, S; Hear Res 1996, V100, P143 CAPLUS
- (12) Furuta, H; Hear Res 1994, V78, P175 CAPLUS
- (13) Garrison, J; Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edn 1990, P575
- (14) Hawkins, J; Ann Otol Rhinol Laryngol 1971, V80, P903
- (15) Hawkins, J; Arch Otorhinolaryngol 1976, V212, P241
- (16) Hawkins, J; Laryngoscope 1972, V82, P1091
- (17) Haynes, R; Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edn 1990, P1431
- (18) Insel, P; Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th edn 1990, P638
- (19) Kanzaki, J; Acta Otolaryngol Suppl 1983, V393, P77 MEDLINE
- (20) Kanzaki, J; Arch Otorhinolaryngol 1981, V230, P5 MEDLINE
- (21) Kanzaki, J; Oto-Rhino-Laryngology 1993, V55, P24 MEDLINE
- (22) Kunihiro, T; Oto-Rhino-Laryngology 1990, V52, P86 MEDLINE
- (23) Lamm, H; Otorhinolaryngol Nova 1995, V5, P161
- (24) Lamm, K; Adv Oto-Rhino Laryngol, in press 1997, V54
- (25) Lamm, K; Adv Oto-Rhino-Laryngol, in press 1997, V54
- (26) Lamm, K; Audiol Neurotol 1996, V1, P148 MEDLINE
- (27) Lamm, K; Otorhinolaryngol Nova 1993, V3, P285
- (28) Lamm, K; Otorhinolaryngol Nova 1995, V5, P153

- (29) Lamm, K; Wien Med Wschr 1992, V20/21, P455
- (30) Lipscomb, D; Acta Otolaryngol (Stockh) 1977, V84, P44 MEDLINE
- (31) Lipscomb, D; Laryngoscope 1973, V83, P259 MEDLINE
- (32) Mattox, D; Ann Otol 1977, V86, P463 MEDLINE
- (33) McMahon, M; Diabetes Metab Rev 1988, V4, P17 CAPLUS
- (34) Michel, O; Otorhinolaryngol Nova 1993, V3, P292
- (35) Miller, J; Am J Otolaryngol 1988, V9, P302 MEDLINE
- (36) Miller, J; Laser-Doppler Blood Flowmetry 1990, P319 CAPLUS
- (37) Miller, J; Otolaryngol Head Neck Surg 1995, V112, P101 MEDLINE
- (38) Moskowitz, D; Laryngoscope 1984, V94, P664 MEDLINE
- (39) Munck, A; Am Rev Respir Dis 1990, V141, PS2 CAPLUS
- (40) Pitovski, D; Acta Otolaryngol (Stockh) 1996, V116, P737 MEDLINE
- (41) Pitovski, D; Brain Res 1993, V601, P273 CAPLUS
- (42) Pitovski, D; Hear Res 1993, V69, P10 CAPLUS
- (43) Pitovski, D; Hear Res 1994, V77, P216 CAPLUS
- (44) Quirk, W; Hear Res 1991, V52, P217 MEDLINE
- (45) Quirk, W; Hear Res 1992, V63, P102 MEDLINE
- (46) Rarey, K; Hear Res 1989, V41, P217 CAPLUS
- (47) Rarey, K; Hear Res 1993, V64, P205 CAPLUS
- (48) Rarey, K; Hear Res 1995, V82, P135 CAPLUS
- (49) Saunders, J; J Acoust Soc Am 1991, V90, P136 MEDLINE
- (50) Ten Cate, W; Am J Physiol 1994, V266, PE269 CAPLUS
- (51) Ten Cate, W; Hear Res 1992, V60, P199 CAPLUS
- (52) Ten Cate, W; Hear Res 1994, V75, P151 MEDLINE
- (53) Ten Cate, W; Laryngoscope 1993, V103, P865 CAPLUS
- (54) Todd, P; Drugs 1988, V35, P244 CAPLUS
- (55) Veldman, J; Acta Otolaryngol (Stockh) 1993, V113, P303 MEDLINE
- (56) Vertes, D; Acta Otolaryngol (Stockh) 1979, V88, P47 MEDLINE
- (57) Vertes, D; Arch Otorhinolaryngol 1981, V230, P285 MEDLINE
- (58) Vischer, M; Otorhinolaryngol Nova 1991, V1, P75
- (59) Wilson, W; Arch Otolaryngol 1980, V106, P772 MEDLINE
- (60) Zuo, J; Acta Otolaryngol (Stockh) 1995, V115, P497 MEDLINE
- (61) Zuo, J; Hear Res 1995, V87, P220 CAPLUS

=> d 135 26 all

L35 ANSWER 26 OF 36 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:700744 CAPLUS
 DN 130:60774
 TI Nonsteroidal anti-inflammatory drugs increase tumor necrosis factor
 production in the periphery but not in the central nervous system in mice
 and rats
 AU Sacco, Silvano; Agnello, Davide; Sottocorno, Marcello; Lozza, Gianluca;
 Monopoli, Angela; Villa, Pia; Ghezzi, Pietro
 CS Laboratory of Neuroimmunology, "Mario Negri" Institute for Pharmacological
 Research, Milan, 20157, Italy
 SO Journal of Neurochemistry (1998), 71(5), 2063-2070
 CODEN: JONRA9; ISSN: 0022-3042
 PB Lippincott-Raven Publishers
 DT Journal
 LA English
 CC 1-7 (Pharmacology)
 AB Nonsteroidal anti-inflammatory drugs (**NSAIDs**), which inhibit
 prostaglandin (PG) synthesis, augment prodn. of tumor necrosis factor
 (TNF) in most exptl. models. We investigated the effect of two
NSAIDs, indomethacin and ibuprofen, on the prodn. of TNF in the
 CNS induced by intracerebroventricular injection of lipopolysaccharide
 (LPS). Indomethacin and ibuprofen, administered i.p., augmented (three-
 to ninefold) the levels of TNF in serum and peripheral organs of mice
 injected i.p. with LPS and in rats with adjuvant arthritis (up to a
 sevenfold increase). However, **NSAIDs** (i.p. or

intracerebroventricularly) did not increase brain TNF prodn. induced by i.v. LPS. In fact, indomethacin decreased (1.4-1.8-fold) TNF levels in the spinal cord of rats with exptl. autoimmune encephalomyelitis and in the cortex of rats with focal cerebral **ischemia**. Systemic administration of iloprost inhibited serum TNF levels after i.p. LPS, whereas intracerebroventricular injection of iloprost or PGE2 did not inhibit brain TNF induced by intracerebroventricular LPS. Both peripheral and central TNF productions were inhibited by cAMP level-elevating agents or dexamethasone. Thus, a PG-driven neg. feedback controls TNF prodn. in the periphery but not in the CNS.

ST antiinflammatory **NSAIDs** TNF peripheral central nervous system

IT Anti-inflammatory agents

Brain

(**NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT Tumor necrosis factors

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(**NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT Encephalomyelitis

(autoimmune; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT Nervous system

(central; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT Brain, disease

(**ischemia**; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT Anti-inflammatory agents

(nonsteroidal; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT Nervous system

(peripheral; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT 53-86-1, Indomethacin 15687-27-1, Ibuprofen

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(**NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT 60-92-4, CAMP

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(**NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Aggarwal, B; J Biol Chem 1985, V260, P2345 CAPLUS
- (2) Asanuma, M; Neurosci Lett 1997, V225, P109 CAPLUS
- (3) Bagby, G; J Appl Physiol 1994, V77, P1542 CAPLUS
- (4) Benigni, F; Mol Med 1995, V1, P568 CAPLUS
- (5) Breder, C; J Comp Neurol 1993, V337, P543 CAPLUS
- (6) Breitner, J; Annu Rev Med 1996, V47, P401 CAPLUS
- (7) Brosnan, C; Neurology 1995, V45(Suppl 6), PS16
- (8) Bruce, A; Nature Med 1996, V2, P788 CAPLUS
- (9) Di Santo, E; Cytokine 1997, V9, P300 CAPLUS
- (10) Di Santo, E; Eur J Pharmacol 1997, V336, P197 CAPLUS
- (11) Di Santo, E; Neuroimmunomodulation 1995, V2, P149 CAPLUS
- (12) Dickson, D; Glia 1993, V7, P75 MEDLINE
- (13) Dinarello, C; Am J Med 1982, V72, P799 CAPLUS
- (14) Dinarello, C; Rev Infect Dis 1988, V10, P168 CAPLUS
- (15) Faggioni, R; Infect Immun 1995, V63, P1473 CAPLUS

(16) Fattori, E; J Exp Med 1994, V180, P1243 CAPLUS
 (17) Gahring, L; Neuroimmunomodulation 1996, V3, P289 CAPLUS
 (18) Grundmann, H; J Infect Dis 1992, V165, P501 CAPLUS
 (19) Haley, T; Br J Pharmacol 1957, V12, P12 CAPLUS
 (20) Honda, A; J Biol Chem 1993, V268, P7759 CAPLUS
 (21) Irani, D; J Immunol 1997, V158, P2318 CAPLUS
 (22) Knudsen, P; J Immunol 1986, V137, P3189 CAPLUS
 (23) Lipton, J; Peptides 1991, V12, P795 CAPLUS
 (24) Liu, T; Stroke 1994, V25, P1481 CAPLUS
 (25) Martich, G; J Exp Med 1991, V173, P1021 CAPLUS
 (26) Meistrell, M; Shock 1997, V8, P341
 (27) Mengozzi, M; Immunology 1994, V82, P207 CAPLUS
 (28) Mustafa, M; Am J Dis Child 1990, V144, P883 MEDLINE
 (29) Mustafa, M; J Clin Invest 1989, V84, P1253 CAPLUS
 (30) Nataf, S; Acta Neurol Scand 1993, V88, P97 CAPLUS
 (31) Noel, P; Life Sci 1990, V47, P1023 CAPLUS
 (32) Olsson, T; Neurology 1995, V45(Suppl 6), PS11
 (33) Reder, A; J Neuroimmunol 1994, V54, P117 CAPLUS
 (34) Renz, H; J Immunol 1988, V141, P2388 CAPLUS
 (35) Ruddie, N; J Exp Med 1990, V172, P1193 CAPLUS
 (36) Saez-Llorens, X; Antimicrob Agents Chemother 1990, V34, P837 CAPLUS
 (37) Saukkonen, K; J Exp Med 1990, V171, P439 CAPLUS
 (38) Schooltink, H; FEBS Lett 1992, V314, P280 CAPLUS
 (39) Selmaj, K; Neurology 1995, V45(Suppl 6), PS44
 (40) Shigeno, T; Surg Neurol 1985, V24, P47 MEDLINE
 (41) Sironi, M; Int J Immunopharmacol 1992, V14, P1045 CAPLUS
 (42) Sommer, N; Nature Med 1995, V1, P244 CAPLUS
 (43) Spengler, R; Infect Immun 1989, V57, P2837 CAPLUS
 (44) Stewart, W; Neurology 1997, V48, P626 MEDLINE
 (45) Sugimoto, Y; J Biol Chem 1992, V267, P6463 CAPLUS
 (46) Sugimoto, Y; Neuroscience 1994, V62, P919 CAPLUS
 (47) van der Poll, T; J Immunol 1995, V155, P5397 CAPLUS
 (48) Watabe, A; J Biol Chem 1993, V268, P20175 CAPLUS
 (49) Zuckerman, S; Eur J Immunol 1989, V19, P301 CAPLUS

=> d his

(FILE 'HOME' ENTERED AT 15:07:02 ON 15 SEP 2003)

FILE 'REGISTRY' ENTERED AT 15:07:15 ON 15 SEP 2003

	E ACETOMINOPHEN
	E ACETOMINOPHEN
	E ACETOMINOPHEN
	E NSAID
L1	9 S E3
	E ASPIRIN
L2	52 S E3
	E INDOMETHACIN
L3	52 S E3
	E KETOPROFIN
	E KETOPROFEN
L4	50 S E3
	E TRILISATR
	E TRILISATE
L5	1 S E3
L6	1158 S SALICYLAMIDE
L7	30 S SODIUM SALICYLATE
L8	6694 S SALICYLIC ACID
	E ACETOMINOPHEN
	E ACETAMINOPHEN
L9	130 S E3

FILE 'CAPLUS' ENTERED AT 15:20:03 ON 15 SEP 2003

L10 17725 S L2
L11 28561 S CNS
L12 28 S L10 AND L11
E TRAUMA
L13 11866 S E3
L14 68 S L13 AND L10
E HEAD
L15 94345 S E3
L16 12 S L14 AND L15
E ISCHEMIA
L17 53069 S E5-E8
L18 356 S L17 AND L10
E CEREBRAL
L19 78138 S E3
L20 14 S L18 AND 19
L21 66 S L18 AND L19
L22 2 S L19 AND L12
L23 211 S L10 AND L19
L24 66 S L23 AND L17
L25 0 S L24 NOT L21
L26 2 S L12 AND L17
L27 10826 S L9
L28 46 S L5
L29 28 S L12 AND L10
E LUPUS
L30 11819 S E3
L31 53 S L30 AND L10
E ALZHEIMERS
L32 1977 S E3
L33 8 S L10 AND L32
E NSAIDS
L34 3367 S E3
L35 36 S L34 AND L17

=> s l11 and l12

L36 28 L11 AND L12

=> s l11 and l17

L37 685 L11 AND L17

=> s l37 and l10

L38 2 L37 AND L10

=> d l38 1-2

L38 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:657907 CAPLUS

DN 137:195592

TI Chimeric compounds co-inducing cholinergic up-regulation and inflammation
down-regulation, and use for treatment and/or prevention of central
nervous system diseases

IN Amitai, Gabriel; Adani, Rachel; Rabinovitz, Ishai; Sod-Moriah, Gali;
Meshulam, Haim

PA Israel Institute for Biological Research, Israel

SO PCT Int. Appl., 139 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.

KIND DATE

APPLICATION NO. DATE

PI WO 2002065977 A2 20020829 WO 2002-IL122 20020217
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CG, CF, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 US 2002160988 A1 20021031 US 2001-906952 20010716
 PRAI US 2001-269343P P 20010220
 US 2001-906952 A 20010716
 OS MARPAT 137:195592

L38 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:488246 CAPLUS
 DN 137:57576
 TI Methods and compositions using ion-dependent cotransporter modulators for
 treating conditions of the central and peripheral nervous systems using
 non-synaptic mechanisms
 IN Hochman, Daryl W.
 PA Cytoscan Sciences L.L.C., USA
 SO U.S. Pat. Appl. Publ., 29 pp., Cont.-in-part of U.S. Ser. No. 470,637.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002082252	A1	20020627	US 2002-56528	20020123
	US 6495601	B1	20021217	US 1999-470637	19991222
PRAI	US 1998-113620P	P	19981223		
	US 1999-470637	A2	19991222		
	US 2001-263830P	P	20010123		

=> e inflammation

E1	2	INFLAMMATIN/BI
E2	3	INFLAMMATIO/BI
E3	98265 -->	INFLAMMATION/BI
E4	3	INFLAMMATONAL/BI
E5	1	INFLAMMATIONDAMAGED/BI
E6	1	INFLAMMATIONINHIBITING/BI
E7	1	INFLAMMATIONMETAB/BI
E8	1660	INFLAMMATIONS/BI
E9	2	INFLAMMATIOON/BI
E10	1	INFLAMMATIORN/BI
E11	8	INFLAMMATIVE/BI
E12	1	INFLAMMATO/BI

=> s e3

L39 98265 INFLAMMATION/BI

=> s l39 and l11

L40 1177 L39 AND L11

=> s l40 and l12

L41 10 L40 AND L12

=> d 141 1-10

L41 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:280985 CAPLUS
DN 139:143565
TI Paracetamol effectively reduces prostaglandin E2 synthesis in brain
macrophages by inhibiting enzymatic activity of cyclooxygenase but not
phospholipase and prostaglandin E synthase
AU Greco, Anita; Ajmone-Cat, Maria Antonietta; Nicolini, Alessia; Sciulli,
Maria Gina; Minghetti, Luisa
CS Laboratory of Pathophysiology, Istituto Superiore di Sanita, Rome,
299-00161, Italy
SO Journal of Neuroscience Research (2003), 71(6), 844-852
CODEN: JNREDK; ISSN: 0360-4012
PB Wiley-Liss, Inc.
DT Journal
LA English
RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:657907 CAPLUS
DN 137:195592
TI Chimeric compounds co-inducing cholinergic up-regulation and
inflammation down-regulation, and use for treatment and/or
prevention of central nervous system diseases
IN Amitai, Gabriel; Adani, Rachel; Rabinovitz, Ishai; Sod-Moriah, Gali;
Meshulam, Haim
PA Israel Institute for Biological Research, Israel
SO PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002065977	A2	20020829	WO 2002-IL122	20020217
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2002160988	A1	20021031	US 2001-906952	20010716
PRAI	US 2001-269343P	P	20010220		
	US 2001-906952	A	20010716		
OS	MARPAT 137:195592				

L41 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:576796 CAPLUS
DN 131:204626
TI Compositions comprising valerian extracts, isovaleric acid or derivatives
thereof with a NSAID
IN Artman, Linda D.; Balandrin, Manuel F.
PA NPS Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9944623	A1	19990910	WO 1999-US4786	19990304
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2321737	AA	19990910	CA 1999-2321737	19990304
	AU 9928945	A1	19990920	AU 1999-28945	19990304
	EP 1059930	A1	20001220	EP 1999-909827	19990304
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002505296	T2	20020219	JP 2000-534224	19990304
	US 6383527	B1	20020507	US 2001-623384	20010222
PRAI	US 1998-76737P	A2	19980304		
	WO 1999-US4786	W	19990304		

OS MARPAT 131:204626

RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:780621 CAPLUS

DN 130:232124

TI Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic **inflammation** within the **CNS** [central nervous system]

AU Hauss-Wegrzyniak, Beatrice; Willard, Lauren B.; Del Soldato, Piero; Pepeu, Giancarlo; Wenk, Gary L.

CS Memory and Aging, Division of Neural Systems, Arizona Research Laboratories, University of Arizona, Tucson, AZ, 85724, USA

SO Brain Research (1999), 815(1), 36-43

CODEN: BRREAP; ISSN: 0006-8993

PB Elsevier Science B.V.

DT Journal

LA English

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:43243 CAPLUS

DN 128:149902

TI Modulation of Brewer's yeast-induced peripheral **inflammation** and nociception in rats by centrally administered prostaglandins and their inhibitors

AU Hore, S. K.; Dumka, V. K.; Tandan, S. K.; Tripathi, H. C.; Kumar, Dinesh

CS Division of Pharmacology and Toxicology, Indian Veterinary Research Institute, Izatnagar, 243 122, India

SO Indian Journal of Pharmacology (1997), 29(6), 416-419

CODEN: INJPD2; ISSN: 0253-7613

PB Indian Pharmacological Society

DT Journal

LA English

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1996:646511 CAPLUS
 DN 125:276575
 TI Preparation of arginine analogs having nitric oxide synthase inhibitor activity
 IN Broquet, Colette; Chabrier, De Lassauniere, Pierre-Etienne
 PA Societe De Conseils De Recherches Et D'application, Fr.
 SO PCT Int. Appl., 32 pp.
 CODEN: PIXXD2
 DT Patent
 LA French
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9627593	A1	19960912	WO 1996-FR337	19960304
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	CA 2215476	AA	19960912	CA 1996-2215476	19960304
	AU 9649479	A1	19960923	AU 1996-49479	19960304
	AU 700871	B2	19990114		
	EP 813529	A1	19971229	EP 1996-905907	19960304
	EP 813529	B1	20020911		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, IE, SI, LT, LV, FI				
	CN 1179774	A	19980422	CN 1996-192885	19960304
	CN 1071328	B	20010919		
	JP 11501043	T2	19990126	JP 1996-526657	19960304
	RU 2168493	C2	20010610	RU 1997-116496	19960304
	AT 223907	E	20020915	AT 1996-905907	19960304
	CZ 290747	B6	20021016	CZ 1997-2687	19960304
	SK 282664	B6	20021106	SK 1997-1121	19960304
	ES 2182964	T3	20030316	ES 1996-905907	19960304
	US 5972940	A	19991026	US 1997-913455	19970910
	HK 1013777	A1	20020705	HK 1998-110921	19980924
PRAI	GB 1995-4350	A	19950304		
	WO 1996-FR337	W	19960304		
OS	MARPAT 125:276575				

L41 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1996:245721 CAPLUS
 DN 125:48415
 TI Effect of NM441 and its active form on GABA receptor binding
 AU Hori, Seiji; Shimada, Jingoro
 CS Div. Clin. Pharmacol. Inst. Med. Sci., St. Marianna Univ. Sch. Med., Kawasaki, 216, Japan
 SO Nippon Kagaku Ryoho Gakkai Zasshi (1996), 44(Suppl. 1), 97-101
 CODEN: NKRZE5; ISSN: 1340-7007
 DT Journal
 LA Japanese

L41 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1994:499126 CAPLUS
 DN 121:99126
 TI Mechanism of quinolone-induced convulsion and anticonvulsant effect of barbiturate for this seizure
 AU Kanemitsu, Keiji
 CS Dep. Intern. Med. and Lab. Med., St. Marianna Univ. Sch. Med., Kawasaki, 216, Japan
 SO Sei Marianna Ika Daigaku Zasshi (1993), 21(6), 1177-85

CODEN: SMIZDS; ISSN: 0387-2289

DT Journal
LA Japanese

L41 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1993:573380 CAPLUS

DN 119:173380

TI Acetylsalicylic acid and related compounds depress nociceptive activity in the thalamus by a central action: indications for the involvement of prostaglandins

AU Jurna, I.

CS Inst. Pharmakol. Toxikol., Univ. Saarlandes, Homburg/Saar, D-6650, Germany

SO Progress in Pharmacology and Clinical Pharmacology (1993), 10(1), 51-68

CODEN: PPCPEP; ISSN: 0934-9545

DT Journal; General Review

LA English

L41 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1969:113689 CAPLUS

DN 70:113689

TI N-Aralkylanthranilic acid derivatives as CNS [central nervous system] depressants

AU Sisodia, P.; Rao, G. S. Rama; Sidhu, Gurbachan S.; Sattur, Prolhad B.; Hashim, Riaz

CS Gandhi Med. Coll., Hyderabad, India

SO CNS (Cent. Nerv. Syst.) Drugs, Symp. (1966), 238-48 Publisher: Counc. Sci. and Ind. Res., New Delhi, India.

CODEN: 20REAT

DT Conference

LA English

=> d his

(FILE 'HOME' ENTERED AT 15:07:02 ON 15 SEP 2003)

FILE 'REGISTRY' ENTERED AT 15:07:15 ON 15 SEP 2003

E ACETOMINOPHEN

E ACETOMINOPHEN

E ACETOMINOPHEN

E NSAID

L1 9 S E3

E ASPIRIN

L2 52 S E3

E INDOMETHACIN

L3 52 S E3

E KETOPROFIN

E KETOPROFEN

L4 50 S E3

E TRILISATR

E TRILISATE

L5 1 S E3

L6 1158 S SALICYLAMIDE

L7 30 S SODIUM SALICYLATE

L8 6694 S SALICYLIC ACID

E ACETOMINOPHEN

E ACETAMINOPHEN

L9 130 S E3

FILE 'CAPLUS' ENTERED AT 15:20:03 ON 15 SEP 2003

L10 17725 S L2

L11 28561 S CNS

L12 28 S L10 AND L11
 E TRAUMA
 L13 11866 S E3
 L14 68 S L13 AND L10
 E HEAD
 L15 94345 S E3
 L16 12 S L14 AND L15
 E ISCHEMIA
 L17 53069 S E5-E8
 L18 356 S L17 AND L10
 E CEREBRAL
 L19 78138 S E3
 L20 14 S L18 AND 19
 L21 66 S L18 AND L19
 L22 2 S L19 AND L12
 L23 211 S L10 AND L19
 L24 66 S L23 AND L17
 L25 0 S L24 NOT L21
 L26 2 S L12 AND L17
 L27 10826 S L9
 L28 46 S L5
 L29 28 S L12 AND L10
 E LUPUS
 L30 11819 S E3
 L31 53 S L30 AND L10
 E ALZHEIMERS
 L32 1977 S E3
 L33 8 S L10 AND L32
 E NSAIDS
 L34 3367 S E3
 L35 36 S L34 AND L17
 L36 28 S L11 AND L12
 L37 685 S L11 AND L17
 L38 2 S L37 AND L10
 E INFLAMMATION
 L39 98265 S E3
 L40 1177 S L39 AND L11
 L41 10 S L40 AND L12

=> e parkinson

E1 2 PARKINSOGENIC/BI
 E2 2 PARKINSOMISM/BI
 E3 12980 --> PARKINSON/BI
 E4 1 PARKINSONAPOS/BI
 E5 1 PARKINSONDISEASE/BI
 E6 1 PARKINSONE/BI
 E7 4 PARKINSONGENIC/BI
 E8 1 PARKINSONHS/BI
 E9 2 PARKINSONI/BI
 E10 60 PARKINSONIA/BI
 E11 1 PARKINSONIAL/BI
 E12 1 PARKINSONIAM/BI

=> s e3

L42 12980 PARKINSON/BI

=> s 142 and 110

L43 20 L42 AND L10

=> d 143 5-20

L43 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2002:449661 CAPLUS
DN 137:33309
TI Preparation of anilinopyrimidines as JNK pathway inhibitors
IN Kois, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.;
Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.
PA Signal Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 199 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046170	A2	20020613	WO 2001-US46402	20011205
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2002027214	A5	20020618	AU 2002-27214	20011205
PRAI	US 2000-251904P	P	20001206		
	WO 2001-US46402	W	20011205		
OS	MARPAT 137:33309				

L43 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:798223 CAPLUS
DN 135:331422
TI Preparation of arylcarbonylaminopyrazolopyridine derivatives as glycogen synthase kinase 3.beta. inhibitors
IN Fukunaga, Kenji; Okabe, Hirotaka; Kohara, Toshiyuki; Fujimura, Masatake; Tanaka, Hiroshi; Takanashi, Shinichi
PA Welfide Corporation, Japan
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2

DT Patent
LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001081345	A1	20011101	WO 2001-JP3329	20010418
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	JP 2000-119198	A	20000420		
OS	MARPAT 135:331422				
RE.CNT	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L43 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:581674 CAPLUS
DN 135:132476
TI Neuroprotective, antithrombotic, and antiinflammatory uses of activated

protein C (APC)
 IN Griffin, John H.; Zlokovic, Berislav Y.
 PA The Scripps Research Institute, USA; The University of Southern California
 SO PCT Int. Appl., 47 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001056532	A2	20010809	WO 2001-US3758	20010205
	WO 2001056532	A3	20011206		
	WO 2001056532	C2	20030109		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2001038034	A5	20010814	AU 2001-38034	20010205
	US 2002028199	A1	20020307	US 2001-777484	20010205
	EP 1255556	A2	20021113	EP 2001-910427	20010205
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRAI	US 2000-180227P	P	20000204		
	WO 2001-US3758	W	20010205		

L43 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:464293 CAPLUS
 DN 135:41780
 TI Methods determining apoE genotype or phenotype for determining the prognosis of a patient with a neurological disease and identification of human subjects for clinical drug trials
 IN Sevigny, Pierre; Wiebusch, Heiko; Schappert, Keith
 PA Nova Molecular, Inc., Can.
 SO U.S., 10 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6251587	B1	20010626	US 1997-991850	19971216
	US 2002086290	A1	20020704	US 2000-548540	20000413
PRAI	US 1997-991850	A1	19971216		

RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:9523 CAPLUS
 DN 134:202638
 TI Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of **Parkinson's** disease
 AU Teismann, Peter; Ferger, Boris
 CS Institute of Pharmacology and Toxicology, Faculty of Pharmacy, University of Marburg, Marburg, Germany
 SO Synapse (New York) (2001), 39(2), 167-174
 CODEN: SYNAET; ISSN: 0887-4476
 PB Wiley-Liss, Inc.

DT Journal
LA English
RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:628201 CAPLUS
DN 133:208198
TI Use of protein conformation for the protection and release of chemical compounds
IN Latham, Keith R.
PA Innovative Technologies, LLC, USA
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000052078	A1	20000908	WO 2000-US5693	20000306
	W:				
	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1257592	A1	20021120	EP 2000-916076	20000306
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	US 2002128177	A1	20020912	US 2001-986426	20011108
PRAI	US 1999-123146P	P	19990305		
	US 1999-411238	B2	19991004		
	WO 2000-US5693	W	20000306		

RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:604982 CAPLUS
DN 133:291007
TI Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro
AU Casper, D.; Yaparalvi, U.; Rempel, N.; Werner, P.
CS Neurosurgery Lab, Department of Neurological Surgery, Montefiore Medical Center, The Bronx, New York, NY, 10467, USA
SO Neuroscience Letters (2000), 289(3), 201-204
CODEN: NELED5; ISSN: 0304-3940
PB Elsevier Science Ireland Ltd.
DT Journal
LA English
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:659188 CAPLUS
DN 131:281583
TI Compositions containing a combination of a creatine compound and a neuroprotective compound for the treatment of nervous system diseases
IN Kaddurah-Daouk, Rima; Beal, M. Flint
PA Avicena Group, Inc., USA; The General Hospital Corporation

SO PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9951097	A1	19991014	WO 1999-US7340	19990402
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2327095	AA	19991014	CA 1999-2327095	19990402
	AU 9933803	A1	19991025	AU 1999-33803	19990402
	AU 759467	B2	20030417		
	EP 1065931	A1	20010110	EP 1999-915245	19990402
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	JP 2002510604	T2	20020409	JP 2000-541878	19990402
PRAI	US 1998-80459P	P	19980402		
	US 1999-283267	A	19990401		
	WO 1999-US7340	W	19990402		

OS MARPAT 131:281583

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:626155 CAPLUS
DN 129:326022
TI Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice
AU Aubin, Nadine; Curet, Olivier; Deffois, Annie; Carter, Chris
CS Central Nervous System Research Department, Synthelabo Recherche, Bagneux, 92225, Fr.
SO Journal of Neurochemistry (1998), 71(4), 1635-1642
CODEN: JONRA9; ISSN: 0022-3042
PB Lippincott-Raven Publishers
DT Journal
LA English

RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:527193 CAPLUS
DN 129:166193
TI Therapeutic treatment and prevention of infections with a bioactive material encapsulated within a biodegradable-biocompatible polymeric matrix
IN Setterstrom, Jean A.; Van Hamont, John E.; Reid, Robert H.; Jacob, Elliot; Jeyanthi, Ramasubbu; Boedeker, Edgar C.; McQueen, Charles E.; Tice, Thomas R.; Roberts, F. Donald; Friden, Phil
PA United States Dept. of the Army, USA; Van Hamont, John E.; et al.
SO PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9832427	A1	19980730	WO 1998-US1556	19980127
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6309669	B1	20011030	US 1997-789734	19970127
	AU 9863175	A1	19980818	AU 1998-63175	19980127
PRAI	US 1997-789734	A	19970127		
	US 1984-590308	B1	19840316		
	US 1992-867301	A2	19920410		
	US 1995-446148	A2	19950522		
	US 1995-446149	B2	19950522		
	US 1996-590973	B2	19960124		
	WO 1998-US1556	W	19980127		

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:484927 CAPLUS
 DN 129:127177
 TI Pharmaceutical preparations of glutathione and methods of administration
 IN Demopoulos, Harry B.; Seligman, Myron L.
 PA Antioxidant Pharmaceuticals Corp., USA
 SO PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9829101	A1	19980709	WO 1997-US23879	19971231
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9856205	A1	19980731	AU 1998-56205	19971231
	EP 957901	A1	19991124	EP 1997-952640	19971231
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001507696	T2	20010612	JP 1998-530206	19971231
	US 6350467	B1	20020226	US 1999-331947	19990628
	US 2002136763	A1	20020926	US 2002-83327	20020225
PRAI	US 1996-34101P	P	19961231		
	WO 1997-US23879	W	19971231		
	US 1999-331947	A2	19990628		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:424361 CAPLUS
 DN 129:38404
 TI Method for determining the prognosis of a patient with a neurological

disease
 IN Sevigny, Pierre; Wiebusch, Heiko; Schappert, Keith
 PA Nova Molecular, Inc., Can.
 SO PCT Int. Appl., 28 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9827226	A2	19980625	WO 1997-IB1641	19971216
	WO 9827226	A3	19980820		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6022683	A	20000208	US 1996-766975	19961216
	AU 9855717	A1	19980715	AU 1998-55717	19971216
	EP 948647	A1	19991013	EP 1997-952129	19971216
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	US 1996-766975	A	19961216		
	WO 1997-IB1641	W	19971216		

L43 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:338114 CAPLUS
 DN 129:12755
 TI Use of selected nonsteroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases
 IN Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco
 PA Universita' Degli Studi di Brescia - Dipartimento di Scienze Biomediche, Italy; Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco
 SO PCT Int. Appl., 24 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9820864	A2	19980522	WO 1997-EP6323	19971113
	WO 9820864	A3	19981015		
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	IT 1996-MI2356		19961113		
OS	MARPAT 129:12755				

L43 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1993:175822 CAPLUS
 DN 118:175822
 TI Cure for diabetes, bronchitis, arthritis, and arteriosclerosis
 IN Carantinos, Spyros
 PA Australia
 SO Pat. Specif. (Aust.), 11 pp.
 CODEN: ALXXAP
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	AU 629520	B2	19921008	AU 1988-26677	19881208
	AU 8826677	A1	19890608		
PRAI	AU 1987-5803		19871208		

L43 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1990:637843 CAPLUS
DN 113:237843
TI Pharmaceutical composition containing ferric ammonium citrate and zinc oxide
IN Carantinos, Spyros
PA Australia
SO Eur. Pat. Appl., 5 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 372676	A1	19900613	EP 1989-305729	19890607
	R: CH, DE, ES, FR, GB, GR, IT, LI, NL, SE				
PRAI	AU 1988-1849		19881208		

L43 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1989:206625 CAPLUS
DN 110:206625
TI Hormone treatment for central nervous system diseases such as Alzheimers disease and Parkinsons disease
IN Aroonsakul, Chaovanee
PA USA
SO U.S., 4 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4791099	A	19881213	US 1984-666254	19841029
	EP 324037	A1	19890719	EP 1988-100233	19880111
	EP 324037	B1	19970903		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 157546	E	19970915	AT 1988-100233	19880111
	ES 2109914	T3	19980201	ES 1988-100233	19880111
	US 4898856	A	19900206	US 1988-156242	19880216
	JP 01216940	A2	19890830	JP 1988-39323	19880222
	JP 09216837	A2	19970819	JP 1997-38275	19880222
	US 4897389	A	19900130	US 1989-293134	19890103
	US 4902680	A	19900220	US 1989-293017	19890103
	US 4898857	A	19900206	US 1989-293132	19890203
PRAI	US 1984-666254		19841029		
	US 1986-852645		19860416		
	EP 1988-100233		19880111		
	US 1988-156242		19880216		
	JP 1988-39323		19880222		

=> d 143 18 all

L43 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1993:175822 CAPLUS
DN 118:175822

TI Cure for diabetes, bronchitis, arthritis, and arteriosclerosis
 IN Carantinos, Spyros
 PA Australia
 SO Pat. Specif. (Aust.), 11 pp.
 CODEN: ALXXAP
 DT Patent
 LA English
 IC ICM A61K031-19
 ICS A61K033-30; A61K031-215
 CC 63-6 (Pharmaceuticals)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	AU 629520	B2	19921008	AU 1988-26677	19881208
	AU 8826677	A1	19890608		
PRAI	AU 1987-5803		19871208		
AB	A pharmaceutical contg. ferric ammonium citrate in admixt. with ZnO and optionally including aspirin, NaHCO ₃ , and citric acid is effective in treating arthritis, bronchitis, diabetes, arteriosclerosis, broken bones, Parkinson's disease, high blood cholesterol, liver cirrhosis, and enlargement of the prostate gland.				
ST	ferric ammonium citrate zinc oxide pharmaceutical				
IT	Antiartherosclerotics				
	Anticholesteremics and Hypolipemics				
	Antidiabetics and Hypoglycemics				
	(ferric ammonium citrate and zinc oxide as)				
IT	Cirrhosis				
	Parkinsonism				
	(treatment of, ferric ammonium citrate and zinc oxide for)				
IT	Inflammation inhibitors				
	(antiarthritics, ferric ammonium citrate and zinc oxide as)				
IT	Prostate gland				
	(disease, hyperplasia, treatment of, ferric ammonium citrate and zinc oxide for)				
IT	Bronchi				
	(diseases, bronchitis, treatment of, ferric ammonium citrate and zinc oxide for)				
IT	Bone, disease				
	(fracture, treatment of, ferric ammonium citrate and zinc oxide for)				
IT	50-78-2, Aspirin 59-43-8, Vitamin B1, biological studies				
	77-92-9, Citric acid, biological studies 94-20-2, Chlorpropamide				
	144-55-8, Sodium bicarbonate, biological studies				
	RL: BIOL (Biological study)				
	(pharmaceuticals contg. ferric ammonium citrate and zinc oxide and, for treatment of infections and immune diseases)				
IT	1314-13-2, Zinc oxide, biological studies				
	RL: BIOL (Biological study)				
	(pharmaceuticals contg. ferric ammonium citrate and, for treatment of infections and immune diseases)				
IT	1185-57-5, Ferric ammonium citrate				
	RL: BIOL (Biological study)				
	(pharmaceuticals contg. zinc oxide and, for treatment of infections and immune diseases)				

=> d 143 17 all

L43 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:338114 CAPLUS
 DN 129:12755
 TI Use of selected nonsteroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases

IN Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco
PA Universita' Degli Studi di Brescia - Dipartimento di Scienze Biomediche,
Italy; Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano,
Pierfranco
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-00
ICS A61K031-60
CC 1-11 (Pharmacology)
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9820864	A2	19980522	WO 1997-EP6323	19971113
	WO 9820864	A3	19981015		
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	IT 1996-MI2356		19961113		
OS	MARPAT 129:12755				
AB	Nonsteroidal antiinflammatory compds. are used for the prevention and the treatment of neurodegenerative diseases, e.g. Alzheimer's disease and Parkinson's disease.				
ST	neurodegenerative disease nonsteroidal antiinflammatory drug; Parkinson disease nonsteroidal antiinflammatory drug; Alzheimer disease nonsteroidal antiinflammatory drug; NSAID neurodegenerative disease				
IT	Transcription factors RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (AP-1 (activator protein 1); nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	Nervous system (Huntington's chorea; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	Transcription factors RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (NF-.kappa.B (nuclear factor .kappa.B); nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	Glutamate receptors RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (NMDA-binding; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	Nervous system (amyotrophic lateral sclerosis; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	Nervous system (ataxia telangiectasia; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	Nervous system (degeneration; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	AIDS (disease) (dementia assocd. with; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	Mental disorder (dementia, multi-infarct; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	Brain (dentate gyrus; nonsteroidal antiinflammatory compds. for prevention				

and treatment of neurodegenerative diseases)

IT Mental disorder
(diffuse Lewy body disease; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Brain
(hippocampus, sector CA1; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Brain
(hippocampus, sector CA3; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Infection
(infective neurodegenerative disease; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Nerve, disease
(injury; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Metabolism
(metabolic neuropathies; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Epilepsy
(neurodegenerative processes related to; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Prion diseases
(neurodegenerative syndromes in; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Hypoxia, animal
(neuropathy from; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Brain, disease
(neuropathy, ischemic; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Nerve, disease
(neuropathy; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Cytoprotective agents
(neuroprotectants; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Anti-Alzheimer's agents
Anti-ischemic agents
Antiparkinsonian agents
Multiple sclerosis
(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Glutamate receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Anti-inflammatory agents
(nonsteroidal; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Nerve, disease
(peripheral neuropathy, ischemic; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Brain, disease
Spinal cord
Spinal cord
(trauma; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT 50-99-7, D-Glucose, biological studies
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)

(blood; glycemic damage-assocd. neuropathy; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT 53-86-1, Indomethacin 56-86-0, L-Glutamic acid, biological studies 6384-92-5, NMDA
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT 50-33-9, Phenylbutazone, biological studies 50-33-9D, Phenylbutazone, metabolites 50-78-2, Acetylsalicylic acid 50-78-2D, Acetylsalicylic acid, derivs. 54-21-7, Sodium salicylate 58-15-1, Aminopyrine 58-15-1D, Aminopyrine, metabolites 60-80-0, Antipyrine 60-80-0D, Antipyrine, metabolites 65-45-2, Salicylamide 65-85-0, Benzoic acid, biological studies 65-85-0D, Benzoic acid, metabolites, biological studies 69-46-5, Calcium acetylsalicylate 87-28-5, Glycol salicylate 89-57-6, Mesalamine 118-57-0, Acetaminosalol 119-36-8, Methyl salicylate 129-20-4, Oxyphenbutazone 129-20-4D, Oxyphenbutazone, metabolites 134-55-4, Phenyl acetylsalicylate 147-90-0, Morpholine salicylate 303-38-8, 2,3-Dihydroxybenzoic acid 303-38-8D, 2,3-Dihydroxybenzoic acid, metabolites 487-48-9, Salacetamide 490-79-9, Gentisic acid 550-97-0, 1-Naphthyl salicylate 552-94-3, Salsalate 580-02-9, Methyl acetylsalicylate 599-79-1, Sulfasalazine 5003-48-5, Benorylate 5104-49-4, Flurbiprofen 5104-49-4D, Flurbiprofen, metabolites 5663-71-8 6385-02-0, Sodium meclofenamate 6385-02-0D, Sodium meclofenamate, metabolites 13539-59-8, Apazone 13539-59-8D, Apazone, metabolites 13586-98-6 15307-86-5, Diclofenac 15307-86-5D, Diclofenac, metabolites 15687-27-1 15687-27-1D, metabolites 15722-48-2, Olsalazine 21256-18-8, Oxaprozin 21256-18-8D, Oxaprozin, metabolites 22071-15-4, Ketoprofen 22071-15-4D, Ketoprofen, metabolites 22204-53-1, Naproxen 22204-53-1D, Naproxen, metabolites 22494-27-5, Flufenisal 22494-42-4 26171-23-3, Tolmetin 26171-23-3D, Tolmetin, metabolites 29679-58-1, Fenoprofen 29679-58-1D, Fenoprofen, metabolites 30653-83-9, Parsalimide 36322-90-4, Piroxicam 36322-90-4D, Piroxicam, metabolites 36364-49-5, Imidazole salicylate 37933-78-1, Lysine acetylsalicylate 38194-50-2, Sulindac 38194-50-2D, Sulindac, metabolites 41340-25-4, Etodolac 41340-25-4D, Etodolac, metabolites 42924-53-8, Nabumetone 42924-53-8D, Nabumetone, metabolites 51803-78-2, Nimesulide 51803-78-2D, Nimesulide, metabolites 53597-27-6, Fendosal 59804-37-4, Tenoxicam 59804-37-4D, Tenoxicam, metabolites 62992-61-4, Etersalate 71125-38-7, Meloxicam 71125-38-7D, Meloxicam, metabolites 74103-06-3, Ketorolac 74103-06-3D, Ketorolac, metabolites 111406-87-2, Zileuton 111406-87-2D, Zileuton, metabolites
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT 7440-70-2, Calcium, biological studies 39391-18-9, Cyclooxygenase
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

=> s 17

L44 5189 L7

=> d hi

'HI' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS -----	GI and AB
ALL -----	BIB, AB, IND, RE
APPS -----	AI, PRAI
BIB -----	AN, plus Bibliographic Data and PI table (default)
CAN -----	List of CA abstract numbers without answer numbers
CBIB -----	AN, plus Compressed Bibliographic Data
DALL -----	ALL, delimited (end of each field identified)
DMAX -----	MAX, delimited for post-processing
FAM -----	AN, PI and PRAI in table, plus Patent Family data
FBIB -----	AN, BIB, plus Patent FAM
IND -----	Indexing data
IPC -----	International Patent Classifications
MAX -----	ALL, plus Patent FAM, RE
PATS -----	PI, SO
SAM -----	CC, SX, TI, ST, IT
SCAN -----	CC, SX, TI, ST, IT (random display, no answer numbers; SCAN must be entered on the same line as the DISPLAY, e.g., D SCAN or DISPLAY SCAN)
STD -----	BIB, IPC, and NCL
IABS -----	ABS, indented with text labels
IALL -----	ALL, indented with text labels
IBIB -----	BIB, indented with text labels
IMAX -----	MAX, indented with text labels
ISTD -----	STD, indented with text labels
OBIB -----	AN, plus Bibliographic Data (original)
OIBIB -----	OBIB, indented with text labels
SBIB -----	BIB, no citations
SIBIB -----	IBIB, no citations
HIT -----	Fields containing hit terms
HITIND -----	IC, ICA, ICI, NCL, CC and index field (ST and IT) containing hit terms
HITRN -----	HIT RN and its text modification
HITSTR -----	HIT RN, its text modification, its CA index name, and its structure diagram
HITSEQ -----	HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields
FHITSTR -----	First HIT RN, its text modification, its CA index name, and its structure diagram
FHITSEQ -----	First HIT RN, its text modification, its CA index name, its structure diagram, plus NTE and SEQ fields
KWIC -----	Hit term plus 20 words on either side
OCC -----	Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.

ENTER DISPLAY FORMAT (BIB):his

'HIS' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AI, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
SCAN must be entered on the same line as the DISPLAY,
e.g., D SCAN or DISPLAY SCAN)
STD ----- BIB, IPC, and NCL

IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IBIB ----- BIB, indented with text labels
IMAX ----- MAX, indented with text labels
ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
containing hit terms
HITRN ----- HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
its structure diagram
HITSEQ ----- HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields
KWIC ----- Hit term plus 20 words on either side
OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field codes. For a list of the display field codes, enter HELP DFIELDS at an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST; TI,IND; TI,SO. You may specify the format fields in any order and the information will be displayed in the same order as the format specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR, FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC to view a specified Accession Number.

ENTER DISPLAY FORMAT (BIB):bib

AN 2003:673799 CAPLUS
 DN 139:185344
 TI Skin cosmetics and hair preparations containing sebum secretion inhibitors
 IN Hata, Yuko; Tsutsumi, Tatsuhiko
 PA Maruzen Pharmaceuticals Co., Ltd., Japan
 SO Jpn. Kokai Tokkyo Koho, 5 pp.
 CODEN: JKXXAF

DT Patent
 LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	JP 2003238379	A2	20030827	JP 2002-32721	20020208
PRAI	JP 2002-32721		20020208		

=> d his

(FILE 'HOME' ENTERED AT 15:07:02 ON 15 SEP 2003)

FILE 'REGISTRY' ENTERED AT 15:07:15 ON 15 SEP 2003

		E ACETOMINOPHEN
		E ACETOMINOPHEN
		E ACETOMINOPHEN
		E NSAID
L1	9	S E3
		E ASPIRIN
L2	52	S E3
		E INDOMETHACIN
L3	52	S E3
		E KETOPROFIN
		E KETOPROFEN
L4	50	S E3
		E TRILISATR
		E TRILISATE
L5	1	S E3
L6	1158	S SALICYLAMIDE
L7	30	S SODIUM SALICYLATE
L8	6694	S SALICYLIC ACID
		E ACETOMINOPHEN
		E ACETAMINOPHEN
L9	130	S E3

FILE 'CAPLUS' ENTERED AT 15:20:03 ON 15 SEP 2003

L10	17725	S L2
L11	28561	S CNS
L12	28	S L10 AND L11
		E TRAUMA
L13	11866	S E3
L14	68	S L13 AND L10
		E HEAD
L15	94345	S E3
L16	12	S L14 AND L15
		E ISCHEMA
L17	53069	S E5-E8
L18	356	S L17 AND L10
		E CEREBRAL
L19	78138	S E3
L20	14	S L18 AND 19
L21	66	S L18 AND L19
L22	2	S L19 AND L12
L23	211	S L10 AND L19

L24 66 S L23 AND L17
 L25 0 S L24 NOT L21
 L26 2 S L12 AND L17
 L27 10826 S L9
 L28 46 S L5
 L29 28 S L12 AND L10
 E LUPUS
 L30 11819 S E3
 L31 53 S L30 AND L10
 E ALZHEIMERS
 L32 1977 S E3
 L33 8 S L10 AND L32
 E NSAIDS
 L34 3367 S E3
 L35 36 S L34 AND L17
 L36 28 S L11 AND L12
 L37 685 S L11 AND L17
 L38 2 S L37 AND L10
 E INFLAMMATION
 L39 98265 S E3
 L40 1177 S L39 AND L11
 L41 10 S L40 AND L12
 E PARKINSON
 L42 12980 S E3
 L43 20 S L42 AND L10
 L44 5189 S L7

=> s 110 and 112

L45 28 L10 AND L12

=> s 144 and 142

L46 4 L44 AND L42

=> d 146 1-4

L46 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2003:162318 CAPLUS
 DN 139:111278
 TI Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac
 or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced
 dopaminergic neurotoxicity in rats
 AU Sairam, Krishnamurthy; Saravanan, Karuppagounder S.; Banerjee, Rebecca;
 Mohanakumar, Kochupurackal P.
 CS Division of Neurosciences, Indian Institute of Chemical Biology, Calcutta,
 700 032, India
 SO Brain Research (2003), 966(2), 245-252
 CODEN: BRREAP; ISSN: 0006-8993
 PB Elsevier Science B.V.
 DT Journal
 LA English
 RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2002:588980 CAPLUS
 DN 137:135080
 TI Modification of NSAIDs by sulfur-containing functional groups
 IN Lai, Ching-San; Wang, Tingmin
 PA Medinox, Inc., USA
 SO U.S., 27 pp., Cont.-in-part of U.S. Ser. No. 602,688.
 CODEN: USXXAM
 DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 6429223	B1	20020806	US 2000-715767	20001117
	US 6355666	B1	20020312	US 2000-602688	20000623
	WO 2002000167	A2	20020103	WO 2001-US19750	20010619
	WO 2002000167	A3	20020404		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001070010	A5	20020108	AU 2001-70010	20010619
	EP 1296929	A2	20030402	EP 2001-948537	20010619
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003088111	A1	20030508	US 2002-97197	20020312
PRAI	US 2000-602688	A2	20000623		
	US 2000-715767	A1	20001117		
	WO 2001-US19750	W	20010619		
RE.CNT 13	THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L46 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1999:749471 CAPLUS

DN 132:30710

TI Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice

AU Ferger, Boris; Teismann, Peter; Earl, Christopher D.; Kuschinsky, Klaus; Oertel, Wolfgang H.

CS Medizinisches Zentrum für Nervenheilkunde, Klinik für Neurologie, Medizinisches Zentrum für Nervenheilkunde, Klinik für Neurologie, Philipps-Universität Marburg, Marburg, D-35033, Germany

SO Naunyn-Schmiedeberg's Archives of Pharmacology (1999), 360(3), 256-261
CODEN: NSAPCC; ISSN: 0028-1298

PB Springer-Verlag

DT Journal

LA English

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:338114 CAPLUS

DN 129:12755

TI Use of selected nonsteroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases

IN Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco
PA Università Degli Studi di Brescia - Dipartimento di Scienze Biomediche, Italy; Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco

SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI WO 9820864 A2 19980522 WO 1997-EP6323 19971113
 WO 9820864 A3 19981015
 W: JP, US
 RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 PRAI IT 1996-MI2356 19961113
 OS MARPAT 129:12755

=> d his

(FILE 'HOME' ENTERED AT 15:07:02 ON 15 SEP 2003)

FILE 'REGISTRY' ENTERED AT 15:07:15 ON 15 SEP 2003

		E ACETOMINOPHEN
		E ACETOMINOPHEN
		E ACETOMINOPHEN
		E NSAID
L1	9	S E3
		E ASPIRIN
L2	52	S E3
		E INDOMETHACIN
L3	52	S E3
		E KETOPROFIN
		E KETOPROFEN
L4	50	S E3
		E TRILISATR
		E TRILISATE
L5	1	S E3
L6	1158	S SALICYLAMIDE
L7	30	S SODIUM SALICYLATE
L8	6694	S SALICYLIC ACID
		E ACETOMINOPHEN
		E ACETAMINOPHEN
L9	130	S E3

FILE 'CAPLUS' ENTERED AT 15:20:03 ON 15 SEP 2003

L10	17725	S L2
L11	28561	S CNS
L12	28	S L10 AND L11
		E TRAUMA
L13	11866	S E3
L14	68	S L13 AND L10
		E HEAD
L15	94345	S E3
L16	12	S L14 AND L15
		E ISCHEMA
L17	53069	S E5-E8
L18	356	S L17 AND L10
		E CEREBRAL
L19	78138	S E3
L20	14	S L18 AND 19
L21	66	S L18 AND L19
L22	2	S L19 AND L12
L23	211	S L10 AND L19
L24	66	S L23 AND L17
L25	0	S L24 NOT L21
L26	2	S L12 AND L17
L27	10826	S L9
L28	46	S L5
L29	28	S L12 AND L10
		E LUPUS
L30	11819	S E3

L31 53 S L30 AND L10
E ALZHEIMERS
L32 1977 S E3
L33 8 S L10 AND L32
E NSAIDS
L34 3367 S E3
L35 36 S L34 AND L17
L36 28 S L11 AND L12
L37 685 S L11 AND L17
L38 2 S L37 AND L10
E INFLAMMATION
L39 98265 S E3
L40 1177 S L39 AND L11
L41 10 S L40 AND L12
E PARKINSON
L42 12980 S E3
L43 20 S L42 AND L10
L44 5189 S L7
L45 28 S L10 AND L12
L46 4 S L44 AND L42

=> s 16

L47 4560 L6

=> s 147 and 142

L48 6 L47 AND L42

=> d 148 1-6

L48 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2003:610420 CAPLUS

DN 139:164713

TI Preparation of isoquinoline derivatives as phosphodiesterase (PDE) 7 inhibitors

IN Ohhata, Akira; Takaoka, Yoshikazu; Ogawa, Mikio; Nakai, Hisao; Yamamoto, Susumu; Ochiai, Hiroshi

PA Ono Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 665 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003064389	A1	20030807	WO 2003-JP877	20030130
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI JP 2002-23845 A 20020131

JP 2002-23846 A 20020131

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L48 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2003:454113 CAPLUS
 DN 139:36517
 TI Preparation of 1-phenyl-oxazolidine-2-ones as protease M inhibitors for
 the treatment of tumor illnesses and neurodegenerative diseases
 IN Buchstaller, Hans-Peter; Poeschke, Oliver; Willems, Andreas
 PA Merck Patent Gmbh, Germany
 SO PCT Int. Appl., 86 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003047572	A1	20030612	WO 2002-EP12162	20021031
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG DE 10159453 A1 20030618 DE 2001-10159453 20011204 PRAI DE 2001-10159453 A 20011204 OS MARPAT 139:36517 RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L48 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 2001:635933 CAPLUS
 DN 135:215973
 TI Use of peptide conjugates for enhancing drug delivery across biological
 membranes and tissues
 IN Rothbard, Jonathan B.; Wender, Paul A.
 PA Cellgate, Inc., USA
 SO PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001062297	A1	20010830	WO 2001-US4459	20010209
	WO 2001062297	C2	20030109		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG US 2002009491 A1 20020124 US 2001-779693 20010207 EP 1263469 A1 20021211 EP 2001-909135 20010209 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR JP 2003523982 T2 20030812 JP 2001-561360 20010209 PRAI US 2000-182166P P 20000214				

US 2001-779693 A 20010207
WO 2001-US4459 W 20010209

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L48 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:472717 CAPLUS
DN 135:61336
TI Preparation of triazaspirodecanones as opioid .delta. receptor agonists
IN Tsushima, Masaki; Tadauchi, Kaori; Mori, Tomohisa; Imai, Masako; Kudo, Toshiaki
PA Meiji Seika Kaisha, Ltd., Japan
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2001046192	A1	20010628	WO 2000-JP9080	20001221
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI JP 1999-364001 A 19991222

OS MARPAT 135:61336

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L48 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:380616 CAPLUS
DN 135:10004
TI Compositions and methods for counteracting effects of reactive oxygen species and free radicals
IN Shashoua, Victor E.
PA Ceremedix, Inc., USA
SO PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2001036454	A1	20010525	WO 2000-US31764	20001117
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP	1232174	A1	20020821	EP 2000-978811	20001117
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP	2003518477	T2	20030610	JP 2001-538943	20001117

PRAI US 1999-166381P P 19991118
WO 2000-US31764 W 20001117

OS MARPAT 135:10004

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L48 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:338114 CAPLUS

DN 129:12755

TI Use of selected nonsteroidal antiinflammatory compounds for the prevention
and the treatment of neurodegenerative diseases

IN Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco

PA Universita' Degli Studi di Brescia - Dipartimento di Scienze Biomediche,
Italy; Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano,
Pierfranco

SO PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	----	-----	-----
PI	WO 9820864	A2	19980522	WO 1997-EP6323	19971113
	WO 9820864	A3	19981015		
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

PRAI IT 1996-MI2356 19961113

OS MARPAT 129:12755

=> e neurotrauma

E1	1	NEUROTRAST/BI
E2	1	NEUROTRASTUM/BI
E3	111 -->	NEUROTRAUMA/BI
E4	19	NEUROTRAUMATIC/BI
E5	1	NEUROTRAUMATIZED/BI
E6	5	NEUROTRAUMATOL/BI
E7	2	NEUROTRAUMATOLOGY/BI
E8	1	NEUROTREND/BI
E9	1	NEUROTRENSIN/BI
E10	2	NEUOTRICHUS/BI
E11	22	NEUOTRIMIN/BI
E12	5	NEUOTRIMINS/BI

=> s 111 and 110

L49 28 L11 AND L10

=> d his

(FILE 'HOME' ENTERED AT 15:07:02 ON 15 SEP 2003)

FILE 'REGISTRY' ENTERED AT 15:07:15 ON 15 SEP 2003

E ACETOMINOPHEN

E ACETOMINOPHEN

E ACETOMINOPHEN

E NSAID

L1 9 S E3

E ASPIRIN

L2 52 S E3

E INDOMETHACIN

L3 52 S E3

E KETOPROFIN

		E KETOPROFEN
L4	50	S E3
		E TRILISATR
		E TRILISATE
L5	1	S E3
L6	1158	S SALICYLAMIDE
L7	30	S SODIUM SALICYLATE
L8	6694	S SALICYLIC ACID
		E ACETAMINOPHEN
		E ACETAMINOPHEN
L9	130	S E3

FILE 'CAPLUS' ENTERED AT 15:20:03 ON 15 SEP 2003

L10	17725	S L2
L11	28561	S CNS
L12	28	S L10 AND L11
		E TRAUMA
L13	11866	S E3
L14	68	S L13 AND L10
		E HEAD
L15	94345	S E3
L16	12	S L14 AND L15
		E ISCHEMA
L17	53069	S E5-E8
L18	356	S L17 AND L10
		E CEREBRAL
L19	78138	S E3
L20	14	S L18 AND 19
L21	66	S L18 AND L19
L22	2	S L19 AND L12
L23	211	S L10 AND L19
L24	66	S L23 AND L17
L25	0	S L24 NOT L21
L26	2	S L12 AND L17
L27	10826	S L9
L28	46	S L5
L29	28	S L12 AND L10
		E LUPUS
L30	11819	S E3
L31	53	S L30 AND L10
		E ALZHEIMERS
L32	1977	S E3
L33	8	S L10 AND L32
		E NSAIDS
L34	3367	S E3
L35	36	S L34 AND L17
L36	28	S L11 AND L12
L37	685	S L11 AND L17
L38	2	S L37 AND L10
		E INFLAMMATION
L39	98265	S E3
L40	1177	S L39 AND L11
L41	10	S L40 AND L12
		E PARKINSON
L42	12980	S E3
L43	20	S L42 AND L10
L44	5189	S L7
L45	28	S L10 AND L12
L46	4	S L44 AND L42
L47	4560	S L6
L48	6	S L47 AND L42
		E NEUROTRAUMA

L49 28 S L11 AND L10

=> e alzheimer

E1 2 ALZHEIMDER/BI
E2 1 ALZHEIME/BI
E3 27161 --> ALZHEIMER/BI
E4 1 ALZHEIMERAPOS/BI
E5 1 ALZHEIMERDEMENTIACASESRESEMBLED/BI
E6 1 ALZHEIMERIC/BI
E7 1 ALZHEIMERISTS/BI
E8 1 ALZHEIMERLIKE/BI
E9 1977 ALZHEIMERS/BI
E10 2 ALZHEIMERSDISEASE/BI
E11 1 ALZHEIMR/BI
E12 1 ALZHEINER/BI

=> s e3

L50 27161 ALZHEIMER/BI

=> s l50 and l10

L51 81 L50 AND L10

=> d l51 60-81

L51 ANSWER 60 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:436597 CAPLUS
DN 131:86121
TI Role of platelet activation in dementia
AU Van Kooten, Fop; Ciabattioni, Giovanni; Patrono, Carlo; Koudstaal, Peter J.
CS Department Neurology, Univ. Rotterdam, Rotterdam, 3015 GD, Neth.
SO Haemostasis (1999), Volume Date 1998, 28(3-4), 202-208
CODEN: HMTSB7; ISSN: 0301-0147
PB S. Karger AG
DT Journal; General Review
LA English
RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 61 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:412670 CAPLUS
DN 131:54044
TI Compositions comprising nicotinylalanine and an inhibitor of glycine
conjugation or vitamin B6, and therapeutic use
IN Shaskan, Edward G.
PA USA
SO U.S., 27 pp., Cont.-in-part of U.S. Ser. No. 581,394, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5916906	A	19990629	US 1997-930234	19970912
	WO 9628167	A1	19960919	WO 1996-US3435	19960313
	W:				
	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW:				
	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
PRAI	US 1995-403676		19950314		
	US 1995-581394		19951229		

WO 1996-US3435 19960313

OS MARPAT 131:54044

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 62 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:103337 CAPLUS
DN 130:280248
TI Increased expression of cyclooxygenases and peroxisome
proliferator-activated receptor-.gamma. in **Alzheimer's** disease
brains
AU Kitamura, Yoshihisa; Shimohama, Shun; Koike, Hideyasu; Kakimura, Jun-Ichi;
Matsuoka, Yasuji; Nomura, Yasuyuki; Gebicke-Haerter, Peter J.; Taniguchi,
Takashi
CS Department of Neurobiology, Kyoto Pharmaceutical University, Kyoto,
607-8412, Japan
SO Biochemical and Biophysical Research Communications (1999), 254(3),
582-586
CODEN: BBRC9; ISSN: 0006-291X
PB Academic Press
DT Journal
LA English

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 63 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:806633 CAPLUS
DN 130:57211
TI Preparation of conjugates of dithiocarbamates with drugs
IN Lai, Ching-san
PA Medinox, Inc., USA
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9855453	A1	19981210	WO 1998-US10295	19980519
W:				
AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG,				
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,				
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,				
UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,				
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,				
CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5916910	A	19990629	US 1997-869158	19970604
AU 9875828	A1	19981221	AU 1998-75828	19980519
AU 743205	B2	20020124		
EP 1001932	A1	20000524	EP 1998-923563	19980519
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, FI				
JP 2002511858	T2	20020416	JP 1999-502493	19980519
US 6407135	B1	20020618	US 1999-453608	19991203
US 2003087840	A1	20030508	US 2002-176396	20020618
PRAI US 1997-869158	A1	19970604		
WO 1998-US10295	W	19980519		
US 1999-453608	A3	19991203		

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 64 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:780621 CAPLUS
 DN 130:232124
 TI Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS [central nervous system]
 AU Hauss-Wegrzyniak, Beatrice; Willard, Lauren B.; Del Soldato, Piero; Pepeu, Giancarlo; Wenk, Gary L.
 CS Memory and Aging, Division of Neural Systems, Arizona Research Laboratories, University of Arizona, Tucson, AZ, 85724, USA
 SO Brain Research (1999), 815(1), 36-43
 CODEN: BRREAP; ISSN: 0006-8993
 PB Elsevier Science B.V.
 DT Journal
 LA English
 RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 65 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:708808 CAPLUS
 DN 129:310911
 TI TGF- β -elevating compounds and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods
 IN Grainger, David J.; Metcalfe, James C.; Kasina, Sudhakar
 PA Neorx Corp., USA
 SO PCT Int. Appl., 153 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9846588	A2	19981022	WO 1998-US7063	19980409
	WO 9846588	A3	19990107		
	W:		AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG		
	AU 9869598	A1	19981111	AU 1998-69598	19980409
	US 6117911	A	20000912	US 1998-57323	19980409
	US 6410587	B1	20020625	US 2000-567558	20000505
	US 2003064970	A1	20030403	US 2002-170971	20020613
PRAI	US 1997-43852P	P	19970411		
	US 1998-57323	A1	19980409		
	WO 1998-US7063	W	19980409		
	US 2000-567558	A3	20000505		
OS	MARPAT 129:310911				

L51 ANSWER 66 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:695603 CAPLUS
 DN 130:105154
 TI Molecular characterization of the neuroprotective activity of salicylates
 AU Grilli, M.; Pizzi, M.; Goffi, F.; Benarese, M.; Gerardi, G. M.; Memo, M.; Spano, P. F.
 CS Division of Pharmacology Department of Biomedical Sciences and Biotechnologies School of Medicine, University of Brescia, Brescia, Italy
 SO Advances in Behavioral Biology (1998), 49(Progress in Alzheimer's and Parkinson's Diseases), 99-103
 CODEN: ADBBBW; ISSN: 0099-6246

PB Plenum Publishing Corp.
DT Journal
LA English

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 67 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:621136 CAPLUS
DN 129:254974
TI Process for increasing the therapeutic effect and reducing the toxicity of
drugs, metals, and organic and inorganic compounds
IN Scherbinin, Vladimir Viktorovich; Chernyshev, Evgeny Andreevich
PA Kuzmin, Konstantin Kuzmich, Russia; Volotovskiy, Andrei Vasilievich
SO PCT Int. Appl., 83 pp.
CODEN: PIXXD2
DT Patent
LA Russian
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9840103	A1	19980917	WO 1997-RU261	19970818
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
	DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,				
	RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN,				
	AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,				
	GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,				
	GN, ML, MR, NE, SN, TD, TG				
	RU 2104032	C1	19980210	RU 1997-103218	19970311
	RU 2104033	C1	19980210	RU 1997-103219	19970311
	AU 9739552	A1	19980929	AU 1997-39552	19970818
PRAI	RU 1997-103218	A	19970311		
	RU 1997-103219	A	19970311		
	WO 1997-RU261	W	19970818		

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 68 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:527193 CAPLUS
DN 129:166193
TI Therapeutic treatment and prevention of infections with a bioactive
material encapsulated within a biodegradable-biocompatible polymeric
matrix
IN Setterstrom, Jean A.; Van Hamont, John E.; Reid, Robert H.; Jacob, Elliot;
Jeyanthi, Ramasubbu; Boedeker, Edgar C.; McQueen, Charles E.; Tice, Thomas
R.; Roberts, F. Donald; Friden, Phil
PA United States Dept. of the Army, USA; Van Hamont, John E.; et al.
SO PCT Int. Appl., 363 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9832427	A1	19980730	WO 1998-US1556	19980127
	W:				
	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
	DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,				
	LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,				
	PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US,				
	UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,				

FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
GA, GN, ML, MR, NE, SN, TD, TG

US 6309669 B1 20011030 US 1997-789734 19970127
AU 9863175 A1 19980818 AU 1998-63175 19980127
PRAI US 1997-789734 A 19970127
US 1984-590308 B1 19840316
US 1992-867301 A2 19920410
US 1995-446148 A2 19950522
US 1995-446149 B2 19950522
US 1996-590973 B2 19960124
WO 1998-US1556 W 19980127

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 69 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:484927 CAPLUS
DN 129:127177
TI Pharmaceutical preparations of glutathione and methods of administration
IN Demopoulos, Harry B.; Seligman, Myron L.
PA Antioxidant Pharmaceuticals Corp., USA
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9829101	A1	19980709	WO 1997-US23879	19971231
	W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9856205	A1	19980731	AU 1998-56205	19971231
	EP 957901	A1	19991124	EP 1997-952640	19971231
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	JP 2001507696	T2	20010612	JP 1998-530206	19971231
	US 6350467	B1	20020226	US 1999-331947	19990628
	US 2002136763	A1	20020926	US 2002-83327	20020225
PRAI	US 1996-34101P	P	19961231		
	WO 1997-US23879	W	19971231		
	US 1999-331947	A2	19990628		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L51 ANSWER 70 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:424361 CAPLUS
DN 129:38404
TI Method for determining the prognosis of a patient with a neurological disease
IN Sevigny, Pierre; Wiebusch, Heiko; Schappert, Keith
PA Nova Molecular, Inc., Can.
SO PCT Int. Appl., 28 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI	WO 9827226	A2	19980625	WO 1997-IB1641	19971216
	WO 9827226	A3	19980820		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6022683	A	20000208	US 1996-766975	19961216
	AU 9855717	A1	19980715	AU 1998-55717	19971216
	EP 948647	A1	19991013	EP 1997-952129	19971216
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	US 1996-766975	A	19961216		
	WO 1997-IB1641	W	19971216		

L51 ANSWER 71 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:338114 CAPLUS
DN 129:12755
TI Use of selected nonsteroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases
IN Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco
PA Universita' Degli Studi di Brescia - Dipartimento di Scienze Biomediche, Italy; Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco
SO PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9820864	A2	19980522	WO 1997-EP6323	19971113
	WO 9820864	A3	19981015		
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	IT 1996-MI2356		19961113		
OS	MARPAT 129:12755				

L51 ANSWER 72 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:25162 CAPLUS
DN 128:97725
TI Therapeutic methods and compositions using R-ibuprofen
IN Xiaotao, Qian; Hall, Stephen D.
PA Advanced Research and Technology Institute, USA; Xiaotao, Qian; Hall, Stephen D.
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9748391	A2	19971224	WO 1997-US10762	19970620
	WO 9748391	A3	19980129		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US,				

UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
 GN, ML, MR, NE, SN, TD, TG

AU 9736415 A1 19980107 AU 1997-36415 19970620
 US 6255347 B1 20010703 US 1997-879870 19970620
 PRAI US 1996-20248P P 19960621
 WO 1997-US10762 W 19970620

L51 ANSWER 73 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1997:454047 CAPLUS

DN 127:60626

TI Method of delaying onset of **Alzheimer's** disease symptoms with a
 non-steroidal anti-inflammatory agent and/or a histamine H2
 receptor-blocking agent

IN Breitner, John C. S.; Welsh, Kathleen A.

PA Duke University, USA

SO U.S., 10 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5643960	A	19970701	US 1994-228019	19940415
	US 6025395	A	20000215	US 1997-843217	19970414
PRAI	US 1994-228019		19940415		

L51 ANSWER 74 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1997:433698 CAPLUS

DN 127:55908

TI Transdermal therapeutic preparation with drug-containing backing layer

IN Horstmann, Michael; Laux, Wolfgang

PA LTS Lohmann Therapie-Systeme GmbH, Germany

SO Ger. Offen., 4 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19546024	A1	19970612	DE 1995-19546024	19951209
	DE 19546024	C2	19980910		
	WO 9721430	A2	19970619	WO 1996-EP5411	19961204
	W: AU, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, SI, SK, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9711764	A1	19970703	AU 1997-11764	19961204
	AU 715763	B2	20000210		
	EP 865274	A2	19980923	EP 1996-942341	19961204
	EP 865274	B1	19990929		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI				
	CN 1204257	A	19990106	CN 1996-198914	19961204
	AT 185069	E	19991015	AT 1996-942341	19961204
	JP 2000501718	T2	20000215	JP 1997-521703	19961204
	ES 2141548	T3	20000316	ES 1996-942341	19961204
	IL 124538	A1	20001206	IL 1996-124538	19961204
	SK 281406	B6	20010312	SK 1998-674	19961204
	CZ 289240	B6	20011212	CZ 1998-1711	19961204
	ZA 9610270	A	19970710	ZA 1996-10270	19961206
	US 6207183	B1	20010327	US 1998-91259	19980608
PRAI	DE 1995-19546024	A	19951209		

WO 1996-EP5411 W 19961204

L51 ANSWER 75 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:97266 CAPLUS
DN 124:135727
TI Method and use of agents to inhibit protein polymerization, methods of
identifying these agents, and use of the agents as antithrombotics and for
the treatment of **Alzheimer's** disease
IN Bjornsson, Thorir D.
PA Thomas Jefferson University, USA
SO PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9531192	A1	19951123	WO 1995-US6383	19950515
	W: CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	US 1994-243114		19940516		
OS	MARPAT 124:135727				

L51 ANSWER 76 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:772802 CAPLUS
DN 123:160855
TI Use of thalidomide for treating neurocognitive disorders
IN Andrulis, Peter J., Jr.
PA Andrulis Pharmaceuticals Corp., USA
SO PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9517154	A2	19950629	WO 1994-US14743	19941222
	WO 9517154	A3	19950713		
	W: AU, CA, CN, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5434170	A	19950718	US 1993-172155	19931223
	AU 9513751	A1	19950710	AU 1995-13751	19941222
	EP 735874	A1	19961009	EP 1995-904954	19941222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
PRAI	US 1993-172155		19931223		
	WO 1994-US14743		19941222		

L51 ANSWER 77 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:374891 CAPLUS
DN 122:142506
TI Use of hydrophilic carotenoids for the treatment of diseases having an
oxidation mechanism
IN Howard, Alan Norman; Hepworth, Lawrence; Thurnham, David I.
PA Howard Foundation, UK
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9500130	A1	19950105	WO 1994-GB1402	19940628

W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE,
 HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ,
 PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN
 RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
 BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9470056 A1 19950117 AU 1994-70056 19940628
 GB 2280110 A1 19950125 GB 1994-12938 19940628
 GB 2280110 B2 19971112
 ZA 9404633 A 19951025 ZA 1994-4633 19940628
 PRAI GB 1993-13266 A 19930628
 US 1994-219897 A 19940330
 WO 1994-GB1402 W 19940628

L51 ANSWER 78 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1994:253358 CAPLUS
 DN 120:253358
 TI Cyclodextrin complexes with polymers, drugs, agrochemicals and cosmetics
 IN Loftsson, Thorsteinn
 PA Iceland
 SO Eur. Pat. Appl., 46 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 579435	A1	19940119	EP 1993-305280	19930706
	EP 579435	B1	19990317		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	US 5324718	A	19940628	US 1992-912853	19920714
	AT 177647	E	19990415	AT 1993-305280	19930706
	ES 2132190	T3	19990816	ES 1993-305280	19930706
	US 5472954	A	19951205	US 1994-240510	19940511
PRAI	US 1992-912853		19920714		
	EP 1993-305280		19930706		

L51 ANSWER 79 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1993:247651 CAPLUS
 DN 118:247651
 TI Nonsteroidal anti-rheumatoid arthritic drugs in the treatment of dementia
 IN McGeer, Patrick L.; Rogers, Joseph; Sibley, John; McGeer, Edith
 PA Can.
 SO U.S., 6 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5192753	A	19930309	US 1991-689499	19910423
	WO 9324115	A1	19931209	WO 1992-CA229	19920529
	W: JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	EP 642336	A1	19950315	EP 1992-910600	19920529
	EP 642336	B1	19980114		
	R: DE, FR, GB, IT				
	JP 07506559	T2	19950720	JP 1992-509619	19920529
PRAI	US 1991-689499		19910423		
	WO 1992-CA229		19920529		

L51 ANSWER 80 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1990:637859 CAPLUS

DN 113:237859
 TI Pharmaceutical composition containing a complexing agent and procaine for
 the treatment of symptoms from narcotic addiction, tinnitus, and
Alzheimer's disease
 IN Sapse, Alfred T.
 PA USA
 SO U.S., 4 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4956391	A	19900911	US 1988-233247	19880817
	US 5064858	A	19911112	US 1990-578030	19900905
PRAI	US 1988-233247		19880817		

L51 ANSWER 81 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1989:206625 CAPLUS
 DN 110:206625
 TI Hormone treatment for central nervous system diseases such as Alzheimers
 disease and Parkinsons disease
 IN Aroonsakul, Chaovanee
 PA USA
 SO U.S., 4 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4791099	A	19881213	US 1984-666254	19841029
	EP 324037	A1	19890719	EP 1988-100233	19880111
	EP 324037	B1	19970903		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 157546	E	19970915	AT 1988-100233	19880111
	ES 2109914	T3	19980201	ES 1988-100233	19880111
	US 4898856	A	19900206	US 1988-156242	19880216
	JP 01216940	A2	19890830	JP 1988-39323	19880222
	JP 09216837	A2	19970819	JP 1997-38275	19880222
	US 4897389	A	19900130	US 1989-293134	19890103
	US 4902680	A	19900220	US 1989-293017	19890103
	US 4898857	A	19900206	US 1989-293132	19890203
PRAI	US 1984-666254		19841029		
	US 1986-852645		19860416		
	EP 1988-100233		19880111		
	US 1988-156242		19880216		
	JP 1988-39323		19880222		

=> d 151 66 all

L51 ANSWER 66 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:695603 CAPLUS
 DN 130:105154
 TI Molecular characterization of the neuroprotective activity of salicylates
 AU Grilli, M.; Pizzi, M.; Goffi, F.; Benarese, M.; Gerardi, G. M.; Memo, M.;
 Spano, P. F.
 CS Division of Pharmacology Department of Biomedical Sciences and
 Biotechnologies School of Medicine, University of Brescia, Brescia, Italy
 SO Advances in Behavioral Biology (1998), 49(Progress in Alzheimer's and
 Parkinson's Diseases), 99-103

CODEN: ADBBBW; ISSN: 0099-6246

PB Plenum Publishing Corp.
DT Journal
LA English
CC 1-11 (Pharmacology)
AB Aspirin and its metabolite sodium salicylate prevent glutamate-induced neurotoxicity in rats. The neuroprotective effect of aspirin does not appear to correlate with the anti-inflammatory properties of this compd.
ST neuroprotectant salicylate antiinflammatory neurodegenerative disorder
Alzheimer
IT Transcription factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(NF-.kappa.B (nuclear factor .kappa.B); mol. characterization of the neuroprotective activity of salicylates)
IT Nervous system
(degeneration; mol. characterization of the neuroprotective activity of salicylates)
IT Anti-**Alzheimer**'s agents
(mol. characterization of the neuroprotective activity of salicylates)
IT Cytoprotective agents
(neuroprotectants; mol. characterization of the neuroprotective activity of salicylates)
IT Anti-inflammatory agents
(nonsteroidal; mol. characterization of the neuroprotective activity of salicylates)
IT 54-21-7, Sodium salicylate
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
(mol. characterization of the neuroprotective activity of salicylates)
IT **50-78-2**, Aspirin 69-72-7D, analogs
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mol. characterization of the neuroprotective activity of salicylates)

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Amin, A; Proc Natl Acad Sci USA 1995, V92, P7926 CAPLUS
- (2) Curran, T; Cell 1988, V55, P395 CAPLUS
- (3) Gallo, V; Proc Natl Acad Sci USA 1982, V79, P7919 CAPLUS
- (4) Garthwaite, G; Neurosci Lett 1989, V97, P316 CAPLUS
- (5) Grilli, M; Int Rev Cytol 1993, V143, P1 CAPLUS
- (6) Grilli, M; J Biol Chem 1995, V270, P26774 CAPLUS
- (7) Grilli, M; J Biol Chem 1996, V271, P15002 CAPLUS
- (8) Grilli, M; Science 1996, V274, P1383 CAPLUS
- (9) Guerrini, L; Proc Natl Acad Sci USA 1995, V92, P9077 CAPLUS
- (10) Insel, P; Goodman and Gilman's The Pharmacological Basis of Therapeutics 1996, P617
- (11) Kaltschmidt, C; Mol Cell Biol 1994, V14, P3981 CAPLUS
- (12) Kaltschmidt, C; Proc Natl Acad Sci USA 1995, V92, P9618 CAPLUS
- (13) Kopp, E; Science 1994, V265, P956 MEDLINE
- (14) Lipton, S; New Engl J Med 1995, V330, P613
- (15) McGeer, P; Brain Res Rev 1995, V21, P195 MEDLINE
- (16) Pizzi, M; Eur J Neurosci 1996, V8, P1516 MEDLINE
- (17) Pizzi, M; Mol Pharmacol 1996, V49, P586 CAPLUS
- (18) Rogers, J; Neurology 1993, V43, P1609 MEDLINE
- (19) Yan, S; Nature Med 1995, V1, P693 CAPLUS

=> d 151 65 all

L51 ANSWER 65 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:708808 CAPLUS

DN 129:310911

TI TGF-.beta.-elevating compounds and therapies for the prevention of
vascular and non-vascular pathologies, and diagnostic methods

IN Grainger, David J.; Metcalfe, James C.; Kasina, Sudhakar

PA Neorx Corp., USA

SO PCT Int. Appl., 153 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07D333-38

ICS A61K031-60; A61K031-135; G01N033-543

CC 1-12 (Pharmacology)

Section cross-reference(s): 15, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 9846588	A2	19981022	WO 1998-US7063	19980409
	WO 9846588	A3	19990107		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9869598	A1	19981111	AU 1998-69598	19980409
	US 6117911	A	20000912	US 1998-57323	19980409
	US 6410587	B1	20020625	US 2000-567558	20000505
	US 2003064970	A1	20030403	US 2002-170971	20020613
PRAI	US 1997-43852P	P	19970411		
	US 1998-57323	A1	19980409		
	WO 1998-US7063	W	19980409		
	US 2000-567558	A3	20000505		
OS	MARPAT 129:310911				
AB	A method is provided for treating a mammal having, or at risk of, an indication assocd. with a TGF-.beta. deficiency, comprising administering one or more agents that is effective to elevate the level of TGF-.beta.. The invention also provides compds. that elevate TGF-beta levels, as well as pharmaceutical compns. comprising compds. that elevate TGF-beta levels and methods for detecting diseases assocd. with endothelial cell activation.				
ST	TGFbeta stimulating compd therapeutic; endothelial cell activation disease diagnosis				
IT	Immunoglobulins RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence) (D; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)				
IT	Immunoglobulins RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence) (G2; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)				
IT	Immunoglobulins RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence) (G; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)				
IT	Heat-shock proteins				

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (HSP 90; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Transcription factors
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (I.kappa.B (inhibitor of NF-.kappa.B), .alpha.; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Transcription factors
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (NF-.kappa.B (nuclear factor .kappa.B); TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Cell nucleus
 (NF-.kappa.B translocation to; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Lipoproteins
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (TGF-.beta. assocn. with lipoprotein particles)

IT Animal cell
 (TGF-.beta. type II receptor-contg. mammalian cell detection; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Anti-~~Alzheimer~~'s agents
 Anticholesteremic agents
 Antiparkinsonian agents
 Antirheumatic agents
 Autoimmune disease
 Blood analysis
 Blood vessel, disease
 Body fluid
 Cell proliferation
 Chylomicrons
 Cytotoxic agents
 Diabetes mellitus
 Drug delivery systems
 Fibrosis
 Hypertriglyceridemia
 Hypolipemic agents
 Immunoassay
 Lupus erythematosus
 Marfan syndrome
 Multiple sclerosis
 (TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Tumor necrosis factors
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Glycerides, biological studies
 Osteopontin
 RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
 (TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Antibodies
Immunoglobulins
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Estrogen receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Antiarteriosclerotics
(antiatherosclerotics; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Cytoprotective agents
(cardioprotective; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Artery, disease
(coronary, stenosis; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Diagnosis
(endothelial cell activation-assocd. disease; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Blood vessel
(endothelium, endothelial cell activation; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Fats and Glyceridic oils, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fish; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Lipoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(high-d.; TGF-.beta. assocn. with lipoprotein particles)

IT Biological transport
(intracellular, NF-.kappa.B translocation to nucleus; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Lipoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(low-d.; TGF-.beta. assocn. with lipoprotein particles)

IT Atherosclerosis
(plaque stability; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Fatty acids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyunsatd., n-3; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Proliferation inhibition
(proliferation inhibitors; TGF-.beta.-elevating compds. and therapies

for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Wine
(red; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Mental disorder
(senile psychosis; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Blood vessel
(smooth muscle; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Drug interactions
(synergistic; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Osteoporosis
(therapeutic agents; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Drug delivery systems
(unit doses; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Lipoproteins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(very-low-d.; TGF-.beta. assocn. with lipoprotein particles)

IT Transforming growth factors
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha.-; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Actins
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
(.alpha.-; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Transforming growth factors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.beta.-; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Transforming growth factor receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.beta.-transforming growth factor type II; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT Transforming growth factor receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.beta.-transforming growth factor; TGF-.beta.-elevating compds. and therapies for the prevention of vascular and non-vascular pathologies, and diagnostic methods)

IT 50-78-2, Aspirin 50-78-2D, Aspirin, derivs. 67-98-1, MER25 493-53-8 7440-50-8D, Copper, aspirinates, biological studies 10540-29-1, Tamoxifen 23325-63-5 32839-18-2,

Docosahexaenoic acid 32839-30-8, Eicosapentaenoic acid 79902-63-9,
Simvastatin 146063-51-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(TGF-.beta.-elevating compds. and therapies for the prevention of
vascular and non-vascular pathologies, and diagnostic methods)

IT 57-88-5, Cholesterol, biological studies

RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological
study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC
(Process)

(TGF-.beta.-elevating compds. and therapies for the prevention of
vascular and non-vascular pathologies, and diagnostic methods)

=> d 151 64 all

L51 ANSWER 64 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:780621 CAPLUS

DN 130:232124

TI Peripheral administration of novel anti-inflammatories can attenuate the
effects of chronic inflammation within the CNS [central nervous system]

AU Hauss-Wegrzyniak, Beatrice; Willard, Lauren B.; Del Soldato, Piero; Pepeu,
Giancarlo; Wenk, Gary L.

CS Memory and Aging, Division of Neural Systems, Arizona Research
Laboratories, University of Arizona, Tucson, AZ, 85724, USA

SO Brain Research (1999), 815(1), 36-43

CODEN: BRREAP; ISSN: 0006-8993

PB Elsevier Science B.V.

DT Journal

LA English

CC 1-7 (Pharmacology)

AB This study investigated whether nitroflurbiprofen (NFP) or nitro-aspirin
can reduce the inflammatory response induced by continuous infusion of
lipopolysaccharide (LPS) into the 4th ventricular space of the rat brain
for 30 days. The chronic LPS infusion produced an extensive inflammation
that was particularly evident in the hippocampus, subiculum and entorhinal
and piriform cortices. Daily peripheral administration of NFP
dose-dependently attenuated the brain inflammation, as indicated by the
decreased d. and reactive state of microglial cells. Daily peripheral
administration of nitro-aspirin also attenuated the brain inflammation,
but to a much lesser degree than NFP. The results demonstrated that
nonsteroidal anti-inflammatory drugs can reduce brain inflammation and
that NFP is an effective anti-inflammatory agent.

ST brain inflammation inhibition nitroflurbiprofen nitroaspirin; nonsteroidal
antiinflammatory drug brain inflammation

IT Encephalitis

(nitroflurbiprofen and nitroaspirin inhibition of)

IT **Alzheimer's** disease

(nitroflurbiprofen and nitroaspirin inhibition of brain inflammation in
relation to)

IT Anti-inflammatory agents

(nonsteroidal; brain inflammation inhibition by nitroflurbiprofen and
nitroaspirin as)

IT **17336-14-0** 158836-71-6, Nitroflurbiprofen

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(brain inflammation inhibition by)

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Aisen, P; Am J Psychiatr 1994, V151, P1105 MEDLINE

- (2) Allison, M; N Engl J Med 1992, V327, P749 MEDLINE
- (3) Altstiel, L; Prog Neuropsychopharmacol Biol Psychiatr 1991, V15, P481 CAPLUS
- (4) Banati, R; Glia 1993, V7, P111 MEDLINE
- (5) Bannwarth, B; Therapie 1986, V41, P409 CAPLUS
- (6) Breder, C; Brain Res 1996, V713, P64 CAPLUS
- (7) Breitner, J; Neurobiol Aging 1996, V17, P789 MEDLINE
- (8) Burrell, R; Crit Rev Microbiol 1990, V17, P188
- (9) Cacabelos, R; Meth Find Exp Clin Pharmacol 1994, V16, P141 MEDLINE
- (10) Chiang, C; Dev Neurosci 1994, V16, P212 CAPLUS
- (11) Das, S; Neuron 1995, V14, P447 CAPLUS
- (12) Eikelenboom, P; Virchows Arch B Cell Pathol 1989, V56, P259 MEDLINE
- (13) Elmquist, J; J Comp Neurol 1997, V381, P119 CAPLUS
- (14) Greenblatt, D; Arzneimittelforschung 1983, V33, P1671 CAPLUS
- (15) Griffin, W; Proc Natl Acad Sci USA 1989, V86, P7611 MEDLINE
- (16) Hauss-Wegrzyniak, B; Brain Res 1998, V794, P211 CAPLUS
- (17) Hauss-Wegrzyniak, B; Brain Res 1998, V780, P294 CAPLUS
- (18) Jenkinson, M; Br J Rheumatol 1989, V28, P86 MEDLINE
- (19) Kitagawa, H; J Pharmacol Exp Therap 1990, V253, P1133 CAPLUS
- (20) Macnaughton, W; Life Sci 1989, V45, P1869 CAPLUS
- (21) McGeer, P; Brain Res Rev 1995, V21, P195 MEDLINE
- (22) McGeer, P; Lancet 1990, V335, P1037 MEDLINE
- (23) McGeer, P; Neurosci Lett 1988, V79, P195
- (24) McGeer, P; Neurosci Lett 1989, V107, P341 MEDLINE
- (25) Mrak, R; Human Pathol 1995, V26, P816 MEDLINE
- (26) Myllykangas-Luosujarvi, R; Br J Rheumatol 1994, V33, P501 MEDLINE
- (27) Rogers, J; Drug Res 1995, V45, P439 CAPLUS
- (28) Rogers, J; Neurobiol Aging 1996, V17, P681 MEDLINE
- (29) Rogers, J; Neurology 1993, V43, P1609 MEDLINE
- (30) Roth, S; Ann Intern Med 1988, V109, P353 MEDLINE
- (31) Santini, G; Eur J Pharmacol 1996, V316, P65 CAPLUS
- (32) Sheng, J; Neurobiol Aging 1996, V17, P761 CAPLUS
- (33) Strauss, S; Lab Invest 1992, V66, P223 MEDLINE
- (34) Vandenabeele, P; Immunol Today 1991, V12, P217 CAPLUS
- (35) Wallace, J; Gastroenterology 1994, V107, P173 CAPLUS
- (36) Wallace, J; Trends Pharmacol Sci 1992, V13, P129 MEDLINE
- (37) Watson; Paxinos 1986

=> d 151 62 all

L51 ANSWER 62 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1999:103337 CAPLUS
 DN 130:280248
 TI Increased expression of cyclooxygenases and peroxisome
 proliferator-activated receptor- γ . in **Alzheimer's** disease
 brains
 AU Kitamura, Yoshihisa; Shimohama, Shun; Koike, Hideyasu; Kakimura, Jun-Ichi;
 Matsuoka, Yasuji; Nomura, Yasuyuki; Gebicke-Haerter, Peter J.; Taniguchi,
 Takashi
 CS Department of Neurobiology, Kyoto Pharmaceutical University, Kyoto,
 607-8412, Japan
 SO Biochemical and Biophysical Research Communications (1999), 254(3),
 582-586
 CODEN: BBRCA9; ISSN: 0006-291X
 PB Academic Press
 DT Journal
 LA English
 CC 14-10 (Mammalian Pathological Biochemistry)
 Section cross-reference(s): 1
 AB Recent studies suggest that inflammatory events are assocd. with plaque
 formation in the brains of patients with **Alzheimer's** disease

(AD). Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) of these patients appears to slow the progression of disease. The authors assessed the occurrence of cyclooxygenases (COX-1 and -2) and peroxisome proliferator-activated receptor-.gamma. (PPAR.gamma.) in temporal cortex from normal and AD brains using specific antibodies. In AD brains, protein levels of COX-1 were increased in both cytosolic and particulate fractions, and COX-2 protein was also increased in the particulate fraction. PPAR.gamma. level was increased in the cytosolic fraction but not in the particulate fraction. Thus, expression levels of COX-1, COX-2, and PPAR.gamma. may change in AD brains. In addn., several NSAIDs which are also PPAR.gamma. activators, such as indomethacin, inhibited COX-2 expression in glial cells. These results suggest that PPAR.gamma. activators have inhibitory effects on inflammatory events in AD brains.
(c) 1999 Academic Press.

- ST brain cyclooxygenase peroxisome proliferator activated receptor gamma
Alzheimer disease
- IT Cytoplasm
(cytosol; increased expression of cyclooxygenases and peroxisome
proliferator-activated receptor-.gamma. in brains from humans with
Alzheimer's disease)
- IT Gene
(expression; increased expression of cyclooxygenases and peroxisome
proliferator-activated receptor-.gamma. in brains from humans with
Alzheimer's disease)
- IT **Alzheimer's** disease
Encephalitis
Neuroglia
(increased expression of cyclooxygenases and peroxisome
proliferator-activated receptor-.gamma. in brains from humans with
Alzheimer's disease)
- IT Anti-inflammatory agents
(nonsteroidal; increased expression of cyclooxygenases and peroxisome
proliferator-activated receptor-.gamma. in brains from humans with
Alzheimer's disease)
- IT Brain
(temporal cortex; increased expression of cyclooxygenases and
peroxisome proliferator-activated receptor-.gamma. in brains from
humans with **Alzheimer's** disease)
- IT Peroxisome proliferator-activated receptors
RL: BOC (Biological occurrence); BSU (Biological study, unclassified);
BIOL (Biological study); OCCU (Occurrence)
(.gamma.; increased expression of cyclooxygenases and peroxisome
proliferator-activated receptor-.gamma. in brains from humans with
Alzheimer's disease)
- IT 39391-18-9
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological
study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC
(Process)
(1 and 2; increased expression of cyclooxygenases and peroxisome
proliferator-activated receptor-.gamma. in brains from humans with
Alzheimer's disease)
- IT 50-78-2, Aspirin 53-86-1, Indomethacin 41598-07-6, PGD2
87893-55-8 123653-11-2, NS398
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(increased expression of cyclooxygenases and peroxisome
proliferator-activated receptor-.gamma. in brains from humans with
Alzheimer's disease)

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Bauer, M; Eur J Biochem 1997, V243, P726 CAPLUS

- (2) Bonventre, J; Nature 1997, V390, P622 CAPLUS
- (3) Chang, J; Neurobiol Aging 1996, V17, P801 CAPLUS
- (4) Clemens, J; Stroke 1996, V27, P527 CAPLUS
- (5) Farooqui, A; Neurochem Int 1997, V30, P517 CAPLUS
- (6) Forman, B; Cell 1995, V83, P803 CAPLUS
- (7) Gattaz, W; Biol Psychiatry 1995, V37, P13 MEDLINE
- (8) Guastadisegni, C; FEBS Lett 1997, V413, P314 CAPLUS
- (9) Jiang, C; Nature 1998, V391, P82 CAPLUS
- (10) Kitamura, Y; Neurosci Lett 1997, V237, P17 CAPLUS
- (11) Lehmann, J; J Biol Chem 1997, V272, P3406 CAPLUS
- (12) Lehtonen, J; Biochemistry 1996, V35, P9407 CAPLUS
- (13) Lukiw, W; J Neurosci Res 1997, V50, P937 CAPLUS
- (14) Mangelsdorf, D; Cell 1995, V83, P835 CAPLUS
- (15) Mirra, S; Neurology 1991, V41, P479 MEDLINE
- (16) Morita, I; J Biol Chem 1995, V270, P10902 CAPLUS
- (17) Nogawa, S; J Neurosci 1997, V17, P2746 CAPLUS
- (18) Oka, A; NeuroReport 1997, V8, P1161 CAPLUS
- (19) Pasinetti, G; Neuroscience 1998, V87, P319 CAPLUS
- (20) Ricote, M; Nature 1998, V391, P79 CAPLUS
- (21) Rogers, J; Neurology 1993, V43, P1609 MEDLINE
- (22) Sanz, O; Neuroscience 1997, V80, P221 CAPLUS
- (23) Shimohama, S; J Neural Transm 1990, V30(Suppl), P69
- (24) Shimohama, S; J Neurochem 1995, V64, P2629 CAPLUS
- (25) Shimohama, S; Neurology 1993, V43, P1407 MEDLINE
- (26) Spencer, A; J Biol Chem 1998, V273, P9886 CAPLUS
- (27) Stephenson, D; Neurobiol Dis 1996, V3, P51 CAPLUS
- (28) Tocco, G; Exp Neurol 1997, V144, P339 CAPLUS
- (29) Vane, J; Ann Rev Pharmacol Toxicol 1998, V38, P97 CAPLUS

=> d 151 76 all

L51 ANSWER 76 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1995:772802 CAPLUS

DN 123:160855

TI Use of thalidomide for treating neurocognitive disorders

IN Andrulis, Peter J., Jr.

PA Andrulis Pharmaceuticals Corp., USA

SO PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K

CC 1-11 (Pharmacology)

Section cross-reference(s): 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 9517154	A2	19950629	WO 1994-US14743	19941222
	WO 9517154	A3	19950713		
	W: AU, CA, CN, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5434170	A	19950718	US 1993-172155	19931223
	AU 9513751	A1	19950710	AU 1995-13751	19941222
	EP 735874	A1	19961009	EP 1995-904954	19941222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
PRAI	US 1993-172155		19931223		
	WO 1994-US14743		19941222		

AB A method is disclosed for treating a central nervous system or peripheral nervous system cholinergic deficit state in a mammalian organism in need of such treatment, the method comprising administering to said mammal an amt. of thalidomide effective in the treatment of a cholinergic deficit

state and for a time sufficient to achieve a suitable blood level to treat the cholinergic deficit state. The thalidomide may be administered with e.g. a non-steroidal antiinflammatory agent. The method of the invention may be used to treat e.g. **Alzheimer's** disease. Capsule formulations of e.g. thalidomide and ibuprofen are included.

ST thalidomide neurocognitive disorder treatment; nervous cholinergic deficit disorder treatment thalidomide

IT Carboxylic acids, biological studies

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nonsteroidal antiinflammatory; thalidomide, with or without other agent, for treating neurocognitive disorder)

IT Nootropics

Senescence

(thalidomide, with or without other agent, for treating neurocognitive disorder)

IT Mental disorder

(**Alzheimer's** disease, thalidomide, with or without other agent, for treating neurocognitive disorder)

IT Proteins, specific or class

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(amyloid A4, inhibitors; thalidomide, with or without other agent, for treating neurocognitive disorder)

IT Lipoproteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(apo-, inhibitors; thalidomide, with or without other agent, for treating neurocognitive disorder)

IT Lipoproteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(apo-, I, agents; thalidomide, with or without other agent, for treating neurocognitive disorder)

IT Pharmaceutical dosage forms

(capsules, thalidomide, with or without other agent, for treating neurocognitive disorder)

IT Nervous system

(central, cholinergic, disease, deficiency, thalidomide, with or without other agent, for treating neurocognitive disorder)

IT Inflammation inhibitors

(nonsteroidal, thalidomide, with or without other agent, for treating neurocognitive disorder)

IT Nervous system

(peripheral, cholinergic, disease, deficiency, thalidomide, with or without other agent, for treating neurocognitive disorder)

IT Inflammation inhibitors

(steroidal, thalidomide, with or without other agent, for treating neurocognitive disorder)

IT 50-35-1, Thalidomide **50-78-2**, Aspirin 64-19-7D, Acetic acid, aryl derivs., mixts. with thalidomide 79-09-4D, Propionic acid, aryl derivs., mixts. with thalidomide 91-40-7D, Fenamic acid, derivs., mixts. with thalidomide 92-52-4D, Biphenyl, carboxylic acid derivs., mixts. with thalidomide 167273-63-4 167273-64-5 167273-65-6 167273-66-7

167273-67-8 167273-68-9 167273-69-0 167273-70-3 167273-71-4

167273-72-5 167273-73-6 167273-74-7 167273-75-8 167273-76-9

167273-77-0 167273-78-1 167273-79-2 167273-80-5 167273-81-6

167273-82-7 167273-83-8 167273-84-9 167273-85-0 167273-86-1

167273-87-2 167273-88-3 167273-89-4 167273-90-7 167273-91-8

167273-92-9 167273-93-0 167273-94-1 167273-95-2 167273-96-3

167273-97-4 167273-98-5 167273-99-6 167274-00-2 167274-01-3

167274-02-4 167274-03-5 167274-04-6 167274-05-7 167274-06-8

167274-07-9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(thalidomide, with or without other agent, for treating neurocognitive disorder)

=> d 151 73 all

L51 ANSWER 73 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:454047 CAPLUS
DN 127:60626
TI Method of delaying onset of **Alzheimer's** disease symptoms with a
non-steroidal anti-inflammatory agent and/or a histamine H2
receptor-blocking agent
IN Breitner, John C. S.; Welsh, Kathleen A.
PA Duke University, USA
SO U.S., 10 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K031-60
ICS A61K031-615; A61K031-54; A61K031-44; A61K031-425; A61K031-42;
A61K031-415; A61K031-40; A61K031-38; A61K031-34; A61K031-195;
A61K031-19

NCL 514570000
CC 1-11 (Pharmacology)
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5643960	A	19970701	US 1994-228019	19940415
	US 6025395	A	20000215	US 1997-843217	19970414
PRAI	US 1994-228019		19940415		

AB A method is disclosed for preventing or delaying the onset of
Alzheimer's disease and related neurodegenerative disorders. The
method involves the administration to individuals at risk of developing
the disease (or disorder) a non-steroidal anti-inflammatory agent and/or a
histamine H2 receptor-blocking agent. The invention also relates to a
method of treating **Alzheimer's** disease and related
neurodegenerative disorders that involves the use of such agents.

ST **Alzheimer** disease NSAID H2 antihistaminic; neurodegenerative
disease NSAID H2 antihistaminic

IT Apolipoproteins

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(E, .epsilon.4 or .epsilon.2 allele at locus for; non-steroidal
anti-inflammatory agent and/or histamine H2 receptor-blocking agent for
preventing, delaying, or treating **Alzheimer's** disease and
related neurodegenerative disorders)

IT Antihistamines

(H2; non-steroidal anti-inflammatory agent and/or histamine H2
receptor-blocking agent for preventing, delaying, or treating
Alzheimer's disease and related neurodegenerative disorders)

IT Nervous system

(degeneration; non-steroidal anti-inflammatory agent and/or histamine
H2 receptor-blocking agent for preventing, delaying, or treating
Alzheimer's disease and related neurodegenerative disorders)

IT **Alzheimer's** disease

Narcotics

Susceptibility (genetic)

(non-steroidal anti-inflammatory agent and/or histamine H2
receptor-blocking agent for preventing, delaying, or treating
Alzheimer's disease and related neurodegenerative disorders)

IT Glucocorticoids

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)

(non-steroidal anti-inflammatory agent and/or histamine H2
receptor-blocking agent for preventing, delaying, or treating

Alzheimer's disease and related neurodegenerative disorders)
 IT Anti-inflammatory agents
 (nonsteroidal; non-steroidal anti-inflammatory agent and/or histamine
 H2 receptor-blocking agent for preventing, delaying, or treating
Alzheimer's disease and related neurodegenerative disorders)
 IT Gene, animal
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
 (Biological study); PROC (Process)
 (.epsilon.4 or .epsilon.2 allele, for apolipoprotein E; non-steroidal
 anti-inflammatory agent and/or histamine H2 receptor-blocking agent for
 preventing, delaying, or treating **Alzheimer's** disease and
 related neurodegenerative disorders)
 IT **50-78-2**, Aspirin 103-90-2, Acetaminophen 22204-53-1, Naproxen
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (non-steroidal anti-inflammatory agent and/or histamine H2
 receptor-blocking agent for preventing, delaying, or treating
Alzheimer's disease and related neurodegenerative disorders)

=> d 151 67 all

L51 ANSWER 67 OF 81 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1998:621136 CAPLUS
 DN 129:254974
 TI Process for increasing the therapeutic effect and reducing the toxicity of
 drugs, metals, and organic and inorganic compounds
 IN Scherbinin, Vladimir Viktorovich; Chernyshev, Evgeny Andreevich
 PA Kuzmin, Konstantin Kuzmich, Russia; Volotovskiy, Andrei Vasilievich
 SO PCT Int. Appl., 83 pp.
 CODEN: PIXXD2
 DT Patent
 LA Russian
 IC ICM A61K047-24
 ICS A61K031-555
 CC 1-4 (Pharmacology)
 Section cross-reference(s): 4, 17, 62, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9840103	A1	19980917	WO 1997-RU261	19970818
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	RU 2104032	C1	19980210	RU 1997-103218	19970311
	RU 2104033	C1	19980210	RU 1997-103219	19970311
	AU 9739552	A1	19980929	AU 1997-39552	19970818
PRAI	RU 1997-103218	A	19970311		
	RU 1997-103219	A	19970311		
	WO 1997-RU261	W	19970818		

AB The invention relates to the field of medicine, and in particular to pharmaceutical therapy, and can be used to increase the therapeutic effect and to reduce the toxicity of drugs, metals, as well as org. and inorg. compds. The embodiment of the invention requires a patient to take in addn. to the mentioned above substances, a daily dose of 0.001 - 0.1 g of 1-hydroxygermatrane (germatranol, 1-hydroxy-1-germa-2,8,9-trioxa-5-

azabicyclo[3.3.3]undecane) and its derivs. and/or the derivs. of 1-germa-2,8-dioxa-5-azacyclooctane. The organogermanic compds. could be conjugated with commonly known drugs or with fragments of their mols.. The process increases the pharmacol. potency of drugs being used to treat a wide variety of illnesses while reducing their toxicity, and notably the toxicity of org. and inorg. substances and of metals.

- ST drug toxicity germatranol organogermanic compd therapy; hydroxygermatrane germadioxaazacyclooctane drug metal toxicity cosmetics; germanium org compd drug toxicity therapy; immunostimulant germanium org compd drug toxicity
- IT Glycosides
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cardiac; potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)
- IT Cosmetics
(creams; potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)
- IT Toxicity
(drug; potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)
- IT Cosmetics
(lotions; potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)
- IT Antitumor agents
(mammary gland; potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)
- IT Mammary gland
(neoplasm, inhibitors; potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)
- IT Drug delivery systems
(ointments, creams; potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)
- IT Periodontium
(periodontosis; potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)
- IT Nerve, disease
(polyneuropathy; potentiation of therapeutic effects and toxicity redn. by germanium org. compds.)
- IT AIDS (disease)
Analgesics
Anti-**Alzheimer's** agents
Anti-inflammatory agents
Antiarrhythmics
Antibacterial agents
Anticoagulants
Anticonvulsants
Antidotes
Antioxidants
Antitumor agents
Antiulcer agents
Antiviral agents
Cardiovascular agents
Cognition enhancers
Cosmetics
Dentifrices
Drug interactions
Food additives
Human herpesvirus
Human immunodeficiency virus 1
Immunostimulants
Influenza virus

Skin preparations (pharmaceutical)
 Tranquilizers
 (potentiation of therapeutic effects and toxicity redn. by germanium
 org. compds.)

IT Heavy metals
 Nitrates, biological studies
 Nitrites
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (potentiation of therapeutic effects and toxicity redn. by germanium
 org. compds.)

IT Adrenoceptor antagonists
 (.alpha.-; potentiation of therapeutic effects and toxicity redn. by
 germanium org. compds.)

IT 64-17-5, Ethanol, biological studies 7632-00-0
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (potentiation of therapeutic effects and toxicity redn. by germanium
 org. compds.)

IT 7440-56-4D, Germanium, org. compds., biological studies 71682-43-4,
 Germatranol 71682-44-5 71682-45-6 71716-22-8 72480-80-9
 88103-02-0 88103-03-1 101182-23-4 106224-61-7 122480-44-8
 213538-70-6 213538-72-8 213538-73-9 213538-74-0 213538-75-1
 213538-76-2 213538-78-4 213538-79-5 213538-80-8 213538-81-9
 213538-82-0 213538-83-1 213538-84-2
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or
 effector, except adverse); BSU (Biological study, unclassified); FFD (Food
 or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (potentiation of therapeutic effects and toxicity redn. by germanium
 org. compds.)

IT 50-06-6, Phenobarbital, biological studies 50-78-2, Aspirin
 54-42-2, Idoxuridine 56-12-2, Aminalon, biological studies 57-44-3,
 Barbitol 65-45-2, Salicylamide 119-36-8, Methylsalicylate 144-02-5,
 Barbitol sodium 439-14-5, Diazepam 768-94-5, Amantadine 2898-12-6,
 Mezepam 4076-02-2, Unitol 5536-17-4, Vidarabin 7491-74-9, Piracetam
 30266-58-1, Oxolin 30516-87-1, Azidothymidine 39322-38-8, Trichopol
 51753-57-2, Phenazepam 59277-89-3, Acyclovir 63585-09-1, Foscarnet
 sodium
 RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (potentiation of therapeutic effects and toxicity redn. by germanium
 org. compds.)

IT 67-52-7D, 2,4,6(1H,3H,5H)-Pyrimidinetrione, derivs.
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (potentiation of therapeutic effects and toxicity redn. by germanium
 org. compds.)

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Asai Germanium Research Institute; FR 2548187 A1 1985 CAPLUS
 (2) Asai Germanium Research Institute Co; US 4919917 A 1990 CAPLUS
 (3) Gorkovsky Meditsinsky Institut; SU 1555933 A1 1996 CAPLUS
 (4) Kakimoto Norihiro; FR 2559488 A1 1985 CAPLUS
 (5) Khusainov, R; Voprosy virusologii 1991, V36(1), P63 MEDLINE
 (6) Sanwa Kagaku Kenkyusho Co Ltd; EP 0435693 A2 1991 CAPLUS
 (7) United Inc; US 4654333 A 1987 CAPLUS

=> e impact

E1	2	IMPACR/BI
E2	1	IMPACRIS/BI
E3	254082 -->	IMPACT/BI
E4	1	IMPACT2/BI
E5	1	IMPACT4/BI
E6	1	IMPACTA/BI

E7	1	IMPACTABILITY/BI
E8	2	IMPACTABLE/BI
E9	1	IMPACTABRASION/BI
E10	1	IMPACTACTIVATED/BI
E11	1	IMPACTACTOR/BI
E12	1	IMPACTAGE/BI

=> s e3

L52 254082 IMPACT/BI

=> s 152 and 119

L53 432 L52 AND L19

=> s 153 and 110

L54 2 L53 AND L10

=> d 154 1-2

L54 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:762124 CAPLUS

DN 137:76946

TI Outcome in patients with symptomatic occlusion of the internal carotid artery or intracranial arterial lesions: a meta-analysis of the role of baseline characteristics and type of antithrombotic treatment

AU Klijn, Catharina J. M.; Kappelle, L. Jaap; Algra, Ale; van Gijn, Jan

CS University Department of Neurology, University Medical Centre Utrecht, Utrecht, Neth.

SO Cerebrovascular Diseases (Basel, Switzerland) (2001), 12(3), 228-234

CODEN: CDISE7; ISSN: 1015-9770

PB S. Karger AG

DT Journal

LA English

RE.CNT 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L54 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1999:517257 CAPLUS

DN 132:2562

TI Brain TXA2 and PGI2 levels in **impact** acceleration diffuse brain injury coupled with secondary insults

AU Fei, Zhou; Zhang, Xiang; Yi, Shengyu; Piper, I. R.; Thomson, D.; Miller, J. D.

CS Xijing Hospital, Xian, 710032, Peop. Rep. China

SO Chinese Journal of Traumatology (English Edition) (1999), 2(1), 35-37

CODEN: CJTRFY; ISSN: 1008-1275

PB Chinese Journal of Traumatology (English Edition)

DT Journal

LA English

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 154 2 all

L54 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1999:517257 CAPLUS

DN 132:2562

TI Brain TXA2 and PGI2 levels in **impact** acceleration diffuse brain injury coupled with secondary insults

AU Fei, Zhou; Zhang, Xiang; Yi, Shengyu; Piper, I. R.; Thomson, D.; Miller, J. D.

CS Xijing Hospital, Xian, 710032, Peop. Rep. China

SO Chinese Journal of Traumatology (English Edition) (1999), 2(1), 35-37
 CODEN: CJTRFY; ISSN: 1008-1275
 PB Chinese Journal of Traumatology (English Edition)
 DT Journal
 LA English
 CC 14-10 (Mammalian Pathological Biochemistry)
 Section cross-reference(s): 1, 2
 AB To study the changes of brain TXA2 and PGI2 levels in a new rodent model of **impact** acceleration diffuse brain injury with hypotension and hypoxia and the effect of diaspirin cross linked Hb soln. (DCLHb) on brain TXA2 and PGI2 levels. Thirty-two male SD rats were randomized into sham, head injury alone, head injury with secondary insults and injury with insults followed by DCLHb administration groups. Animals were physiologically monitored throughout the experiment and the prostanooids were measured via RIA (RIA). There were no changes in TXB2 and 6-keto-PGF1.alpha. (stable metabolites of TXA2 and PGI2) levels in injury alone group while TXB2 level in secondary insults group elevated significantly and both TXB2 and 6-keto-PGF1.alpha. levels in injury with insults followed by DCLHb administration augmented significantly in comparison with the corresponding value of sham at 4 h postimpact. The only increase in TXA2 level in secondary insults rats suggests that there may be both thrombotic episodes and vasoconstriction leading to focal increase in micro-circulatory resistance which contributes to a decreased focal **cerebral** blood flow (CBF). And it is hypothesized that DCLHb may exert its protective properties through increasing PGI2 production in injured brain by affecting CBF and **cerebral** perfusion pressure (CPP).
 ST TXA2 PGI2 brain injury hypotension hypoxia; diaspirin cross linked with Hb brain injury treatment
 IT Hypotension
 Hypoxia, animal
 (brain TXA2 and PGI2 levels in **impact** acceleration diffuse brain injury coupled with secondary insults in rats)
 IT Circulation
 (**cerebral**; brain TXA2 and PGI2 levels in **impact** acceleration diffuse brain injury coupled with secondary insults in rats)
 IT Hemoglobins
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (diaspirin cross linked with; brain TXA2 and PGI2 levels in **impact** acceleration diffuse brain injury coupled with secondary insults in rats)
 IT Brain, disease
 Head
 (injury; brain TXA2 and PGI2 levels in **impact** acceleration diffuse brain injury coupled with secondary insults in rats)
 IT Prostaglandins
 RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
 (prostanoids; brain TXA2 and PGI2 levels in **impact** acceleration diffuse brain injury coupled with secondary insults in rats)
 IT 35121-78-9, PGI2 57576-52-0, TXA2
 RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)
 (brain TXA2 and PGI2 levels in **impact** acceleration diffuse brain injury coupled with secondary insults in rats)
 IT 58962-34-8
 RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological

study, unclassified); MFM (Metabolic formation); BIOL (Biological study);
FORM (Formation, nonpreparative); OCCU (Occurrence); PROC (Process)
(brain TXA2 and PGI2 levels in **impact** acceleration diffuse
brain injury coupled with secondary insults in rats)

IT 578-19-8, Diaspirin

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)

(crosslinked with Hb; brain TXA2 and PGI2 levels in **impact**
acceleration diffuse brain injury coupled with secondary insults in
rats)

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Cole, D; Anesth Analg 1996, V83, P324
- (2) Cole, D; Anesthesiology 1993, V78, P335 CAPLUS
- (3) Cortbus, F; Acta Neurochir (Wien) 1994, V130, P117 MEDLINE
- (4) Fei, Z; Chin J Traumatol Eng Ed 1998, V1, P49 CAPLUS
- (5) Hamberg, M; Pro Natl Acad Sci (USA) 1974, V71, P3400 CAPLUS
- (6) Jones, P; J Neurosurg Anesthesiol 1994, V6, P4 MEDLINE
- (7) Katayama, Y; Adv Neurol 1990, V52, P105 MEDLINE
- (8) Marmarou, A; J Neurosurg 1994, V80, P291 MEDLINE
- (9) Nishisho, T; Neurosurgery 1996, V39, P950 MEDLINE
- (10) Shohami, E; Nuerosurgery 1988, V22, P859 MEDLINE
- (11) Weksler, B; Proc Natl Acad Sci USA 1977, V74, P3922 CAPLUS

=> d his

(FILE 'HOME' ENTERED AT 15:07:02 ON 15 SEP 2003)

FILE 'REGISTRY' ENTERED AT 15:07:15 ON 15 SEP 2003

	E ACETOMINOPHEN
	E ACETOMINOPHEN
	E ACETOMINOPHEN
	E NSAID
L1	9 S E3
	E ASPIRIN
L2	52 S E3
	E INDOMETHACIN
L3	52 S E3
	E KETOPROFIN
	E KETOPROFEN
L4	50 S E3
	E TRILISATR
	E TRILISATE
L5	1 S E3
L6	1158 S SALICYLAMIDE
L7	30 S SODIUM SALICYLATE
L8	6694 S SALICYLIC ACID
	E ACETOMINOPHEN
	E ACETAMINOPHEN
L9	130 S E3

FILE 'CAPLUS' ENTERED AT 15:20:03 ON 15 SEP 2003

L10	17725 S L2
L11	28561 S CNS
L12	28 S L10 AND L11
	E TRAUMA
L13	11866 S E3
L14	68 S L13 AND L10
	E HEAD
L15	94345 S E3

L16 12 S L14 AND L15
 E ISCHEMA
 L17 53069 S E5-E8
 L18 356 S L17 AND L10
 E CEREBRAL
 L19 78138 S E3
 L20 14 S L18 AND 19
 L21 66 S L18 AND L19
 L22 2 S L19 AND L12
 L23 211 S L10 AND L19
 L24 66 S L23 AND L17
 L25 0 S L24 NOT L21
 L26 2 S L12 AND L17
 L27 10826 S L9
 L28 46 S L5
 L29 28 S L12 AND L10
 E LUPUS
 L30 11819 S E3
 L31 53 S L30 AND L10
 E ALZHEIMERS
 L32 1977 S E3
 L33 8 S L10 AND L32
 E NSAIDS
 L34 3367 S E3
 L35 36 S L34 AND L17
 L36 28 S L11 AND L12
 L37 685 S L11 AND L17
 L38 2 S L37 AND L10
 E INFLAMMATION
 L39 98265 S E3
 L40 1177 S L39 AND L11
 L41 10 S L40 AND L12
 E PARKINSON
 L42 12980 S E3
 L43 20 S L42 AND L10
 L44 5189 S L7
 L45 28 S L10 AND L12
 L46 4 S L44 AND L42
 L47 4560 S L6
 L48 6 S L47 AND L42
 E NEUROTRAUMA
 L49 28 S L11 AND L10
 E ALZHEIMER
 L50 27161 S E3
 L51 81 S L50 AND L10
 E IMPACT
 L52 254082 S E3
 L53 432 S L52 AND L19
 L54 2 S L53 AND L10

=> s 153 and 127

L55 0 L53 AND L27

=> d his

(FILE 'HOME' ENTERED AT 15:07:02 ON 15 SEP 2003)

FILE 'REGISTRY' ENTERED AT 15:07:15 ON 15 SEP 2003

E ACETOMINOPHEN
 E ACETOMINOPHEN
 E ACETOMINOPHEN
 E NSAID

L1	9	S	E3
		E	ASPIRIN
L2	52	S	E3
		E	INDOMETHACIN
L3	52	S	E3
		E	KETOPROFIN
		E	KETOPROFEN
L4	50	S	E3
		E	TRILISATR
		E	TRILISATE
L5	1	S	E3
L6	1158	S	SALICYLAMIDE
L7	30	S	SODIUM SALICYLATE
L8	6694	S	SALICYLIC ACID
		E	ACETAMINOPHEN
		E	ACETAMINOPHEN
L9	130	S	E3

FILE 'CAPLUS' ENTERED AT 15:20:03 ON 15 SEP 2003

L10	17725	S	L2
L11	28561	S	CNS
L12	28	S	L10 AND L11
		E	TRAUMA
L13	11866	S	E3
L14	68	S	L13 AND L10
		E	HEAD
L15	94345	S	E3
L16	12	S	L14 AND L15
		E	ISCHEMA
L17	53069	S	E5-E8
L18	356	S	L17 AND L10
		E	CEREBRAL
L19	78138	S	E3
L20	14	S	L18 AND 19
L21	66	S	L18 AND L19
L22	2	S	L19 AND L12
L23	211	S	L10 AND L19
L24	66	S	L23 AND L17
L25	0	S	L24 NOT L21
L26	2	S	L12 AND L17
L27	10826	S	L9
L28	46	S	L5
L29	28	S	L12 AND L10
		E	LUPUS
L30	11819	S	E3
L31	53	S	L30 AND L10
		E	ALZHEIMERS
L32	1977	S	E3
L33	8	S	L10 AND L32
		E	NSAIDS
L34	3367	S	E3
L35	36	S	L34 AND L17
L36	28	S	L11 AND L12
L37	685	S	L11 AND L17
L38	2	S	L37 AND L10
		E	INFLAMMATION
L39	98265	S	E3
L40	1177	S	L39 AND L11
L41	10	S	L40 AND L12
		E	PARKINSON
L42	12980	S	E3
L43	20	S	L42 AND L10

L44 5189 S L7
 L45 28 S L10 AND L12
 L46 4 S L44 AND L42
 L47 4560 S L6
 L48 6 S L47 AND L42
 E NEUROTRAUMA
 L49 28 S L11 AND L10
 E ALZHEIMER
 L50 27161 S E3
 L51 81 S L50 AND L10
 E IMPACT
 L52 254082 S E3
 L53 432 S L52 AND L19
 L54 2 S L53 AND L10
 L55 0 S L53 AND L27

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	388.01	446.40
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-15.62	-15.62

STN INTERNATIONAL LOGOFF AT 16:40:48 ON 15 SEP 2003

Welcome to STN International! Enter x:x

LOGINID:sssptaul25rxt

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Feb 24	PCTGEN now available on STN
NEWS	4	Feb 24	TEMA now available on STN
NEWS	5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	6	Feb 26	PCTFULL now contains images
NEWS	7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	8	Mar 24	PATDPAFULL now available on STN
NEWS	9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	10	Apr 11	Display formats in DGENE enhanced
NEWS	11	Apr 14	MEDLINE Reload
NEWS	12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	13	SEP 09	CA/CAPLUS records now contain indexing from 1907 to the present
NEWS	14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	15	Apr 28	RDISCLOSURE now available on STN
NEWS	16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	18	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS	19	May 19	Simultaneous left and right truncation added to WSCA
NEWS	20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS	21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS	22	Jun 06	PASCAL enhanced with additional data
NEWS	23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS	24	Jun 25	HSDB has been reloaded
NEWS	25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS	26	Jul 21	Identification of STN records implemented
NEWS	27	Jul 21	Polymer class term count added to REGISTRY
NEWS	28	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS	29	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS	30	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS	31	AUG 15	PATDPAFULL: one FREE connect hour, per account, in September 2003
NEWS	32	AUG 15	PCTGEN: one FREE connect hour, per account, in September 2003
NEWS	33	AUG 15	RDISCLOSURE: one FREE connect hour, per account, in September 2003
NEWS	34	AUG 15	TEMA: one FREE connect hour, per account, in September 2003
NEWS	35	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS	36	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS	37	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Right Truncation


AN 1998:605885 CAPLUS
 DN 129:339797
 TI Influence of aspirin on nerve injury of experimental **cerebral ischemia** in rabbits
 AU Liu, Shi-Xiang; Hou, Jing-Bian; Yang, Qing-Zhou; Zhang, Jia-Lin; Huang, Li-Chun; Liang, Yan
 CS Dep. Neurol., Kunming Gen. Hosp., Kunming, 650032, Peop. Rep. China
 SO Zhongguo Bingli Shengli Zazhi (1997), 13(2), 162-164
 CODEN: ZBSZEB; ISSN: 1000-4718
 PB Jinan Daxue
 DT Journal
 LA Chinese
 CC 1-11 (Pharmacology)
 AB Platelet play an important role in **cerebral** ischemial nerve injury. Aspirin (ASA) had been used to treat and prevent stroke in clinic. 30 Rabbits were randomly divided into A, B and C groups. In group A ASA was given orally at a daily dosage of 15 mg/kg per rabbit for 5 days before **cerebral ischemia**; group B **cerebral ischemia** without giving ASA, and group C was normal rabbits as controls. The **cerebral** ischemial model was produced by occluding bilateral carotid arteries and bleeding from femoral artery. The results indicated that there was an obvious decrease of platelet aggregation and TXA2 and had no significance changes in free radicals increasing and Ca2+ rising from **cerebral** tissue in group A. The **cerebral** edema of group A was less severe than group B. It seemed that ASA had a protective effect on the nerve injury of **cerebral ischemia**. The derangement of ASA, platelet, free radicals and calcium ions interrelation and their significance on the nerve injury should be further studied.
 ST aspirin nerve injury brain **ischemia** TXA2
 IT Brain, disease
 (**cerebral** cortex, **ischemia**; influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)
 IT Platelet aggregation inhibitors
 (influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)
 IT Nerve, disease
 (injury; influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)
 IT Cytoprotective agents
 (neuroprotectants; influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)
 IT 50-78-2, Aspirin
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)
 IT 57576-52-0, Thromboxane A2
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (influence of aspirin on nerve injury of exptl. **cerebral ischemia** in rabbits)

=>

AN 1992:504057 CAPLUS
 DN 117:104057
 TI **Intrathecal** injection of acetylsalicylic acid, salicylic acid
 and indometacin depresses C fiber-evoked activity in the rat thalamus and
 spinal cord
 AU Jurna, Ilmar; Spohrer, Birgit; Bock, Rudolf
 CS Inst. Pharmakol. Toxikol., Univ. Saarlandes, Homburg/Saar, D-6650, Germany
 SO Pain (1992), 49(2), 249-56
 CODEN: PAINDB; ISSN: 0304-3959
 DT Journal
 LA English
 CC 1-11 (Pharmacology)
 AB It was aimed to assess if **intrathecal** (i.t.) injections of
 acetylsalicylic acid and salicylic acid depress C-fiber-evoked activity in
 the sensory part of the nociceptive system. In rats under urethane
 anesthesia, activity was elicited in single neurons in the dorsomedial
 part of the ventral nucleus (VDM) of the thalamus and in ascending axons
 of the spinal cord by supramaximal elec. stimulation of the sural nerve.
 Acetylsalicylic acid and salicylic acid injected i.t. significantly
 reduced the activity evoked in thalamic neurons. The max. depression
 amounted to about 50% of the activity evoked in the controls and was
 produced by acetylsalicylic acid at a dose of 50 .mu.g (0.28 .mu.mol)/rat
 and by salicylic acid at a dose of 37.5 .mu.g (0.27 .mu.mol)/rat.
 Indometacin injected i.t. also reduced C-fiber-evoked activity in the
 thalamus in a dose-dependent fashion, 100 .mu.g producing a 50%
 depression. Salicylic acid (37.5 .mu.g/rat, i.t.) depressed
 C-fiber-evoked activity in ascending axons but had no effect on A.beta.
 fiber-evoked activity. It is concluded that i.t. injection of
 acetylsalicylic acid selectively inhibits nociceptive impulse transmission
 in the spinal cord by an action of the salicylic acid moiety. It is
 possible that prostaglandins are involved in the central action of
 salicylic acid.
 ST C fiber thalamus spinal cord analgesic; acetylsalicylate C fiber thalamus
 spinal cord; salicylate C fiber thalamus spinal cord; indomethacin C fiber
 thalamus spinal cord
 IT Spinal cord
 (C-fiber-evoked activity in, acetylsalicylic and salicylic acids effect
 on, analgesic mechanism in relation to)
 IT Prostaglandins
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); BIOL (Biological study)
 (in central analgesic action of salicylic acid)
 IT Analgesics
 (**intrathecal**, C-fiber-evoked activity inhibition by, in
 thalamus and spinal cord, mechanism of)
 IT Nerve
 (C-fiber, acetylsalicylic and salicylic acids effect on, of thalamus
 and spinal cord, analgesic mechanism in relation to)
 IT Nerve
 (nociceptive, axon, acetylsalicylic and salicylic acids effect on, of
 thalamus and spinal cord, analgesic mechanism in relation to)
 IT Brain
 (thalamus, C-fiber-evoked activity in, acetylsalicylic and salicylic
 acids effect on, analgesic mechanism in relation to)
 IT **50-78-2**, Acetylsalicylic acid 53-86-1, Indomethacin 69-72-7,
 Salicylic acid, biological studies
 RL: BIOL (Biological study)
 (**intrathecal**, C-fiber-evoked activity inhibition by, in
 thalamus and spinal cord, mechanism of)

=>

AN 1981:561869 CAPLUS
 DN 95:161869
 TI A study on constrictor responses of dog **coronary** arteries to
 acetylsalicylic acid
 AU Sakanashi, M.; Araki, H.; Furukawa, T.; Rokutanda, M.; Yonemura, K.
 CS Med. Sch., Kumamoto Univ., Kumamoto, 860, Japan
 SO Archives Internationales de Pharmacodynamie et de Therapie (1981), 252(1),
 86-96
 CODEN: AIPTAK; ISSN: 0003-9780
 DT Journal
 LA English
 CC 1-4 (Pharmacodynamics)
 GI



AB In isolated and perfused dog hearts an intracoronary **injection**
 of acetylsalicylic acid (I) [50-78-2] (10 mg) decreased
coronary blood flow concomitant with diminution of myocardial
 contractile force, but did not change heart rate. Contractions were
 produced in isolated dog **coronary** arterial strips by I (10⁻⁴ M)
 and these were significantly inhibited by Ca²⁺-free soln., diltiazem,
 nifedipine, phospholipase A2, arachidonate, and prostaglandin E1.
 Apparently, I at a high dose produces **coronary** arterial
 contraction probably through inhibition of intravascular synthesis of
 vasodilating prostaglandins.
 ST acetylsalicylate **coronary** artery contraction; prostaglandin
 acetylsalicylate **coronary** artery contraction
 IT Prostaglandins
 RL: BIOL (Biological study)
 (**coronary** artery contraction from acetylsalicylic acid in
 relation to)
 IT Artery
 (**coronary**, contraction of, from aspirin, prostaglandins in
 relation to)
 IT 50-78-2
 RL: BIOL (Biological study)
 (**coronary** artery contraction by, prostaglandin in relation
 to)

=>

AN 1979:36972 CAPLUS
 DN 90:36972
 TI Entry of protein into cerebral ventricles during ventriculo-cisternal perfusion and the administration of anti-inflammatory agents
 AU Haywood, J. R.; Vogh, B. P.
 CS Dep. Pharmacol Ther., Univ. Florida, Gainesville, FL, USA
 SO Journal of Neurochemistry (1978), 30(6), 1621-3
 CODEN: JONRA9; ISSN: 0022-3042
 DT Journal
 LA English
 CC 13-13 (Mammalian Biochemistry)
 Section cross-reference(s): 1
 AB During brain ventriculo-cisternal perfusion (VCP) in cats, entry of protein into the ventricles was stable over 30-150 min, after which the rate increased up to the end of the exptl. period (330 min). When the VCP procedures involved increased trauma to meningeal tissues, e.g., by using a blunted needle, the early and late stable mean rate of influx was higher and probably more direct leakage occurred due to the invasive technique itself. Gentamicin, tobramycin, acetylsalicylic acid (15-30 mg/kg i.v. or 200 .mu.M **intrathecally**), indomethacin (3.4 .mu.M), and meclofenamic acid (1.7 .mu.M) all failed to reduce the protein entry, but dexamethasone given i.v. at the beginning of perfusion (0.3 mg/kg, i.v.) and in repeated doses (0.15 mg/kg/h) lowered the initial rate of protein entry and markedly attenuated the subsequent rise in protein influx.
 ST ventriculocisternal perfusion protein entry ventricle; antiinflammatory ventriculocisternal perfusion protein influx; dexamethasone ventriculocisternal perfusion protein influx; brain ventricle protein entry perfusion
 IT Proteins
 RL: BIOL (Biological study)
 (brain ventricle influx of, in ventriculo-cisternal perfusion)
 IT Cerebrospinal fluid
 (protein entry into, in ventriculo-cisternal perfusion)
 IT Inflammation inhibitors
 (protein influx into brain ventricles in ventriculo-cisternal perfusion response to)
 IT Brain
 (ventricle, protein entry into, in ventriculo-cisternal perfusion)
 IT 50-02-2 **50-78-2** 53-86-1 644-62-2 1403-66-3 32986-56-4
 RL: BIOL (Biological study)
 (protein influx into brain ventricles in ventriculo-cisternal perfusion response to)

=>

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 12:17:29 ON 29 SEP 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 28 SEP 2003 HIGHEST RN 594810-89-6

DICTIONARY FILE UPDATES: 28 SEP 2003 HIGHEST RN 594810-89-6

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP
PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> s aspirin

L1 52 ASPIRIN

=> e nsajds

E1	4	NSAH9/BI
E2	9	NSAID/BI
E3	0 -->	NSAIDS/BI
E4	1	NSAN/BI
E5	1	NSANI/BI
E6	1	NSANIDI/BI
E7	1	NSANIDINE/BI
E8	2	NSANT1/BI
E9	6	NSAP1/BI
E10	16	NSB/BI
E11	2	NSB1/BI
E12	1	NSB105/BI

=> e nsaid

E1	2	NSAF/BI
E2	4	NSAH9/BI
E3	9 -->	NSAID/BI
E4	1	NSAN/BI
E5	1	NSANI/BI
E6	1	NSANIDI/BI
E7	1	NSANIDINE/BI
E8	2	NSANT1/BI
E9	6	NSAP1/BI
E10	16	NSB/BI
E11	2	NSB1/BI
E12	1	NSB105/BI

=> s e3

L2 9 NSAID/BI

=> d 12 9

L2 ANSWER 9 OF 9 REGISTRY COPYRIGHT 2003 ACS on STN
RN 204298-06-6 REGISTRY
CN **DNA (rat liver NSAID-regulated gene protein-specifying cDNA
594-nucleic acid) (9CI)** (CA INDEX NAME)

OTHER NAMES:

CN 8: PN: WO0138579 PAGE: 13 claimed DNA
FS NUCLEIC ACID SEQUENCE
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

RELATED SEQUENCES AVAILABLE WITH SEQLINK

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***

1 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	10.92	11.13

FILE 'CAPLUS' ENTERED AT 12:18:24 ON 29 SEP 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Sep 2003 VOL 139 ISS 14

FILE LAST UPDATED: 28 Sep 2003 (20030928/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> e nsaid5

E1	1	NSAID5/BI
E2	1	NSAIDH/BI
E3	3396 -->	NSAIDS/BI
E4	3	NSAIDSS/BI
E5	1	NSAIFA/BI
E6	1	NSAIFD/BI
E7	2	NSAIDS/BI
E8	1	NSAIO/BI
E9	6	NSAIS/BI
E10	1	NSAISS/BI

E11 2 NSAIW/BI
E12 1 NSAJDS/BI

=> s e3
L3 3396 NSAIDS/BI

=> s l1
L4 17770 L1

=> e intrathecaly
E1 1682 INTRATHECALLY/BI
E2 1 INTRATHECALT/BI
E3 1 --> INTRATHECALT/BI
E4 1 INTRATHECAL/BI
E5 1 INTRATHECOL/BI
E6 1 INTRATHEKAL/BI
E7 1 INTRATHELIAL/BI
E8 1 INTRATHEORY/BI
E9 4 INTRATHERAPEUTIC/BI
E10 6 INTRATHERAPY/BI
E11 6 INTRATHERM/BI
E12 1 INTRATHERMOCLINE/BI

=> s e1-e3
1682 INTRATHECALLY/BI
1 INTRATHECALT/BI
1 INTRATHECALT/BI
L5 1682 (INTRATHECALLY/BI OR INTRATHECALT/BI OR INTRATHECALT/BI)

=> s l3 and l5
L6 6 L3 AND L5

=> d l6 1-6

L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:122594 CAPLUS
DN 139:62895
TI Involvement of serotonin mechanisms in the antinociceptive effect of
S(+)-ketoprofen
AU Diaz-Reval, M. Irene; Ventura-Martinez, Rosa; Deciga-Campos, Myrna;
Terron, Jose A.; Cabre, Francesc; Lopez-Munoz, Francisco J.
CS Cinvestav-IPN, Departamento de Farmacobiologia, Cinvestav-IPN, Mexico,
C.P. 14330, Mex.
SO Drug Development Research (2002), 57(4), 187-192
CODEN: DDREDK; ISSN: 0272-4391
PB Wiley-Liss, Inc.
DT Journal
LA English
RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:79511 CAPLUS
DN 139:30426
TI Carbachol interactions with nonsteroidal anti-inflammatory drugs
AU Miranda, H. F.; Sierralta, F.; Pinardi, G.
CS Pharmacology Program, ICBM, Faculty of Medicine, University of Chile,
Santiago, 7, Chile
SO Canadian Journal of Physiology and Pharmacology (2002), 80(12), 1173-1179
CODEN: CJPPA3; ISSN: 0008-4212
PB National Research Council of Canada
DT Journal

LA English

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:417314 CAPLUS
DN 138:11228
TI Paracetamol exerts a spinal, tropisetron-reversible, antinociceptive effect in an inflammatory pain model in rats
AU Alloui, Abdelkrim; Chassaing, Claude; Schmidt, Jeannot; Ardid, Denis; Dubray, Claude; Cloarec, Alix; Eschaliere, Alain
CS Faculte de Medecine, Laboratoire de Pharmacologie Medicale, EMI INSERM/UdA 9904, Clermont-Ferrand, 63001, Fr.
SO European Journal of Pharmacology (2002), 443(1-3), 71-77
CODEN: EJPHAZ; ISSN: 0014-2999
PB Elsevier Science B.V.
DT Journal
LA English

RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:695300 CAPLUS
DN 136:31578
TI Interactions of prazosin with non-steroidal anti-inflammatory drugs
AU Miranda, H. F.; Pinardi, G.
CS Pharmacology Program, ICBM, Faculty of Medicine, University of Chile, Chile
SO Pharmacology Reviews and Communications (2001), 11(3), 253-262
CODEN: PHRCF6; ISSN: 1028-8945
PB Harwood Academic Publishers
DT Journal
LA English

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:932070 CAPLUS
DN 124:21986
TI Intrathecal steroids to reduce pain after lumbar disk surgery: A double-blind, placebo-controlled prospective study
AU Langmayr, Johann J.; Obwegeser, Alois A.; Schwarz, Andreas B.; Laimer, Ilse; Ulmer, Hanno; Ortler, Martin
CS Universitaetsklinik Neurochirurgie, Innsbruck, 6020, Austria
SO Pain (1995), 62(3), 357-61
CODEN: PAINDB; ISSN: 0304-3959
PB Elsevier
DT Journal
LA English

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:453105 CAPLUS
DN 122:256081
TI Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol: experimental studies in the rat
AU Bjoerkman, Roland
CS Department of Pharmacology, University of Gothenburg, Goeteborg, Swed.
SO Acta Anaesthesiologica Scandinavica, Supplementum (1995), 103, 44pp.
CODEN: AASXAP; ISSN: 0515-2720
PB Munksgaard
DT Journal
LA English

=> d 16 5 all

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:932070 CAPLUS
DN 124:21986
TI Intrathecal steroids to reduce pain after lumbar disk surgery: A
double-blind, placebo-controlled prospective study
AU Langmayr, Johann J.; Obwegeser, Alois A.; Schwarz, Andreas B.; Laimer,
Ilse; Ulmer, Hanno; Ortler, Martin
CS Universitaetsklinik Neurochirurgie, Innsbruck, 6020, Austria
SO Pain (1995), 62(3), 357-61
CODEN: PAINDB; ISSN: 0304-3959
PB Elsevier
DT Journal
LA English
CC 2-4 (Mammalian Hormones)
AB This double-blind, placebo-controlled prospective study investigated
whether corticosteroids (beta-methasone) influence residual radicular pain
after lumbar disk surgery. The study population consisted of 26 patients
undergoing surgery for a herniated lumbar disk at our University
Neurosurgical Department. Thirteen patients received beta-methasone
intrathecally prior to wound closure, and 13- patients received
normal saline. Main outcome measures were pain intensity graded on a
100-mm visual analog pain scale (VAS) and consumption of non-steroidal
anti-inflammatory agents (**NSAIDs**). Both patient groups had
comparable presurgical findings and pain intensity level (55 mm and 54 mm,
resp., on a 100-mm VAS). After surgery, residual pain declined gradually
in the placebo group (mean 39, 29, 24, 20 mm on days 1-4; 10 mm on day 8)
and abruptly in the corticosteroid group (mean 15, 15, 11, 8, mm on days
1-4; 5 mm on day 8). Anal. of variance (ANOVA) showed a highly
significant influence of time ($P < 0.001$), a significant influence of
steroid application ($P = 0.014$) and interaction between time and
application of steroids ($P = 0.042$). Mean daily consumption of
NSAIDs did not differ significantly in either group: 124 mg in the
treatment vs. 150 mg in the placebo group ($P > 0.25$). At follow-up after
6 mo, residual radicular pain was rated equally by both groups (4 mm in
the treatment vs. 5 mm in the placebo group, $P > 0.5$). Intrathecal
application of steroids provides short-lasting, statistically significant
pain redn. after lumbar disk surgery. Benefits of intrathecal steroids
are probably outweighed by the risks assocd. with violation of the dural
barrier.
ST steroid lumbar disk surgery pain
IT Pain
Surgery
(intrathecal steroids to reduce pain after lumbar disk surgery in
humans)
IT Spinal column
(lumbar intervertebral disk, intrathecal steroids to reduce pain after
lumbar disk surgery in humans)
IT 378-44-9, Beta-methasone
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(intrathecal steroids to reduce pain after lumbar disk surgery in
humans)

=> d 16 6 all

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1995:453105 CAPLUS
 DN 122:256081
 TI Central antinociceptive effects of non-steroidal anti-inflammatory drugs
 and paracetamol: experimental studies in the rat
 AU Bjoerkman, Roland
 CS Department of Pharmacology, University of Gothenburg, Goeteborg, Swed.
 SO Acta Anaesthesiologica Scandinavica, Supplementum (1995), 103, 44pp.
 CODEN: AASXAP; ISSN: 0515-2720
 PB Munksgaard
 DT Journal
 LA English
 CC 1-11 (Pharmacology)
 AB These studies were undertaken to investigate the site and nature of the
 antinociceptive effect of **NSAIDs** (Non-Steroidal
 Anti-Inflammatory Drugs) and paracetamol in the central nervous system
 (CNS). Different nociceptive test models were employed: the tail-flick
 and hot-plate tests (thermoreceptors), the writhing test (visceral
 chemoreceptors) the "scratching, biting, licking" (SBL) behavior and the
 colorectal distension test (mechanoreceptors). Drugs were given i.p.,
 intracerebroventricularly (i.c.v.), **intrathecally** (i.t.) or as
 local injection via cannulae implanted stereotactically. Nerve
 destruction was made by local injection of the neurotoxin
 5,7-dihydroxytryptamine (5,7-DHT). Whole brain and spinal cord contents
 of serotonin and 5-hydroxyindole acetic acid (5-HIAA) were analyzed by
 high pressure liq. chromatog. (HPLC). Injections of diclofenac induced
 antinociception in visceral pain models (writhing test, colorectal
 distension test), but not in two models of somatosensory pain (tail-flick
 and hot-plate test). The antinociceptive effect of diclofenac (i.p.,
 i.c.v., or i.t.) was reversed by i.p. naloxone. Naloxone also reversed
 the effect of diclofenac injected locally into thalamic and hypothalamic
 areas involved in pain transmission as well as in n. paragigantocellularis
 or n. raphe magnus. In addn., chem. destruction of the n. raphe region
 attenuated the antinociceptive effect of diclofenac. Inhibition of
 serotonergic transmission by pretreatment with methiothepin, ritanserin,
 parachlorophenylalanine (PCPA) or 5,7-DHT also reduced the antinociceptive
 effect of diclofenac in a visceral pain model. Pretreatment with
 diclofenac or ibuprofen blocked pain behavior (SBL) after activation of
 excitatory amino acid receptors of the NMDA type, but not pain behavior
 after activation of AMPA or substance P (SP) receptors. Paracetamol
 inhibited hyperalgesia after both NMDA and SP. The antinociceptive
 effects of diclofenac, ibuprofen and paracetamol were reversed by
 L-arginine, but not by D-arginine. The antinociceptive effect of
 diclofenac involves a central nervous component which may be elicited from
 several defined areas in the CNS. Part of the antinociceptive effect
 seems to be mediated by descending inhibitory opioid, serotonin and/or
 other neurotransmitter systems interfering with visceral pain impulse
 traffic at the spinal level. **NSAIDs** and paracetamol interfere
 with nociception assocd. with spinal NMDA receptor activation. This
 effect involves an inhibitory action on spinal nitric oxide (NO)
 mechanisms. Possibly, the supraspinal antinociceptive effect of
NSAIDs may be explained by an analogous action.
 ST NSAID paracetamol analgesia CNS site mechanism
 IT Analgesics
 Inflammation inhibitors
 (central antinociceptive effects of non-steroidal anti-inflammatory
 drugs and paracetamol)
 IT Nervous system
 (central, central antinociceptive effects of non-steroidal
 anti-inflammatory drugs and paracetamol)
 IT Receptors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (glutamatergic, methyl-D-aspartate-binding, in central antinociceptive

effects of non-steroidal anti-inflammatory drugs and paracetamol)

IT Neurohormones
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (neurotransmitters, in central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol)

IT 53-86-1, Indomethacin 54-21-7, Sodium salicylate 103-90-2, Paracetamol 15307-79-6, Diclofenac sodium 22204-53-1, Naproxen 36322-90-4, Piroxicam 51146-56-6 51146-57-7, R(-)-Ibuprofen
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol)

IT 10102-43-9, Nitric oxide, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (in central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol)

=> s 14 and 15

L7 3 L4 AND L5

=> d 17 1-3

L7 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1994:289642 CAPLUS
 DN 120:289642
 TI Intrathecal acetylsalicylic acid and indomethacin are not analgesic for a supramaximal stimulus
 AU Antognini, Joseph F.
 CS Dep. Anesthesiol., Univ. California, Davis, CA, USA
 SO Anesthesia & Analgesia (Baltimore, MD, United States) (1993), 76(5), 1079-82
 CODEN: AACRAT; ISSN: 0003-2999
 DT Journal
 LA English

L7 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1985:589740 CAPLUS
 DN 103:189740
 TI Acetylsalicylic acid, paracetamol and morphine inhibit behavior responses to **intrathecally** administered substance P or capsaicin
 AU Hunskaar, Steinar; Fasmer, Ole Bernt; Hole, Kjell
 CS Dep. Physiol., Univ. Bergen, Bergen, N-5000, Norway
 SO Life Sciences (1985), 37(19), 1835-41
 CODEN: LIFSAK; ISSN: 0024-3205
 DT Journal
 LA English

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1979:36972 CAPLUS
 DN 90:36972
 TI Entry of protein into cerebral ventricles during ventriculo-cisternal perfusion and the administration of anti-inflammatory agents
 AU Haywood, J. R.; Vogh, B. P.
 CS Dep. Pharmacol Ther., Univ. Florida, Gainesville, FL, USA
 SO Journal of Neurochemistry (1978), 30(6), 1621-3
 CODEN: JONRA9; ISSN: 0022-3042
 DT Journal
 LA English

=> d 17 3 all

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1979:36972 CAPLUS
DN 90:36972
TI Entry of protein into cerebral ventricles during ventriculo-cisternal
perfusion and the administration of anti-inflammatory agents
AU Haywood, J. R.; Vogh, B. P.
CS Dep. Pharmacol Ther., Univ. Florida, Gainesville, FL, USA
SO Journal of Neurochemistry (1978), 30(6), 1621-3
CODEN: JONRA9; ISSN: 0022-3042
DT Journal
LA English
CC 13-13 (Mammalian Biochemistry)
Section cross-reference(s): 1
AB During brain ventriculo-cisternal perfusion (VCP) in cats, entry of
protein into the ventricles was stable over 30-150 min, after which the
rate increased up to the end of the exptl. period (330 min). When the VCP
procedures involved increased trauma to meningeal tissues, e.g., by using
a blunted needle, the early and late stable mean rate of influx was higher
and probably more direct leakage occurred due to the invasive technique
itself. Gentamicin, tobramycin, acetylsalicylic acid (15-30 mg/kg i.v. or
200 .mu.M **intrathecally**), indomethacin (3.4 .mu.M), and
meclofenamic acid (1.7 .mu.M) all failed to reduce the protein entry, but
dexamethasone given i.v. at the beginning of perfusion (0.3 mg/kg, i.v.)
and in repeated doses (0.15 mg/kg/h) lowered the initial rate of protein
entry and markedly attenuated the subsequent rise in protein influx.
ST ventriculocisternal perfusion protein entry ventricle; antiinflammatory
ventriculocisternal perfusion protein influx; dexamethasone
ventriculocisternal perfusion protein influx; brain ventricle protein
entry perfusion
IT Proteins
RL: BIOL (Biological study)
(brain ventricle influx of, in ventriculo-cisternal perfusion)
IT Cerebrospinal fluid
(protein entry into, in ventriculo-cisternal perfusion)
IT Inflammation inhibitors
(protein influx into brain ventricles in ventriculo-cisternal perfusion
response to)
IT Brain
(ventricle, protein entry into, in ventriculo-cisternal perfusion)
IT 50-02-2 50-78-2 53-86-1 644-62-2 1403-66-3 32986-56-4
RL: BIOL (Biological study)
(protein influx into brain ventricles in ventriculo-cisternal perfusion
response to)

=> e intraventricularly

E1	1	INTRAVENT/BI
E2	22	INTRAVENTICULAR/BI
E3	6 -->	INTRAVENTICULARLY/BI
E4	1	INTRAVENTION/BI
E5	19	INTRAVENTRAL/BI
E6	1	INTRAVENTRALLY/BI
E7	1	INTRAVENTRI/BI
E8	7	INTRAVENTRICALLY/BI
E9	4	INTRAVENTRICLE/BI
E10	1	INTRAVENTRICUIAR/BI
E11	1	INTRAVENTRICULALR/BI
E12	5324	INTRAVENTRICULAR/BI

=> s e2-e3

```

                22 INTRAVENTICULAR/BI
                6 INTRAVENTICULARLY/BI
L8              28 (INTRAVENTICULAR/BI OR INTRAVENTICULARLY/BI)

```

```
=> s l8 and l4
```

```
L9              0 L8 AND L4
```

```
=> e coronary
```

```

E1              1      CORANAPHENES/BI
E2              1      CORANARIUM/BI
E3              2 --> CORANARY/BI
E4              5      CORANATE/BI
E5              12     CORAND/BI
E6              6      CORANDOMIZATION/BI
E7              15     CORANDOMIZED/BI
E8              1      CORANDONI/BI
E9              11     CORANDS/BI
E10             1      CORANE/BI
E11             1      CORANENE/BI
E12             1      CORANF/BI

```

```
=> e coronary
```

```

E1              2      CORONARUM/BI
E2              1      CORONARVIRUS/BI
E3              50167 --> CORONARY/BI
E4              1      CORONARYARTERY/BI
E5              1      CORONARYDILATATORY/BI
E6              3      CORONARYDILATING/BI
E7              1      CORONARYDILATORS/BI
E8              1      CORONARYHEARTDISEASE/BI
E9              1      CORONARYR/BI
E10             1      CORONARYRESISTANT/BI
E11             1      CORONARYSINUS/BI
E12             1      CORONARYSYNDROME/BI

```

```
=> s e3
```

```
L10             50167 CORONARY/BI
```

```
=> s l10 and l4
```

```
L11             646 L10 AND L4
```

```
=> e injection
```

```

E1              6      INJECTION/BI
E2              1      INJECTIONION/BI
E3              420947 --> INJECTION/BI
E4              1      INJECTION2/BI
E5              10     INJECTIONABLE/BI
E6              13     INJECTIONAL/BI
E7              2      INJECTIONALLY/BI
E8              1      INJECTIONAN/BI
E9              1      INJECTIONAND/BI
E10             2      INJECTIONCOOKING/BI
E11             1      INJECTIONDIODES/BI
E12             10     INJECTIONE/BI

```

```
=> s e3
```

```
L12             420947 INJECTION/BI
```

```
=> s l11 and l12
```

```
L13             23 L11 AND L12
```

```
=> d l13 10-23
```

L13 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:228739 CAPLUS
DN 131:53782
TI Production of Prostanoids and Nitric Oxide by Infarcted Heart in Situ and the Effect of Aspirin
AU Yamamoto, Tadahiko; Cohen, Anna M.; Kakar, N. Rani; Yamamoto, Masako; Johnson, Paul E.; Cho, Y. Kelly; Bing, Richard J.
CS Department of Experimental Cardiology, Huntington Medical Research Institutes, Pasadena, CA, 91101, USA
SO Biochemical and Biophysical Research Communications (1999), 257(2), 488-493
CODEN: BBRCA9; ISSN: 0006-291X
PB Academic Press
DT Journal
LA English
RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:610470 CAPLUS
DN 130:10440
TI Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial
AU Cohen, Marc; Demers, Christine; Gurfinkel, Enrique P.; Turpie, Alexander G. G.; Fromell, Gregg J.; Goodman, Shaun; Langer, Anatoly; Califf, Robert M.; Fox, Keith A. A.; Premmureur, Jerome; Bigonzi, Frederique
CS Division of Cardiology, Hahnemann Division, Allegheny University of the Health Sciences, Philadelphia, PA, 19102-1192, USA
SO American Journal of Cardiology (1998), 82(5B), 19L-24L
CODEN: AJCDAG; ISSN: 0002-9149
PB Excerpta Medica, Inc.
DT Journal
LA English
RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:466083 CAPLUS
DN 129:188157
TI Intravenous administration of the glycoprotein IIb-IIIa receptor antagonist 7E3 induces reperfusion of an acute thrombotic occlusion of the canine **coronary** artery
AU Shetler, Timothy J.; Bailey, Blanche D.; Jakubowski, Joseph A.; Jackson, Charles V.
CS Lilly Research Laboratories, Cardiovascular Research Division, Eli Lilly and Company, Indianapolis, IN, 46285-0524, USA
SO Thrombosis Research (1998), 90(2), 95-100
CODEN: THBRAA; ISSN: 0049-3848
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:164133 CAPLUS
DN 128:266004
TI Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by combination with a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, in a rhesus monkey model of **coronary** thrombosis

AU Kawasaki, Tomihisa; Sato, Kazuo; Suzuki, Kenichi; Sakai, Yumiko; Taniuchi, Yuta; Kaku, Seiji; Yano, Shinya; Inagaki, Osamu; Tomioka, Kenichi; Masuho, Yasuhiko; Yanagisawa, Isao; Takenaka, Toichi
CS Institute Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tsukuba, 305, Japan
SO Thrombosis and Haemostasis (1998), 79(3), 663-667
CODEN: THHADQ; ISSN: 0340-6245
PB F. K. Schattauer Verlagsgesellschaft mbH
DT Journal
LA English

L13 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:567812 CAPLUS
DN 127:214894
TI A comparison of low-molecular-weight heparin with unfractionated heparin for unstable **coronary** artery disease
AU Cohen, Marc; Demers, Christine; Gurfinkel, Enrique P.; Turpie, Alexander G. G.; Fromell, Gregg J.; Goodman, Shaun; Langer, Anatoly; Califf, Robert M.; Fox, Keith A. A.; Premmureur, Jerome; Bigonzi, Frederique
CS Division of Cardiology, Allegheny University Hospitals-Hahnemann Division, Philadelphia, PA, 19102, USA
SO New England Journal of Medicine (1997), 337(7), 447-452
CODEN: NEJMAG; ISSN: 0028-4793
PB Massachusetts Medical Society
DT Journal
LA English

L13 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:843056 CAPLUS
DN 123:275572
TI A new animal model of **coronary** thrombosis and effects of antithrombotic agents
AU Zhang, Weidong; Wang, Peng; Chen, Zhan; Fan, Yaming
CS Anzhen Hospital, Beijing, 100029, Peop. Rep. China
SO Chinese Medical Journal (Beijing, English Edition) (1995), 108(5), 370-2
CODEN: CMJODS; ISSN: 0366-6999
PB Chinese Medical Association
DT Journal
LA English

L13 ANSWER 16 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:499714 CAPLUS
DN 122:255894
TI Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa
AU Turner, Nancy A.; Moake, Joel L.; Kamat, Suraj G.; Schafer, Andrew I.; Kleiman, Neal S.; Jordan, Robert; McIntire, Larry V.
CS Cox Laboratory for Biomedical Engineering, Rice University, Houston, TX, 77251, USA
SO Circulation (1995), 91(5), 1354-62
CODEN: CIRCAZ; ISSN: 0009-7322
DT Journal
LA English

L13 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:153339 CAPLUS
DN 120:153339
TI Combined effect of the 5-HT₂ receptor antagonist DV-7028 and aspirin or heparin on **coronary** cyclic flow reductions in dogs
AU Tanaka, Tsuyoshi; Morishima, Yoshiyuki; Watanabe, Kazuo; Shibutani, Tomoko; Yasuoka, Megumi; Shibano, Toshiro

CS Explor. Res. Lab. II, Daiichi Pharm. Co. Ltd., Tokyo, 134, Japan
 SO Cardiovascular Research (1993), 27(7), 1374-9
 CODEN: CVREAU; ISSN: 0008-6363
 DT Journal
 LA English

L13 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1993:52101 CAPLUS
 DN 118:52101
 TI Hirudin and sulotroban improve **coronary** blood flow after
 reperfusion induced by the novel recombinant plasminogen activator BM
 06.022 in a canine model of **coronary** artery thrombosis
 AU Martin, Ulrich; Sponer, Gisbert; Strein, Klaus
 CS Dep. Pharmacol., Boehringer Mannheim GmbH, Mannheim, D-6800/31, Germany
 SO International Journal of Hematology (1992), 56(2), 143-53
 CODEN: IJHEEY; ISSN: 0925-5710
 DT Journal
 LA English

L13 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1992:233034 CAPLUS
 DN 116:233034
 TI Cardioprotective effects of ischemic preconditioning are not mediated by
 prostanoids
 AU Li, Yuwei; Kloner, Robert A.
 CS Heart Inst., Res. Hosp. of the Good Samaritan, Los Angeles, CA, 90017, USA
 SO Cardiovascular Research (1992), 26(3), 226-31
 CODEN: CVREAU; ISSN: 0008-6363
 DT Journal
 LA English

L13 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1989:107894 CAPLUS
 DN 110:107894
 TI Effects of exogenous vasoconstrictors on **coronary** vascular
 resistance and prostacyclin production of the quiescent heart: the
 inhibitory effect of aspirin
 AU Lee, Shwu Luan; Levitsky, Sidney; Feinberg, Harold
 CS Coll. Med., Univ. Illinois, Chicago, IL, USA
 SO Journal of Pharmacology and Experimental Therapeutics (1989), 248(1), 44-9
 CODEN: JPETAB; ISSN: 0022-3565
 DT Journal
 LA English

L13 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1981:561869 CAPLUS
 DN 95:161869
 TI A study on constrictor responses of dog **coronary** arteries to
 acetylsalicylic acid
 AU Sakanashi, M.; Araki, H.; Furukawa, T.; Rokutanda, M.; Yonemura, K.
 CS Med. Sch., Kumamoto Univ., Kumamoto, 860, Japan
 SO Archives Internationales de Pharmacodynamie et de Therapie (1981), 252(1),
 86-96
 CODEN: AIPTAK; ISSN: 0003-9780
 DT Journal
 LA English

L13 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1980:90037 CAPLUS
 DN 92:90037
 TI Noninvasive radioisotopic technique for detection of platelet deposition
 in **coronary** artery bypass grafts in dogs and its reduction with


platelet-inhibitors

AU Dewanjee, M. K.; Fuster, V.; Kaye, M. P.; Josa, M.
CS Mayo Clin. and Mayo Found., Rochester, MN, 55901, USA
SO Radiopharm. 2, Proc. Int. Symp., 2nd (1979), 361-74. Editor(s): Sorenson, James A. Publisher: Soc. Nucl. Med., Inc., New York, N. Y.
CODEN: 42GGAE
DT Conference
LA English

L13 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1979:534570 CAPLUS
DN 91:134570
TI Excitation of afferent fibers in the cardiac sympathetic nerves induced by **coronary** occlusion and **injection** of bradykinin. The influence of acetylsalicylic acid and dipyron
AU Vogt, A.; Vetterlein, F.; Dal Ri, H.; Schmidt, G.
CS Inst. Pharmakol. Toxikol., Univ. Goettingen, Goettingen, D-3400, Fed. Rep. Ger.
SO Archives Internationales de Pharmacodynamie et de Therapie (1979), 239(1), 86-98
CODEN: AIPTAK; ISSN: 0003-9780
DT Journal
LA English

=> d 113 17 all

L13 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:153339 CAPLUS
DN 120:153339
TI Combined effect of the 5-HT₂ receptor antagonist DV-7028 and aspirin or heparin on **coronary** cyclic flow reductions in dogs
AU Tanaka, Tsuyoshi; Morishima, Yoshiyuki; Watanabe, Kazuo; Shibutani, Tomoko; Yasuoka, Megumi; Shibano, Toshiro
CS Explor. Res. Lab. II, Daiichi Pharm. Co. Ltd., Tokyo, 134, Japan
SO Cardiovascular Research (1993), 27(7), 1374-9
CODEN: CVREAU; ISSN: 0008-6363
DT Journal
LA English
CC 1-8 (Pharmacology)
GI



AB The aim was to study the combined effect of DV-7028 (I), a selective 5-HT₂ receptor antagonist, and aspirin or heparin on cyclic flow redns. in the canine **coronary** artery. Anesthetized open chest beagle dogs under artificial respiration were used. Cyclic flow redns. were induced by partial occlusion of the left anterior descending **coronary** artery at the site of endothelial injury. After induction of cyclic flow redns., test drugs were given to the animals i.v. DV-7028 (0.1 mg.cntdot.kg⁻¹) reduced the frequency of cyclic flow redns. by 77% and improved the nadir of **coronary** blood flow velocity that indicated the severity of cyclic flow redns. Also, aspirin (1 or 3

mg.cntdot.kg-1) or heparin (200 U.cntdot.kg-1) attenuated the cyclic flow redns. In expts. with drug combinations, DV-7028 was given to animals that had already received aspirin (1 mg.cntdot.kg-1) or heparin (200 U.cntdot.kg-1). DV-7028 (0.1 mg.cntdot.kg-1) completely abolished the cyclic flow redns. remaining after aspirin treatment in three of four animals. Heparin inhibited the cyclic flow redns. in one of five animals and the addn. of DV-7028 abolished the remaining cyclic flow redns. in the other four animals. After combined **injection** of DV-7028 with aspirin or heparin, the **coronary** blood flow with cyclical redns. returned to the baseline. The 5-HT₂ receptor antagonist DV-7028 can inhibit the cyclic flow redns. that are resistant to aspirin or heparin. The combined regimen of DV-7028 and aspirin or heparin in treatment of acute **coronary** stenosis is more effective than that of aspirin or heparin alone.

- ST DV7028 aspirin heparin interaction **coronary** stenosis; cyclic flow redn **coronary** DV7028 antithrombotic
- IT Anticoagulants and Antithrombotics
(DV-7028 and aspirin and heparin, cyclic flow redns. inhibition by, acute **coronary** stenosis treatment in relation to)
- IT Drug interactions
(additive, of DV-7028 with aspirin and heparin, cyclic flow redns. inhibition and acute **coronary** stenosis treatment in relation to)
- IT Circulation
(**coronary**, DV-7028 and aspirin and heparin effect on, cyclic flow redns. inhibition and acute **coronary** stenosis treatment in relation to)
- IT Artery, disease
(**coronary**, stenosis, acute, DV-7028 and aspirin and heparin in treatment of, cyclic flow redns. inhibition in relation to)
- IT 133364-63-3, DV-7028
RL: BIOL (Biological study)
(cyclic flow redns. inhibition by, as 5-HT₂ receptor antagonist, in **coronary** stenosis, interaction with aspirin and heparin in relation to)
- IT 50-78-2, Aspirin 9005-49-6, Heparin, biological studies
RL: BIOL (Biological study)
(cyclic flow redns. inhibition by, in **coronary** stenosis)

=> d 113 19 all

- L13 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN
- AN 1992:233034 CAPLUS
- DN 116:233034
- TI Cardioprotective effects of ischemic preconditioning are not mediated by prostanoids
- AU Li, Yuwei; Kloner, Robert A.
- CS Heart Inst., Res. Hosp. of the Good Samaritan, Los Angeles, CA, 90017, USA
- SO Cardiovascular Research (1992), 26(3), 226-31
CODEN: CVREAU; ISSN: 0008-6363
- DT Journal
- LA English
- CC 14-5 (Mammalian Pathological Biochemistry)
Section cross-reference(s): 1
- AB The mechanism of ischemic preconditioning may be mediated through the synthesis and release of prostaglandin/prostacyclin. Aspirin, an inhibitor of cyclooxygenase, could block or prevent the protective effect of preconditioning. Rats were preconditioned by episodes of 3 min of **coronary** occlusion and 5 min of reperfusion, and then subjected to 90 min of occlusion followed by 4 h of reperfusion. Aspirin (10 mg/kg) was given 10 min prior to the preconditioning. Planimetry was used to

measure area at risk (AR) following blue dye **injection** and area of necrosis (AN) after tetrazolium staining. All groups had comparable AR. AN/AR was reduced in the preconditioning group and the aspirin + preconditioning group compared with the control group. The incidence of ventricular tachycardia and/or fibrillation was also reduced in the preconditioning and aspirin + preconditioning groups. Preconditioning both with and without aspirin reduced the infarct size and the incidence of ventricular tachycardia and/or fibrillation. The effects of preconditioning were not prevented by aspirin. The cardioprotective effects of preconditioning may not be mediated by prostanoids in this rat model.

ST heart ischemia preconditioning prostaglandin mechanism aspirin

IT Prostaglandins

RL: BIOL (Biological study)

(heart ischemia preconditioning lack of mediation by)

IT Heart, disease

(ischemia, preconditioning against, prostanoids lack of role in)

IT **50-78-2**, Aspirin

RL: BIOL (Biological study)

(heart ischemia preconditioning lack of response to)

=> d 113 21 all

L13 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1981:561869 CAPLUS

DN 95:161869

TI A study on constrictor responses of dog **coronary** arteries to acetylsalicylic acid

AU Sakanashi, M.; Araki, H.; Furukawa, T.; Rokutanda, M.; Yonemura, K.

CS Med. Sch., Kumamoto Univ., Kumamoto, 860, Japan

SO Archives Internationales de Pharmacodynamie et de Therapie (1981), 252(1), 86-96


CODEN: AIPTAK; ISSN: 0003-9780

DT Journal

LA English

CC 1-4 (Pharmacodynamics)

GI



AB In isolated and perfused dog hearts an intracoronary **injection** of acetylsalicylic acid (I) [**50-78-2**] (10 mg) decreased **coronary** blood flow concomitant with diminution of myocardial contractile force, but did not change heart rate. Contractions were produced in isolated dog **coronary** arterial strips by I (10⁻⁴ M) and these were significantly inhibited by Ca²⁺-free soln., diltiazem, nifedipine, phospholipase A₂, arachidonate, and prostaglandin E₁. Apparently, I at a high dose produces **coronary** arterial contraction probably through inhibition of intravascular synthesis of vasodilating prostaglandins.

ST acetylsalicylate **coronary** artery contraction; prostaglandin

acetylsalicylate **coronary** artery contraction

IT Prostaglandins

RL: BIOL (Biological study)

(**coronary** artery contraction from acetylsalicylic acid in

relation to)
 IT Artery
 (coronary, contraction of, from aspirin, prostaglandins in
 relation to)
 IT 50-78-2
 RL: BIOL (Biological study)
 (coronary artery contraction by, prostaglandin in relation
 to)

=> e intrathecal

E1	1	INTRATHECALLY/BI
E2	2	INTRATHECAL/BI
E3	4695 -->	INTRATHECAL/BI
E4	1682	INTRATHECALLY/BI
E5	1	INTRATHECALTY/BI
E6	1	INTRATHECALY/BI
E7	1	INTRATHECHAL/BI
E8	1	INTRATHECOL/BI
E9	1	INTRATHEKAL/BI
E10	1	INTRATHELIAL/BI
E11	1	INTRATHEORY/BI
E12	4	INTRATHERAPEUTIC/BI

=> s e3-e4

	4695	INTRATHECAL/BI
	1682	INTRATHECALLY/BI
L14	5398	(INTRATHECAL/BI OR INTRATHECALLY/BI)

=> s l4 and l14

L15 12 L4 AND L14

=> d his

(FILE 'HOME' ENTERED AT 12:17:21 ON 29 SEP 2003)

FILE 'REGISTRY' ENTERED AT 12:17:29 ON 29 SEP 2003

L1	52 S ASPIRIN
	E NSAIDS
	E NSAID
L2	9 S E3

FILE 'CAPLUS' ENTERED AT 12:18:24 ON 29 SEP 2003

	E NSAIDS
L3	3396 S E3
L4	17770 S L1
	E INTRATHECALY
L5	1682 S E1-E3
L6	6 S L3 AND L5
L7	3 S L4 AND L5
	E INTRAVENTICULARLY
L8	28 S E2-E3
L9	0 S L8 AND L4
	E CORANARY
	E CORONARY
L10	50167 S E3
L11	646 S L10 AND L4
	E INJECTION
L12	420947 S E3
L13	23 S L11 AND L12
	E INTRATHECAL
L14	5398 S E3-E4

L15 12 S L4 AND L14

=> d l15 not l7

L7 IS NOT VALID HERE

For an explanation, enter "HELP DISPLAY".

=> s l15 not l7

L16 9 L15 NOT L7

=> d l16 1-9

L16 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2003:610193 CAPLUS

DN 139:159967

TI .kappa.-PVIIA-related conotoxins as organ protectants

IN Pemberton-Goodman, Karen E.; Jones, Robert M.; Temple, Davis L., Jr.;
McIntosh, J. Michael; Olivera, Baldomero M.

PA Cognetix, Inc., USA; University of Utah Research Foundation

SO PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003063782	A2	20030807	WO 2003-US2384	20030128
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				
	PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,				
	UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,				
	CY, DE, DK, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE,				
	SI, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,				
	TD, TG				

PRAI US 2002-352219P P 20020129

L16 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2003:202477 CAPLUS

DN 138:215285

TI Use of .mu.-opioid receptor agonists and opioid receptor antagonists as
combination drugs for the treatment of cancer

IN Geisslinger, Gerd; Tegeder, Irmgard

PA Paz Arzneimittel-Entwicklungs Gesellschaft m.b.H., Germany

SO PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003020277	A1	20030313	WO 2002-EP8181	20020723
	W:				
	AU, CA, CN, IL, JP, MX, RU, US				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT,				
	LU, MC, NL, PT, SE, SK, TR				
	DE 10142996	A1	20030327	DE 2001-10142996	20010901

PRAI DE 2001-10142996 A 20010901

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2001:856855 CAPLUS
DN 136:194095
TI Antinociceptive profiles of aspirin and acetaminophen in formalin,
substance P and glutamate pain models
AU Choi, Seong-Soo; Lee, Jin-Koo; Suh, Hong-Won
CS Department of Pharmacology, Hallym University, College of Medicine, and
Institute of Natural Medicine, Kangwon-Do, Chunchon, 200-702, S. Korea
SO Brain Research (2001), 921(1,2), 233-239
CODEN: BRREAP; ISSN: 0006-8993
PB Elsevier Science B.V.
DT Journal
LA English
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:407083 CAPLUS
DN 127:104060
TI Effects of **intrathecal** or intracerebroventricular administration
of nonsteroidal anti-inflammatory drugs on a C-fiber reflex in rats
AU Bustamante, Diego; Paeile, Carlos; Willer, Jean-Claude; Le Bars, Daniel
CS Dep. of Pharmacology, Faculty of Medicine, University of Chile, Santiago,
Chile
SO Journal of Pharmacology and Experimental Therapeutics (1997), 281(3),
1381-1391
CODEN: JPETAB; ISSN: 0022-3565
PB Williams & Wilkins
DT Journal
LA English

L16 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:261080 CAPLUS
DN 120:261080
TI **Intrathecal** injection of lysine acetylsalicylic acid in the rat:
a neurotoxicological study
AU Svensson, B. A.; Karlsten, R.; Kristensen, J. D.; Sottile, A.; Bennett,
A.; Gordh, T. Jr.
CS Dep. Anat., Uppsala Univ., Uppsala, Swed.
SO Acta Anaesthesiologica Scandinavica (1993), 37(8), 799-805
CODEN: AANEAB; ISSN: 0001-5172
DT Journal
LA English

L16 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:645527 CAPLUS
DN 117:245527
TI Antinociceptive actions of spinal nonsteroidal anti-inflammatory agents on
the formalin test in the rat
AU Malmberg, Annika B.; Yaksh, Tony L.
CS Dep. Anesthesiol., Univ. California, San Diego, La Jolla, CA, USA
SO Journal of Pharmacology and Experimental Therapeutics (1992), 263(1),
136-46
CODEN: JPETAB; ISSN: 0022-3565
DT Journal
LA English

L16 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:504057 CAPLUS
DN 117:104057
TI **Intrathecal** injection of acetylsalicylic acid, salicylic acid
and indometacin depresses C fiber-evoked activity in the rat thalamus and
spinal cord

AU Jurna, Ilmar; Spohrer, Birgit; Bock, Rudolf
CS Inst. Pharmakol. Toxikol., Univ. Saarlandes, Homburg/Saar, D-6650, Germany
SO Pain (1992), 49(2), 249-56
CODEN: PAINDB; ISSN: 0304-3959
DT Journal
LA English

L16 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1988:180862 CAPLUS
DN 108:180862
TI Prostaglandins inhibit endogenous pain control mechanisms by blocking transmission at spinal noradrenergic synapses
AU Taiwo, Yetunde O.; Levine, Jon D.
CS Dep. Med., Univ. California, San Francisco, CA, 94143, USA
SO Journal of Neuroscience (1988), 8(4), 1346-9
CODEN: JNRSDS; ISSN: 0270-6474
DT Journal
LA English

L16 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1986:583773 CAPLUS
DN 105:183773
TI Spinal cord toxicity of lysine acetylsalicylate and ketamine hydrochloride given by the **intrathecal** route in the rat
AU Amiot, J. F.; Palacci, J. H.; Vedrenne, C.; Pellerin, M.
CS Dep. Anesth.-Reanim., CHG Robert-Ballanger, Aulnay-sous-Bois, F 93602, Fr.
SO Annales Francaises d'Anesthesie et de Reanimation (1986), 5(4), 462
CODEN: AFAREO; ISSN: 0750-7658
DT Journal
LA French

=> d 116 7 all

L16 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1992:504057 CAPLUS
DN 117:104057
TI **Intrathecal** injection of acetylsalicylic acid, salicylic acid and indometacin depresses C fiber-evoked activity in the rat thalamus and spinal cord
AU Jurna, Ilmar; Spohrer, Birgit; Bock, Rudolf
CS Inst. Pharmakol. Toxikol., Univ. Saarlandes, Homburg/Saar, D-6650, Germany
SO Pain (1992), 49(2), 249-56
CODEN: PAINDB; ISSN: 0304-3959
DT Journal
LA English
CC 1-11 (Pharmacology)
AB It was aimed to assess if **intrathecal** (i.t.) injections of acetylsalicylic acid and salicylic acid depress C-fiber-evoked activity in the sensory part of the nociceptive system. In rats under urethane anesthesia, activity was elicited in single neurons in the dorsomedial part of the ventral nucleus (VDM) of the thalamus and in ascending axons of the spinal cord by supramaximal elec. stimulation of the sural nerve. Acetylsalicylic acid and salicylic acid injected i.t. significantly reduced the activity evoked in thalamic neurons. The max. depression amounted to about 50% of the activity evoked in the controls and was produced by acetylsalicylic acid at a dose of 50 .mu.g (0.28 .mu.mol)/rat and by salicylic acid at a dose of 37.5 .mu.g (0.27 .mu.mol)/rat. Indometacin injected i.t. also reduced C-fiber-evoked activity in the thalamus in a dose-dependent fashion, 100 .mu.g producing a 50% depression. Salicylic acid (37.5 .mu.g/rat, i.t.) depressed C-fiber-evoked activity in ascending axons but had no effect on A.beta.

fiber-evoked activity. It is concluded that i.t. injection of acetylsalicylic acid selectively inhibits nociceptive impulse transmission in the spinal cord by an action of the salicylic acid moiety. It is possible that prostaglandins are involved in the central action of salicylic acid.

ST C fiber thalamus spinal cord analgesic; acetylsalicylate C fiber thalamus spinal cord; salicylate C fiber thalamus spinal cord; indomethacin C fiber thalamus spinal cord

IT Spinal cord
(C-fiber-evoked activity in, acetylsalicylic and salicylic acids effect on, analgesic mechanism in relation to)

IT Prostaglandins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(in central analgesic action of salicylic acid)

IT Analgesics
(**intrathecal**, C-fiber-evoked activity inhibition by, in thalamus and spinal cord, mechanism of)

IT Nerve
(C-fiber, acetylsalicylic and salicylic acids effect on, of thalamus and spinal cord, analgesic mechanism in relation to)

IT Nerve
(nociceptive, axon, acetylsalicylic and salicylic acids effect on, of thalamus and spinal cord, analgesic mechanism in relation to)

IT Brain
(thalamus, C-fiber-evoked activity in, acetylsalicylic and salicylic acids effect on, analgesic mechanism in relation to)

IT **50-78-2**, Acetylsalicylic acid 53-86-1, Indomethacin 69-72-7, Salicylic acid, biological studies

RL: BIOL (Biological study)
(**intrathecal**, C-fiber-evoked activity inhibition by, in thalamus and spinal cord, mechanism of)

=> d 116 5 all

L16 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1994:261080 CAPLUS

DN 120:261080

TI **Intrathecal** injection of lysine acetylsalicylic acid in the rat: a neurotoxicological study

AU Svensson, B. A.; Karlsten, R.; Kristensen, J. D.; Sottile, A.; Bennett, A.; Gordh, T. Jr.

CS Dep. Anat., Uppsala Univ., Uppsala, Swed.

SO Acta Anaesthesiologica Scandinavica (1993), 37(8), 799-805
CODEN: AANEAB; ISSN: 0001-5172

DT Journal

LA English

CC 1-11 (Pharmacology)

AB Lysine acetylsalicylic acid has been reported to induce analgesic effects in humans after **intrathecal** (i.t.) injection. Before conducting further studies in humans with this drug, it is important to evaluate potential toxicol. effects on the spinal cord in animals. In the present study the effects of chronic **intrathecal** administration of provocative doses of lysine acetylsalicylic acid (L-ASA) on the rat spinal cord were evaluated using light and electron microscopy and a quant. morphometric method. The authors also investigated the effects of single doses of the drug on the spinal cord blood flow (SCBF) using the laser-Doppler flowmetry technique. No histopathol. changes or differences in no. or d. of neuronal cells could be seen after chronic administration of L-ASA as compared to controls. The SCBF decreased immediately after i.t. injection of a large dose (4 mg) of L-ASA and returned to predrug

levels within 10 min. At the end of the expt. metabolic acidosis was detected, indicating a systemic effect of acetylsalicylic acid. It is concluded that no neurotoxic effects on the spinal cord were seen after chronic i.t. injection of L-ASA. From a neurotoxicol. point of view, the authors' findings do not contraindicate the spinal use of L-ASA in humans.

ST lysine acetylsalicylic acid toxicity spinal cord; analgesic lysine acetylsalicylic acid toxicity
IT Analgesics
 (lysine acetylsalicylic acid as, neurotoxicity of, to spinal cord, after **intrathecal** injection)
IT Spinal cord
 (lysine acetylsalicylic acid neurotoxicity to, after **intrathecal** injection)
IT Nerve, toxic chemical and physical damage
 (lysine acetylsalicylic acid toxicity to, in spinal cord, after **intrathecal** injection)
IT Acidosis
 (neurotoxic effect of lysine acetylsalicylic acid in relation to, in spinal cord, after **intrathecal** injection)
IT Circulation
 (of spinal cord, lysine acetylsalicylic acid effect on, neurotoxicity after **intrathecal** injection in relation to)
IT **62952-06-1**
 RL: PRP (Properties)
 (neurotoxicity of, to spinal cord, after **intrathecal** injection)

=> s cardiac injection
 95738 CARDIAC
 420947 INJECTION
L17 14 CARDIAC INJECTION
 (CARDIAC(W) INJECTION)

=> d l17 and l4
L4 IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY".

=> s l17 and l4
L18 0 L17 AND L4

=> d his

(FILE 'HOME' ENTERED AT 12:17:21 ON 29 SEP 2003)

FILE 'REGISTRY' ENTERED AT 12:17:29 ON 29 SEP 2003

L1 52 S ASPIRIN
 E NSAIDS
 E NSAID
L2 9 S E3

FILE 'CAPLUS' ENTERED AT 12:18:24 ON 29 SEP 2003

 E NSAIDS
L3 3396 S E3
L4 17770 S L1
 E INTRATHECALY
L5 1682 S E1-E3
L6 6 S L3 AND L5
L7 3 S L4 AND L5
 E INTRAVENTICULARLY
L8 28 S E2-E3
L9 0 S L8 AND L4

E CORANARY
 E CORONARY
 L10 50167 S E3
 L11 646 S L10 AND L4
 E INJECTION
 L12 420947 S E3
 L13 23 S L11 AND L12
 E INTRATHECAL
 L14 5398 S E3-E4
 L15 12 S L4 AND L14
 L16 9 S L15 NOT L7
 L17 14 S CARDIAC INJECTION
 L18 0 S L17 AND L4

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	93.44	104.57
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-5.21	-5.21

STN INTERNATIONAL LOGOFF AT 12:45:07 ON 29 SEP 2003

DN 130:105154
 TI Molecular characterization of the neuroprotective activity of salicylates
 AU Grilli, M.; Pizzi, M.; Goffi, F.; Benarese, M.; Gerardi, G. M.; Memo, M.; Spano, P. F.
 CS Division of Pharmacology Department of Biomedical Sciences and Biotechnologies School of Medicine, University of Brescia, Brescia, Italy
 SO Advances in Behavioral Biology (1998), 49(Progress in Alzheimer's and Parkinson's Diseases), 99-103
 CODEN: ADBBBW; ISSN: 0099-6246
 PB Plenum Publishing Corp.
 DT Journal
 LA English
 CC 1-11 (Pharmacology)
 AB Aspirin and its metabolite sodium salicylate prevent glutamate-induced neurotoxicity in rats. The neuroprotective effect of aspirin does not appear to correlate with the anti-inflammatory properties of this compd.
 ST neuroprotectant salicylate antiinflammatory neurodegenerative disorder
Alzheimer
 IT Transcription factors
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (NF-.kappa.B (nuclear factor .kappa.B); mol. characterization of the neuroprotective activity of salicylates)
 IT Nervous system
 (degeneration; mol. characterization of the neuroprotective activity of salicylates)
 IT Anti-**Alzheimer**'s agents
 (mol. characterization of the neuroprotective activity of salicylates)
 IT Cytoprotective agents
 (neuroprotectants; mol. characterization of the neuroprotective activity of salicylates)
 IT Anti-inflammatory agents
 (nonsteroidal; mol. characterization of the neuroprotective activity of salicylates)
 IT 54-21-7, Sodium salicylate
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); MFM (Metabolic formation); THU (Therapeutic use); BIOL (Biological study); FORM (Formation, nonpreparative); USES (Uses)
 (mol. characterization of the neuroprotective activity of salicylates)
 IT 50-78-2, Aspirin 69-72-7D, analogs
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (mol. characterization of the neuroprotective activity of salicylates)
 RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE
 (1) Amin, A; Proc Natl Acad Sci USA 1995, V92, P7926 CAPLUS
 (2) Curran, T; Cell 1988, V55, P395 CAPLUS
 (3) Gallo, V; Proc Natl Acad Sci USA 1982, V79, P7919 CAPLUS
 (4) Garthwaite, G; Neurosci Lett 1989, V97, P316 CAPLUS
 (5) Grilli, M; Int Rev Cytol 1993, V143, P1 CAPLUS
 (6) Grilli, M; J Biol Chem 1995, V270, P26774 CAPLUS
 (7) Grilli, M; J Biol Chem 1996, V271, P15002 CAPLUS
 (8) Grilli, M; Science 1996, V274, P1383 CAPLUS
 (9) Guerrini, L; Proc Natl Acad Sci USA 1995, V92, P9077 CAPLUS
 (10) Insel, P; Goodman and Gilman's The Pharmacological Basis of Therapeutics 1996, P617
 (11) Kaltschmidt, C; Mol Cell Biol 1994, V14, P3981 CAPLUS
 (12) Kaltschmidt, C; Proc Natl Acad Sci USA 1995, V92, P9618 CAPLUS
 (13) Kopp, E; Science 1994, V265, P956 MEDLINE
 (14) Lipton, S; New Engl J Med 1995, V330, P613
 (15) McGeer, P; Brain Res Rev 1995, V21, P195 MEDLINE

- (16) Pizzi, M; Eur J Neurosci 1996, V8, P1516 MEDLINE
- (17) Pizzi, M; Mol Pharmacol 1996, V49, P586 CAPLUS
- (18) Rogers, J; Neurology 1993, V43, P1609 MEDLINE
- (19) Yan, S; Nature Med 1995, V1, P693 CAPLUS

=>

AN 1997:454047 CAPLUS
 DN 127:60626
 TI Method of delaying onset of **Alzheimer's** disease symptoms with a
 non-steroidal anti-inflammatory agent and/or a histamine H2
 receptor-blocking agent
 IN Breitner, John C. S.; Welsh, Kathleen A.
 PA Duke University, USA
 SO U.S., 10 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 IC ICM A61K031-60
 ICS A61K031-615; A61K031-54; A61K031-44; A61K031-425; A61K031-42;
 A61K031-415; A61K031-40; A61K031-38; A61K031-34; A61K031-195;
 A61K031-19
 NCL 514570000
 CC 1-11 (Pharmacology)
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5643960	A	19970701	US 1994-228019	19940415
	US 6025395	A	20000215	US 1997-843217	19970414
PRAI	US 1994-228019		19940415		

AB A method is disclosed for preventing or delaying the onset of
Alzheimer's disease and related neurodegenerative disorders. The
 method involves the administration to individuals at risk of developing
 the disease (or disorder) a non-steroidal anti-inflammatory agent and/or a
 histamine H2 receptor-blocking agent. The invention also relates to a
 method of treating **Alzheimer's** disease and related
 neurodegenerative disorders that involves the use of such agents.

ST **Alzheimer** disease NSAID H2 antihistaminic; neurodegenerative
 disease NSAID H2 antihistaminic

IT Apolipoproteins
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (E, .epsilon.4 or .epsilon.2 allele at locus for; non-steroidal
 anti-inflammatory agent and/or histamine H2 receptor-blocking agent for
 preventing, delaying, or treating **Alzheimer's** disease and
 related neurodegenerative disorders)

IT Antihistamines
 (H2; non-steroidal anti-inflammatory agent and/or histamine H2
 receptor-blocking agent for preventing, delaying, or treating
Alzheimer's disease and related neurodegenerative disorders)

IT Nervous system
 (degeneration; non-steroidal anti-inflammatory agent and/or histamine
 H2 receptor-blocking agent for preventing, delaying, or treating
Alzheimer's disease and related neurodegenerative disorders)

IT **Alzheimer's** disease
 Narcotics
 Susceptibility (genetic)
 (non-steroidal anti-inflammatory agent and/or histamine H2
 receptor-blocking agent for preventing, delaying, or treating
Alzheimer's disease and related neurodegenerative disorders)

IT Glucocorticoids
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); BIOL (Biological study)
 (non-steroidal anti-inflammatory agent and/or histamine H2
 receptor-blocking agent for preventing, delaying, or treating
Alzheimer's disease and related neurodegenerative disorders)

IT Anti-inflammatory agents
 (nonsteroidal; non-steroidal anti-inflammatory agent and/or histamine
 H2 receptor-blocking agent for preventing, delaying, or treating
Alzheimer's disease and related neurodegenerative disorders)

IT Gene, animal
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(.epsilon.4 or .epsilon.2 allele, for apolipoprotein E; non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)

IT **50-78-2**, Aspirin 103-90-2, Acetaminophen 22204-53-1, Naproxen
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(non-steroidal anti-inflammatory agent and/or histamine H2 receptor-blocking agent for preventing, delaying, or treating **Alzheimer**'s disease and related neurodegenerative disorders)

=>

AN 1998:780621 CAPLUS
 DN 130:232124
 TI Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS [central nervous system]
 AU Hauss-Wegrzyniak, Beatrice; Willard, Lauren B.; Del Soldato, Piero; Pepeu, Giancarlo; Wenk, Gary L.
 CS Memory and Aging, Division of Neural Systems, Arizona Research Laboratories, University of Arizona, Tucson, AZ, 85724, USA
 SO Brain Research (1999), 815(1), 36-43
 CODEN: BRREAP; ISSN: 0006-8993
 PB Elsevier Science B.V.
 DT Journal
 LA English
 CC 1-7 (Pharmacology)
 AB This study investigated whether nitroflurbiprofen (NFP) or nitro-aspirin can reduce the inflammatory response induced by continuous infusion of lipopolysaccharide (LPS) into the 4th ventricular space of the rat brain for 30 days. The chronic LPS infusion produced an extensive inflammation that was particularly evident in the hippocampus, subiculum and entorhinal and piriform cortices. Daily peripheral administration of NFP dose-dependently attenuated the brain inflammation, as indicated by the decreased d. and reactive state of microglial cells. Daily peripheral administration of nitro-aspirin also attenuated the brain inflammation, but to a much lesser degree than NFP. The results demonstrated that nonsteroidal anti-inflammatory drugs can reduce brain inflammation and that NFP is an effective anti-inflammatory agent.
 ST brain inflammation inhibition nitroflurbiprofen nitroaspirin; nonsteroidal antiinflammatory drug brain inflammation
 IT Encephalitis
 (nitroflurbiprofen and nitroaspirin inhibition of)
 IT **Alzheimer's** disease
 (nitroflurbiprofen and nitroaspirin inhibition of brain inflammation in relation to)
 IT Anti-inflammatory agents
 (nonsteroidal; brain inflammation inhibition by nitroflurbiprofen and nitroaspirin as)
 IT **17336-14-0** 158836-71-6, Nitroflurbiprofen
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (brain inflammation inhibition by)
 RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
 RE
 (1) Aisen, P; Am J Psychiatr 1994, V151, P1105 MEDLINE
 (2) Allison, M; N Engl J Med 1992, V327, P749 MEDLINE
 (3) Altstiel, L; Prog Neuropsychopharmacol Biol Psychiatr 1991, V15, P481 CAPLUS
 (4) Banati, R; Glia 1993, V7, P111 MEDLINE
 (5) Bannwarth, B; Therapie 1986, V41, P409 CAPLUS
 (6) Breder, C; Brain Res 1996, V713, P64 CAPLUS
 (7) Breitner, J; Neurobiol Aging 1996, V17, P789 MEDLINE
 (8) Burrell, R; Crit Rev Microbiol 1990, V17, P188
 (9) Cacabelos, R; Meth Find Exp Clin Pharmacol 1994, V16, P141 MEDLINE
 (10) Chiang, C; Dev Neurosci 1994, V16, P212 CAPLUS
 (11) Das, S; Neuron 1995, V14, P447 CAPLUS
 (12) Eikelenboom, P; Virchows Arch B Cell Pathol 1989, V56, P259 MEDLINE
 (13) Elmquist, J; J Comp Neurol 1997, V381, P119 CAPLUS
 (14) Greenblatt, D; Arzneimittel-Forschung 1983, V33, P1671 CAPLUS
 (15) Griffin, W; Proc Natl Acad Sci USA 1989, V86, P7611 MEDLINE
 (16) Hauss-Wegrzyniak, B; Brain Res 1998, V794, P211 CAPLUS
 (17) Hauss-Wegrzyniak, B; Brain Res 1998, V780, P294 CAPLUS
 (18) Jenkinson, M; Br J Rheumatol 1989, V28, P86 MEDLINE

- (19) Kitagawa, H; J Pharmacol Exp Therap 1990, V253, P1133 CAPLUS
- (20) Macnaughton, W; Life Sci 1989, V45, P1869 CAPLUS
- (21) McGeer, P; Brain Res Rev 1995, V21, P195 MEDLINE
- (22) McGeer, P; Lancet 1990, V335, P1037 MEDLINE
- (23) McGeer, P; Neurosci Lett 1988, V79, P195
- (24) McGeer, P; Neurosci Lett 1989, V107, P341 MEDLINE
- (25) Mrak, R; Human Pathol 1995, V26, P816 MEDLINE
- (26) Myllykangas-Luosujarvi, R; Br J Rheumatol 1994, V33, P501 MEDLINE
- (27) Rogers, J; Drug Res 1995, V45, P439 CAPLUS
- (28) Rogers, J; Neurobiol Aging 1996, V17, P681 MEDLINE
- (29) Rogers, J; Neurology 1993, V43, P1609 MEDLINE
- (30) Roth, S; Ann Intern Med 1988, V109, P353 MEDLINE
- (31) Santini, G; Eur J Pharmacol 1996, V316, P65 CAPLUS
- (32) Sheng, J; Neurobiol Aging 1996, V17, P761 CAPLUS
- (33) Strauss, S; Lab Invest 1992, V66, P223 MEDLINE
- (34) Vandenabeele, P; Immunol Today 1991, V12, P217 CAPLUS
- (35) Wallace, J; Gastroenterology 1994, V107, P173 CAPLUS
- (36) Wallace, J; Trends Pharmacol Sci 1992, V13, P129 MEDLINE
- (37) Watson; Paxinos 1986

=>

AN 1999:103337 CAPLUS
 DN 130:280248
 TI Increased expression of cyclooxygenases and peroxisome
 proliferator-activated receptor-.gamma. in **Alzheimer's** disease
 brains
 AU Kitamura, Yoshihisa; Shimohama, Shun; Koike, Hideyasu; Kakimura, Jun-Ichi;
 Matsuoka, Yasuji; Nomura, Yasuyuki; Gebicke-Haerter, Peter J.; Taniguchi,
 Takashi
 CS Department of Neurobiology, Kyoto Pharmaceutical University, Kyoto,
 607-8412, Japan
 SO Biochemical and Biophysical Research Communications (1999), 254(3),
 582-586
 CODEN: BBRCA9; ISSN: 0006-291X
 PB Academic Press
 DT Journal
 LA English
 CC 14-10 (Mammalian Pathological Biochemistry)
 Section cross-reference(s): 1
 AB Recent studies suggest that inflammatory events are assocd. with plaque
 formation in the brains of patients with **Alzheimer's** disease
 (AD). Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) of
 these patients appears to slow the progression of disease. The authors
 assessed the occurrence of cyclooxygenases (COX-1 and -2) and peroxisome
 proliferator-activated receptor-.gamma. (PPAR.gamma.) in temporal cortex
 from normal and AD brains using specific antibodies. In AD brains,
 protein levels of COX-1 were increased in both cytosolic and particulate
 fractions, and COX-2 protein was also increased in the particulate
 fraction. PPAR.gamma. level was increased in the cytosolic fraction but
 not in the particulate fraction. Thus, expression levels of COX-1, COX-2,
 and PPAR.gamma. may change in AD brains. In addn., several NSAIDs which
 are also PPAR.gamma. activators, such as indomethacin, inhibited COX-2
 expression in glial cells. These results suggest that PPAR.gamma.
 activators have inhibitory effects on inflammatory events in AD brains.
 (c) 1999 Academic Press.
 ST brain cyclooxygenase peroxisome proliferator activated receptor gamma
Alzheimer disease
 IT Cytoplasm
 (cytosol; increased expression of cyclooxygenases and peroxisome
 proliferator-activated receptor-.gamma. in brains from humans with
Alzheimer's disease)
 IT Gene
 (expression; increased expression of cyclooxygenases and peroxisome
 proliferator-activated receptor-.gamma. in brains from humans with
Alzheimer's disease)
 IT **Alzheimer's** disease
 Encephalitis
 Neuroglia
 (increased expression of cyclooxygenases and peroxisome
 proliferator-activated receptor-.gamma. in brains from humans with
Alzheimer's disease)
 IT Anti-inflammatory agents
 (nonsteroidal; increased expression of cyclooxygenases and peroxisome
 proliferator-activated receptor-.gamma. in brains from humans with
Alzheimer's disease)
 IT Brain
 (temporal cortex; increased expression of cyclooxygenases and
 peroxisome proliferator-activated receptor-.gamma. in brains from
 humans with **Alzheimer's** disease)
 IT Peroxisome proliferator-activated receptors
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified);
 BIOL (Biological study); OCCU (Occurrence)
 (.gamma.; increased expression of cyclooxygenases and peroxisome

proliferator-activated receptor-.gamma. in brains from humans with
Alzheimer's disease)

IT 39391-18-9

RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence); PROC (Process)

(1 and 2; increased expression of cyclooxygenases and peroxisome
proliferator-activated receptor-.gamma. in brains from humans with
Alzheimer's disease)

IT 50-78-2, Aspirin 53-86-1, Indomethacin 41598-07-6, PGD2
87893-55-8 123653-11-2, NS398

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(increased expression of cyclooxygenases and peroxisome
proliferator-activated receptor-.gamma. in brains from humans with
Alzheimer's disease)

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Bauer, M; Eur J Biochem 1997, V243, P726 CAPLUS
- (2) Bonventre, J; Nature 1997, V390, P622 CAPLUS
- (3) Chang, J; Neurobiol Aging 1996, V17, P801 CAPLUS
- (4) Clemens, J; Stroke 1996, V27, P527 CAPLUS
- (5) Farooqui, A; Neurochem Int 1997, V30, P517 CAPLUS
- (6) Forman, B; Cell 1995, V83, P803 CAPLUS
- (7) Gattaz, W; Biol Psychiatry 1995, V37, P13 MEDLINE
- (8) Guastadisegni, C; FEBS Lett 1997, V413, P314 CAPLUS
- (9) Jiang, C; Nature 1998, V391, P82 CAPLUS
- (10) Kitamura, Y; Neurosci Lett 1997, V237, P17 CAPLUS
- (11) Lehmann, J; J Biol Chem 1997, V272, P3406 CAPLUS
- (12) Lehtonen, J; Biochemistry 1996, V35, P9407 CAPLUS
- (13) Lukiw, W; J Neurosci Res 1997, V50, P937 CAPLUS
- (14) Mangelsdorf, D; Cell 1995, V83, P835 CAPLUS
- (15) Mirra, S; Neurology 1991, V41, P479 MEDLINE
- (16) Morita, I; J Biol Chem 1995, V270, P10902 CAPLUS
- (17) Nogawa, S; J Neurosci 1997, V17, P2746 CAPLUS
- (18) Oka, A; NeuroReport 1997, V8, P1161 CAPLUS
- (19) Pasinetti, G; Neuroscience 1998, V87, P319 CAPLUS
- (20) Ricote, M; Nature 1998, V391, P79 CAPLUS
- (21) Rogers, J; Neurology 1993, V43, P1609 MEDLINE
- (22) Sanz, O; Neuroscience 1997, V80, P221 CAPLUS
- (23) Shimohama, S; J Neural Transm 1990, V30(Suppl), P69
- (24) Shimohama, S; J Neurochem 1995, V64, P2629 CAPLUS
- (25) Shimohama, S; Neurology 1993, V43, P1407 MEDLINE
- (26) Spencer, A; J Biol Chem 1998, V273, P9886 CAPLUS
- (27) Stephenson, D; Neurobiol Dis 1996, V3, P51 CAPLUS
- (28) Tocco, G; Exp Neurol 1997, V144, P339 CAPLUS
- (29) Vane, J; Ann Rev Pharmacol Toxicol 1998, V38, P97 CAPLUS

=>

AN 1998:338114 CAPLUS
 DN 129:12755
 TI Use of selected nonsteroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases
 IN Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco
 PA Universita' Degli Studi di Brescia - Dipartimento di Scienze Biomediche, Italy; Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco
 SO PCT Int. Appl., 24 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM A61K031-00
 ICS A61K031-60
 CC 1-11 (Pharmacology)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9820864	A2	19980522	WO 1997-EP6323	19971113
	WO 9820864	A3	19981015		
	W: JP, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	IT 1996-MI2356		19961113		
OS	MARPAT 129:12755				
AB	Nonsteroidal antiinflammatory compds. are used for the prevention and the treatment of neurodegenerative diseases, e.g. Alzheimer's disease and Parkinson's disease.				
ST	neurodegenerative disease nonsteroidal antiinflammatory drug; Parkinson disease nonsteroidal antiinflammatory drug; Alzheimer disease nonsteroidal antiinflammatory drug; NSAID neurodegenerative disease				
IT	Transcription factors RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (AP-1 (activator protein 1); nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	Nervous system (Huntington's chorea; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	Transcription factors RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (NF-.kappa.B (nuclear factor .kappa.B); nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	Glutamate receptors RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process) (NMDA-binding; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	Nervous system (amyotrophic lateral sclerosis; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	Nervous system (ataxia telangiectasia; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	Nervous system (degeneration; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	AIDS (disease) (dementia assocd. with; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)				
IT	Mental disorder				

(dementia, multi-infarct; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Brain
(dentate gyrus; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Mental disorder
(diffuse Lewy body disease; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Brain
(hippocampus, sector CA1; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Brain
(hippocampus, sector CA3; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Infection
(infective neurodegenerative disease; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Nerve, disease
(injury; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Metabolism
(metabolic neuropathies; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Epilepsy
(neurodegenerative processes related to; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Prion diseases
(neurodegenerative syndromes in; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Hypoxia, animal
(neuropathy from; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Brain, disease
(neuropathy, ischemic; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Nerve, disease
(neuropathy; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Cytoprotective agents
(neuroprotectants; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Anti-Alzheimer's agents
Anti-ischemic agents
Antiparkinsonian agents
Multiple sclerosis
(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Glutamate receptors
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Anti-inflammatory agents
(nonsteroidal; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Nerve, disease
(peripheral neuropathy, ischemic; nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)

IT Brain, disease
Spinal cord
Spinal cord
(trauma; nonsteroidal antiinflammatory compds. for prevention and

treatment of neurodegenerative diseases)

IT 50-99-7, D-Glucose, biological studies
 RL: BOC (Biological occurrence); BSU (Biological study, unclassified);
 BIOL (Biological study); OCCU (Occurrence)
 (blood; glycemic damage-assocd. neuropathy; nonsteroidal
 antiinflammatory compds. for prevention and treatment of
 neurodegenerative diseases)

IT 53-86-1, Indomethacin 56-86-0, L-Glutamic acid, biological studies
 6384-92-5, NMDA
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); BIOL (Biological study)
 (nonsteroidal antiinflammatory compds. for prevention and treatment of
 neurodegenerative diseases)

IT 50-33-9, Phenylbutazone, biological studies 50-33-9D, Phenylbutazone,
 metabolites **50-78-2**, Acetylsalicylic acid **50-78-2D**,
 Acetylsalicylic acid, derivs. 54-21-7, Sodium salicylate 58-15-1,
 Aminopyrine 58-15-1D, Aminopyrine, metabolites 60-80-0, Antipyrine
 60-80-0D, Antipyrine, metabolites 65-45-2, Salicylamide 65-85-0,
 Benzoic acid, biological studies 65-85-0D, Benzoic acid, metabolites,
 biological studies **69-46-5**, Calcium acetylsalicylate 87-28-5,
 Glycol salicylate 89-57-6, Mesalamine 118-57-0, Acetaminosalol
 119-36-8, Methyl salicylate 129-20-4, Oxyphenbutazone 129-20-4D,
 Oxyphenbutazone, metabolites **134-55-4**, Phenyl acetylsalicylate
 147-90-0, Morpholine salicylate 303-38-8, 2,3-Dihydroxybenzoic acid
 303-38-8D, 2,3-Dihydroxybenzoic acid, metabolites 487-48-9, Salacetamide
 490-79-9, Gentisic acid 550-97-0, 1-Naphthyl salicylate 552-94-3,
 Salsalate **580-02-9**, Methyl acetylsalicylate 599-79-1,
 Sulfasalazine **5003-48-5**, Benorylate 5104-49-4, Flurbiprofen
 5104-49-4D, Flurbiprofen, metabolites 5663-71-8 6385-02-0, Sodium
 meclofenamate 6385-02-0D, Sodium meclofenamate, metabolites
 13539-59-8, Apazone 13539-59-8D, Apazone, metabolites 13586-98-6
 15307-86-5, Diclofenac 15307-86-5D, Diclofenac, metabolites 15687-27-1
 15687-27-1D, Diclofenac, metabolites 15722-48-2, Olsalazine 21256-18-8, Oxaprozin
 21256-18-8D, Oxaprozin, metabolites 22071-15-4, Ketoprofen
 22071-15-4D, Ketoprofen, metabolites 22204-53-1, Naproxen 22204-53-1D,
 Naproxen, metabolites 22494-27-5, Flufenisal 22494-42-4 26171-23-3,
 Tolmetin 26171-23-3D, Tolmetin, metabolites 29679-58-1, Fenoprofen
 29679-58-1D, Fenoprofen, metabolites 30653-83-9, Parsalmide
 36322-90-4, Piroxicam 36322-90-4D, Piroxicam, metabolites 36364-49-5,
 Imidazole salicylate 37933-78-1, Lysine acetylsalicylate 38194-50-2,
 Sulindac 38194-50-2D, Sulindac, metabolites 41340-25-4, Etodolac
 41340-25-4D, Etodolac, metabolites 42924-53-8, Nabumetone 42924-53-8D,
 Nabumetone, metabolites 51803-78-2, Nimesulide 51803-78-2D,
 Nimesulide, metabolites 53597-27-6, Fendosal 59804-37-4, Tenoxicam
 59804-37-4D, Tenoxicam, metabolites 62992-61-4, Etersalate 71125-38-7,
 Meloxicam 71125-38-7D, Meloxicam, metabolites 74103-06-3, Ketorolac
 74103-06-3D, Ketorolac, metabolites 111406-87-2, Zileuton
 111406-87-2D, Zileuton, metabolites
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)
 (nonsteroidal antiinflammatory compds. for prevention and treatment of
 neurodegenerative diseases)

IT 7440-70-2, Calcium, biological studies 39391-18-9, Cyclooxygenase
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
 (Biological study); PROC (Process)
 (nonsteroidal antiinflammatory compds. for prevention and treatment of
 neurodegenerative diseases)

=>

AN 1993:175822 CAPLUS
 DN 118:175822
 TI Cure for diabetes, bronchitis, arthritis, and arteriosclerosis
 IN Carantinos, Spyros
 PA Australia
 SO Pat. Specif. (Aust.), 11 pp.
 CODEN: ALXXAP
 DT Patent
 LA English
 IC ICM A61K031-19
 ICS A61K033-30; A61K031-215
 CC 63-6 (Pharmaceuticals)
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	AU 629520	B2	19921008	AU 1988-26677	19881208
	AU 8826677	A1	19890608		
PRAI	AU 1987-5803		19871208		
AB	A pharmaceutical contg. ferric ammonium citrate in admixt. with ZnO and optionally including aspirin, NaHCO ₃ , and citric acid is effective in treating arthritis, bronchitis, diabetes, arteriosclerosis, broken bones, Parkinson's disease, high blood cholesterol, liver cirrhosis, and enlargement of the prostate gland.				
ST	ferric ammonium citrate zinc oxide pharmaceutical				
IT	Antiartherosclerotics				
	Anticholesteremics and Hypolipemics				
	Antidiabetics and Hypoglycemics				
	(ferric ammonium citrate and zinc oxide as)				
IT	Cirrhosis				
	Parkinsonism				
	(treatment of, ferric ammonium citrate and zinc oxide for)				
IT	Inflammation inhibitors				
	(antiarthritics, ferric ammonium citrate and zinc oxide as)				
IT	Prostate gland				
	(disease, hyperplasia, treatment of, ferric ammonium citrate and zinc oxide for)				
IT	Bronchi				
	(diseases, bronchitis, treatment of, ferric ammonium citrate and zinc oxide for)				
IT	Bone, disease				
	(fracture, treatment of, ferric ammonium citrate and zinc oxide for)				
IT	50-78-2, Aspirin 59-43-8, Vitamin B1, biological studies				
	77-92-9, Citric acid, biological studies 94-20-2, Chlorpropamide				
	144-55-8, Sodium bicarbonate, biological studies				
	RL: BIOL (Biological study)				
	(pharmaceuticals contg. ferric ammonium citrate and zinc oxide and, for treatment of infections and immune diseases)				
IT	1314-13-2, Zinc oxide, biological studies				
	RL: BIOL (Biological study)				
	(pharmaceuticals contg. ferric ammonium citrate and, for treatment of infections and immune diseases)				
IT	1185-57-5, Ferric ammonium citrate				
	RL: BIOL (Biological study)				
	(pharmaceuticals contg. zinc oxide and, for treatment of infections and immune diseases)				

=>

AN 1998:700744 CAPLUS
 DN 130:60774
 TI Nonsteroidal anti-inflammatory drugs increase tumor necrosis factor production in the periphery but not in the central nervous system in mice and rats
 AU Sacco, Silvano; Agnello, Davide; Sottocorno, Marcello; Lozza, Gianluca; Monopoli, Angela; Villa, Pia; Ghezzi, Pietro
 CS Laboratory of Neuroimmunology, "Mario Negri" Institute for Pharmacological Research, Milan, 20157, Italy
 SO Journal of Neurochemistry (1998), 71(5), 2063-2070
 CODEN: JONRA9; ISSN: 0022-3042
 PB Lippincott-Raven Publishers
 DT Journal
 LA English
 CC 1-7 (Pharmacology)
 AB Nonsteroidal anti-inflammatory drugs (**NSAIDs**), which inhibit prostaglandin (PG) synthesis, augment prodn. of tumor necrosis factor (TNF) in most exptl. models. We investigated the effect of two **NSAIDs**, indomethacin and ibuprofen, on the prodn. of TNF in the CNS induced by intracerebroventricular injection of lipopolysaccharide (LPS). Indomethacin and ibuprofen, administered i.p., augmented (three- to ninefold) the levels of TNF in serum and peripheral organs of mice injected i.p. with LPS and in rats with adjuvant arthritis (up to a sevenfold increase). However, **NSAIDs** (i.p. or intracerebroventricularly) did not increase brain TNF prodn. induced by i.v. LPS. In fact, indomethacin decreased (1.4-1.8-fold) TNF levels in the spinal cord of rats with exptl. autoimmune encephalomyelitis and in the cortex of rats with focal cerebral **ischemia**. Systemic administration of iloprost inhibited serum TNF levels after i.p. LPS, whereas intracerebroventricular injection of iloprost or PGE2 did not inhibit brain TNF induced by intracerebroventricular LPS. Both peripheral and central TNF productions were inhibited by cAMP level-elevating agents or dexamethasone. Thus, a PG-driven neg. feedback controls TNF prodn. in the periphery but not in the CNS.

ST antiinflammatory **NSAIDs** TNF peripheral central nervous system
 IT Anti-inflammatory agents
 Brain
 (**NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT Tumor necrosis factors
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
 (**NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT Encephalomyelitis
 (autoimmune; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT Nervous system
 (central; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT Brain, disease
 (**ischemia**; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT Anti-inflammatory agents
 (nonsteroidal; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT Nervous system
 (peripheral; **NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT 53-86-1, Indomethacin 15687-27-1, Ibuprofen
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)

(**NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

IT 60-92-4, CAMP

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(**NSAIDs** increase TNF prodn. in peripheral but not central nervous system in mice and rats)

RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE

- (1) Aggarwal, B; J Biol Chem 1985, V260, P2345 CAPLUS
- (2) Asanuma, M; Neurosci Lett 1997, V225, P109 CAPLUS
- (3) Bagby, G; J Appl Physiol 1994, V77, P1542 CAPLUS
- (4) Benigni, F; Mol Med 1995, V1, P568 CAPLUS
- (5) Breder, C; J Comp Neurol 1993, V337, P543 CAPLUS
- (6) Breitner, J; Annu Rev Med 1996, V47, P401 CAPLUS
- (7) Brosnan, C; Neurology 1995, V45(Suppl 6), PS16
- (8) Bruce, A; Nature Med 1996, V2, P788 CAPLUS
- (9) Di Santo, E; Cytokine 1997, V9, P300 CAPLUS
- (10) Di Santo, E; Eur J Pharmacol 1997, V336, P197 CAPLUS
- (11) Di Santo, E; Neuroimmunomodulation 1995, V2, P149 CAPLUS
- (12) Dickson, D; Glia 1993, V7, P75 MEDLINE
- (13) Dinarello, C; Am J Med 1982, V72, P799 CAPLUS
- (14) Dinarello, C; Rev Infect Dis 1988, V10, P168 CAPLUS
- (15) Faggioni, R; Infect Immun 1995, V63, P1473 CAPLUS
- (16) Fattori, E; J Exp Med 1994, V180, P1243 CAPLUS
- (17) Gahring, L; Neuroimmunomodulation 1996, V3, P289 CAPLUS
- (18) Grundmann, H; J Infect Dis 1992, V165, P501 CAPLUS
- (19) Haley, T; Br J Pharmacol 1957, V12, P12 CAPLUS
- (20) Honda, A; J Biol Chem 1993, V268, P7759 CAPLUS
- (21) Irani, D; J Immunol 1997, V158, P2318 CAPLUS
- (22) Knudsen, P; J Immunol 1986, V137, P3189 CAPLUS
- (23) Lipton, J; Peptides 1991, V12, P795 CAPLUS
- (24) Liu, T; Stroke 1994, V25, P1481 CAPLUS
- (25) Martich, G; J Exp Med 1991, V173, P1021 CAPLUS
- (26) Meistrell, M; Shock 1997, V8, P341
- (27) Mengozzi, M; Immunology 1994, V82, P207 CAPLUS
- (28) Mustafa, M; Am J Dis Child 1990, V144, P883 MEDLINE
- (29) Mustafa, M; J Clin Invest 1989, V84, P1253 CAPLUS
- (30) Nataf, S; Acta Neurol Scand 1993, V88, P97 CAPLUS
- (31) Noel, P; Life Sci 1990, V47, P1023 CAPLUS
- (32) Olsson, T; Neurology 1995, V45(Suppl 6), PS11
- (33) Reder, A; J Neuroimmunol 1994, V54, P117 CAPLUS
- (34) Renz, H; J Immunol 1988, V141, P2388 CAPLUS
- (35) Ruddle, N; J Exp Med 1990, V172, P1193 CAPLUS
- (36) Saez-Llorens, X; Antimicrob Agents Chemother 1990, V34, P837 CAPLUS
- (37) Saukkonen, K; J Exp Med 1990, V171, P439 CAPLUS
- (38) Schooltink, H; FEBS Lett 1992, V314, P280 CAPLUS
- (39) Selmaj, K; Neurology 1995, V45(Suppl 6), PS44
- (40) Shigeno, T; Surg Neurol 1985, V24, P47 MEDLINE
- (41) Sironi, M; Int J Immunopharmacol 1992, V14, P1045 CAPLUS
- (42) Sommer, N; Nature Med 1995, V1, P244 CAPLUS
- (43) Spengler, R; Infect Immun 1989, V57, P2837 CAPLUS
- (44) Stewart, W; Neurology 1997, V48, P626 MEDLINE
- (45) Sugimoto, Y; J Biol Chem 1992, V267, P6463 CAPLUS
- (46) Sugimoto, Y; Neuroscience 1994, V62, P919 CAPLUS
- (47) van der Poll, T; J Immunol 1995, V155, P5397 CAPLUS
- (48) Watabe, A; J Biol Chem 1993, V268, P20175 CAPLUS
- (49) Zuckerman, S; Eur J Immunol 1989, V19, P301 CAPLUS

=>

AN 1979:36972 CAPLUS
 DN 90:36972
 TI Entry of protein into cerebral ventricles during ventriculo-cisternal perfusion and the administration of anti-inflammatory agents
 AU Haywood, J. R.; Vogh, B. P.
 CS Dep. Pharmacol Ther., Univ. Florida, Gainesville, FL, USA
 SO Journal of Neurochemistry (1978), 30(6), 1621-3
 CODEN: JONRA9; ISSN: 0022-3042
 DT Journal
 LA English
 CC 13-13 (Mammalian Biochemistry)
 Section cross-reference(s): 1
 AB During brain ventriculo-cisternal perfusion (VCP) in cats, entry of protein into the ventricles was stable over 30-150 min, after which the rate increased up to the end of the exptl. period (330 min). When the VCP procedures involved increased trauma to meningeal tissues, e.g., by using a blunted needle, the early and late stable mean rate of influx was higher and probably more direct leakage occurred due to the invasive technique itself. Gentamicin, tobramycin, acetylsalicylic acid (15-30 mg/kg i.v. or 200 .mu.M **intrathecally**), indomethacin (3.4 .mu.M), and meclofenamic acid (1.7 .mu.M) all failed to reduce the protein entry, but dexamethasone given i.v. at the beginning of perfusion (0.3 mg/kg, i.v.) and in repeated doses (0.15 mg/kg/h) lowered the initial rate of protein entry and markedly attenuated the subsequent rise in protein influx.
 ST ventriculocisternal perfusion protein entry ventricle; antiinflammatory ventriculocisternal perfusion protein influx; dexamethasone ventriculocisternal perfusion protein influx; brain ventricle protein entry perfusion
 IT Proteins
 RL: BIOL (Biological study)
 (brain ventricle influx of, in ventriculo-cisternal perfusion)
 IT Cerebrospinal fluid
 (protein entry into, in ventriculo-cisternal perfusion)
 IT Inflammation inhibitors
 (protein influx into brain ventricles in ventriculo-cisternal perfusion response to)
 IT Brain
 (ventricle, protein entry into, in ventriculo-cisternal perfusion)
 IT 50-02-2 **50-78-2** 53-86-1 644-62-2 1403-66-3 32986-56-4
 RL: BIOL (Biological study)
 (protein influx into brain ventricles in ventriculo-cisternal perfusion response to)

=>